0001213900-18-004408.txt : 20180413 0001213900-18-004408.hdr.sgml : 20180413 20180413134337 ACCESSION NUMBER: 0001213900-18-004408 CONFORMED SUBMISSION TYPE: 10-KT PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20171231 FILED AS OF DATE: 20180413 DATE AS OF CHANGE: 20180413 FILER: COMPANY DATA: COMPANY CONFORMED NAME: American BriVision (Holding) Corp CENTRAL INDEX KEY: 0001173313 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 260014658 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-KT SEC ACT: 1934 Act SEC FILE NUMBER: 333-91436 FILM NUMBER: 18753876 BUSINESS ADDRESS: STREET 1: 11 SAWYERS PEAK DRIVE CITY: GOSHEN STATE: NY ZIP: 10924 BUSINESS PHONE: 845-551-8728 MAIL ADDRESS: STREET 1: 11 SAWYERS PEAK DRIVE CITY: GOSHEN STATE: NY ZIP: 10924 FORMER COMPANY: FORMER CONFORMED NAME: METU BRANDS, INC. DATE OF NAME CHANGE: 20150908 FORMER COMPANY: FORMER CONFORMED NAME: ECOLOGY COATINGS, INC. DATE OF NAME CHANGE: 20080821 FORMER COMPANY: FORMER CONFORMED NAME: Ecology Coatings, Inc. DATE OF NAME CHANGE: 20070711 10-KT 1 f10kt2017_americanbrivision.htm ANNUAL REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

☐  ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended: December 31, 2017

 

OR

 

☒  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from October 1, 2017 to December 31, 2017

 

Commission file number: 333-91436

 

AMERICAN BRIVISION (HOLDING) CORPORATION

(Exact name of Company in its charter)

 

Nevada   26-0014658
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification)

 

11 Sawyers Peak Drive, Goshen, NY, 10924

(Address of principal executive offices, including zip code)

 

Registrant's Telephone number, including area code: (845) 291-1291

 

Securities registered pursuant to Section 12(b) of the Act:  None

 

Securities registered pursuant to Section 12(g) of the Act:  None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act.  Yes ☐ No ☒

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.406 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for at least the part 90 days. Yes ☒ No ☐

 

Indicate by check mark if disclosure of delinquent filers in response to Item 405 of Regulation S-K is not contained hereof, and will not be contained, to will be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

  Large accelerated filer ☐  Accelerated filer   ☐
  Non-accelerated filer Smaller Reporting Company   ☒
      Emerging growth company     ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of June 30, 2017, approximately 34,962,153 shares of our common stock, par value $0.001 per share, were held by non-affiliates, which had a market value of approximately $69,924,306 based on  the available OTCQB closing price of $2.00 per share on June 30, 2017.

 

As of March 28, 2018, the registrant had 213,926,475 shares of common stock outstanding and 0 shares of convertible preferred stock outstanding. 

 

 

 

 

 

 

 

AMERICAN BRIVISION (HOLDING) CORPORATION

Form 10-K

For the Fiscal Year Ended December 31, 2017

 

Table of Contents

 

  Page
Part I
Item 1. Business 1
Item 1A. Risk Factors 11
Item 1B.  Unresolved staff comments 23
Item 2.  Properties 23
Item 3.  Legal Proceedings 23
Item 4.  Mine Safety Disclosures 23
   
Part II
Item 5.  Market for Registrant's Common Equity, Related Stockholders Matters and Issuer Purchases of Equity Securities 24
Item 6.  Selected Financial Data 24
Item 7.  Management's Discussion and Analysis of Financial Condition and Results of Operations 24
Item 7A.  Quantitative and Qualitative Disclosures about Market Risk 36
Item 8.  Financial Statements and Supplementary Data F-1
Item 9.  Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 37
Item 9A.  Controls and Procedures 37
Item 9B.  Other Information 37
   
Part III
Item 10.  Directors, Executive Officers and Corporate Governance 38
Item 11.  Executive Compensation 39
Item 12.  Securities Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 42
Item 13.  Certain Relationships and Related Transactions, and Director Independence 43
Item 14.  Principal Accountant Fees and Services 45
   
Part IV
Item 15.  Exhibits, Financial Statement Schedules 46
Signatures 48

  

 

 

  

PART I

 

Except for statements of historical fact, the information presented herein constitutes forward-looking statements. These forward-looking statements generally can be identified by phrases such as “anticipates,” “believes,” “estimates,” “expects,” “forecasts,” “foresees,” “intends,” “plans,” or other words of similar import.  Similarly, statements herein that describe our business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  Such factors include, but are not limited to, our ability to: successfully commercialize our technology; generate revenues and achieve profitability in an intensely competitive industry; compete in products and prices with substantially larger  and better capitalized competitors; secure, maintain and enforce a strong intellectual property portfolio; attract additional capital sufficient to finance our working capital requirements, as well as any investment of plant, property and equipment; develop a sales and marketing infrastructure; identify and maintain relationships with third party suppliers who can provide us a reliable source of raw materials; acquire, develop, or identify for our own use, a manufacturing capability; attract and retain talented individuals; continue operations during periods of uncertain general economic or market conditions, and; other events, factors and risks previously and from time to time disclosed in our filings with the Securities and Exchange Commission.

 

Although we believe the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we do not undertake to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

 

ITEM 1.   DESCRIPTION OF BUSINESS

 

The Industry

 

The biotechnology industry focuses on developing breakthrough products and technologies to combat various types of diseases through efficient industrial manufacturing process. Such industry is an important business sector in the world's economies and plays a key role in human health. Biotechnology companies generally require large amounts of capital investment for their Research & Development activities.  It may take up to tens of years to develop and commercialize a new drug or a new medical device. American BriVision (Holding) Corporation (“we” or the “Company”) is an early stage biotechnology company with a pipeline of six new drugs and one medical device under development, all of which are licensed from related parties of the Company.

 

Business Overview

 

We are a clinical stage biopharmaceutical company focused on utilizing our licensed technology to (i) further the development of pharmaceutical products with focuses on cancer and central nervous system indications, (ii) target patients that may potentially respond to such pharmaceutical products and (iii) obtain regulatory approvals for and commercialize such pharmaceutical products in various markets. Our business model includes the following steps and stages: 1) engaging medical research institutions, such as Memorial Sloan Kettering Cancer Center (“MSKCC”) and MD Anderson Cancer Center, to conducting clinical trials of translational medicine for Proof of Concept (“POC”) on behalf of the Company; 2) retaining ownership of the research results by the Company, and 3) out-licensing the research results and data to pharmaceutical companies who will develop the products. We currently have no revenue generated from clinical research and development of six new drugs and one medical device, which is our primary business operations. Currently, we concentrate on the research and development of six compounds licensed to us by BioLite Inc. (“BioLite”), a company formed in Taiwan who is one of our principal shareholders. The six compounds are ABV- 1501  Triple Negative Breast Cancer, ABV-1502  Solid Tumor with Anti-PD1, ABV-1503  Combination therapy for Chronic Lymphocytic Leukemia, ABV-1504  Major Depressive Disorder, ABV-1505  Attention Deficit Hyperactivity Disorder and Maitake Combination Therapy. In addition, we are licensed to research and develop a medical device, BFC-1401 Vitreous Substitute for Vitrectomy, a new medical device licensed from BioFirst Corporation, (“BioFirst”). BioFirst is a related party of the Company because a control beneficiary shareholder of YuanGene Corporation and the Company is one of the directors and primary shareholder of BioFirst.

 

 1 

 

   

Collaboration Agreement with BioLite

 

On December 29, 2015, American BriVision Corporation (“BriVision”), a Delaware corporation and our wholly owned subsidiary, entered into a Collaboration Agreement with BioLite pursuant to which BioLite granted BriVision the sole licensing rights to research and develop, for therapeutic purposes in the territories of the United States and Canada (collectively the “North America Region”), the following products (the “Products”): BLI-1005 CNS-Major Depressive Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity Disorder; BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1; BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer; and BLI-1501 Hematology-Chronic Lymphocytic Leukemia. BioLite and our company are related parties as Eugene Jiang is our Chairman of the Board and a director of BioLite.

 

The material terms of the Collaboration Agreement are as follows:

 

  BriVision is responsible to make up-front, milestone and royalty payments to BioLite, as further described below.

 

  BioLite owns all files, data, confidential and non-public information, including, without limitation, all IND packages and clinical study reports, regarding the Compounds (collectively, the “Compound IP”), to the extent that the Compound IP were and are developed in Taiwan, and BriVision owns all Compound IP to the extent they are developed in the North America Region. BioLite grants an exclusive license to its Compound IP to BriVision for the purpose of further development and commercialization of the Products in the North America Region. BioLite and BriVision share the responsibility of preparing for clinical trials by delivering Compound IP and preparing related materials.

 

  BriVision is and has been responsible for all clinical trial expenses incurred in the North America Region.  BioLite paid all clinical trial expenses for trials conducted in Taiwan as of the date of this annual report on Form 10-K.

 

  The Collaboration Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in the North America Region. Either party may terminate upon thirty days’ prior written notice for breach or insolvency.

 

  BriVision agreed to pay to BioLite an aggregate of up to One Hundred Million Dollars ($100,000,000) (the “Aggregate Amount”) in milestone payments during the term of the agreement, payable in cash or the Company or its parent company’s equity. A certain percentage of the Aggregate Amount will be paid to BioLite upon completion of each milestone by BioLite as set forth in the Collaboration Agreement. An upfront payment of $3,500,000 (the “Milestone Payment”), or 3.5% of the Aggregate Amount, was due under the Collaboration Agreement. On May 6, 2016, BriVision and Biolite amended the payment terms under the Collaboration Agreement by entering into a Milestone Payment Agreement, pursuant to which we paid BioLite $2,600,000 in cash and $900,000 in newly issued shares of our common stock, based on a price of $1.60 per share, for an aggregate number of 562,500 shares.

  

  Milestones shall be reached upon BioLite’s submissions of IND and NDAs for the Products, and completion of various phases in the application processes, as set forth in the Collaboration Agreement.

 

  In addition to the Aggregate Amount, BriVision will pay BioLite five percent (5%) of net sales of Products in the North America Region when any of the Products are approved for marketing and sales in such Region.

 

 2 

 

  

On January 12, 2017, we entered into an Addendum (the “Addendum”) to the Collaboration Agreement dated December 29, 2015 and as amended May 6, 2016. Pursuant to the Addendum, BioLite agreed to license us to research and develop an additional new drug, “Maitake Combination Therapy” (the “Sixth Product”) worldwide. The ownership of any clinical trial data and Intellectual Property as defined in the Collaboration Agreement shall belong to us. We shall pay for all clinical trials and other expenses associated with all clinical trials and shall have the right to sublicense Five Products in the North America Region and the Sixth Product worldwide. There is no additional Milestone Payments as defined in paragraph 3 of the Collaboration Agreement that needs to be made now or in the future with respect to the Sixth Product. In the event that BioLite is obligated to pay its licensor in excess of 3% of the net sales, BioLite and us shall renegotiate and increase the Royalty Charge to a percentage to be later agreed upon as opposed to the original amount of 5% of the net sales as defined in paragraph 4 of the Collaboration Agreement.

 

Our Compounds Licensed from BioLite

 

We currently are granted from BioLite the sole licensing rights to develop six compounds for therapeutic purposes. Below is the description of each of the six compounds.

 

  I. ABV- 1501  Triple Negative Breast Cancer - Combination therapy for Triple Negative Breast Cancer (TNBC)

 

  ABV- 1501 is developed from BLI-1401-2 whose active pharmaceutical ingredient is Yukiguni Maitake Extract 404. MSKCC conducted the Phase I clinical trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom), which is very similar to Yukiguni Maitake Extract 404.  The Phase I trial focused on Grifola frondosa extract’s immunological effects on breast cancer patients. The results of the Phase I trial showed that oral administration of a polysaccharide extract from Maitake mushroom is associated with both immunologically stimulatory and inhibitory measurable effects in peripheral blood.  
     
  Our Investigational New Drug (“IND”) application of ABV-1501 for the Phase II clinical trials referenced with MSKCC Maitake and such Phase II IND was approved in March 2016 by the U.S. FDA.
     
  We are currently speaking with a medical center located in California, United States with respect to potential cooperation opportunities on ABV-1501’s Phase II clinical study.

 

  II. ABV-1502  Solid Tumor with Anti-PD1 - Combination therapy for solid tumors with Anti-PD1

 

  In addition to ABV-1501, we plan to develop ABV-1501 for the potential treatment of solid tumor with anti-PD1, which is also derived from Maitake mushroom extract.  
     
  Currently, we are coordinating with a U.S. health center to prepare the Phase I IND package for ABV-1502. 

 

 3 

 

 

 

As stated above, ABV-1501 and ABV-1502 share the same Active Pharmaceutical Ingredient, Maitake mushroom extract. IND and study details are as follows:

 

  During the Phase I/II clinical trial of Maitake mushroom extract, a total of 34 eligible study subjects were enrolled from March 2004 to January 2007. The primary endpoints were safety and tolerability. The test drug was orally administrated and a polysaccharide extract from Maitake mushroom was associated with both immunologically stimulatory and inhibitory measurable effects in peripheral blood. The IND number is 68853 and MSKCC received filing confirmation from the FDA on Jan 22, 2004.

  

Generally, Phase I clinical trials are performed with healthy subjects to test for safety and Phase II clinical trials are performed with patient subjects for efficacy as well as safety. However, trials of cancer-related drugs must involve subjects with the targeted cancer, and as such, Phase I/II studies involving cancer patients include primary endpoints of safety and tolerability and a secondary endpoint of efficacy.

 

  III. ABV-1503  Combination therapy for Chronic Lymphocytic Leukemia (CLL)

 

  We are currently preparing the IND package for the Phase II clinical study of Epigallocatechin gallate (EGCG) for CLL. BioLite is preparing the Compound IP for the Chemistry, Manufacture, and Control (CMC) part of the IND. We and MSKCC are collaborating to design the protocols for the clinical trials and the IRB documents. The trial period, test subject number, primary and secondary endpoint and method of administration have not been decided yet, and are still being negotiated between us and MSKCC.
     
  We are cooperating with MSKCC to prepare a clinical trial agreement once the IND of ABV-1503 is approved by the U.S. FDA.

 

  IV. ABV-1504  Major Depressive Disorder - Major Depressive Disorder (MDD) 

 

  This is Polygala extract for the potential treatment of Major Depressive Disorder
     
  BioLite performed Phase I clinical trial of ABV-1504 and has obtained US FDA Phase II Part One/Part Two IND approval. The results of Phase II Part One clinical trial of ABV-1504 are described below.
     
   ● We started the Phase II Part Two clinical trial of ABV-1504 in the third quarter of 2016 and the study is being conducted in the following sites in Taiwan: Taipei Veterans General Hospital, Linkou Chang Gung Memorial Hospital, Taipei City Hospital (Songde Branch), Tri-Service General Hospital and Wan Fang Hospital. We plan to commence such clinical trial at Stanford University in the United States soon.

 

  V. ABV-1505  Attention Deficit Hyperactivity Disorder (“ADHD”)

 

  This is a Polygala extract for Attention Deficit Hyperactivity Disorder.

 

  BioLite has obtained U.S. FDA approval for our IND application of Phase II study of ABV-1505  on January 25, 2016, and is currently negotiating with qualified  medical sites and research institutions for Phase II clinical trials.

 

 4 

 

  

ABV-1504 and ABV-1505 have the same Active Pharmaceutical Ingredient: the extract of Radix Polygalae (Polygala tenuifolia Willd/PDC-1421 Capsule).

 

  A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients with Major Depressive Disorder

 

IND Number: 112567

 

Primary Study Objective: To assess the efficacy profile of PDC-1421 Capsule in major depressive disorder with Montgomery-Asberg Depression Rating Scale (MADRS).

 

Secondary Study Objective: To evaluate the efficacy and safety profile

 

Study period: 2 years.

 

Total 72 study subjects will be enrolled.

 

Study site: There are five sites in Taiwan and one site in US (Stanford University, currently preparing for IRB approval and Clinical Trial Agreement.)

 

Sponsor: BioLite, Inc.

 

For ABV-1504 Phase II part one---total subject: 12, trial period: 2/11/2016-7/14/2016, administered route: oral, test results are as follows:

 

Trial Progress Report:

 

1. Part I trial has been completed with 12 subjects (screening: 14, enrolling: 12). The six subjects were in the Part I high dosage group.

 

2. Under the suicide risk assessment (C-SSRS) Subject X indicated that the suicidal ideation scores were 4 for both Visit 7 and Visit 8. The PI confirmed that the subject had external pressures (moving, etc.), which produced constant suicidal thoughts, and such observation was reflected in Dr. A’s (PI) evaluation. The subject expressed his/her intention to stay positive in a counseling session, and the subject was contacted by a researcher (Research Nurse) after leaving the facility. After reviewing by the researcher, a justification was made that the suicidal behavior was irrelevant to the drug administered.

 

3. Clinical data of the six high-dosage administered subjects with data exceeding normal value:

    - NCS- Non-Clinical Significant judged by PI. CS: Clinical Significant judged by PI.

    -After data safety review board carefully reviewed, they agree to proceed to part two clinical trial.

 

For ABV-1504 Phase II part two: this phase currently is conducted in 5 clinical sites in Taiwan (started in Q3 2016) and one US site is under IRB review.

 

For “A Dose Escalation Phase I Study of PDC-1421 Capsule Targeting in Depression:” Trial period: 11/13/2012-7/5/2013, final report date 11/12/2013. Enroll subject: 30, 23 PDC-1421, 7 placebo control.

 

Study Conclusions:

 

“(1) No subject had serious adverse event and no subject discontinued due to adverse event;

 

(2) No clinically significant findings were observed in physical examinations; vital signs, electrocardiograms, laboratory measurements, and C-SSRS were observed throughout the treatment period;

 

(3) The oral administration of PDC-1421 in healthy volunteers was safe and well-tolerated for the dose from 380 mg to 3800 mg”.

 

For “A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients with Major Depressive Disorder”:

 

Part One- study period 2/11/2016-7/12/2016. Total subject: 12.

 

We purchase the extract of Radix Polygalae (Polygala tenuifolia Willd/PDC-1421 Capsule) from Herng Fa Fa Pharmaceutical Technology, and have Industrial Technology Research Institute (“ITRI”) process such extract. There are no limits on availability to us on any of these ingredients.

 

 5 

 

  

Collaboration Agreement with BioFirst

 

On July 24, 2017, BriVision, one of our wholly-owned subsidiaries entered into a collaboration agreement (the “BioFirst Agreement”) with BioFirst Corporation (“BioFirst”), a corporation incorporated under the laws of Taiwan, pursuant to which BioFirst granted BriVision the global license to co-develop BFC-1401 Vitreous Substitute for Vitrectom (“BFC-1401”) for medical purposes. BioFirst is a related party to the Company because BioFirst and Yuangene Corporation (“Yuangene”), the Company’s controlling shareholder, are under common control of the controlling beneficiary shareholder of Yuangene.

 

According to the BioFirst Agreement, we co-develop and commercialize BFC-1401 with BioFirst and are obligated to pay BioFirst $3,000,000 (the “Total Payment”) in cash or common stock of the Company on or before September 30, 2018 in two installments. An upfront payment of $300,000, representing 10% of the Total Payment due under the Collaboration Agreement, was paid upon execution of the Collaboration Agreement. The Company is entitled to receive 50% of the future net licensing income or net sales profit when BFC-1401 is sublicensed or commercialized. For more information about the BioFirst Agreement, please refer to the current report on Form 8-K filed on July 24, 2017.  

 

Co-development Agreement with Rgene

 

On May 26, 2017, BriVision entered into a co-development agreement (the “Co-Dev Agreement”) with Rgene Corporation, a corporation incorporated under the laws of Taiwan (“Rgene”), to co-develop and commercialize in the global markets three new drug products that are included in the Sixth Product as defined in the Addendum. The three drugs licensed to Rgene are ABV-1507 HER2/neu Positive Breast Cancer Combination Therapy, ABV-1511 Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy.

 

Pursuant to the Co-Dev Agreement, Rgene should pay to the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017 in three installments. The payment is for the compensation of BriVision’s past research efforts and contributions made by BriVision before the Co-Dev Agreement was signed and it does not relate to any future commitments made by BriVision and Rgene in this Co-Dev Agreement. Besides $3,000,000, the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene, if any, and any development cost shall be equally shared by both BriVision and Rgene.

 

On June 1, 2017, the Company has delivered all research, technical, data and development data to Rgene. Because both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of Yuangene Corporation and the Company, the Company has recorded the full amount of $3,000,000 in connection with the Co-Dev Agreement as additional paid-in capital during the year ended September 30, 2017. As of the date of this report, the Company has received $450,000 in cash. For more information about the Co-Dev Agreement, please refer to the current report on Form 8-K we filed on May 30, 2017.

 

As of date of this report, no net licensing income and/or net sales profit has occurred.

 

Market Opportunity and Growth Strategy/Business Plan

 

ABVC focuses on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of ABVC includes integrating research achievements from world-renowned medical research institutions, such as MSKCC and MD Anderson Cancer Center, conducting clinical trials of translational medicine for proof of concept (“POC”), out-licensing to international pharmaceutical companies and indirectly getting involved in the global market opportunities. In the United States, any qualified clinic can conduct clinical trials. We currently strive to continue collaborating with top medical research institutions. However, if for any reason we cannot maintain the collaboration with any of such medical centers, we will seek to select qualified clinics to further develop our new drug and medical device products in the pipeline. Our primary goal is to pursue collaborations with top medical centers.

 

Our business plan is to conduct and complete Phase II clinical trials for all of our products in the pipeline in the US and/or Canada. If we obtain satisfactory results in the Phase II clinical trial for any such compounds or BFC-1401, we will seek strategic partners to out-license any such compounds tor BFC-1401 to established pharmaceutical companies for further development. Furthermore, we will continue to search for potential products (drugs or medical devices) worldwide to expand our product pipeline for their research and development in North America.

 

 6 

 

  

The competitive advantages of our business model include:

 

1. Once we successfully complete POC of any product in the pipeline, we will seek strategic partners, such as respected pharmaceutical companies in the United States and boutique qualified clinics, to co-develop such mature product. In consideration for our licensing of the mature product, we expect to receive capital which we plan to use for our research and development of other products in the pipeline or selection of other new drugs or medical devices.

 

2. Sublicensing our products that pass Phase II clinic trials to other pharmaceutical companies saves us the time and resources to conduct Phase III clinical trials and provides a quicker return on our investment in our products.

 

3. We have six new drug products related to central nervous system and cancers and one new medical device for vitreous substitutes under development. This development portfolio diversifies our research risks by focusing on three different medical fields.

 

We are currently negotiating with potential medical center partners regarding conducting clinical trials on certain compounds in our pipeline. Furthermore, certain international pharmaceutical companies have contacted us to express their interest in certain of our licensed compounds. However, we cannot provide any assurance that we will find a qualified medical center to conduct clinical trials of any of our new drug products or enter into a definitive licensing agreement with any pharmaceutical companies.

  

In accordance with the Collaboration Agreement with BioLite and Addendum and pursuant to existing practice, we own all intellectual property rights to the six products developed in Canada and the U.S. BioLite owns all intellectual property developed with respect to the six products developed outside Canada and the U.S. We have the right to sublicense our intellectual property to develop such products in Canada and the U.S.

  

Currently, we are in the process of developing seven products and will continue searching for other new drug candidates and medical device candidates for further development and ultimate licensing for Phase III development by the sub-licensees.

 

Intellectual Property 

 

The Products are dependent on, or are the subject of the following patents and patent applications.

 

No.  Status  Patent No.  Patent Starting Date 

Patent Expiration

Date

  Patent Name  Territory  Patent Owner(1)(2)
1  granted  6911222  6/28/2005  1/10/2022  Anti-depression Pharmaceutical Composition Containing Polygala Extract, Part 1  The U.S.  MPITDC
2  granted  7175861  2/13/2007  1/10/2022  Anti-depression Pharmaceutical Composition Containing Polygala Extract, Part 2  The U.S.  MPITDC
3  granted  7179496  2/20/2007  1/10/2022  Anti-depression Pharmaceutical Composition Containing Polygala Extract, Part 3  The U.S.  MPITDC
4  granted  7223425  5/29/2007  1/10/2022  Anti-depression Pharmaceutical Composition Containing Polygala Extract, Part 4  The U.S.  MPITDC
5  granted  0001337647  1/31/2007  1/10/2022  Anti-depression Pharmaceutical Composition Containing Polygala Extract  Italy  MPITDC
6  granted  CH693499   9/15/2003  1/10/2022  Anti-depression Pharmaceutical Composition Containing Polygala Extract  Switzerland  MPITDC
7  granted  10220149   4/26/2007  1/10/2022  Anti-depression Pharmaceutical Composition Containing Polygala Extract  Germany  MPITDC
8  granted  GB2383951   6/7/2006  1/10/2022  Anti-depression Pharmaceutical Composition Containing Polygala Extract  United Kingdom  MPITDC
9  granted  4109907  6/6/2002  6/5/2022  Anti-depression Pharmaceutical Composition Containing Polygala Extract  Japan  MPITDC
10  granted  FR2834643   7/18/2003  1/10/2022  Anti-depression Pharmaceutical Composition Containing Polygala Extract  France  MPITDC
11  granted  I295576  4/11/2008  1/10/2022  Anti-depression Pharmaceutical Composition Containing Polygala Extract  Taiwan  MPITDC
12  granted  DE202007003503 U1  8/23/2007  9/20/2026  Novel Polygalatenosides and use thereof as an antidepressant agent  Germany  MPITDC
13  granted  7531519  5/12/2009  9/20/2026  Novel Polygalatenosides and use thereof as an antidepressant agent  The U.S.  MPITDC
14  granted  4620652  11/20/2006  11/19/2026  Novel Polygalatenosides and use thereof as an antidepressant agent  Japan  MPITDC
15  granted  I 314453  9/21/2006  9/20/2026  Novel Polygalatenosides and use thereof as an antidepressant agent  Taiwan  MPITDC
16  granted  I389713  3/21/2013  10/13/2030  Cross-linked oxidized hyaluronic acid for use as a vitreous substitute  (3)  Taiwan  NHRI
17  granted  US 8197849 B2  6/12/2012  8/30/2030  Cross-linked oxidized hyaluronic acid for use as a vitreous substitute  The U.S.  NHRI

 

 

 7 

 

 

No.  Status  Patent No.  Patent Starting Date 

Patent Expiration

Date

  Patent Name  Territory  Patent Owner(1)(2)
18  granted  AU 2011/215775 B2  4/17/2014  2/9/2031  Cross-linked oxidized hyaluronic acid for use as a vitreous substitute  Australia  NHRI
19  granted  KR 10-1428898  8/4/2014  2/9/2031  Cross-linked oxidized hyaluronic acid for use as a vitreous substitute  Korea  NHRI
20  granted  CA 2786911 (C)  10/6/2015  2/10/2031  Cross-linked oxidized hyaluronic acid for use as a vitreous substitute  Canada  NHRI
21  granted  WO2011100469 A1  N/A(4)  N/A(4)  Cross-linked oxidized hyaluronic acid for use as a vitreous substitute  PCT  NHRI
22  granted  EP 2534200  4/8/2015  2/9/2031  Cross-linked oxidized hyaluronic acid for use as a vitreous substitute  European Union (Germany, United Kingdom, France, Switzerland, Spain, Italy)  NHRI
23  granted  特許第
5885349號
  2/9/2011  2/9/2031  Cross-linked oxidized hyaluronic acid for use as a vitreous substitute  Japan  NHRI
24  granted  ZL 201180005494.7  12/24/2014  2/9/2031  Cross-linked oxidized hyaluronic acid for use as a vitreous substitute(3)  China  NHRI
25  granted  HK1178188  3/6/2015  6/21/2030  Cross-linked oxidized hyaluronic acid for use as a vitreous substitute(3)  Hong Kong (5)   NHRI

 

(1) “MPITDC” stands for Medical and Pharmaceutical Industry Technology and Development Center, Taiwan.

 

(2) “NHRI” stands for National Health Research Institutes, Taiwan.

 

(3) The patent name is translated into English and the original patent name is written as “交联氧化透明质酸作为眼球玻璃体之替代物.”

 

(4) The starting date and expiration date of patents under PTC are subject to the laws of the specific participating jurisdiction where the patent application is filed. We have subsequently submitted such patent to the jurisdictions listed in No.22 herein above.

 

(5) NHRI has obtained standard patent in Hong Kong based on the registration of the patent (listed as No.24 herein) granted by the State Intellectual Property Office, People's Republic of China.

 

The Products are dependent on, or are the subject of the following patents and patent applications.

 

Title  Patent
Number
  Type  Country  Issue
Date
  Expiration
Date
                
Anti-depression pharmaceutical Composition containing polygala Extract  6911222  Patent  US  6/28/2005  8/24/2022
                
Anti-depression pharmaceutical Composition containing Polygala Extract  7175861  Patent  US  2/13/2007  4/28/2023
                
Anti-depression pharmaceutical Composition containing Polygala Extract  7179496  Patent  US  2/20/2007  4/28/2023
                
Anti-depression pharmaceutical Composition containing polygala Extract  7223425  Patent  US  5/29/2007  4/26/2023
                
Anti-depression Pharmaceutical Composition Containing Polygala Extract  1337647  Patent  IT  1/31/2007  4/24/2022
                
Anti-depression Pharmaceutical Composition Containing Polygala Extract  693499  Patent  CH  9/15/2003  5/2/2022
                
Anti-depression Pharmaceutical Composition Containing Polygala Extract  10220149  Patent  DE  4/26/2007  5/26/2022
                
Anti-depression Pharmaceutical Composition Containing Polygala Extract  GB2383951  Patent  GB  6/7/2006  5/10/2020
                
Anti-depression Pharmaceutical Composition Containing Polygala Extract  4109907  Patent  JP  4/11/2008  6/6/2022

 

 8 

 

 

Title  Patent
Number
  Type  Country  Issue
Date
  Expiration
Date
                
Anti-depression Pharmaceutical Composition Containing Polygala Extract  207794  Patent  FR  4/15/2005  6/24/2022
                
Polygalatenosides and use thereof as an antidepressant agent  202007003503  Patent  DE  7/19/2007  4/9/2025
                
Polygalatenosides and use thereof as an antidepressant agent  7531519  Patent  US  5/12/2009  1/11/2028
                
Polygalatenosides and use thereof as an antidepressant agent  4620652  Patent  JP  11/5/2011  11/20/2026
                
Anti-depression Pharmaceutical Composition Containing Polygala Extract  I 295576  Patent  TW  4/11/2008  1/11/2022
                
Polygalatenosides and use thereof as an antidepressant agent  I 314453  Patent  TW  9/11/2009  9/11/2026
                
從Grifola提取的抗腫瘤物質  CN1120173  Patent  CN  9/3/2003  9/3/2023
                
Antitumor substance extracted from grifola  US5854404 A  Patent  US  12/29/1998  6/22/2022
                
Antitumor substance extracted from hen-of-the-woods  EP0893449  Patent  EP  2004/8/25  3/31/2015
                
マイタケから抽出した抗腫瘍物質  特許 第2859843号  Patent  JP  3/8/2002  3/8/2016

 

Our Facilities

 

Address  Size 

Leased/Owned/

Granted

  Function  Monthly
Rent
 
11 Sawyers Peak Drive,
Goshen, NY 10924
  1,000 sq. feet  Leased  Corporate office  $0.00 
               
11F., No.36, Songren Rd., Xinyi Dist.,
Taipei City 110, Taiwan (R.O.C.)
  1,318 sq. feet  Leased  Corporate office  $5,000 

 

 9 

 

  

Government Regulation

 

Regulations by governmental authorities in the U.S. and other countries are a significant factor in developing manufacturing and marketing of our pharmaceutical products. The nature and extent to which such regulation applies to us may vary depending on the nature of our products. We anticipate that many, if not all, of our products will require regulatory approval by governmental agencies prior to commercialization. Our products are subject to rigorous pre-clinical testing and clinical trials and other approval procedures of the FDA, and similar regulatory authorities in Europe and other countries. Various governmental statutes and regulations also govern or influence clinical trials, Chemistry, Manufacture and Control (CMC) related to such products and their marketing. The approval process and subsequent compliance with related statutes and regulations require substantial time and capital commitment, and there can be no guarantee that approvals will be granted.

  

U.S. FDA Approval Process and other U.S. Regulatory Authorities

 

Prior to commencement of clinical studies, pre-clinical testing of new pharmaceutical products is generally conducted on animals in laboratories to evaluate the potential efficacy and safety of the new drug candidate. The results of these studies are submitted to the FDA as a part of an Investigational New Drug (“IND”) application, which must become effective before clinical trials. Typically, clinical trials involve a time-consuming and costly three-phase process. Phase I clinical trials are conducted on a small number of healthy human subjects to establish a safety pattern of drug distribution and metabolism within subjects’ bodies. Phase II clinical trials are conducted with groups of patients afflicted with the target disease that the new drug is designed to treat in order to determine preliminary efficacy, possible dosages and expanded evidence of safety. In some cases, an initial clinical trial is conducted on diseased patients to assess both preliminary efficacy and preliminary safety and patterns of drug metabolism and distribution, in which case such trial is referred to as a Phase I/II trial. Phase III clinical trials are large-scale, multi-center, comparative trials that are conducted on patients afflicted with a target disease in order to provide enough data to demonstrate the efficacy and safety required by the FDA. The FDA closely monitors the progress of each of the three phases of clinical testing; and may, at its discretion, re-evaluate, alter, suspend or terminate the testing based upon the data which have been accumulated to a point whereby the risk/benefit ratio of the new drug candidate is below a certain level. Monitoring of all aspects of the study to minimize risks is a continuing process. All adverse events must be reported to the FDA.

 

The results of the pre-clinical and clinical testing on a non-biologic drug and certain diagnostic drugs are submitted to the FDA in the form of a New Drug Application (“NDA”) for approval prior to commencement of commercial sales. In responding to an NDA, the FDA may grant marketing approval, request additional information or refuse to approve if the FDA determines that the application does not satisfy its regulatory approval criteria. There can be no assurance that approvals will be granted on a timely basis, if at all, for any of our proposed products.

 

We are also subject to various U.S. federal, state, local and international laws, regulations and recommendations relating to the treatment of oocyte donors, the manufacturing environment under which human cells for therapy are derived, safe working conditions, laboratory and manufacturing practices and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents. We cannot accurately predict the influence on our research operations caused by regulatory changes .

 

European and Other Regulatory Approval

 

Whether or not FDA approval has been obtained, approval of a product by comparable regulatory authorities in Europe and other countries will likely be necessary prior to commencement of marketing such product in such countries. The regulatory authorities in each country may impose their own requirements and may refuse to grant an approval, or may require additional data before approving it, even though the relevant product has been approved by the FDA or another authority. The regulatory authorities in the European Union (“EU”), Australia and other developed countries have lengthy approval processes for pharmaceutical products. The process for gaining an approval in a particular country may vary from the process in another country, but generally follows a similar sequence to that described for FDA approval. In Europe, the European Committee for Proprietary Medicinal Products provides a mechanism for EU-member states to exchange information on all aspects of product licensing. The EU has established a European agency for the evaluation of medical products, with both a centralized community procedure and a decentralized procedure, the latter being based on the principle of licensing within one member country followed by mutual recognition by the other member countries.

 

Employees

 

We have nine full-time employees and one consultant. None of our employees are represented by a labor organization and we consider our relationship with our employees to be good.

 

 10 

 

  

ITEM 1A.  RISK FACTORS

 

Discussion of our business and operations included in this Annual Report on Form 10–K should be read together with the risk factors set forth below. They describe various risks and uncertainties to which we are or may become subject. These risks and uncertainties, together with other factors described elsewhere in this report, have the potential to affect our business, financial condition, results of operations, cash flows, strategies or prospects in a material and adverse manner. New risks may emerge at any time, and we cannot predict those risks or estimate the extent to which they may affect our financial performance. Each of the risks described below could adversely impact the value of our securities. These statements, like all statements in this report, speak only as of the date of this prospectus (unless another date is indicated), and we undertake no obligation to update or revise the statements in light of future developments.

 

Risks Relating to Our Business

 

We are a pre-revenue biopharmaceutical company and are thus subject to the risks associated with new businesses in that industry.

 

We acquired the sole licensing rights to develop and commercialize for therapeutic purposes six compounds and the right to co-develop with BioFirst a medical device (the “Pipeline Products”) recently during the period of January 2017 to July 2017. As such, we are a clinical stage biopharmaceutical company with no revenue-generating operations although we have licensed three new drug candidates to Rgene for further joint development. Our assets consist solely of the intellectual property and receivables from collaboration parties, which are related parties as well. Therefore, we are, and expect to be for a period of time, subject to all the risks and uncertainties inherent in a new business, in particular new businesses engaged in the development of pharmaceuticals. We are establishing and implementing many important functions necessary to operate a business, including the clinical research and development of the Pipieline Products, establishment of our managerial and administrative structure and implementation of our accounting systems and internal controls.

 

Accordingly, you should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by pre-revenue stage companies in the pharmaceutical field. Potential investors should carefully consider the risks and uncertainties that a new company with a limited operating history faces. In particular, potential investors should consider that there are significant risks that we will not be able to:

 

  implement or execute our current business plan, or generate profits;
     
  attract and maintain a skillful management team;
     
  raise sufficient funds in the capital markets or otherwise to effectuate our business plan;
     
  determine that the processes and technologies that we have developed are commercially viable; and/or
     
  attract, enter into or maintain contracts with, potential commercial partners such as licensors of technology and suppliers.

 

 11 

 

  

If any of the above risks occurs, our business may fail, in which case you may lose the entire amount of your investment in the Company. To date, we are still setting up our pipeline products. We cannot assure that any of our efforts will be successful or result in the development or timely launch of new products, or ultimately produce any material revenue.

 

In addition, as a pre-revenue biopharmaceutical company, we need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be able to reach such transition point or make such a transition, which would have a material adverse effect on our company.

 

If we fail to raise additional capital, our ability to implement our business plan could be compromised.

 

We have limited capital resources and operations. To date, our operations have been funded partially from equity and debt financings from our shareholders or our management.

 

If we do not raise a sufficient amount to fund our ongoing development activities, it is likely that we will be unable to carry out our business. We may not be able to obtain additional financing on terms acceptable to us, or at all. Even if we obtain financing for our near term operations and product development, we may require additional capital beyond the near term. If we are unable to raise capital when needed, our business, financial condition and results of operations will be materially adversely affected, and we will have to reduce or discontinue our operations.

 

We are highly dependent on our license agreement with BioLite, and the loss of which will materially impair our business plan and viability.

 

We have secured sole rights to develop and commercialize five products from BioLite in the North America Region and the Sixth Product worldwide. These six products are currently our only new drug candidates. As such, our Collaboration Agreement with BioLite is critical to our business. In the event that our Collaboration Agreement with BioLite is terminated involuntarily, we would lose the ability to develop and commercialize all the new drug products, and our business prospects would be materially damaged, which could lead to the loss of your investment.

 

We have no history in obtaining regulatory approval for, or commercializing, any new drug candidate.

 

As a newly-incorporated company, we have never obtained regulatory approval for, or commercialized, any new drug candidate. It is possible that the FDA may refuse to accept our planned New Drug Application (or NDA) for any of the six products for substantive review, or may conclude after review of our data that our application is insufficient to obtain regulatory approval of the new drug candidates. If the FDA does not accept or approve our planned NDA for our product candidates, it may require that we conduct additional clinical, preclinical or manufacturing validation studies, which may be costly. Depending on the FDA required studies, approval of any NDA or application that we submit may be significantly delayed, possibly for several years, or may require us to expend more resources than we have. Any delay in obtaining, or inability to obtain, regulatory approvals of any of our drug candidate will prevent us from sublicensing such product. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA. If any of these outcomes occurs, we may be forced to abandon our planned NDA for such drug candidate, which materially adversely affects our business and could potentially cause us to cease operations. We face similar regulatory risks in a foreign jurisdiction.

 

Dependence on Key Personnel.

 

Our success depend, to a large degree, upon the efforts and abilities of our officers and key employees. The loss of the services of one or more of our key employees could have a material adverse effect on our operations. In addition, as our business model is implemented, we will need to recruit and retain additional management and key employees in virtually all phases of our operations. Key employees will require a strong background in the pharmaceutical industry. We cannot assure that we are able to maintain a skillful management team as we have now and will be able to successfully attract more talented and experienced key employees in the future.

 

 12 

 

   

Our growth is dependent on our ability to successfully develop, acquire or license new drugs.

 

Our growth is supported by continuous investment in time, resources and capital to identify and develop new products or new formulations for the market via geographic expansion and market penetration. If we are unable to either develop new products on our own or acquire licenses for new products from third parties, our ability to grow revenues and market share will be adversely affected. In addition, we may not be able to recover our investment in the development of new drugs and medical devices, given that projects may be interrupted, unsuccessful, not as profitable as initially contemplated or we may not be able to obtain necessary financing for such development. Similarly, there is no assurance that we can successfully secure such rights from third parties on economically feasible terms.

 

We may not be able to develop our existing licensed compounds and our business plan is entirely dependent on entering into co-development agreements with qualified pharmaceutical companies for the development or commercialization of our product candidates.

 

There is no guarantee that any of our desired results will be realized by any of our licensed product candidates. We do not have the resources to independently develop the licensed compounds and we intend to enter into co-development agreements with qualified pharmaceutical companies for the development or commercialization of our product candidates. Currently we have one co-development agreement with Rgene which is a related party to the Company. We cannot provide assurance that we will enter into other co-development agreements respecting any of our drug candidates or on desirable terms. Failure to do so may materially affect our business operations and the Company’s ability to make profits.

 

Expansion of our business may put pressure on our management and the operational infrastructure, which could impede our ability to meet an increased demand for our products.

 

Our business plan is to develop new drugs and finish Phase II clinical trials for our drug candidates. We plan to license to established pharmaceutical companies or clinics the new drug candidates, which have passed Phase II trials, for the next stage development. The advantages are

 

Growth in our business may place a significant strain on our personnel, management, financial systems and other resources. If we are successful in obtaining rapid market growth of our products, we will be required to deliver large volumes of good-quality products and services on a timely basis at a reasonable cost to the customers. Meeting any such increased demands will require us to expand our manufacturing facilities, to increase our ability to purchase raw materials, to expand our work force, to expand our quality control capabilities and to increase the scale upon which we provide our products and services.  Such demands would require more working capital than we currently have and we may not be able to meet the needs of our customers, which could adversely affect our relationship with our customers and reduce our revenues.

  

Our growth strategy includes the pursuit of acquisitions, and new product development, which could have a materially adverse effect on our business, financial condition, results of operations and growth prospects.

 

Our business strategy includes growth through strategic acquisitions, and the development of new products, medical devices and technologies, which will involve significant capital expenditure and risks. Innovative pharmaceutical development involves R&D costs, but it may achieve no tangible results and instead may adversely affect our future profitability. In addition, any business acquisition or combination that we consummate will likely involve, among other things, the payment of cash, the incurrence of contingent liabilities and the amortization of expenses related to goodwill and other intangible assets, and transaction costs, which may adversely affect our business, financial condition, results of operations and growth prospects. Our ability to integrate and organize any new businesses and/or products, whether internally or externally, will likely require significant expansion of our operations. There is no assurance that we will be able to obtain the necessary resources for such expansion, and the failure to do so could have a materially adverse effect on our business, financial condition, results of operations and growth prospects.  In addition, future acquisitions or combinations by us involve risks of, among other things, entering into markets or segments in which we have no or limited experience, the potential loss of key employees, difficulty, delay or failure in the integration of the operations of any such new business with our current business, and operating and financial difficulties of any new operations, any of which could have a materially adverse effect on our business, financial condition, results of operations and growth prospects.  Moreover, there can be no assurance that the anticipated benefits of any internally developed new business segment or business combination will be realized.

 

 13 

 

  

Our current products have certain side effects.  If the side effects associated with our current or future products are not identified prior to their marketing and sale, we may be required to withdraw such products from the market, perform lengthy additional clinical trials or change the labeling of our products, any of which could adversely impact our growth.

 

Side effects associated with ABV-1501 and ABV-1502 “Maitake mushroom extract” include nausea, joint swelling, rash, pruritus, eosinophilia, diarrhea, fainting, pain and/or bruising. Serious adverse events associated with this compound are listed below and further detailed here: https://clinicaltrials.gov/show/NCT01099917. Pruritus means itching (according to WebMD) and is defined as an unpleasant sensation that provokes the desire to scratch (according to Medscape). Eosinophilia is defined as an increase in peripheral blood eosinophilic leukocytes to more than 600 cells per microliter (μL) of blood. Emphasis is placed on the number of eosinophils circulating in the peripheral blood. Parasitic diseases and allergic reactions to medication are among the more common causes of eosinophilia. Eosinophils are derived from hematopoietic stem cells initially committed to the myeloid line and then to the basophil-eosinophil granulocyte lineage. Nonpathologic functions of eosinophils and the cationic enzymes of their granules include mediating parasite defense reactions, allergic response, tissue inflammation, and immune modulation. The foregoing information was collected from the Mayo Clinic and Medscape.

 

According to the MSKCC clinical trial on Myelodysplastic Syndrome (MDS), “Maitake mushroom extract,” only two patients withdrew prior to completion of the study due to grade I possibly related side effects: one reported nausea and joint swelling; the other withdrew reportedly due to a grade I allergic reaction (rash and pruritus). Other serious side events were not reported in the journal, as they were determined not relevant to this product after careful review by the principal investigator.

 

The following serious adverse events were observed in one out of twenty-one participants, or at a rate of 4.76%: Total, serious adverse events, Leukocytosis, Platelet count decreased, Eye disorders – Other, Abdominal pain, Gastrointestinal disorders – Other, Aphonia, Lung infection, Muscle weakness right-sided, Confusion, Edema cerebral, Stroke, Dyspnea, Wheezing and Pruritus (itching).

  

Side effects associated with ABV-1504 and ABV-1505 “Radix Polygalae (Polygala tenuifolia Willd/PDC-1421 Capsule)” may come from administration of the study medicine or examination procedure, such as the procedure of taking blood (fainting, pain and/or bruising). You may find other side effects in this paper: Preclinical evidence of rapid-onset antidepressant-like effect in Radix Polygalae extract.

 

According to the “Phase I Study of PDC-1421” “Radix Polygalae (Polygala tenuifolia Willd/PDC-1421 Capsule)” by BioLite, radix polygalae has no serious adverse effects but did have adverse events, but such adverse events may not be the result of a causal relationship with the study medication or clinical study.

 

Serious Adverse Events

 

   PDC-1421  Placebo Control
Total, serious adverse events      
# participants affected / at risk  0/23 (0.00%)   0/7 (0.00%)

 

 14 

 

  

Other Adverse Events

 

   PDC-1421   Placebo Control 
Total, other (not including serious) adverse events        
# participants affected / at risk   3/23 (13.04%)    2/7 (28.57%) 
Gastrointestinal disorders          
Abdominal fullness *[2]           
# participants affected / at risk   2/23 (8.70%)    1/7 (14.29%) 
# events   2    1 
Constipation *[3]           
# participants affected / at risk   1/23 (4.35%)    0/7 (0.00%) 
# events   1    0 
Nervous system disorders          
Drowsiness *[4]           
# participants affected / at risk   0/23 (0.00%)    1/7 (14.29%) 
# events   0    1 
Sleepiness * [5]           
# participants affected / at risk   1/23 (4.35%)    1/7 (14.29%) 
# events   1    1 
Oral ulcer *[6]           
# participants affected / at risk   1/23 (4.35%)    0/7 (0.00%) 
# events   1    0 

 

  PDC-1421 was observed to be associated with some adverse effects in serum electrolytes and GI function, but none were clinically significant. Therefore, potential risks of PDC-1421 are fluctuated electrolyte levels and gastrointestinal discomfort. We monitored these in the Phase I study and there was no deviation of electrolyte level and no significant gastrointestinal discomfort during monitoring in the clinical trial. The cardiovascular systems will be monitored in the clinical study.

 

  WebMD warns that radix polygalae, when ingested on a long-term basis, can be unsafe, and that it is unsafe to ingest for pregnant women because it can cause miscarriages. Other adverse effects of radix polygalae described on medical education websites like WebMD and Medscape include nausea, vomiting and uterus contraction. None of the foregoing effects are applicable to our product candidate because the dosage of radix polygalae used in our product candidate is smaller than would be necessary to trigger these effects.

   

If significant side effects of our medicines are identified after they are marketed and sold:

 

  1) regulatory authorities may withdraw or modify their approvals of such medicines;

 

  2) we may be required to reformulate these medicines, change the ways in which they are marketed, conduct additional clinical trials, change the labeling of these medicines or implement changes to obtain new approvals for our manufacturing facilities;

 

  3) we may have to recall these medicines from the market and may not be able to re-launch them;

 

  4) we may experience a significant decline in sales of the affected products;

 

  5) our reputation may suffer; and

 

  6) We may become a target of lawsuits.

 

The occurrence of any of these events would harm our sales of these medicines and substantially increase the costs and expenses of marketing these medicines, which in turn could cause our revenues and net income to decline. In addition, the reputation and sales of our medicines could be adversely affected due to the severe side effects discovered.

 

 15 

 

  

We may be subject to product liability claims in the future, which could divert our resources, incur substantial liabilities and limit commercialization of any products that we may develop.

 

We face an inherent business risk of exposure to product liability claims in the event that the uses of our products are alleged to have caused adverse side effects. Side effects or marketing or manufacturing problems pertaining to any of our products could result in product liability claims or adverse publicity. These risks will exist for those products in clinical development and with respect to those products that receive regulatory approval for commercial sale.  Furthermore, although we have not historically experienced any problems associated with claims by users of our products, we do not currently maintain product liability insurance and there could be no assurance that we are able to acquire product liability insurance with terms that are commercially feasible.

 

We face an inherent risk of product liability claims as a result of the clinical testing of our products and potentially commercially selling any products that we may develop. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidate. Regardless of the merits or eventual outcome, liability claims may result in:

 

  decreased demand for our product candidate or products that we may develop;
     
  injury to our reputation and significant negative media attention;
     
  withdrawal of clinical trial participants;

 

  significant costs to defend resulting litigation;
     
  substantial monetary awards to trial participants or patients;
     
  loss of revenue;
     
  reduced resources of our management to pursue our business strategy; and
     
  the inability to commercialize any products that we may develop.

 

We currently do not maintain general liability insurance; and even if we have a general liability insurance in the future this insurance may not fully cover potential liabilities that we may incur. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. We will need to increase our insurance coverage if and when we begin selling any product candidate that receives marketing approval. In addition, insurance coverage is becoming increasingly expensive. If we are unable to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development and commercial production and sale of our product candidates, which could adversely affect our business, financial condition, results of operations and prospects.

 

If we are unable to keep up with rapid technological changes in our field or compete effectively, we will be unable to operate profitably.

 

We are engaged in a rapidly changing field. Other products of similar functions and targeted indications will compete with our new drug candidates. Most of our competing companies have significantly greater financial resources and expertise in discovery and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing. Certain medium and small companies may also be significant competitors, particularly through collaborative arrangements with established biopharmaceutical or biotechnology companies. Many of these competitors have products that have been approved or have sufficient capital to finance the discovery and development programs. Academic institutions, governmental agencies and other public and private research organizations also conduct research, seek patent protection and establish collaborative arrangements for therapeutic products and clinical development and marketing. These companies and institutions compete with us in recruiting and retaining highly qualified scientific and management personnel. In addition to the above factors, we will face competition based on product efficacy and safety, the timing and scope of regulatory approvals, availability of supply, marketing and sales capability, reimbursement coverage, price and patent position. There is no assurance that our competitors will not develop more effective or more affordable products, or achieve earlier patent protection or product commercialization, than our own.

 

 16 

 

  

Other companies may succeed in developing proof of concept (POC) earlier than us respecting similar new drug candidates, obtaining FDA approvals for such products more rapidly than we will. While we will seek to expand our technological capabilities in order to remain competitive, there can be no assurance that research and development by others will not render our technology or products obsolete or non-competitive or result in treatments or cures superior to any therapy we develop, or that any therapy we develop will be preferred to any existing or newly developed technologies.

 

We have conducted, and may in the future conduct, clinical trials for our certain new drug candidates at sites outside the United States, as a result of which the FDA may not accept data from trials conducted in such locations.

 

We have conducted and may in the future choose to conduct one or more clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of such data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. Generally, the patient population for any clinical trials conducted outside of the United States must be representative of the population for whom we intend to seek approval in the United States. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its determination that the trials also complied with all applicable U.S. laws and regulations. There can be no assurance that the FDA will accept data from trials conducted outside the United States. If the FDA does not accept the data from any of our clinical trials that we conduct outside the United States, it is likely to result in the need for additional trials, which are costly and time-consuming and delay or permanently halt our development of the new drug candidates.

  

In addition, the conduct of clinical trials outside the United States could have a significant impact on us. Risks inherent in conducting clinical trials outside the United States include:

 

  foreign regulatory requirements that could restrict or limit our ability to conduct our clinical trials;
     
  administrative burdens of conducting clinical trials under multiple foreign regulatory schema;
     
  foreign exchange fluctuations; and
     
  diminished protection of intellectual property in some countries.

 

If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA and comparable foreign regulators, we may incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our product candidates.

 

We are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Comparable non-U.S. regulatory authorities impose similar restrictions. We may never receive such approvals. We must complete extensive preclinical development and clinical trials to demonstrate the safety and efficacy of our product candidate before we will be able to obtain these approvals.

 

 17 

 

  

Clinical testing is expensive, inherently uncertain, difficult to design and implement and can take many years to complete. Any inability to successfully complete preclinical and clinical development could result in additional costs to us and impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties. In addition, if (1) we are required to conduct additional clinical trials or other testing of our product candidate beyond the trials and testing that we contemplate, (2) we are unable to successfully complete clinical trials of any of our product candidates or other testing, (3) the results of these trials or tests are unfavorable, uncertain or are only modestly favorable, or (4) there are unacceptable safety concerns associated with any of our product candidates, we, in addition to incurring additional costs, may:

 

  be delayed in obtaining marketing approval for our product candidates;

 

  not obtain marketing approval at all;

 

  obtain approval for indications or patient populations that are not as broad as we intended or desired;

 

  obtain approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including boxed warnings;

 

  be subject to additional post-marketing testing or other requirements; or

 

  be required to remove the product from the market after obtaining marketing approval.

  

Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third party payors and others in the medical community necessary for commercial success and the market opportunity for the product candidate may be smaller than we estimate.

 

We have never commercialized a new drug product. Even if our products are approved by the appropriate regulatory authorities for marketing and sale, they may nonetheless fail to gain sufficient market acceptance from physicians, patients, third party payors and others in the medical community. For example, doctors may be reluctant to recommend to their patients our new drugs even when our new drugs offer effective or convenient treatments. Further, patients often acclimate to the therapy that they are currently taking and do not want to switch therapies.

 

Efforts to educate the medical community and third party payors on the benefits of our new drug candidates may require significant resources and may not be successful. If our product candidates are approved but do not achieve an adequate level of market acceptance, we may not generate significant revenues and may not become profitable. The degree of market acceptance of our products, if approved for commercial sale, will depend on a number of factors, including:

 

  the efficacy and safety of our drug candidates;

 

  the potential advantages of our drug candidates compared to alternative treatments;

 

  the prevalence and severity of any side effects;

 

  the clinical indications for which our drug candidates are approved;

 

  whether our drug candidates are designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy;

 

  limitations or warnings, including distribution or use restrictions, contained in our drug candidates approved for labeling;

 

  our ability to offer our drug candidates for sale at competitive prices;

 

  our ability to establish and maintain pricing sufficient to realize a meaningful return on our investment;

 

  our drug candidates’ convenience for administration compared to alternative treatments;

 

  the willingness of the target patient population to try, and of physicians to prescribe, our drug candidates;

 

  the strength of sales, marketing and distribution support;

 

  the approval of other new products for the same indications;

 

 18 

 

  

  changes in the standard of care for the targeted indications for our drug candidates;

 

  the timing of market introduction of our approved products as well as competitive products and other therapies;

 

  availability and amount of reimbursement from government payors, managed care plans and other third party payors;

 

  adverse publicity about the products or favorable publicity about competitive products; and

 

  potential product liability claims.

  

The potential market opportunities for our drug candidates are difficult to estimate. Our estimates of the potential market opportunities are predicated on many assumptions, including industry knowledge and publications, third party research reports and other surveys. While we believe that our internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain and the reasonableness of these assumptions has not been assessed by an independent source. If any of the assumptions proves to be inaccurate, the actual markets for our new drug candidates could be smaller than our estimates of the potential market opportunities.

 

We rely on a limited number of suppliers to provide and process the raw materials for our drug candidates and the loss of any of our suppliers, or delays or problems in the supply of materials used in our products, could materially and adversely affect our operations.

 

We generally rely on a limited number of suppliers for most of the primary materials used in our products.  Our suppliers may not be able to supply the necessary materials without interruption and we may not have adequate remedies for such failure, which could result in a shortage of supply for our new drug candidates.  If one of our suppliers fails or refuses to supply us for any reason, it could take time and capital for us to obtain a new supplier.  In addition, our failure to maintain existing relationships with our suppliers or to establish new relationships in the future could negatively affect our ability to obtain the materials used in our products in a timely manner.  The search for new suppliers could potentially delay the manufacture of the new drug candidates for research and trials.  If any of our suppliers fails to comply with applicable legal requirements, such supplier will be subject to possible legal or regulatory action, which may adversely affect their ability to supply us with the raw or processed materials.  Any delay in supplying, or failure to supply, materials for our new drug candidates by any of our suppliers could result in our inability to meet the schedule for our research and development, and could adversely affect our business and operations.

 

We may seek to enter into collaborative relationships with third parties for the development and commercialization of our product candidates. If we fail to enter into such collaborations, or such collaborations are not successful, we may not be able torealize profits from our drug candidates.

 

We may seek third-party collaborators for development and commercialization of our new drug candidates. We are seeking large and mid-size pharmaceutical companies, regional and national pharmaceutical companies, non-profit organizations, government agencies, and biotechnology companies as collaborators for any marketing, distribution, development, licensing or broader collaboration arrangements for our new drug candidates. Our ability to generate revenues from these arrangements will depend on our collaborators’ abilities to successfully perform the functions assigned to them in these arrangements.

 

Collaborative development of our products will pose the following risks to us:

 

  collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations;

 

  collaborators may not pursue development and commercialization of our product candidate or may elect not to continue or renew development or commercialization programs based on preclinical or clinical trial results, changes in the collaborators’ strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;

 

 19 

 

  

  collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;

 

  collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidate if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;

 

  collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;

  

  collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;

 

  collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;

 

  disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidate or that result in costly litigation or arbitration that diverts management attention and resources; and

 

  collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.

 

Collaboration agreements may not lead to development or commercialization of our product candidate in the most efficient manner or at all. If a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated.

 

We are dependent on obtaining certain patents and protecting our proprietary rights.

 

Our success will depend, in part, on our ability to obtain patents, maintain trade secret protection and operate without infringing on the proprietary rights of third parties or having third parties circumvent our rights. We are licensing patented technologies for our products. The patent positions of biotechnology, biopharmaceutical and pharmaceutical companies can be highly uncertain and involve complex legal and factual questions. Thus, there can be no assurance that any of our patent applications will result in the issuance of patents, that we will develop additional proprietary products that are patentable, that any patents issued to us or those that already have been issued will provide us with any competitive advantages or will not be challenged by any third parties, that the patents of others will not impede our ability to do business or that third parties will not be able to circumvent our patents. Furthermore, there can be no assurance that others will not independently develop similar products, duplicate any of our products not under patent protection, or, if patents are issued to us, design around the patented products we developed or will develop.

  

We may be required to obtain licenses from third parties to avoid infringing patents or other proprietary rights. No assurance can be given that any licenses required under any such patents or proprietary rights would be made available, if at all, on terms we find acceptable. If we do not obtain such licenses, we could encounter delays in the introduction of products or could find that the development, manufacture or sale of such products prohibitive.

 

A number of pharmaceutical, biopharmaceutical and biotechnological companies and research and academic institutions have developed technologies, filed patent applications or received patents on various technologies that may be related to or affect our business. Some of these technologies, applications or patents may conflict with our technologies or patent applications. Such conflict could limit the scope of the patents, if any, that we may obtain or result in the denial of our patent application. In addition, if patents that cover our activities are issued to other companies, there can be no assurance that we will be able to obtain licenses to these patents at a reasonable cost or be able to develop or obtain alternative technology. If we do not obtain such licenses, we will encounter delays in the introduction of products, or could find that the development, manufacture or sale of products requiring such licenses could be prohibited. In addition, we could incur substantial costs in defending ourselves in suits brought against us regarding potential patent infringement.

 

 20 

 

  

We are subject to various government regulations.

 

The manufacture and sale of therapeutic and diagnostic products in the U.S. and foreign jurisdictions are governed by a variety of statutes and regulations. These laws require approval of manufacturing facilities, controlled research and testing of products and government review and approval of a submission containing manufacturing, preclinical and clinical data in order to obtain marketing approval based on establishing the safety and efficacy of the product for each use sought, including adherence to current PIC/S Guide to Good Manufacturing Practice for Medicinal Products during production and storage, and control of marketing activities, including advertising and labeling.

 

The new drug candidates we are currently developing require significant preclinical and clinical testing and investment of substantial funds prior to its commercialization. The process of obtaining required approvals can be costly and time-consuming, and there can be no assurance that the new drugs will be successfully developed and receive applicable regulatory approvals. Foreign regulatory authorities have similar restrictions. Potential investors and shareholders should be aware of the risks, problems, delays, expenses and difficulties which we may encounter in view of the extensive regulatory environment which governs our business.

 

Our existing indebtedness may adversely affect our ability to obtain additional funds and may increase our vulnerability to economic or business downturns.

 

We are subject to a number of risks associated with our indebtedness, including: 1) we must dedicate a portion of our cash flows from operations to pay debt service costs, and therefore we have less funds available for operations and other purposes; 2) it may be more difficult and expensive to obtain additional funds through financings, if available at all; 3) we are more vulnerable to economic downturns and fluctuations in interest rates, less able to withstand competitive pressures and less flexible in reacting to changes in our industry and general economic conditions; and 4) if we default under any of our existing credit facilities or if our creditors demand payment of a portion or all of our indebtedness, we may not have sufficient funds to make such payments. As of December 31, 2017, our outstanding debt was $4,229,320 which was due to related parties.

 

We have recurring losses from operations and a significant accumulated deficit. In addition, we continue to experience negative cash flows from operations. These factors raise substantial doubt about our ability to continue as a going concern. If we do not generate revenues, do not achieve profitability and do not have other sources of financing for our business, we may have to curtail or cease our development plans and operations, which could cause investors to lose the entire amount of their investment. With the doubt about our ability to continue as a going concern, we may also face difficulties to raise additional funds.

 

If we are unable to establish appropriate internal financial reporting controls and procedures, it could cause us to fail to meet our reporting obligations, result in the restatement of our financial statements, harm our operating results, subject us to regulatory scrutiny and sanction, cause investors to lose confidence in our reported financial information and have a negative effect on the market price of our Common Stock.

 

Effective internal controls are necessary for us to provide reliable financial reports and effectively prevent fraud. We maintain a system of internal control over financial reporting, which is defined as a process designed by, or under the supervision of, our principal executive officer and principal financial officer, or persons performing similar functions, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

  

 21 

 

 

We cannot assure you that we will not, in the future, identify areas requiring improvement in our internal control over financial reporting.  We cannot assure you that the measures we will take to remediate any areas in need of improvement will be successful or that we will implement and maintain adequate controls over our financial processes and reporting in the future as we continue our growth.  If we are unable to establish appropriate internal financial reporting controls and procedures, it could cause us to fail to meet our reporting obligations, result in the restatement of our financial statements, harm our operating results, subject us to regulatory scrutiny and sanction, cause investors to lose confidence in our reported financial information and have a negative effect on the market price for shares of our Common Stock.

 

Risks Relating to Our Securities

 

Insiders have substantial control over us, and they could delay or prevent a change in our corporate control even if our other stockholders wanted it to occur.

 

Our executive officers, directors, and principal stockholders own, in the aggregate, approximately 69.17% of our outstanding Common Stock. As a result of their stockholdings, these stockholders are able to assert substantial control over matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This could delay or prevent an outside party from acquiring or merging with us even if our other stockholders wanted it to occur.

 

The market price of our Common Stock may be volatile and there may not be sufficient liquidity in the market for our securities in order for investors to sell their securities.

 

The market price of our Common Stock has been and will likely continue to be highly volatile, as is the stock market in general. Factors that may materially affect the market price of our Common Stock are beyond our control, these factors may materially adversely affect the market price of our Common Stock, regardless of our performance.  In addition, the public stock markets have experienced extreme price and trading volume volatility. These broad market fluctuations may influence the market price of our Common Stock. There is currently only a limited public market for our Common Stock, which is listed on the OTCQB Market, and there can be no assurance that a trading market will develop further or be maintained in the future.

  

Our articles of incorporation allow for our board to create new series of preferred stock without further approval by our stockholders, which could adversely affect the rights of the holders of our common stock.

 

Our Board of Directors has the authority to fix and determine the relative rights and preferences of preferred stock without stockholder approval. As a result, our Board of Directors could authorize the issuance of a series of preferred stock that would grant to holders the preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders of common stock and the right to the redemption of the shares, together with a premium, prior to the redemption of our common stock. In addition, our Board of Directors could authorize the issuance of a series of preferred stock that has greater voting power than our common stock or that is convertible into our common stock, which could decrease the relative voting power of our common stock or result in dilution to our existing stockholders. Although we have no present intention to issue any additional shares of preferred stock or to create any additional series of preferred stock, we may issue such shares in the future. 

 

Our independent auditors have issued an audit opinion for our company, which includes a statement describing our going concern status. Our financial status creates a doubt whether we will continue as a going concern.

 

Our auditors have issued a going concern opinion regarding our company. This means there is substantial doubt we can continue as an ongoing business for the next twelve months. The financial statements do not include any adjustments that might result from the uncertainty regarding our ability to continue in business. As such we may have to cease operations and investors could lose part or all of their investment in our company.

 

 22 

 

  

There is not now and may not be an active liquid trading market for the Company’s Common Stock.

 

There is no established active public trading market for the Company’s Common Stock. We cannot provide assurance that we will develop an active trading market for the Common Stock. Without an active market, the liquidity of the Common Stock will remain limited.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

Not applicable to us since we are not an accelerated filer, a large accelerated filer or a well-known seasoned issuer under SEC rules.

  

ITEM 2. PROPERTIES

 

Our Facilities

 

Address  Size  Leased/Owned/Granted  Function  Monthly
Rent
 
11 Sawyers Peak Drive,
Goshen, NY 10924
  1,000sq. feet  Leased  Corporate office  $0.00 
               

11F., No.36, Songren Rd., Xinyi Dist.,

Taipei City 110, Taiwan (R.O.C.)

  1,318sq. feet  Leased  Office space  $825.00 

 

ITEM 3.  LEGAL PROCEEDINGS

  

We filed for Chapter 7 bankruptcy protection on May 15, 2013 and subsequently the corporate shell emerged as its only unencumbered asset on September 19, 2014 using "fresh start" accounting under section 852-10-45-17 as of date of sale of the corporate shell to reflect an intangible assets sale through section 363 of the US bankruptcy code.  Any business description below and all reporting results of the operating results reported in this filing for the fiscal year ending September 30, 2016 and 2015 are post "fresh start" activity and not comparable to prior results. Post-bankruptcy we have been operating a web site for the sale of women's apparel. Other than disclosed herein, we are currently not a party to any material legal or administrative proceedings and are not aware of any pending legal or administrative proceedings against us. We may from time to time become a party to various legal or administrative proceedings arising in the ordinary course of our business.

 

ITEM 4.  MINE SAFETY DISCLOSURES.

 

Not applicable

 

 23 

 

  

PART II

 

ITEM 5.  MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Item 5(a)

 

a)  Market Information.  Our common stock, par value $.001 per share (the “Common Stock”), is currently quoted on the OTCQB under the symbol “ABVC”.

 

The following table sets forth the range of high and low bid quotations for our common stock.  The quotations represent inter-dealer prices without retail markup, markdown or commission, and may not necessarily represent actual transactions.

 

Quarter Ended  High Bid  Low Bid
       
3/31/17  2.00  2.00
6/30/17  2.00  2.00
9/30/17  2.00  2.00
12/31/2017  2.00  2.00
       
3/31/16  0.01  0.00
6/30/16  0.00  0.00
9/30/16  2.00  1.50
12/31/16  2.00  2.00

 

b)  Holders.  As of March 28, 2018, we had approximately 169 shareholders of record of our common stock.  

 

c)  Dividends.  Holders of our common stock are entitled to receive such dividends as may be declared by our board of directors.  No dividends on our common stock have ever been paid, and we do not anticipate that dividends will be paid on our common stock in the foreseeable future.

 

d)  Securities authorized for issuance under equity compensation plans.  On February17, 2016, pursuant to the 2016 Equity Incentive Plan (the “2016 Plan”), 157,050 (50,000 pre-stock split shares) shares were granted to the employees.

 

e)  Performance graph.  Not applicable.

 

f) Sale of unregistered securities.   

 

On February 23, 2017, the Company issued an aggregate of 2,925,000 shares valued at a price of $2.00 per share to BioLite, Inc. in satisfaction of its milestone payment obligation upon BioLite’s IND submission for BLI-1005 for treatment of major depressive disorder to the FDA pursuant to the BioLite Collaboration Agreement and the Milestone Payment Agreement.

 

ITEM 6  SELECTED FINANCIAL DATA

 

Not applicable since we are a smaller reporting company as defined under the applicable SEC rules.

 

ITEM 7.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion provides information which management believes is relevant to an assessment and understanding of our results of operations and financial condition. The discussion should be read along with our consolidated financial statements for the three months ended December 31, 2017 and years ended September 30, 2017 and 2016, and notes thereto contained elsewhere in this Report, and our annual report on Form 10--K for the period ended December 31, 2017. The following discussion and analysis contains forward-looking statements, which involve risks and uncertainties. Our actual results may differ significantly from the results, expectations and plans discussed in these forward-looking statements. See “Cautionary Note Concerning Forward-Looking Statements.”

 

As used in this Report, the terms “we”, “us”, “our”, and “our Company” and “the Company” refer to American BriVision (Holding) Corporation (formerly known as Metu Brands, Inc.) and its subsidiaries, unless otherwise indicated.

 

 24 

 

  

Introduction

 

Currently, we are a holding company operating through our wholly owned subsidiary, American BriVision Corporation, a Delaware corporation (“BriVision”). BriVision was incorporated in 2015 in the State of Delaware. It is a biotechnology company focused on the development of new drugs and innovative medical devices to fulfill unmet medical needs.  Following the Share Exchange (as described herein below), we have abandoned our prior business plan and we are now pursuing BriVision’s historical businesses and proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs.  Our business model is to integrate research achievements from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept (“POC”), out-license to international pharmaceutical companies, and exploit global markets.

  

Overview

 

Prior to the Share Exchange, we were a company operating a web site for the sale of women's apparel.

 

We have had limited operations and have been issued a "going concern" opinion by our auditor, based upon our reliance on the sale of our common stock as the sole source of funds for our future operations.

 

On February 8, 2016, a Share Exchange Agreement (“Share Exchange Agreement”) was entered into by and among American BriVision (Holding) Corporation (the “Company”), American BriVision Corporation, a Delaware Corporation (“BriVision”), Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People's Republic of China (“Euro-Asia”), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock of the Company, and the persons listed in Exhibit A thereof (the “BriVision Shareholders”), being the owners of record of all of the issued share capital of BriVision (the “BriVision Stock”).

 

Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issued 166,273,921(52,936,583 pre-stock split) shares (the “Acquisition Stock”) (subject to adjustment for fractionalized shares as set forth below) of the Company’s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company’s common stock owned by Euro-Asia should be cancelled and retired to treasury.

 

The Acquisition Stock collectively represented 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of BriVision’s common stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583 pre-stock split) shares of Company’s common stock and BriVision became a wholly owned subsidiary, of the Company. The holders of the Company’s common stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of the Company’s common stock. Because of the exchange of the BriVision Stock for the Acquisition Stock (the “Share Exchange”), BriVision became a wholly owned subsidiary (the “Subsidiary”) of the Company and there was a change of control of the Company following the closing.  There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.

 

As a result of the consummation of the Share Exchange, BriVision is now our wholly-owned subsidiary and its shareholders own approximately 79.70% of our issued and outstanding common stock.

 

All references to the “Combined Company” refer to American BriVision (Holding) Corporation and its wholly owned subsidiary, American BriVision Corporation.

 

 25 

 

  

Accounting Treatment of the Merger

 

For financial reporting purposes, the Share Exchange represented a “reverse merger” rather than a business combination and BriVision was deemed to be the accounting acquirer in the transaction. The Share Exchange was accounted for as a reverse-merger and recapitalization. BriVision is the acquirer for financial reporting purposes and the Company is the acquired company. Consequently, the assets and liabilities and the operations that are reflected in the historical financial statements prior to the Share Exchange are those of BriVision and are recorded at the historical cost basis of BriVision, and the consolidated financial statements after completion of the Share Exchange includes the assets and liabilities of the Company and BriVision, and the historical operations of BriVision and operations of the combined entities (American Brivision (Holding) Corporation and its wholly owned subsidiary Brivision) from the closing date of the Share Exchange.

 

For more information about the Share Exchange, please refer to the current report on Form 8-K filed on February 12, 2016.

  

Following the Share Exchange, we have abandoned our prior business plan and we are now pursuing BriVision’s historical businesses and proposed businesses. BriVision is a biotechnology company focused on the development of new drugs to fulfill unmet medical needs.  Our business model is integrating research achievements from world-famous institutions, such as Memorial Sloan Kettering Cancer Center (“MSKCC”) and MD Anderson Cancer Center, conducting clinical trials for Proof of Concept (“POC”), out-licensing to pharmaceutical companies.

 

We currently have seven products that are licensed to us:

 

  ABV-1501 Triple Negative Breast Cancer - Combination therapy for Triple Negative Breast Cancer (TNBC)
     
  ABV-1502 Solid Tumor with Anti-PD1 - Combination therapy for solid tumors
     
  ABV-1503 Chronic Lymphocytic Leukemia - Combination therapy for Chronic Lymphocytic Leukemia
     
  ABV-1504 Major Depressive Disorder - Major Depressive Disorder (MDD)
     
  ABV-1505 Attention Deficit Hyperactivity Disorder - Attention Deficit Hyperactivity Disorder
     
  Maitake Combination Therapy
     
  BFC-1401 Vitreous Substitute for Vitrectom (“BFC-1401”)

 

Except ABV-1502, the rest of the six new drug candidates all are ready to go into phase II clinical study. ABV-1504 already started its phase II clinical study in Taiwan and we expect it will start the clinical trials in the United States soon.  ABV-1505 received IND Phase II clinical trial approval by the U.S. FDA on January 2016.  ABV-1501’s Phase II IND was approved in March 2016.  ABV-1502 and ABV-1503 are preparing IDE packages now.

 

Recent Developments

 

Forward Stock Split

 

On March 21, 2016, our Board approved an amendment to our Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which became effective on April 8, 2016. The amendment to our Articles of Incorporation was approved by the majority of the shareholders of the Company.

 

Collaborative Agreement

 

On December 29, 2015, BriVision, our wholly-owned subsidiary, entered into a Collaboration Agreement with BioLite, of which Eugene Jiang, our chairman, is a director and principal shareholder. Pursuant to the Collaboration Agreement, BioLite granted BriVision sole licensing rights for drug and therapeutic use of five products (the “Products”): BLI-1005 CNS-Major Depressive Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity Disorder; BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1; BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer, BLI-1501 Hematology-Chronic Lymphocytic Leukemia in the U.S. and Canada.

 

 26 

 

  

This Collaborative Agreement has a term of fifteen years from the first commercial sales of the Products in the U.S. or Canada and automatically renews for five more years unless either party gives the other party six month written notice of termination prior to the expiration date of the term.

 

Pursuant to the Collaborative Agreement, an upfront payment of $3,500,000 (the “Milestone Payment”), which is 3.5% of total payments due under the Collaborative Agreement, was to be paid upon execution of that agreement.

 

 Under the Collaborative Agreement, BriVision is obligated to pay a total of up to $100,000,000 in cash or stock of BriVision with equivalent value, according to the following schedule:

 

  upfront payment waspayable upon the signing of this Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week.

 

  upon the first IND submission, BriVision was obligated to pay, but no later than December 15, 2016: 6.5% of total payment. After receiving the second payment from BriVision, BioLite has to deliver the IND package to BriVision in one week.

 

  at the completion of first phase II clinical trial, BriVision was obligated to pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver the phase II clinical study report to BriVision in three months.

  

  upon the phase III IND submission, BriVision is obligated to pay, but no later than December 15, 2018: 20% of total payment. After receiving the fourth payment from BriVision, BioLite has to deliver the  IND package to BriVision in one week.

 

  at the completion of phase III, BriVision is obliged to pay, but no later than September 15, 2019: 25% of total payment. After receiving the fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months.

 

  upon the NDA submission, BriVision obliged to pay, but no later than December 15, 2020, 30% of total payment. After receiving the sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week.

 

On May 6, 2016, we and Biolite entered into the Milestone Payment Agreement in order to amend the Collaborative Agreement, whereby BriVision has agreed to pay the Milestone Payment to BioLite as in the form of $2,600,000 in cash and $900,000 in newly issued shares of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares.

 

Under the Collaborative Agreement, BioLite is also entitled to 5% of net sales of the Products. There have not been any commercial sales since the Collaborative Agreement became effective. 

 

As our collaboration with BioLite continues under the Collaborative Agreement, we intend to work together to select potential drug candidates (including but not limited to botanical drugs) from different research institutes, start to develop it from pre-clinical stage (including all CMC process and animal study) to clinical study stage. When the phase II clinical trial is finished and the efficacy is approved, we will have reached the “proof of concept” stage. We then plan to out license our drugs to big pharmaceutical companies, coordinate with them to develop and enhance the drugs and exploit global markets.

 

 27 

 

  

On January 12, 2017, we entered into an Addendum (the “Addendum”) to the Collaboration Agreement dated December 29, 2015 and as amended May 6, 2016. Pursuant to the Addendum, BioLite agreed to license us to research and develop an additional new drug, “Maitake Combination Therapy” (the “Sixth Product”) worldwide. The ownership of any clinical trial data and Intellectual Property as defined in the Collaboration Agreement shall belong to us. We shall pay for all clinical trials and other expenses associated with all clinical trials and shall have the right to sublicense Five Products in the North America Region and the Sixth Product worldwide. There is no additional Milestone Payments as defined in paragraph 3 of the Collaboration Agreement that need to be made now or in the future with respect to the Sixth Product. In the event that BioLite is obligated to pay its licensor in excess of 3% of the net sales, BioLite and us shall renegotiate and increase the Royalty Charge to a percentage to be later agreed upon as opposed to the original amount of 5% of the net sales as defined in paragraph 4 of the Collaboration Agreement.

 

On July 24, 2017, BriVision, one of our wholly-owned subsidiaries entered into a collaboration agreement (the “BioFirst Agreement”) with BioFirst Corporation (“BioFirst”), a corporation incorporated under the laws of Taiwan, pursuant to which BioFirst granted BriVision the global license to co-develop BFC-1401 Vitreous Substitute for Vitrectom (“BFC-1401”) for medical purposes. BioFirst is a related party to the Company because BioFirst and Yuangene Corporation (“Yuangene”), the Company’s controlling shareholder, are under common control of the controlling beneficiary shareholder of Yuangene.

 

According to the BioFirst Agreement, we co-develop and commercialize BFC-1401 with BioFirst and should pay BioFirst $3,000,000 (the “Total Payment”) in cash or common stock of the Company on or before September 30, 2018 in two installments. An upfront payment of $300,000, representing 10% of the Total Payment due under the Collaboration Agreement, was paid upon execution of the Collaboration Agreement. The Company is entitled to receive 50% of the future net licensing income or net sales profit when BFC-1401 is sublicensed or commercialized. For more information about the BioFirst Agreement, please refer to the current report on Form 8-K filed on July 24, 2017.  

 

Co-development Agreement with Rgene

 

On May 26, 2017, BriVision entered into a co-development agreement (the “Co-Dev Agreement”) with Rgene Corporation, a corporation incorporated under the laws of Taiwan (“Rgene”), to co-develop and commercialize in the global markets three new drug products that are included in the Sixth Product as defined in the Addendum. The three drugs licensed to Rgene are ABV-1507 HER2/neu Positive Breast Cancer Combination Therapy, ABV-1511 Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy.

 

Pursuant to the Co-Dev Agreement, Rgene should pay to the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017 in three installments. The payment is for the compensation of BriVision’s past research efforts and contributions made by BriVision before the Co-Dev Agreement was signed and it does not relate to any future commitments made by BriVision and Rgene in this Co-Dev Agreement. Besides of $3,000,000, the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene, if any, and any development cost shall be equally shared by both BriVision and Rgene.

 

On June 1, 2017, the Company has delivered all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of Yuangene Corporation and the Company, the Company has recorded the full amount of $3,000,000 in connection with the Co-Dev Agreement as additional paid-in capital during the year ended September 30, 2017. As of the date of this report, the Company has received $450,000 in cash. For more information about the Co-Dev Agreement, please refer to the current report on Form 8-K we filed on May 30, 2017.

 

Revenue Generation

 

Most of our licensed products are still under development and trial stage. Therefore, no revenue is expected in the near term.

 

Research and Development

 

During the year ended September 30, 2017, we spent approximately $3,151,162 on research and development. During the three months ended December 31, 2017, we spent approximately $45,701 on research and development.

  

 28 

 

  

Critical Accounting Policies and Estimates

 

We believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating this “Management’s Discussion and Analysis of Financial Condition and Results of Operation.”

  

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the “U.S. GAAP”). All significant intercompany transactions and account balances have been eliminated.

 

This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company’s financial statements are expressed in U.S. dollars.

 

Fiscal Year

 

The Company changed its fiscal year from the period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January 1, 2018. As a result, the current fiscal period is a three-month transition period ended on December 31, 2017. In these consolidated statements, including the notes thereto, the current period financial results ended December 31, 2017 are for a three-month period. Audited results for the twelve months ended September 30, 2017 and 2016 are both for twelve-month periods. In addition, the Company's consolidated statements of operations and consolidated statements of cash flows include unaudited comparative amounts for the three-month period ended December 31, 2016. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year. 

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.

 

Reclassifications

 

Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.

 

Forward Stock split

 

On March 21, 2016, the Board of Directors of the Company approved an amendment to its Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to its Articles of Incorporation.

 

Fair Value Measurements

 

The Company applies the provisions of ASC Subtopic 820-10, “Fair Value Measurements”, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements.  ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.

 

 29 

 

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  When determining the fair value measurements for assets and liabilities, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.

 

ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

 

-         Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

-         Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.

 

-         Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

 

There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of September 30, 2017 and 2016.

 

Cash and Cash Equivalents

 

The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of December 31, 2017 and September 30, 2017, the Company’s cash and cash equivalents amounted to $93,332 and $204,851, respectively. Some of the Company’s cash deposits are held in financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.

 

Concentration of Credit Risk

 

The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation’s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes. Concentration of credit risk with respect to trade and notes receivables is limited due to the wide variety of customers and markets in which the Company transacts business, as well as their dispersion across many geographical areas. The Company performs ongoing credit evaluations of its customers and generally does not require collateral, but does require advance deposits on certain transactions.

 

Receivable from Collaboration Partners

 

Receivable from collaboration partners is stated at carrying value less estimates made for doubtful receivables. An allowance for impairment of receivable from collaboration partners is established if the collection of a receivable becomes doubtful. Such receivable becomes doubtful when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of the receivables. Significant financial difficulties of the debtor, probability that the debtor will enter into bankruptcy or financial reorganization, and default or delinquency in payments are considered indicators that the receivable is impaired. The amount of the allowance is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. An impairment loss is recognized in the statement of operations, as are subsequent recoveries of previous impairments.

 

 30 

 

 

Research and Development Expenses

 

The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred.

 

Stock-based Compensation

 

The Company measures expense associated with all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with ASC Topic 718 “Compensation-Stock Compensation”. Total employee stock-based compensation expenses were $0 for the three months ended December 31, 2017, and $0 and $397,960 for the years ended September 30, 2017 and 2016, respectively.

 

 The Company accounted for stock-based compensation to non-employees in accordance with ASC Topic 505-50 “Equity-Based Payments to Non-Employees” which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee stock-based compensation expenses were $17,362 for the three months ended December 31, 2017, and $138,038 and $0 for the years ended September 30, 2017 and 2016, respectively.

 

 Income Taxes

 

The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.

 

 Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the three months ended December 31, 2017 and for the years ended September 30, 2017 and September, 30, 2016. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.

 

For the three months ended December 31, 2017, the Company’s income tax expense amounted to $0. For the years ended September 30, 2017 and 2016, the Company’s income tax expense amounted to $830 and $836, respectively.

 

On December 22, 2017, the SEC issued Staff Accounting Bulletin (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions we may take. The Company is continuing to gather additional information to determine the final impact.

 

 31 

 

 

Loss Per Share of Common Stock

 

The Company reports loss per share in accordance with ASC Topic 260-10 "Earnings per Share." Basic earnings (loss) per share are computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available.

 

Commitments and Contingencies

 

The Company has adopted ASC Topic 450 “Contingencies” subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.

 

Recent Accounting Pronouncements

 

Revenue Recognition:     In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (ASU 2014-09), to supersede nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for us in our first quarter of fiscal 2018 using either of two methods: (i) retrospective to each prior reporting period presented with the option to elect certain practical expedients as defined within ASU 2014-09 (full retrospective method); or (ii) retrospective with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined per ASU 2014-09 (modified retrospective method). We are currently assessing the materiality of the impact to our consolidated financial statements, and have not yet selected a transition approach.

 

Disclosure of Going Concern Uncertainties:     In August 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern(ASU 2014-15), to provide guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective for us in our fourth quarter of fiscal 2017 with early adoption permitted. We do not believe the impact of our pending adoption of ASU 2014-15 on the Company’s financial statements will be material.

 

 32 

 

 

Leases: In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-2”), which provides guidance on lease amendments to the FASB Accounting should Standard Codification. This ASU will be effective for us beginning in May 1, 2019. We are currently in the process of evaluating the impact of the adoption of ASU 2016-2on our consolidated financial statements.

 

Stock-based Compensation:    In March 2016, the FASB issued ASU 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Stock-Based Payment Accounting (ASU 2016-09). ASU 2016-09 changes how companies account for certain aspects of stock-based awards to employees, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU 2016-09 is effective for us in the first quarter of 2018, and earlier adoption is permitted. We are still evaluating the effect that this guidance will have on our consolidated financial statements and related disclosures.

 

Financial Instruments - Credit Losses: In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): The amendments in this Update require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments broaden the information that an entity must consider in developing its expected credit loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss, which will be more decision useful to users of the financial statements. ASU 2016-13 is effective for the Company for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is allowed as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is still evaluating the effect that this guidance will have on the Company’s consolidated financial statements and related disclosures.

 

Statement of Cash Flows: In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): The amendments in this Update apply to all entities, including both business entities and not-for-profit entities that are required to present a statement of cash flows under Topic 230. The amendments in this Update provide guidance on the following eight specific cash flow issues. The amendments are an improvement to GAAP because they provide guidance for each of the eight issues, thereby reducing the current and potential future diversity in practice described above. ASU 2016-15 is effective for the Company for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is still evaluating the effect that this guidance will have on the Company’s consolidated financial statements and related disclosures.

 

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): “Restricted Cash”(“ASU 2016-18”). ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. ASU 2016-18 will become effective for us beginning April 1, 2018, or fiscal 2019. ASU 2016-18 is required to be applied retrospectively. Upon the adoption, amounts described as restricted cash will be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period amounts shown on the statements of cash flows.

 

 33 

 

 

Business Combination:  In January 2017, the FASB issued ASU No. 2017-1 “Topic 805, Business Combinations: Clarifying the Definition of a Business”. The amendments in this update provide a screen to determine when a set is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. The amendments in this update affect all reporting entities that must determine whether they have acquired or sold a business. Public business entities should apply the amendments in this update to annual periods beginning after December 15, 2017, including interim periods within those periods. All other entities should apply the amendments to annual periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019. We do not expect the adoption of ASU 2017-1 to have a material impact on our consolidated financial statements.

 

From time to time, new accounting pronouncements are issued by FASB that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company's financial statements upon adoption. Management does not believe that any recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying financial statements. 

 

Limited Operating History; Need for Additional Capital

 

There is no historical financial information about us upon which to base an evaluation of our performance.  As of the date of this filing, we have not generated any revenues from operations. We cannot guarantee we will be successful in our business operations.  Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources, possible delays in the launching of our games and market or wider economic downturns. We do not believe we have sufficient funds to operate our business for the next 12 months.

 

We have no assurance that future financing will be available to us on acceptable terms, or at all.  If financing is not available on satisfactory terms, we may be unable to continue, develop or expand our operations.  Equity financing could result in additional dilution to existing shareholders.

  

If we are unable to raise additional capital to maintain our operations in the future, we may be unable to carry out our full business plan or we may be forced to cease operations.

 

The following discussion and analysis should be read in conjunction with our audited financial statements for the years ended December 31, 2017 and September 30, 2017 and accompanying notes that appear in our Annual Report on Form 10-K.

 

Results of Operation

 

Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation. We expect we will require additional capital to meet our long term operating requirements. We expect to raise additional capital through, among other things, the sale of equity or debt securities, but we cannot guarantee that we will be able to achieve the same.

  

 34 

 

 

Results of Operations — Three Months Ended December 31, 2017 Compared to Three Months Ended December 31, 2016. 

 

The following table presents, for the period indicated, our consolidated statements of operations information.

 

  

Three Months Ended
December 31,

 
   2017   2016 
       (Restated and unaudited) 
Revenues  $-   $- 
           
Cost of revenues   -    - 
           
Gross profit (loss)   -    - 
           
Operating expenses          
Selling, general and administrative expenses   289,731    185,188 
Research and development expenses   45,701    25,198 
Stock based compensation expenses   17,362    - 
           
Loss from operations   (352,794)   (210,386)
           
Other income(expenses)          
Interest income   80    49 
Gain on exchange differences   -    - 
Interest expense   (28,500)   - 
Total other income (expenses)   (28,420)   49 
           
Loss from continuing operations before provision income tax   (381,214)   (210,337)
           
Provision income tax   -    - 
           
Net Loss  $(381,214)  $(210,337)

  

Revenues.  We did not generate any revenue during the three months ended December 31, 2017 and 2016. As such, we did not incur any cost associated with revenues during the same periods.

 

Operating Expenses. Our operating expenses were $352,794 for the three months ended December 31, 2017 as compared to $210,386 for the three months ended December 31, 2016. The increase in operating expenses in the amount of $142,408 or 67.68% in the three months ended December 31, 2017 was primarily caused by the increase in professional service fees and consulting fees.

        

Interest Expense. The interest expense was $28,500 for three months ended December 31, 2017 as compared to $0 for the three-month period ended December 31, 2016. The increase of interest expenses by $28,500 was attributable to the loan in the principal amount of $950,000 from BioFirst Corporation.

 

Net Loss. As a result of the above factors, the net loss was $381,214 and $210,337 for the three months ended December 31, 2017 and 2016. The increase of net loss in the three months ended December 31, 2017 as compared to the same period ended December 31, 2016 was in an amount of $170,877 or by 81.23%.

  

Liquidity and Capital Resources

 

Working Capital Summary

  

   As of December 31, 2017
($)
   As of December 31, 2016
($)
 
       (Restated and unaudited) 
Current Assets   2,643,332    18,645 
Current Liabilities   4,400,247    6,538,100 
Working Capital   (1,756,915)   (6,519,455)

 

 35 

 

  

Cash Flows

 

   Three Months Ended   Years Ended 
   December 31,   September 30, 
   2017   2016   2017   2016 
       (Unaudited and Restated)       (Restated) 
Cash Flows Used in Operating Activities  $(111,519)  $(224,892)  $(1,598,686)  $(3,474,707)
Cash Flows Provided by Financing Activities   -    70,000    1,630,000    2,653,414 
Net (Decrease) Increase in Cash During Period  $(111,519)  $(154,892)  $31,314   $(821,293)

 

Cash Flow from Operating Activities

 

Net cash used in operating activities was $111,519 during the three months ended December 31, 2017 (the transition period) compared to $224,892 in the 2016 comparable period, representing a decrease of $113,373, or 50.41%. This decrease was primarily driven by the increase in due to related parties and accrued expenses, partially offset by the increase in net loss.

 

During the years ended September 30, 2017 and 2016, the net cash used in operating activities were $1,598,686 and $3,474,707, respectively, reflecting a decrease of $1,876,021 or 54.0%. Such decrease was primarily caused by the change in due to related parties during the year ended September 30, 2016.

  

Cash Flow from Investing Activities

 

There was no net cash used or generated from investing activities during the three months ended December 31, 2017 and 2016 and during the years ended September 30, 2017 and 2016.

 

Cash Flow from Financing Activities

 

During the three months ended December 31, 2017 and 2016, net cash generated from financing activities was $0 and $70,000. The decrease in net cash generated from financing activities was because the amount of $70,000 was generated by a one-time consulting service provided to LionGene Corporation during the three months ended September 30, 2016.

 

During the years ended September 30, 2017 and 2016, the net cash provided by financing activities were $1,630,000 and $2,653,414, respectively, representing a decrease of $1,023,414 or 38.6%. The decrease in cash flow provided by financing activities during the year ended September 30, 2017 as compared to the year of 2016 was mainly due to the reduced amounts of equity private placements, partially offset by the increase in capital contribution and loans from related parties during the twelve-month period ended September 30, 2017. 

 

Critical Accounting Policy and Estimates

 

We believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating this “Management’s Discussion and Analysis of Financial Condition and Results of Operation.”

 

Going Concern Consideration

 

We have incurred losses since its inception resulting in an accumulated deficit of $15,776,598 as of December 31, 2017 and net losses of $381,214 and a decreased cash flow of $111,519 during the three months ended December 31, 2017. These conditions raise substantial doubt about our ability to continue as a going concern for the next twelve months. 

 

We expect to finance operations primarily through capital contributions from principal shareholders. In the event that we require additional funding to finance the growth of our current and expected future operations as well as to achieve our strategic objectives, our principal shareholders have indicated the intent and ability to provide additional equity financing.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material to investors.

 

ITEM 7A.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

 36 

 

  

Item 8.  Financial Statements and Supplementary Data

 

AMERICAN BRIVISION (HOLDING) CORPORATION AND SUBSIDIARIES

Index to the Financial Statements

 

  Page
Report of Independent Registered Public Accounting Firms F-2
   
Consolidated Balance Sheets at December 31, 2017 and September 30, 2017 F-4
   
Consolidated Statements of Operations for the three months ended December 31, 2017 and for the years ended September 30, 2017 and 2016 F-5
   
Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the three months ended December 31, 2017 and for the years ended September 30, 2017 and 2016 F-6
   
Consolidated Statements of Cash Flows for the three months ended December 31, 2017 and for the years ended September 30, 2017 and 2016 F-7
   
Notes to Consolidated Financial Statements F-8

  

 F-1 

 

 

   

Audit • Tax • Consulting •  Financial Advisory 

Registered with Public Company Accounting Oversight Board (PCAOB)

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Shareholders of

American BriVision (Holding) Corporation and Subsidiaries

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of American BriVision (Holding) Corporation and subsidiaries (collectively “the Company”) as of December 31, 2017 and September 30, 2017, the related statement of operations, stockholders’ equity, and cash flows for the three months ended December 31, 2017 and for the year ended September 30, 2017, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the consolidated financial position of the Company at December 31, 2017 and September 31, 2017, and the consolidated results of its operations and its cash flows for the three months ended December 31, 2017 and for the year ended September 30, 2017, in conformity with the U.S. generally accepted accounting principles.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB.  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.  Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

The accompanying consolidated financial statements have been prepared assuming that American BriVision (Holding) Corporation and subsidiaries will continue as a going concern.  As described in Note 4 to the consolidated financial statements, the Company has incurred losses from operations, has a working capital deficit, and is in need of additional capital to grow its operations so that it can become profitable.  These factors raise substantial doubt about the Company’s ability to continue as a going concern.  Management’s plans with regard to these matters are described in Note 4. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

/s/ KCCW Accountancy Corp.

 

We have served as the Company’s auditor since 2017.

Diamond Bar, California

March 1, 2018

 

KCCW Accountancy Corp.

3333 S Brea Canyon Rd. #206, Diamond Bar, CA 91765, USA

Tel: +1 909 348 7228 • Fax: +1 909 895 4155 • info@kccwcpa.com

 

 F-2 

 

 

中正達會計師事務所有限公司

Centurion ZD CPA Limited

Certified Public Accountants (Practising)

 

Unit 1304, 13/F, Two Harbourfront, 22 Tak Fung Street, Hunghom, Hong Kong.

香港 紅磡 德豐街22號 海濱廣場二期 13樓1304室

Tel 電話: (852) 2126 2388      Fax 傳真: (852) 2122 9078

Email 電郵: info@czdcpa.com

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Shareholders of American BriVision Corporation and subsidiaries

 

We have audited the accompanying consolidated statements of operations, stockholders’ equity and cash flows of American BriVision Corporation and subsidiaries (“the Company”) for the year ended September 30, 2016.

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audit.

 

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

 

In our opinion, the financial statements referred to above present fairly, in all material respects, the results of its operations and its cash flows for the year ended September 30, 2016 in conformity with accounting principles generally accepted in the United States of America.

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 4 to the consolidated financial statements, the Company has suffered recurring losses from operations and has a significant accumulated deficit. In addition, the Company continues to experience negative cash flows from operations. These factors raise substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. 

 

As discussed in Note 2 to the financial statements, the 2016 financial statements have been restated to correct misstatements in the research and development expenses and the typographical errors.

 

/s/ Centurion ZD CPA Limited

 

Certified Public Accountants

(Practising) Hong Kong

 

Dated: January 12, 2017

Except for Note 2 which was dated at May 22, 2017

 

 F-3 

 

 

AMERICAN BRIVISION (HOLDING) CORPORATION AND SUBSIDIARIES

(formerly METU BRANDS, INC.)

CONSOLIDATED BALANCE SHEETS

 

  

December 31,

2017

  

September 30,

2017

 
         
Assets 
Current assets          
Cash  $93,332   $204,851 
Receivable from collaboration partners – related parties   2,550,000    2,550,000 
Total Current Assets   2,643,332    2,754,851 
           
Total Assets  $2,643,332   $2,754,851 
           
Liabilities and Equity 
Accrued expense  $170,927   $34,914 
Due to related parties   4,229,320    4,113,000 
Total Liabilities  $4,400,247   $4,147,914 
           
Commitments and Contingencies          
           
Stockholders’ deficit          
Common Stock 360,000,000 authorized at $0.001 par value; shares issued and outstanding 213,746,647 at December 31, 2017 and September 30, 2017   213,747    213,747 
Additional paid-in capital   13,805,936    13,788,574 
Accumulated deficit   (15,776,598)   (15,395,384)
Total stockholders’ deficit   (1,756,915)   (1,393,063)
Total Liabilities and Equity  $2,643,332   $2,754,851 

  

* All shares outstanding for all periods have been retroactively restated to reflect Company’s 1 to 3:141 forward stock split, which was effective on April 8, 2016.

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 F-4 

 

 

AMERICAN BRIVISION (HOLDING) CORPORATION AND SUBSIDIARIES

(formerly METU BRANDS, INC.)

CONSOLIDATED STATEMENTS OF OPERATIONS

 

   Three months ended   Years ended 
   December 31,
2017
   September 30, 2017   September 30, 2016 
           (Restated) 
Revenues  $-   $-   $- 
                
Cost of revenues   -    -    32 
                
Gross profit   -    -    (32)
                
Operating expenses               
   Selling, general and administrative expenses   289,731    707,142    599,303 
   Research and development expenses   45,701    3,151,162    10,000,000 
   Stock based compensation   17,362    138,038    397,960 
                
Loss from operations   (352,794)   (3,996,342)   (10,997,295)
                
Other income (expense)               
   Interest income   80    149    361 
   Interest expense   (28,500)   (74,960)   (10,170)
   Gain on exchange differences   -    -    141 
       Total other expenses   (28,420)   (74,811)   (9,668)
                
Loss before provision income tax   (381,214)   (4,071,153)   (11,006,963)
                
Provision for income tax   -    830    836 
                
Net loss   (381,214)   (4,071,983)   (11,007,799)
                
Net loss per share:               
      Basic and diluted  $(0.00)  $(0.02)  $(0.06)
                
Weighted average number of common shares outstanding:               
      Basic and diluted   213,746,647    212,648,770    193,981,153 

 

* All shares outstanding for all periods have been retroactively restated to reflect Company’s 1 to 3:141 forward stock split, which was effective on April 8, 2016.

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 F-5 

 

 

AMERICAN BRIVISION (HOLDING) CORPORATION AND SUBSIDIARIES

(formerly METU BRANDS, INC.)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

 

   Common stock   Additional           Stockholders’ 
   Number of       paid-in   Subscription   Accumulated   equity 
   shares   Amount   capital   receivable   deficit   (deficit) 
Balance at July 21, 2015 (inception)   159,622,964   $159,623   $1,087,378   $(350,000)  $-   $897,001 
   Issuance of common shares   6,650,957    6,651    45,307    -    -    51,958 
   Net loss for the period   -    -    -    -    (315,602)   (315,602)
Balance at September 30, 2016   166,273,921    166,274    1,132,685    (350,000)   (315,602)   633,357 
   Reverse merger recapitalization   42,359,253    42,359    (44,995)   -    -    (2,636)
   Issuance of common shares   2,031,423    2,032    3,247,968    -    -    3,250,000 
   Stock based compensation   157,050    157    397,803    -    -    397,960 
   Receipt of subscription receivable   -    -    -    350,000    -    350,000 
   Net loss for the year   -    -    -    -    (11,007,799)   (11,007,799)
Balance at September 30, 2016   210,821,647    210,822    4,733,461    -    (11,323,401)   (6,379,118)
   Issuance of common shares   2,925,000    2,925    5,847,075    -    -    5,850,000 
   Stock based compensation   -    -    138,038    -    -    138,038 
   Capital contribution from related parties under common control   -    -    3,070,000    -    -    3,070,000 
    Net loss for the year   -    -    -    -    (4,071,983)   (4,071,983)
Balance at September 30, 2017   213,746,647   $213,747   $13,788,574   $-   $(15,395,384)  $(1,393,063)
   Stock based compensation   -    -    17,362    -    -    17,362 
   Net loss for the three months   -    -    -    -    (381,214)   (381,214)
Balance at December 31, 2017   213,746,647   $213,747   $13,805,936   $-   $(15,776,598)  $(1,756,915)

 

* All shares outstanding for all periods have been retroactively restated to reflect Company’s 1 to 3:141 forward stock split, which was effective on April 8, 2016.

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 F-6 

 

 

AMERICAN BRIVISION (HOLDING) CORPORATION AND SUBSIDIARIES

(formerly METU BRANDS, INC.)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   Three Months ended
December 31,
   Years ended
September 30,
 
   2017   2017   2016 
           (Restated) 
Cash flows from operating activities            
Net loss from continuing operations  $(381,214)  $(4,071,983)  $(11,007,799)
Adjustments to reconcile net loss to net cash used in operating activities:               
Issuance of common stock for compensation and recapitalization   -    -    1,295,324 
Stock based compensation for nonemployees   17,362    138,038      
Changes in operating assets and liabilities:               
Decrease in prepaid expenses and deposits   -    3,815    3,815 
Increase (decrease) in accounts payable   -    (18,370)   18,370 
Increase (decrease) in accrued expenses and other current liabilities   136,013    (3,186)   (261,900)
Increase in due to related parties   116,320    2,353,000    6,477,483 
Net cash used in operating activities   (111,519)   (1,598,686)   (3,474,707)
Cash flows from financing activities               
Capital contribution from related parties under common control   -    520,000    - 
Borrowings from related parties   -    1,110,000    - 
Decrease in due to shareholder   -    -    (46,586)
Proceeds from subscription receivable   -    -    350,000 
Proceeds from issuance of common shares   -    -    2,350,000 
Net cash provided by financing activities   -    1,630,000    2,653,414 
                
Effect of exchange rate changes on cash and cash equivalents   -    -    - 
                
Net increase (decrease) in cash and cash equivalents   (111,519)   31,314    (821,293)
                
Cash and cash equivalents               
Beginning   204,851    173,537    994,830 
Ending  $93,332   $204,851   $173,537 
                
Supplemental disclosure of cash flows               
Cash paid during the year for:               
Interest expense paid  $19,500   $66,500   $- 
Income taxes paid  $-   $830   $836 
                
Non-cash financing and investing activities               
Common shares issued for due to related parties  $-   $5,850,000   $- 
Capital contribution from related parties under common control  $-   $2,550,000   $- 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 F-7 

 

 

AMERICAN BRIVISION (HOLDING) CORPORATION AND SUBSIDIARIES

(formerly METU BRANDS, INC.)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

AS OF DECEMBER 31, 2017

 

1. ORGANIZATION AND DESCRIPTION OF BUSINESS


American BriVision (Holding) Corporation (the “Company” or “Holding entity”), a Nevada corporation, through the Company’s operating entity, American BriVision Corporation (the “BriVision”), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology and focuses on the development of new drugs and innovative medical devices to fulfill unmet medical needs.  The business model of the Company is to integrate research achievements from world-famous institutions (such as Memorial Sloan Kettering Cancer Center (“MSKCC”) and MD Anderson Cancer Center), conduct clinical trials of translational medicine for Proof of Concept (“POC”), out-license to international pharmaceutical companies, and exploit global markets. BriVision had to predecessor operations prior to its formation on July 21, 2015.

 

Reverse Merger

 

On February 8, 2016, a Share Exchange Agreement (the “Share Exchange Agreement”) was entered into by and among American BriVision (Holding) Corporation, American BriVision Corporation (“BriVision”), and Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People's Republic of China (“Euro-Asia”), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock of the Company, and the owners of record of all of the issued share capital of BriVision (the “BriVision Stock”).

 

Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the “Acquisition Stock”) (subject to adjustment for fractionalized shares as set forth below) of the Company’s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company’s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger (the “Merger”).

 

Pursuant to the Merger, all of the issued and outstanding common shares of BriVision were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583pre-stock split) common shares of the Company and BriVision has become a wholly owned subsidiary of the Company. The holders of Company’s common stock as of immediately prior to the Merger held an aggregate of 205,519,223(65,431,144 pre-stock split) shares of Company’s common stock. Because of the exchange of the BriVision Stock for the Acquisition Stock (the “Share Exchange”), BriVision has become a wholly owned subsidiary (the “Subsidiary”) of the Company and there was a change of control of the Company following the closing.  There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.

 

Because of the consummation of the Share Exchange, BriVision is now our wholly owned subsidiary and its shareholders own approximately 79.70% of our issued and outstanding common stock.

 

Following the Share Exchange, we have abandoned our prior business plan and we are now pursuing BriVision’s historically proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs.  The business model of the Company is to integrate research achievements from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept (“POC”), out-license to international pharmaceutical companies, and exploit global markets.

 

Accounting Treatment of the Reverse Merger

 

For financial reporting purposes, the Share Exchange represents a “reverse merger” rather than a business combination and BriVision is deemed the accounting acquirer in the transaction. The Share Exchange is being accounted for as a reverse-merger and recapitalization. BriVision is the acquirer for financial reporting purposes and the Company is the acquired company. Consequently, the assets and liabilities and the operations reflected in the historical financial statements prior to the Share Exchange will be those of BriVision and recorded at the historical cost basis of BriVision. In addition, the consolidated financial statements after completion of the Share Exchange will include the assets and liabilities of the Company and BriVision, and the historical operations of BriVision and operations of the Combined Company from the closing date of the Share Exchange.

 

 F-8 

 

 

2. CORRECTIONS TO PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS

 

The Company discovered that it had erroneously stated that the research and development expenses were understated during the year ended September 30, 2016. Instead, our research and development expenses were $10,000,000 for the year ended September 30, 2016 and were restated in the Adjustments No. 1 column. Moreover, there were typographical errors on Selling, General and Administration expenses which were corrected in the Adjustments No. 2 column.

 

The following tables present the effect of the corrections discussed above and other adjustments on selected line items of our previously reported consolidated financial statements as of and for the year ended September 30, 2016,

 

ITEMS  Previously  Reported on Form 10K   Adjustments No.1   Adjustments No.2   Restated 
                 
Consolidated Balance Sheets                
As of September 30, 2016                
Due to related party   -    6,500,000    -    6,500,000 
Total Liabilities   56,470    6,500,000    -    6,556,470 
Additional paid-in capital   4,733,401    -    60    4,733,461 
Accumulated deficit   (4,823,401)   (6,500,000)   -    (11,323,401)
Total equity (deficit)   120,882    (6,500,000)   -    (6,379,118)
                     
Consolidated Statements of Operations and Comprehensive Loss                    
For the year ended September 30, 2016                    
Selling, general and administrative expenses   4,497,263    (3,500,060)   60    997,263 
Research and development expenses   -    10,000,000    -    10,000,000 
Net loss from operations   (4,497,295)   (6,499,940)   (60)   (10,997,295)
Loss from continuing operations before income taxes   (4,506,963)   (6,499,940)   (60)   (11,006,963)
Net Loss   (4,507,799)   (6,499,940)   (60)   (11,007,799)
Basic and diluted loss per share   (0.00)   (0.06)   (0.00)   (0.06)
                     
Consolidated Statements of Cash Flow                    
For the year ended September 30, 2016                    
Net loss from continuing operations   (4,507,799)   (6,499,940)   (60)   (11,007,799)
Issuance of common stock for compensation   1,295,324    (60)   60    1,295,324 
(Decrease) increase in due to related party   (22,517)   6,500,000         6,477,483 

 

As a result of the restatement of the consolidated balance sheet as of September 30, 2016, Due to related party and Total liabilities were increased by $6,500,000; changed from $0 to $6,500,000 and from $56,470 to $6,556,470. Additional paid in capital was increased by $60 and changed from $4,733,401 to $4,733,461. Accumulated deficit was increased by $6,500,000 and changed from $(4,823,401) to $(11,323,401). Total equity (deficit) was decreased by $6,500,000 and changed from $120,882 to $(6,379,118).

 

As a result of the restatement of the consolidated statement of operations and comprehensive loss for the year ended September 30, 2016, Selling, general and administrative expenses were decreased by $3,500,000 and changed from $4,497,263 to $997,263. Research and development expenses were increased by $10,000,000 and changed from $0 to $10,000,000. Net loss from operations was increased by $6,500,000 and changed from $(4,497,295) to $(10,997,295). Loss from continuing operations before taxes was increased by $6,500,000 and changed from $(4,506,963) to $(11,006,963). Net loss was increased by $6,500,000 and changed from $(4,507,799) to $(11,007,799). Basic and diluted loss per share were also increased by 0.06 and changed from $0 to $(0.06).

 

As a result of the restatement of the consolidated statement of cash flow for the year ended September 30, 2016, Net loss from continuing operations was increased by $6,500,000; changed from $(4,507,799) to $(11,007,799). Issuance of common stock for compensation did not have changes and stated as $1,295,324. (Decrease) increase in due to related party was increased by $6,500,000 and changed from $(22,517) to $6,477,483. There were no changes in Net cash used in operating activities.

  

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the “U.S. GAAP”). All significant intercompany transactions and account balances have been eliminated.

 

This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company’s financial statements are expressed in U.S. dollars.

 

 F-9 

 

 

Fiscal Year

 

The Company changed its fiscal year from the period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January 1, 2018. As a result, the current fiscal period is a three-month transition period ended on December 31, 2017. In these consolidated statements, including the notes thereto, the current period financial results ended December 31, 2017 are for a three-month period. Audited results for the twelve months ended September 30, 2017 and 2016 are both for twelve-month periods. In addition, the Company's consolidated statements of operations and consolidated statements of cash flows include unaudited comparative amounts for the three-month period ended December 31, 2016. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.

 

Reclassifications

 

Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.

 

Forward Stock split

 

On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to Articles of Incorporation.

 

Fair Value Measurements

 

The Company applies the provisions of ASC Subtopic 820-10, “Fair Value Measurements”, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements.  ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  When determining the fair value measurements for assets and liabilities, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.

 

ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

 

-         Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

-         Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.

 

-         Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

 

There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of September 30, 2017 and 2016.

 

Cash and Cash Equivalents

 

The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of December 31, 2017 and September 30, 2017, the Company’s cash and cash equivalents amounted $93,332 and $204,851, respectively. Some of the Company’s cash deposits are held in financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.

 

 F-10 

 

 

Concentration of Credit Risk

 

The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation’s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes. Concentration of credit risk with respect to trade and notes receivables is limited due to the wide variety of customers and markets in which the Company transacts business, as well as their dispersion across many geographical areas. The Company performs ongoing credit evaluations of its customers and generally does not require collateral, but does require advance deposits on certain transactions.

 

Receivable from Collaboration Partners

 

Receivable from collaboration partners is stated at carrying value less estimates made for doubtful receivables. An allowance for impairment of receivable from collaboration partners is established if the collection of a receivable becomes doubtful. Such receivable becomes doubtful when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of the receivables. Significant financial difficulties of the debtor, probability that the debtor will enter into bankruptcy or financial reorganization, and default or delinquency in payments are considered indicators that the receivable is impaired. The amount of the allowance is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. An impairment loss is recognized in the statement of operations, as are subsequent recoveries of previous impairments.

 

Research and Development Expenses

 

The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred.


Stock-based Compensation

 

The Company measures expense associated with all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with ASC Topic 718 “Compensation-Stock Compensation”. Total employee stock-based compensation expenses were $0 for the three months ended December 31, 2017, and $0 and $397,960 for the years ended September 30, 2017 and 2016, respectively.

 

The Company accounted for stock-based compensation to non-employees in accordance with ASC Topic 505-50 “Equity-Based Payments to Non-Employees” which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee stock-based compensation expenses were $17,362 for the three months ended December 31, 2017, and $138,038 and $0 for the years ended September 30, 2017 and 2016, respectively.

 

Income Taxes

 

The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.

 

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the three months ended December 31, 2017 and for the years ended September 30, 2017 and September, 30, 2016. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.

 

For the three months ended December 31, 2017, the Company’s income tax expense amounted $0. For the years ended September 30, 2017 and 2016, the Company’s income tax expense amounted $830 and $836, respectively.

 

 F-11 

 

 

On December 22, 2017, the SEC issued Staff Accounting Bulletin (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions we may take. The Company is continuing to gather additional information to determine the final impact.

 

Loss Per Share of Common Stock

 

The Company reports loss per share in accordance with ASC Topic 260-10 "Earnings per Share." Basic earnings (loss) per share are computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available.

 

Commitments and Contingencies

 

The Company has adopted ASC Topic 450 “Contingencies” subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.

 

Recent Accounting Pronouncements

 

Revenue Recognition:     In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (ASU 2014-09), to supersede nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for us in our first quarter of fiscal 2018 using either of two methods: (i) retrospective to each prior reporting period presented with the option to elect certain practical expedients as defined within ASU 2014-09 (full retrospective method); or (ii) retrospective with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined per ASU 2014-09 (modified retrospective method). We are currently assessing the materiality of the impact to our consolidated financial statements, and have not yet selected a transition approach.

 

Disclosure of Going Concern Uncertainties:     In August 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern(ASU 2014-15), to provide guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective for us in our fourth quarter of fiscal 2017 with early adoption permitted. We do not believe the impact of our pending adoption of ASU 2014-15 on the Company’s financial statements will be material.

 

Leases:     In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-2”), which provides guidance on lease amendments to the FASB Accounting should Standard Codification. This ASU will be effective for us beginning in May 1, 2019. We are currently in the process of evaluating the impact of the adoption of ASU 2016-2on our consolidated financial statements.

 

Stock-based Compensation:    In March 2016, the FASB issued ASU 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Stock-Based Payment Accounting (ASU 2016-09). ASU 2016-09 changes how companies account for certain aspects of stock-based awards to employees, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU 2016-09 is effective for us in the first quarter of 2018, and earlier adoption is permitted. We are still evaluating the effect that this guidance will have on our consolidated financial statements and related disclosures.

 

 F-12 

 

 

Financial Instruments - Credit Losses: In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): The amendments in this Update require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments broaden the information that an entity must consider in developing its expected credit loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss, which will be more decision useful to users of the financial statements. ASU 2016-13 is effective for the Company for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is allowed as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is still evaluating the effect that this guidance will have on the Company’s consolidated financial statements and related disclosures.

 

Statement of Cash Flows: In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): The amendments in this Update apply to all entities, including both business entities and not-for-profit entities that are required to present a statement of cash flows under Topic 230. The amendments in this Update provide guidance on the following eight specific cash flow issues. The amendments are an improvement to GAAP because they provide guidance for each of the eight issues, thereby reducing the current and potential future diversity in practice described above. ASU 2016-15 is effective for the Company for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is still evaluating the effect that this guidance will have on the Company’s consolidated financial statements and related disclosures.

 

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): “Restricted Cash”(“ASU 2016-18”). ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. ASU 2016-18 will become effective for us beginning April 1, 2018, or fiscal 2019. ASU 2016-18 is required to be applied retrospectively. Upon the adoption, amounts described as restricted cash will be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period amounts shown on the statements of cash flows.

 

Business Combination:  In January 2017, the FASB issued ASU No. 2017-1 “Topic 805, Business Combinations: Clarifying the Definition of a Business”. The amendments in this update provide a screen to determine when a set is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. The amendments in this update affect all reporting entities that must determine whether they have acquired or sold a business. Public business entities should apply the amendments in this update to annual periods beginning after December 15, 2017, including interim periods within those periods. All other entities should apply the amendments to annual periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019. We do not expect the adoption of ASU 2017-1 to have a material impact on our consolidated financial statements.

 

From time to time, new accounting pronouncements are issued by FASB that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company's financial statements upon adoption. Management does not believe that any recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying financial statements 

 

4. GOING CONCERN

 

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since its inception resulting in an accumulated deficit of $15,776,598 and $15,395,384 as of December 31, 2017 and September 30, 2017, respectively, and incurred net loss of $381,214 for the three months ended December 31, 2017, and $4,071,983 during the year ended September 30, 2017. The Company also had working capital deficiency of $1,756,915 and $1,393,063 at December 31, 2017 and September 30, 2017, respectively.  The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company upon signing of that agreement. On May 6, 2016, the Company and BioLite agreed to amend the BioLite Collaborative Agreement, through enter into the Milestone Payment Agreement, whereby the Company has agreed to pay the Milestone Payment to BioLite $2,600,000 in cash and $900,000 in newly issued shares of its common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares. The cash payment and shares issuance were completed in June 2016. Pursuant to the BioLite Collaborative Agreement, the 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. On February 2017, the Company agreed to pay this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of its common stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. The cash payment and shares issuance were completed in February 2017. This BioLite Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen years as of the first commercial sales of the Product in the Territory and automatically renew for five more years unless either party gives the other party six month written notice of termination prior to the expiration date of the term.

 

 F-13 

 

 

In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management’s plans to obtain such resources for the Company include (1) obtaining capital from the sale of its equity securities (2) short-term and long-term borrowings from banks and third-parties, and (3) short-term borrowings from stockholders or other related party(ies) when needed. However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans.

 

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually to secure other sources of financing and attain profitable operations.

 

5. COLLABORATIVE AGREEMENTS

 

Collaborative agreement with BioLite Inc., a related party

 

On December 29, 2015, American BriVision Corporation entered into a collaborative agreement (the “BioLite Collaborative Agreement”) with BioLite Inc. (the “BioLite”), a related party (See Note 7), pursuant to which BioLite granted BriVision sole licensing rights for drug and therapeutic use of five products, including BLI-1005 CNS-Major Depressive Disorder, BLI-1008 CNS-Attention Deficit Hyperactivity Disorder, BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1, BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer, and BLI-1501 Hematology-Chronic Lymphocytic Leukemia, in the U.S.A and Canada. Under the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of BriVision with equivalent value, according to the following schedule:

 

  ●  upfront payment shall upon the signing of this BioLite Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week.
     
  upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week.
     
  at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months.
     
  upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week.
     
  at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months.
     
  upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week. 

 

This BioLite Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen years as of the first commercial sales of the Product in the Territory and automatically renew for five more years unless either party gives the other party six month written notice of termination prior to the expiration date of the term.

 

Pursuant to the BioLite Collaborative Agreement, an upfront payment of $3,500,000 (the “Milestone Payment”), which is 3.5% of total payments due under the BioLite Collaborative Agreement, was to be paid by the Company upon signing of that agreement. On May 6, 2016, the Company and BioLite agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company agreed to pay the Milestone Payment to BioLite with $2,600,000 in cash and $900,000 in the form of newly issued shares of its common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares. The cash payment and shares issuance were completed in June 2016.

 

Pursuant to the BioLite Collaborative Agreement, the 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. On February 2017, the Company agreed to pay this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of its common stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. The cash payment and shares issuance were completed in February 2017.

 

Pursuant to the BioLite Collaborative Agreement, the 15% of total payment, $15,000,000 shall be made at the completion of first phase II clinical trial. As of December 31, 2017, the first phase II clinical trial research has not completed yet.

  

 F-14 

 

 

The Company determined to fully expense the entire amount of $10,000,000 since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence the entire amount is fully expensed as research and development expense.

 

On January 12, 2017, the Company entered into an Addendum (the “Addendum”) to the BioLite Collaborative Agreement which was previously entered into with BioLite. Pursuant to the Addendum, the Company and BioLite agreed to include one more product, namely, “Maitake Combination Therapy” as one of the Products defined in the BioLite Collaborative Agreement (the “Sixth Product’) and defined the Territory of the Sixth Product to be worldwide and restate the Territory of the Five Products to be the U.S.A and Canada.

 

Co-Development agreement with Rgene Corporation, a related party

 

On May 26, 2017, American BriVision Corporation entered into a co-development agreement (the “Co-Dev Agreement”) with Rgene Corporation (the “Rgene”), a related party under common control by controlling beneficiary shareholder of Yuangene Corporation and the Company (See Note 7). Pursuant to Co-Dev Agreement, BriVison and Rgene agreed to co-develop and commercialize certain products that are included in the Sixth Product as defined in the Addendum. Under the terms of the Co-Dev Agreement, Rgene should pay the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017. The payment is for the compensation of BriVision’s past research efforts and contributions made by BriVision before the Co-Dev Agreement was signed and it does not relate to any future commitments made by BriVision and Rgene in this Co-Dev Agreement. Besides of $3,000,000, the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene, if any, and any development cost shall be equally shared by both BriVision and Rgene.

 

On June 1, 2017, the Company has delivered all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of Yuangene Corporation and the Company, the Company has recorded the full amount of $3,000,000 in connection with the Co-Dev Agreement as additional paid-in capital during the year ended September 30, 2017. As of the date of this report, the Company has received $450,000 in cash. The Company is still in discussion with Rgene with respect to the schedule of the outstanding balance.

 

Collaborative agreement with BioFirst Corporation, a related party

 

On July 24, 2017, American BriVision Corporation entered into a collaborative agreement (the “BioFirst Collaborative Agreement”) with BioFirst Corporation (“BioFirst”), pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the “Product”): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a controlling beneficiary shareholder of Yuangene Corporation and the Company is one of the directors and common stock shareholders of BioFirst (See Note 7).

 

Pursuant to the BioFirst Collaborative Agreement, the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $3,000,000 in cash or stock of the Company before September 30, 2018. The amount of $3,000,000 is in connection with the compensation for BioFirst’s past research efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate to any future commitments made by BioFirst and BriVision in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive 50% of the future net licensing income or net sales profit, if any, and any development cost shall be equally shared by both BriVision and BioFirst.

 

On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision. No payment has been made by the Company as of the date of this report. The Company determined to fully expense the entire amount of $3,000,000 since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence the entire amount of $3,000,000 is fully expensed as research and development expense during the year ended September 30, 2017.

  

6. ACCRUED EXPENSES

 

Accrued expenses as of December 31, 2017 and September 30, 2017 consisted of:

 

   December 31,
2017
   September 30,
2017
 
Accrued consulting fee  $29,075   $2,609 
Accrued professional service fees   13,592    - 
Accrued interest expense – related party(Note 7)   17,460    8,460 
Accrued payroll   110,800    23,845 
Total  $170,927   $34,914 

 

 F-15 

 

 

7. RELATED PARTIES TRANSACTIONS

 

The related parties of the company with whom transactions are reported in these financial statements are as follows:

 

Name of entity or Individual   Relationship with the Company and its subsidiaries
BioLite Inc. (the “BioLite”)   Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene
BioFirst Corporation (the “BioFirst”)   Entity controlled by controlling beneficiary shareholder of Yuangene
Rgene Corporation (the “Rgene”)   Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene
Liongene Corporation (the “Liongene”)   Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene
Yuangene Corporation (the “Yuangene”)   Controlling beneficiary shareholder of the Company
Asiangene Corporation (the “Asiangene”)   Shareholder; entity controlled by controlling beneficiary shareholder of Yuangene
Euro-Asia Investment & Finance Corp Ltd. (the “Euro-Asia”)   Shareholder of the Company
Kimho Consultants Co., Ltd. (the “Kimho”)   Shareholder of the Company
Eugene Jiang   Former President and Chairman

 

Due to related parties

 

Amount due to related parties consisted of the following as of the periods indicated:

 

   December 31,   September 30, 
   2017   2017 
BioLite Inc.  $109,220   $- 
BioFirst Corporation   3,957,000    3,950,000 
Asiangene Corporation   160,000    160,000 
Yuangene Corporation   3,000    3,000 
Eugene Jiang   100    - 
Total  $4,229,320   $4,113,000 

 

Related party transactions

 

(1)During the three months ended December 31, 2017, BioLite advanced in an aggregate amount of $109,220 to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand. As of December 31, 2017 and September 30, 2017, the outstanding advance balance is $109,220 and $0, respectively.

 

(2)On January 26, 2017, the Company and BioFirst entered into a loan agreement for a total commitment (non-secured indebtedness) of $950,000 to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The loan will be matured on February 1, 2018. As of December 31, 2017 and September 30, 2017, the outstanding loan balance is $950,000 and $950,000, and accrued interest is $17,460 and $8,460, respectively (See Note 6). Interest expenses in connection with this loan is $28,500 for the three months ended December 31, 2017, and $74,960 and $0 for the years ended September 30, 2017 and 2016, respectively.

 

(3)On July 24, 2017, BriVision entered into a collaborative agreement (the “BioFirst Collaborative Agreement”) with BioFirst (See Note 5). In September 2017, BioFirst has delivered all research, technical, data and development data to BriVision, and the Company has recorded full amount of $3,000,000 due to BioFirst. As of December 31, 2017 and September 30, 2017, the outstanding balance is $3,000,000 and $3,000,000, respectively.

 

(4)During the three months ended December 31, 2017, BioFirst also advanced in an aggregate amount of $7,000 to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand. As of December 31, 2017 and September 30, 2017, the outstanding advance balance is $7,000 and $0, respectively.

 

(5)In September 2017, Asiangene entered an investment and equity transfer agreement (the “Investment and Equity Transfer Agreement”) with Everfront Biotech Inc. (the “Everfront”), a third party. Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by Asiangene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. Asiangene also agreed to loan the proceeds to the Company for working capital purpose. The non-secured loan bears 0% interest rate and is due on demand. As of December 31, 2017 and September 30, 2017, the outstanding loan balance is $160,000 and $160,000, respectively.

 

(6)During the year ended September 30, 2017, Yuangene Corporation advanced in an aggregate amount of $3,000 to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand. As of December 31, 2017 and September 30, 2017, the outstanding advance balance is $3,000 and $3,000, respectively.

 

 F-16 

 

 

(7)During the three months ended December 31, 2017, Eugene Jiang, the former President and Chairman of the Company, has advanced in an aggregate amount of $100 to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand. As of December 31, 2017 and September 30, 2017, the outstanding advance balance is $100 and $0, respectively.

 

(8)On May 26, 2017, BriVision entered into a co-development agreement (the “Co-Dev Agreement”) with Rgene (See Note 5). As of December 31, 2017, the Company has received an aggregate amount of $450,000 in cash and has recorded $2,550,000 as receivable from collaboration partners. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of Yuangene Corporation, the Company has recorded the full amount of $3,000,000 in connection with the Co-Dev Agreement as additional paid-in capital during the year ended September 30, 2017.

 

(9)On January 1, 2017, Euro-Asia Investment & Finance Corp Ltd. and the Company entered into a service agreement (the “Euro-Asia Agreement”) for the maintenance of the listing in the U.S. stock exchange market. During the three months ended December 31, 2017 and during the year ended September 30, 2017, the Company recognized non-employee stock based compensation expenses of $5,000 and $55,000 in connection with the terms in the Euro-Asia Agreement, respectively.

 

(10)On January 1, 2017, Kimho Consultants Co., Ltd. and the Company entered into a service agreement (the “Kimho Agreement”) for the maintenance of the listing in the U.S. stock exchange market. During the three months ended December 31, 2017 and during the year ended September 30, 2017, the Company recognized non-employee stock based compensation expenses of $10,000 and $80,000 in connection with the terms in the Kimho Agreement, respectively.

 

(11)During the year ended September 30, 2017, the Company provided a one-time consulting service to Liongene Corporation for $70,000. Since both Liongene and the Company are related parties and under common control by a controlling beneficiary shareholder of Yuangene Corporation, the Company has recorded the full amount of $70,000 as additional paid-in capital during the year ended September 30, 2017.

 

(12)During the year ended September 30, 2017, the Company entered an operating lease agreement with Asiangene for an office space in Taiwan for the period from October 1, 2016 to July 31, 2017. The monthly base rent is approximately $5,000. Rent expenses under this lease agreement amounted to $52,205 and $0 for the years ended September 30, 2017 and 2016, respectively.

 

8. EQUITY

 

During October 2015, $350,000 of subscription receivable was fully collected from the shareholders.

 

On February 8, 2016, a Share Exchange Agreement (“Share Exchange Agreement”) was entered into by and among American BriVision (Holding) Corporation (the “Company”), American BriVision Corporation (“BriVision”), Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People's Republic of China (“Euro-Asia”), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock of the Company, and the owners of record of all of the issued share capital of BriVision (the “BriVision Stock”). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the “Acquisition Stock”) (subject to adjustment for fractionalized shares as set forth below) of the Company’s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company’s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of BriVision’s common stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583 pre-stock split) shares of Company’s common stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company’s common stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company’s common stock, Because of the exchange of the BriVision Stock for the Acquisition Stock (the “Share Exchange”), BriVision became a wholly owned subsidiary (the “Subsidiary”) of the Company and there was a change of control of the Company following the closing.  There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.

 

On February17, 2016, pursuant to the 2016 Equity Incentive Plan (the “2016 Plan”), 157,050 (50,000 pre-stock split) shares were granted to the employees.

 

On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the “Forward Stock Split”) and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.

 

 F-17 

 

 

The majority of the shareholders of the Company approved the amendment to Articles of Incorporation.

 

On May 6, 2016, the Company and BioLite agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of our first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016.

 

On August 26, 2016, the Company issued 1,468,750 shares (“Shares”) of the Company’s common stock, par value $0.001 (the “Offering”) to BioLite, Inc., a non-U.S. accredited investor (the “Purchaser”) pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the “SPA”). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. The proceeds may be used for general corporate purposes. 

 

Pursuant to the BioLite Collaborative Agreement (See Note 5), BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. In February 2017, the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of our common stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares.

 

On October 1, 2016, the Company entered into a consulting agreement with Kazunori Kameyama (“Kameyama”) for the provision of services related to the clinical trials and other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company’s common stock at $1.00 per share for any amount exceeding $3,000. The Company’s stocks shall be calculated and issued in December every year. On October 1, 2017, the Company and Kameyama agreed to extend the service period for one more year expiring on September 30, 2018. As a result, the non-employee stock-based compensation related to this consulting agreement was $2,362 during the three months ended December 31, 2017 and $3,038 for the year ended September 30, 2017.

 

On January 1, 2017, Euro-Asia Investment & Finance Corp Ltd. and the Company entered into a service agreement (the “Euro-Asia Agreement”) for the maintenance of the listing in the U.S. stock exchange market. During the three months ended December 31, 2017 and during the year ended September 30, 2017, the Company recognized professional fees of $18,000 and $69,000, and non-employee stock based compensation expenses of $5,000 and $55,000 in connection with the terms in the Euro-Asia Agreement, respectively.

 

On January 1, 2017, Kimho Consultants Co., Ltd. and the Company entered into a service agreement (the “Kimho Agreement”) for the maintenance of the listing in the U.S. stock exchange market. During the three months ended December 31, 2017 and during the year ended September 30, 2017, the Company recognized professional fees of $21,000 and $113,000, and non-employee stock based compensation expenses of $10,000 and $80,000 in connection with the terms in the Kimho Agreement, respectively.

 

Pursuant to ASC 505-50-30, the transactions with the non-employees were measured based on the fair value of the equity instruments issued as the Company determined that the fair value of the equity instruments issued in a stock-based payment transaction with nonemployees was more reliably measurable than the fair value of the consideration received. The Company measured the fair value of the equity instruments in these transactions using the stock price on the date at which the commitments Kameyama, Euro-Asia, and Kimho for performance were rendered.

  

9. INCOME TAX

 

The Company files income tax returns in the U.S. federal jurisdiction, and various state and local jurisdictions. The Company is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years before 2013.

 

On December 22, 2017 H.R. 1, originally known as the Tax Cuts and Jobs Act, (the “Tax Act”) was enacted. Among the significant changes to the U.S. Internal Revenue Code, the Tax Act lowers the U.S. federal corporate income tax rate (“Federal Tax Rate”) from 35% to 21% effective January 1, 2018The 21% Federal Tax Rate will apply to earnings reported for the full 2018 fiscal year. In addition, the Company must re-measure its net deferred tax assets and liabilities using the Federal Tax Rate that will apply when these amounts are expected to reverse. As of December 31, 2017, the Company can determine a reasonable estimate for certain effects of tax reform and is recording that estimate as a provisional amount. The provisional remeasurement of the deferred tax assets and allowance valuation of deferred tax assets at December 31, 2017 resulted in a net effect of $0 discrete tax expenses (benefit) which lowered the effective tax rate by 13% for the year ended December 31, 2017. The provisional remeasurement amount is anticipated to change as data becomes available allowing more accurate scheduling of the deferred tax assets and liabilities primarily related to net operating loss carryover.

 

 F-18 

 

 

Components of income tax (benefits) for the three months ended December 31, 2017, and for the years ended September 30, 2017 and 2016 are as follows:

 

   Three Months ended
December 31, 2017
   Year ended
September 30, 2017
   Year ended
September 30, 2016
 
   Federal   State   Total   Federal   State   Total   Federal   State   Total 
Current  $        -   $       -   $       -   $            -   $830   $830   $         -   $836   $836 
Deferred   -    -    -    -    -    -    -    -    - 
   $-   $-   $-   $-   $830   $830   $-   $836   $836 

 

Significant components of the Company’s deferred tax accounts at December 31, 2017 and September 30, 2017:

 

Deferred Tax Account - noncurrent:  December 31, 2017   September 30, 2017 
Tax losses carryforwards  $594,501   $832,913 
Less: Valuation allowance   (594,501)   (832,913)
Total deferred tax account - noncurrent  $-   $- 

 

The difference between the effective rate reflected in the provision for income taxes on loss before taxes and the amounts determined by applying the applicable statutory U.S. tax rate are analyzed below:

 

   Three Months ended December 31,   Years ended
September 30,
 
   2017   2017   2016 
Statutory federal tax benefit, net of state tax effects   31%   31%   31%
State income taxes   8.84%   8.84%   8.84%
Provisional remeasurement of deferred taxes   (13)%   -%   -%
Nondeductible/nontaxable items   -%   (29)%   (36)%
Change in valuation allowance   (26.84)%   (10.84)%   (3.84)%
Effective income tax rate   -%   -%   -%

 

10. LOSS PER SHARE

 

Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed by dividing net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the year.

 

   Three Months Ended
December 31,
   Years Ended
September 30,
 
   2017   2017   2016 
             
Numerator:            
Net loss  $(381,214)  $(4,071,983)  $(11,007,799)
                
Denominator:               
Weighted-average shares outstanding:               
Weighted-average shares outstanding - Basic   213,746,647    212,648,770    193,981,153 
Stock options   -    -    - 
Weighted-average shares outstanding - Diluted   213,746,647    212,648,770    193,981,153 
                
Loss per share               
-Basic  $(0.00)  $(0.02)  $(0.06)
-Diluted  $(0.00)  $(0.02)  $(0.06)

 

Diluted loss per share takes into account the potential dilution that could occur if securities or other contracts to issue common stock were exercised and converted into common stock.

 

 F-19 

 

 

11. COMMITMENTS AND CONTINGENCIES

 

Operating Commitment

 

The total future minimum lease payments under the non-cancellable operating lease with respect to the office as of December 31, 2017 are payable as follows:

 

As of December 31,  Amount 
2018  $4,950 
Total minimum payments  $4,950 

 

Rental expense was $2,482 for the three months ended December 31, 2017. Rental expense was $61,093 and 29,129 for the year ended September 30, 2017 and 2016, respectively. 

 

12. TRANSITION PERIOD COMPARATIVE DATA

 

The following table presents certain financial information for the three months ended December 31, 2017 and 2016, respectively:

 

   Three Months Ended 
   December 31,
2017
   December 31,
2016
 
       (Unaudited) 
       (Restated) 
         
Revenues  $-   $- 
           
Cost of revenues   -    - 
           
Gross profit   -    - 
           
Operating expenses          
Selling, general and administrative expenses   289,731    185,188 
Research and development expenses   45,701    25,198 
Stock based compensation   17,362    - 
           
Loss from operations   (352,794)   (210,386)
           
Other income (expense)          
Interest income   80    49 
Interest expense   (28,500)   - 
Total other income (expenses)   (28,420)   49 
           
Loss from continuing operations before provision income tax   (381,214)   (210,337)
           
Provision for income tax   -    - 
           
Net loss   (381,214)   (210,337)
           
Net loss per share attributable to common stockholders          
Basic and diluted  $(0.00)  $(0.00)
           
Weighted average number of common shares outstanding          
Basic and diluted   213,746,647    210,821,647 

 

13. SUBSEQUENT EVENT

 

The Company has evaluated subsequent events through the date which the financial statements were available to be issued. All subsequent events requiring recognition as of December 31, 2017 have been incorporated into these financial statements and there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events.” 

 

******

 

 F-20 

 

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None.

 

ITEM 9A. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of the design and operation of our “disclosure controls and procedures,” as such term is defined in Rule 13a-15(e) or Rule 15d-15(e) promulgated under the Exchange Act as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this report to provide reasonable assurance that material information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms.

 

Management’s Report on Internal Control over Financial Reporting

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f) or Rule 15d-15(f). Our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, our management concluded that our internal controls over financial reporting were not effective as of September 30, 2017 because we lack effective monitoring of financial controls and lack segregation of duties in financial reporting due to the small size of our financial staff (one person).

 

This annual report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our independent registered public accounting firm pursuant to rules of the Securities and Exchange Commission that permit us to provide only management’s report in this annual report.

 

Changes in Internal Control over Financial Reporting

 

There has been no change in our internal control over financial reporting during year ended September 30, 2017.

 

ITEM 9B.  OTHER INFORMATION

 

None.

  

 37 

 

 

PART III

 

ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

 

The following table sets forth as of December 31, 2017, the name, age, and position of each executive officer and director and the term of office of each such person.

 

Name   Position   Term(s) of Office
Eugene Jiang (31)   Chief Executive Officer, President, Chairman  

CEO and President from September 2015 to September 15, 2017

Chairman of the Board from September 2015 till the date of this Annual Report

Kira Huang (48)   Former Chief Financial Officer, Former Secretary, Former Treasurer   February 2016 to September 15, 2017
Dr. Howard Doong (60)   Chief Executive Officer   From September 15, 2017 till the date of this Annual Report
Chun Mu Hung (41)    Chief Financial Officer, Secretary, Treasurer   From September 15, 2017 till the date of this Annual Report

 

Set forth below is certain biographical information regarding each of our directors and officers as of September 30, 2017.

 

Eugene Jiang – Chairman

 

Mr. Eugene Jiang, age 31, has served as our CEO and President since the Company’s inception in July 2015 until he resigned on September 15, 2017. He remains the Chairman of the Board. From June 2015 until present, Mr. Jiang also serves as Director for BioLite Incorporation. He also serves as CEO for Genepro Investment Company since March 2010. Mr Jiang obtained an EMBA degree from the University of Texas in Arrington in 2009. And in 2008, Mr. Jiang received a bachelor’s degree in Physical Education from Fu Jen Catholic University.

 

Dr. Howard Doong-- CEO

 

Dr. Howard Doong was appointed as the Company’s new CEO on September 15, 2017. In addition to the position at the Company, Dr. Doong also serves as the CEO and Chief Scientific Officer (“CSO”) of LifeCode Biotechnology Company (“LifeCode”), a Taiwan company in the biotechnology business, since 2017. At the same time, he also serves as the CEO and CSO of Wuhan Frasergen Genomic Medicine Company (“Wuhan Frasergen Genomic”), a Chinese company in the biotechnology business, since 2016. He served as the CSO of Cold Spring Biotech Corporation, a Taiwan corporation in the biotechnology business from 2014 to 2016. He served as the CEO of iKnowledge-Care Bioscience Corp, a Taiwan company in the biotechnology business from 2014 to 2015. He served as the director of Taipei Veteran General Hospital-LilPao Laboratory of Cancer Genomic Medicine from 2012 to 2013. He served as the Vice President and director of Quality Assurance, TrimGen Corporation, a Maryland corporation in the biotechnology business from 2009 to 2011. Dr. Doong received his Ph.D. degree from University of Chicago, the Department of Organismal Biology and Anatomy and the Department of Surgery. He received his M.D and Ph.D. degree from Harvard-MIT Division of Health Sciences and Technology. He received his M.S. degree from the University of New Hampshire, Genetics Program and B.S. degree from Fu-Jen University, Taiwan, Department of Biology.

 

Chun Mu Hung—CFO, Secretary and Treasury

 

Mr. Chun Mu Hung was appointed as the Company’s CFO, Secretary and Treasury on September 15, 2017. Mr. Hung served as the Assistant Manager at the financial department of NES Limited since February 2017. From August 2011 to February 2017, Mr. Hung served as the Section Manager at the Financial Department of Fujitec Taiwan Co., Ltd., a Taiwan limited company. During April 2009 to August 2011 and March 2005 to December 2006, Mr. Hung served as the Assistant Manager of Toppest CPAs Firm. From December 2006 to April 2009, Mr. Hung served as an auditor at Deloitte Taiwan CPAs Firm. Mr. Hung received his bachelor degree of accounting from Chung Yuan Christian University in 1999.

 

Kira Huang-Chief Financial Officer, Secretary, Treasurer

 

Kira Huang, has served as our Chief Financial Officer since February 2016 until her resignation on September 15, 2017 due to the change of management team.

 

 38 

 

 

Significant Employees

 

The following are employees who are not executive officers, but who are expected to make significant contributions to our business:

 

Dr. Chi-Hsin Richard King—Chief Scientific Officer

 

Effective September 15, 2017, the Board appointed Dr. Chi-Hsin Richard King as the CSO of the Company. Dr. Chi-Hsin Richard King, 69, retired since July 2017. He served as the consultant at TaiGen Biotechnology Co. Ltd (“TaiGen”), a Taiwan company in the biotechnology business, from August 2016 to July 2017, the Senior Vice President at TaiGen from July 2008 to August 2016 and as the Vice President at Research and Development of TaiGen from June 2005 to July 2008. Dr. King served as the Director at Albany Molecular Research Inc. (“AMRI”), a New York corporation, from January 2003 to June 2005, the Assistant Director at Medicinal Chemistry Department of AMRI from January 2000 to December 2002 and the Assistant Director at Chemical Development Department of AMRI from August 1997 to January 2000. Dr. King received the Ph. D. degree of organic chemistry from University of Utah in March 1980, and B.S. degree of chemistry from National Taiwan Normal University in July 1972.

 

Compliance with Section 16(a) of the Exchange Act

 

Our common stock is not registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Accordingly, officers, directors and principal shareholders are not subject to the beneficial ownership reporting requirements of Section 16(a) of the Exchange Act.

 

ITEM 11. EXECUTIVE COMPENSATION

 

The following tables set forth, for each of the last two completed fiscal years of us, the total compensation awarded to, earned by or paid to any person who was a principal executive officer during the preceding fiscal year and every other highest compensated executive officers earning more than $100,000 during the last fiscal year (together, the “Named Executive Officers”). The tables set forth below reflect the compensation of the Named Executive Officers.

 

Summary Compensation Table

 

Name and Principal Position  Year   Salary
($)
   Bonus
($)
     Stock Awards
($)
   Option Awards
($)
  

Non-Equity

Incentive Plan

Compensation
($)

  

Change in

Pension
Value and
Nonqualified

Deferred

Compensation

Earnings
($)

  

All Other

Compensation
($)

   Total
($)
 
                                     
Howard Doong (1)   2017    33,333                                                                                   33,333 
                                              
Chun Mu Hung (2)   2017    13,333                                  13,333 
                                              
Eugene Jiang (3)   2016    55,000                                  55,000 
    2017    60,000                                  60,000 
                                              
Kira Huang (4)   2016    49,500         79,592                        129,092 
    2017    40,500                                  40,500 

 

(1) Dr. Doong was appointed as the CEO on September 15, 2017.

 

(2) Mr. Hung was appointed as the CFO, Secretary and Treasury on September 15, 2017.

 

(3)  Mr. Jiang resigned as the CEO and President of the Company on September 15, 2017.

 

(4) Ms. Huang resigned as the CFO, Secretary and Treasury of the Company on September 15, 2017.

  

 39 

 

 

Narrative Disclosure to Summary Compensation Table

 

Other than set out below, there are no arrangements or plans in which we provide pension, retirement or similar benefits for directors or executive officers. Our directors and executive officers may receive share options at the discretion of our board of directors in the future. We do not have any material bonus or profit sharing plans pursuant to which cash or non-cash compensation is or may be paid to our directors or executive officers, except that share options may be granted at the discretion of our board of directors.

 

Stock Option Plan

 

We adopted an Equity Incentive Plan on February 17, 2016.

  

Grants of Plan-Based Awards

 

There were no grants of plan-based awards during the year ended September 30, 2015. In fiscal year 2016, we awarded 10,000 shares of common stock to each of five employees. Due to the forward split detailed in our 10-Q filed June 30, 2016, each of such employees has been awarded 31,410 shares of the Company’s Common Stock. As a result, an aggregate of 157,050 shares were granted to the employees pursuant to the 2016 Plan as of December 31, 2017.

 

Outstanding Equity Awards at Fiscal Year End

 

The following table summarizes outstanding unexercised options, unvested stocks and equity incentive plan awards held by each of our named executive officers, as of December 31, 2017:

 

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END

  

OPTION AWARDS   STOCK AWARDS  
Name   Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
    Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable
    Equity Incentive
Plan Awards:
Number of
Securities
Underlying
Unexercised
Unearned Options
(#)
    Options
Exercise
Prices ($)
    Option
Expiration
Date
    Number of
Shares or
Units of
Stock That
Have Not
Vested (#)
    Market
Value of
Shares or
Units of
Stock That
Have Not
Vested
($)
    Equity
Incentive Plan
Awards:
Number of
Unearned
Shares, Units
or Other
Rights That
Have Not
Been Issued
(#)
    Equity Incentive
Plan Awards:
Market or Payout
Value of Unearned
Shares, Units or
Other Rights That
Have Not Been
Issued ($)
 
Kira Huang(1)                                                31,410     $ 79,592 (2)

  

(1) On February 17, 2016, we awarded 10,000 shares of common stock to each of five employees, of whom Kira Huang, the former Chief Financial Officer, was the only officer. Due to the forward split detailed in our 10-Q filed June 30, 2016, each of such employees has been awarded 31,410 shares of common stock.

 

(2) The dollar amount shown is determined by multiplying the number of shares of common stock reported in the table by the closing price of a share of our common stock on February 17, 2016 ($7.9592), which was the day of such issuance.

 

 40 

 

 

Option Exercises and Stock Vested

 

No options have been awarded by the Company as of December 31, 2017.

 

Compensation of Directors

 

We do not have any agreements for compensating our directors for their services in their capacity as directors as of December 31, 2017.

 

Pension, Retirement or Similar Benefit Plans

 

There are no arrangements or plans in which we provide pension, retirement or similar benefits for directors or executive officers. We have no material bonus or profit sharing plans pursuant to which cash or non-cash compensation is or may be paid to our directors or executive officers, except that stock options may be granted at the discretion of the board of directors or a committee thereof.

 

Employment Contracts

 

We entered into an employment contract with Kira Huang on March 1, 2016 according to which, among other terms,  Ms. Huang is required to, as Chief Financial Officer,  perform duties and undertake the responsibilities in a professional manner including reporting on financials and related matters to our Board of Directors; developing the financial planning and overseeing tax reporting activities; monitoring and submitting all required reports to SEC on timely basis, planning and overseeing annual budgets and other duties as may arise from time to time and as may be assigned to her. Pursuant to such employment agreement, we shall compensate Mrs. Huang with salary of $4,500 per month subject to normal statutory deduction and annual review. Additional bonus or stock options will be determined by our Board. Ms. Huang resigned from the position as CFO, Secretary and Treasury on September 15, 2017 and terminated the employment agreement with the Company. We paid Ms. Huang $3,000 for each month of September and October 2017 for her continuous consulting services and thereafter have not had any outstanding obligations towards Ms. Huang under such employment agreement.

 

 Dr. Howard Doong has entered into an employment agreements (“Doong Employment Agreement”) with the Company, pursuant to which he shall receive an annual base salary of $100,000. As of December 31, 2017, we paid Mr. Doong 20,833 shares of the Company’s common stock at a per share price of $1.60 as opposed to cash compensation. Under Doong Employment Agreement, Dr. Doong is employed as our CEO and President of the Company. We may terminate the employment for cause, at any time, without notice or remuneration, for certain acts of the executive officer, such as conviction or plea of guilty to a felony or grossly negligent or dishonest acts to our detriment, or misconduct or a failure to perform agreed duties. In such case, the executive officer will not be entitled to receive payment of any severance benefits or other amounts by reason of the termination, and the executive officer’s right to all other benefits will terminate, except as required by any applicable law. We may also terminate an executive officer’s employment without cause upon one-month advance written notice. In such case of termination by us, we are required to provide compensation to the executive officer, including severance pay equal to 12 months of base salary. The executive officer may terminate the employment at any time with a one-month advance written notice if there is any significant change in the executive officer’s duties and responsibilities or a material reduction in the executive officer’s annual salary. In such case, the executive officer will be entitled to receive compensation equivalent to 12 months of the executive officer's base salary.

 

Mr. Chun Mu Hung has entered into an employment agreement (“Hung Employment Agreement”) with the Company, pursuant to which he shall receive an annual base salary of $40,000. As of December 31, 2017, we paid Mr. Hung 2,083 shares of the Company’s common stock at a per share price of $1.60 as opposed to cash compensation. Under Hung Employment Agreement, Mr. Hung is employed as the CFO, Secretary and Treasurer of the Company. We may terminate the employment for cause, at any time, without notice or remuneration, for certain acts of the executive officer, such as conviction or plea of guilty to a felony or grossly negligent or dishonest acts to our detriment, or misconduct or a failure to perform agreed duties. In such case, the executive officer will not be entitled to receive payment of any severance benefits or other amounts by reason of the termination, and the executive officer’s right to all other benefits will terminate, except as required by any applicable law. We may also terminate an executive officer’s employment without cause upon one-month advance written notice. In such case of termination by us, we are required to provide compensation to the executive officer, including severance pay equal to 12 months of base salary. The executive officer may terminate the employment at any time with a one-month advance written notice if there is any significant change in the executive officer’s duties and responsibilities or a material reduction in the executive officer’s annual salary. In such case, the executive officer will be entitled to receive compensation equivalent to 12 months of the executive officer's base salary.

 

 41 

 

 

Dr. Chi-Hsin Richard King has entered into an employment agreements (“King Employment Agreement”) with the Company, pursuant to which he shall receive an annual base salary of $50,000. As of December 31, 2017, we paid Mr. King 10,416 shares of the Company’s common stock at a per share price of $1.60 as opposed to cash compensation. Under King Employment Agreement, Dr. King is employed as the CSO of the Company. We may terminate the employment for cause, at any time, without notice or remuneration, for certain acts of the executive officer, such as conviction or plea of guilty to a felony or grossly negligent or dishonest acts to our detriment, or misconduct or a failure to perform agreed duties. In such case, the executive officer will not be entitled to receive payment of any severance benefits or other amounts by reason of the termination, and the executive officer’s right to all other benefits will terminate, except as required by any applicable law. We may also terminate an executive officer’s employment without cause upon one-month advance written notice. In such case of termination by us, we are required to provide compensation to the executive officer, including severance pay equal to 12 months of base salary. The executive officer may terminate the employment at any time with a one-month advance written notice if there is any significant change in the executive officer’s duties and responsibilities or a material reduction in the executive officer’s annual salary. In such case, the executive officer will be entitled to receive compensation equivalent to 12 months of the executive officer's base salary.

 

ITEM 12. SECURITY OWENERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

Beneficial Owners

 

The following table sets forth certain information regarding beneficial ownership of our common stock as of March 28, 2018 (i) each person (or group of affiliated persons) who is known by us to own more than five percent (5%) of the outstanding shares of our common stock, (ii) each director, executive officer and director nominee, and (iii) all of our directors, executive officers and director nominees as a group.

 

Beneficial ownership is determined in accordance with SEC rules and generally includes voting or investment power with respect to securities. For purposes of this table, a person or group of persons is deemed to have “beneficial ownership” of any shares of common stock that such person has the right to acquire within 60 days of the date of the respective table. For purposes of computing the percentage of outstanding shares of our common stock held by each person or group of persons named above, any shares that such person or persons has the right to acquire within 60 days of the date of the respective table is deemed to be outstanding for such person, but is not deemed to be outstanding for the purpose of computing the percentage ownership of any other person. The inclusion herein of any shares listed as beneficially owned does not constitute an admission of beneficial ownership.

 

Unless otherwise noted, the business address of each beneficial owner listed is 11 Sawyers Peak Drive, Goshen, NY 10924. Except as otherwise indicated, the persons listed below have sole voting and investment power with respect to all shares of our common stock owned by them, except to the extent that power may be shared with a spouse.

 

As of March 28, 2018, we had 213,926,475 shares of common stock issued and outstanding.

  

Name of Beneficial Owner  Amount and
Nature of
Beneficial
Ownership
  

Percent
of

Class

 
Eugene Jiang   147,842,856    69.11%
Howard Doong   31,250    * 
Chun Mu Hung   3,125    * 
Tsang Ming Jiang   -    - 
Ming-Fong Wu   -    - 
Norimi Sakamoto   -    - 
Yen-Hsin Chou   -    - 
All officers and directors as a group ( seven persons)   147,877,231    69.13%

 

* less than 1%.

 

(1) These shares are owned by YuanGene Corporation, a corporation incorporated in Samoa. Eugene Jiang is the sole shareholder of YuanGene Corporation and therefore will be deemed as the beneficial owner of the shares held by YuanGene Corporation.

 

 42 

 

 

Changes in Control

 

As a result of the Share Exchange, BriVision became our wholly owned subsidiary and the former shareholders of BriVision collectively own approximately 79.70% of the shares of us outstanding post-exchange common stock. As a result, such persons now collectively control our shares.

 

ITEM 13.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, DIRECTOR INDEPENDENCE

 

Collaboration Agreement with BioLite, Inc.

 

On December 29, 2015, American BriVision Corporation entered into a Collaborative Agreement with BioLite Inc., a related party, pursuant to which BioLite granted the Company sole licensing rights for drug and therapeutic use of five products: BLI-1005 CNS-Major Depressive Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity Disorder; BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1; BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer; and BLI-1501 Hematology-Chronic Lymphocytic Leukemia, in USA and Canada. Under the Collaborative Agreement, BriVision would be required to pay a total of $100,000,000 in cash or stock of BriVision with equivalent value, according to the following schedule:

 

Pursuant to the BioLite Collaborative Agreement, an upfront payment of $3,500,000 (the “Milestone Payment”), which is 3.5% of total payments due under the BioLite Collaborative Agreement, was to be paid by the Company upon signing of that agreement. On May 6, 2016, the Company and BioLite agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company agreed to pay the Milestone Payment to BioLite with $2,600,000 in cash and $900,000 in the form of newly issued shares of its common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares. The cash payment and shares issuance were completed in June 2016.

 

Pursuant to the BioLite Collaborative Agreement, the 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. On February 2017, the Company agreed to pay this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of its common stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. The cash payment and shares issuance were completed in February 2017.

 

Pursuant to the BioLite Collaborative Agreement, the 15% of total payment, $15,000,000 shall be made at the completion of first phase II clinical trial. As of September 30, 2017, the first phase II clinical trial research has not completed yet.

   

On January 12, 2017, the Company entered into an Addendum (the “Addendum”) to the BioLite Collaborative Agreement which was previously entered into with BioLite. Pursuant to the Addendum, the Company and BioLite agreed to include one more product, namely, “Maitake Combination Therapy” as one of the Products defined in the BioLite Collaborative Agreement (the “Sixth Product’) and defined the Territory of the Sixth Product to be worldwide and restate the Territory of the Five Products to be the U.S.A and Canada.

 

As of September 30, 2017 and 2016, the amount due to BioLite is $0 and $6,500,000 respectively.

 

Collaboration agreement with BioFirst Corporation

 

On July 24, 2017, American BriVision Corporation entered into a collaborative agreement (the “BioFirst Collaborative Agreement”) with BioFirst Corporation (“BioFirst”), pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the “Product”): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a controlling beneficiary shareholder of Yuangene Corporation and the Company is one of the directors and common stock shareholders of BioFirst.

 

 43 

 

 

Pursuant to the BioFirst Collaborative Agreement, the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $3,000,000 in cash or stock of the Company before September 30, 2018. As of September 30, 2017, BioFirst has delivered all research, technical, data and development data to BriVision. No payment has been made by the Company as of the date of this report. As of September 30, 2017, BioFirst has delivered all research, technical, data and development data to BriVision, and the Company has recorded full amount of $3,000,000 due to BioFirst.

 

Loan from BioFirst

 

On January 26, 2017, the Company and BioFirst entered into a loan agreement for a total commitment (non-secured indebtedness) of $950,000 from BioFirst to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The loan will be matured on February 1, 2018. As of September 30, 2017, the outstanding loan balance is $950,000 and accrued interest is $8,460. Interest expenses were $74,960 and $0 for the years ended September 30, 2017 and 2016, respectively. 

 

Co-Development agreement with Rgene Corporation

 

On May 26, 2017, American BriVision Corporation entered into a co-development agreement (the “Co-Dev Agreement”) with Rgene Corporation (the “Rgene”), a related party under common control by controlling beneficiary shareholder of YuanGene Corporation and the Company. Pursuant to Co-Dev Agreement, BriVison and Rgene agreed to co-develop and commercialize certain products that are included in the Sixth Product as defined in the Addendum. Under the terms of the Co-Dev Agreement, Rgene should pay the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017.

 

On June 1, 2017, the Company has delivered all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of YuanGene Corporation and the Company, the Company has recorded the full amount of $3,000,000 in connection with the Co-Dev Agreement as additional paid-in capital during the year ended September 30, 2017. As of the date of this report, the Company has received $450,000 in cash. The Company is still in discussion with Rgene with respect to the schedule of the outstanding balance.

 

Euro-Asia Agreement

 

On January 1, 2017, Euro-Asia Investment & Finance Corp Ltd. and the Company entered into a service agreement (the “Euro-Asia Agreement”) for the maintenance of the listing in the U.S. stock exchange market. During the year ended September 30, 2017, the Company recognized non-employee stock based compensation expenses of $55,000 in connection with the terms in the Euro-Asia Agreement. Euro-Asia Investment & Finance Corp Ltd. is a shareholder of the Company.

 

Kimho Agreement

 

On January 1, 2017, Kimho Consultants Co., Ltd. and the Company entered into a service agreement (the “Kimho Agreement”) for the maintenance of the listing in the U.S. stock exchange market. During the year ended September 30, 2017, the Company recognized non-employee stock based compensation expenses of $80,000 in connection with the terms in the Kimho Agreement. Kimho Consultants Co., Ltd. is a shareholder of the Company.

 

Consulting Service to LionGene

 

During the year ended September 30, 2017, the Company provided a one-time consulting service to LionGene Corporation for $70,000. Since both LionGene and the Company are related parties and under common control by a controlling beneficiary shareholder of YuanGene Corporation, the Company has recorded the full amount of $70,000 as additional paid-in capital during the year ended September 30, 2017.

 

 44 

 

 

Asiangene Related Transactions

 

During the year ended September 30, 2017, the Company entered an operating lease agreement with Asiangene for an office space in Taiwan for the period from October 1, 2016 to July 31, 2017. The monthly base rent is approximately $5,000. Rent expenses under this lease agreement amounted to $52,205 and $0 for the years ended September 30, 2017 and 2016, respectively.

 

In September 2017, Asiangene entered an investment and equity transfer agreement (the “Investment and Equity Transfer Agreement”) with Everfront Biotech Inc. (the “Everfront”), a third party. Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by Asiangene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. Asiangene also agreed to loan the proceeds to the Company for working capital purpose. The non-secured loan bears 0% interest rate and is due on demand. As of September 30, 2017, the outstanding loan balance is $160,000.

 

Promoters and Certain Control Persons

 

None of our management or other control persons were “promoters” (within the meaning of Rule 405 under the Securities Act), and none of such persons took the initiative in the formation of our business or received any of our debt or equity securities or any of the proceeds from the sale of such securities in exchange for the contribution of property or services, during the last five years.

 

ITEM 14.  PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

Various audit, audit related and non-audit services to us is as follows:

 

   For the Year Ended
December 31,
 
   2017   2016 
Audit Fees  $36,930   $10,700 
Audit Related Fees   0    0 
Tax Fees   0    0 
All Other Fees   0    0 
Total Fees  $36,930   $10,700 

 

Audit Fees.   Audit Fees consists of fees for professional services rendered by our principal accountants for the contemporaneous audit of our annual financial statements and the review of quarterly financial statements or services that are normally provided by our principal accountants in connection with statutory and regulatory filings or engagements.

 

Audit Related Fees.   Audit Related Fees consists of fees for assurance and related services by our principal accountants that are reasonably related to the performance of the audit or review of our financial statements and are not reported under “Audit Fees.”

 

Tax Fees and All Other Fees.   Tax Fees and All Other Fees Consists of fees for products and services provided by our principal accountants, other than the services reported under “Audit Fees,” “Audit-Related Fees” and “Tax Fees” above.

 

 45 

 

 

PART IV

 

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

  

(a)(1)  List of Financial statements included in Part II hereof

 

Balance Sheets, December 31, 2017 and September 30, 2017

Statements of Operations for the three months ended December 31, 2017, the years ended September 30, 2017 and 2016

Statements of Stockholders’ Equity (Deficit) for the three months ended December 31, 2017, the years ended September 30, 2017 and 2016

Statements of Cash Flows for the three months ended December 31, 2017, the years ended September 30, 2017 and 2016

Notes to the Financial Statements

 

(a)(2) List of Financial Statement schedules included in Part IV hereof:  None.

 

(a)(3) Exhibits

 

The following exhibits are included herewith:

 

Exhibit No.   Description
2.1   Share Exchange Agreement, dated February 8, 2016 (1)
3.1   Articles of Incorporation of the Company (2)
3.2   Bylaws of the Company (3)
3.3   Certificate of Amendment to Articles of Incorporation filed on March 21, 2016 (4)
3.4   Certificate of Amendment to Articles of Incorporation filed on December 21, 2016 (5)
10.1   Collaboration Agreement dated December 29, 2015 (6)
10.2   Collaborative Agreement and Milestone Payment Agreement dated June 9, 2016 (7)
10.3   Employment Agreement with Kira Huang (8)
10.4   Addendum to the Collaboration Agreement dated January 12, 2017 (9)
10.5   Collaboration Agreement with BioFirst dated July 24, 2017 (10)
10.6   Co-Deve Agreement with Rgene dated May 26, 2017 (11)
10.7   Employment Agreement with Dr. Howard Doong (12)
10.8   Employment Agreement with Chun Mu Hung (13)
10.9   Employment Agreement with Dr. Chi-Hsin Richard King (14)
14.1   Code of Ethics (15)
21.1   List of subsidiaries (16)
31.1   Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002+
31.2   Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002+
32.1   Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002+
32.2   Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002+
     
101.INS   XBRL Instance Document+
101.SCH   XBRL Taxonomy Extension Schema Document+
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document+
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document+
101.LAB   XBRL Taxonomy Extension Label Linkbase Document+
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document+

 

+ Filed herewith

  

(1) Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on February 16, 2016.

 

 46 

 

 

(2) Incorporated by reference to Exhibit 3.01 to the Company’s Form SB-2 filed on June 28, 2002

 

(3) Incorporated by reference to Exhibit 3.02 to the Company’s Form SB-2, filed on June 28, 2002

 

(4) Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed on March 28, 2016.

 

(5) Incorporated by reference to Exhibit 3.4 to the Company’s Form S-1, filed on September 13, 2016. (3.4)

 

(6) Incorporated by reference to Exhibit 10.2 the Company’s Current Report on Form 8-K, filed on February 16, 2016.

 

(7) Incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K, filed on June 9, 2016.

 

(8) Incorporated by reference to Exhibit 10.3 to the Company’s Annual Report on Form 10-K, filed on January 12, 2017.

 

(9) Incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K, filed on February 22, 2017.

 

(10) Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on July 24, 2017.

 

(11) Incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K, filed on May 30, 2017.

 

(12) Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on September 20, 2017.

 

(13) Incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed on September 20, 2017.

 

(14) Incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed on September 20, 2017.

 

(15) Incorporated by reference to Exhibit 14.1 to the Company’s Amendment No.1 to Form S-1, filed on November 14, 2016.

 

(16) Incorporated by reference to 21.1 to the Company’s Form S-1, filed on September 13, 2016.

 

 47 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on April 12, 2018.

 

  American BriVision (Holding) Corporation
     
  By: /s/ Howard Doong
    Howard Doong
    Chief Executive Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:

 

Signature   Title   Date
         
/s/ Howard Doong        
Howard Doong   Chief Executive Officer   April 12, 2018
         
/s/ Chun-Mu Hung        
Chun-Mu Hung   Chief Financial Officer, Secretary and Treasury   April 12, 2018
         
/s/ Eugene Jiang                            
Eugene Jiang                        Chairman of the Board   April 12, 2018
         
/s/ Tsang Ming Jiang        
Tsang Ming Jiang   Director   April 12, 2018
         
/s/ Ming-Fong Wu        
Ming-Fong Wu   Director   April 12, 2018
         
/s/ Yen-Hsin Chou         
Yen-Hsin Chou                       Director   April 12, 2018

 

/s/ Norimi Sakamoto        
Norimi Sakamoto   Director      April 12, 2018

 

 

48

 

 

EX-31.1 2 f10k2017n2ex31-1_american.htm CERTIFICATION

EXHIBIT 31.1

 

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

 

I, Howard Doong, certify that:

 

1 I have reviewed this annual report on Form 10-K for the year ended December 31, 2017 of American BriVision (Holding) Corporation;
   
2 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3 Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4 The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   
  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
     
5 The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
   
  a.   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
     
  b.   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: April 12, 2018 By: /s/ Howard Doong
    Howard Doong
    Chief Executive Officer
    (Principal Executive Officer)

 

EX-31.2 3 f10k2017n2ex31-2_american.htm CERTIFICATION

EXHIBIT 31.2

 

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

 

I, Chun-Mu Hung, certify that:

 

1 I have reviewed this annual report on Form 10-K for the year ended December 31, 2017 of American BriVision (Holding) Corporation;
   
2 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3 Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4 The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   
  a.   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b.   Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c.    Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d.   Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
     
5 The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
   
  a.   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
     
  b.   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: April 12, 2018 By: /s/ Chun-Mu Hung
    Chun-Mu Hung
    Chief Financial and Accounting Officer
    (Principal Finance Officer)

 

EX-32.1 4 f10k2017n2ex32-1_american.htm CERTIFICATION

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

SECTION 906 OF SARBANES-OXLEY ACT OF 2002

 

I, Howard Doong, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

 

  1. The Annual Report on Form 10-K of American BriVision (Holding) Corporation  (the “Company”) for the year ended December 31, 2017 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (U.S.C. 78m or 78o(d)); and
     
  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

  

Date: April 12, 2018 By: /s/ Howard Doong
    Howard Doong
   

Chief Executive Officer

(Principal Executive Officer)

 

The foregoing certification is being furnished solely pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) and is not being filed as part of a separate disclosure document.

EX-32.2 5 f10k2017n2ex32-2_american.htm CERTIFICATION

EXHIBIT 32.2

 

CERTIFICATION PURSUANT TO

SECTION 906 OF SARBANES-OXLEY ACT OF 2002

 

I, Chun-Mu Hung, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

 

  1. The Annual Report on Form 10-K of American BriVision (Holding) Corporation (the “Company”) for the period ended December 31, 2017 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (U.S.C. 78m or 78o(d)); and
 
  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: April 12, 2018 By: /s/ Chun-Mu Hung
    Chun-Mu Hung
   

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

The foregoing certification is being furnished solely pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) and is not being filed as part of a separate disclosure document.

GRAPHIC 6 image_001.jpg GRAPHIC begin 644 image_001.jpg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image_002.jpg GRAPHIC begin 644 image_002.jpg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abvc-20171231.xml XBRL INSTANCE FILE 0001173313 2017-10-01 2017-12-31 0001173313 2015-09-30 0001173313 2016-09-30 0001173313 2017-09-30 0001173313 2017-12-31 0001173313 us-gaap:CollaborativeArrangementMember 2015-12-29 0001173313 abvc:CollaborativeArrangementOneMember 2016-08-26 0001173313 abvc:AdjustmentsMember 2016-09-30 0001173313 us-gaap:ScenarioPreviouslyReportedMember 2016-09-30 0001173313 us-gaap:RestatementAdjustmentMember 2016-09-30 0001173313 abvc:AdjustmentsOneMember 2016-09-30 0001173313 abvc:BioliteIncMember 2017-12-31 0001173313 abvc:BioFirstCorporationMember 2017-12-31 0001173313 abvc:AsiangeneCorporationMember 2017-12-31 0001173313 abvc:YuangeneCorporationMember 2017-12-31 0001173313 abvc:BioLiteOneMember 2017-12-31 0001173313 abvc:CodevelopmentagreementMember 2017-05-26 0001173313 abvc:CodevelopmentagreementMember 2017-06-01 0001173313 us-gaap:CollaborativeArrangementMember 2017-07-24 0001173313 abvc:BioliteIncMember 2017-09-30 0001173313 abvc:BioFirstCorporationMember 2017-09-30 0001173313 abvc:AsiangeneCorporationMember 2017-09-30 0001173313 abvc:YuangeneCorporationMember 2017-09-30 0001173313 abvc:BioLiteOneMember 2017-09-30 0001173313 2015-07-20 0001173313 us-gaap:CommonStockMember 2015-07-20 0001173313 us-gaap:AdditionalPaidInCapitalMember 2015-07-20 0001173313 abvc:SubscriptionReceivableMember 2015-07-20 0001173313 us-gaap:RetainedEarningsMember 2015-07-20 0001173313 us-gaap:CommonStockMember 2015-09-30 0001173313 us-gaap:AdditionalPaidInCapitalMember 2015-09-30 0001173313 abvc:SubscriptionReceivableMember 2015-09-30 0001173313 us-gaap:RetainedEarningsMember 2015-09-30 0001173313 us-gaap:CommonStockMember 2016-09-30 0001173313 us-gaap:AdditionalPaidInCapitalMember 2016-09-30 0001173313 abvc:SubscriptionReceivableMember 2016-09-30 0001173313 us-gaap:RetainedEarningsMember 2016-09-30 0001173313 us-gaap:CommonStockMember 2017-09-30 0001173313 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0001173313 abvc:SubscriptionReceivableMember 2017-09-30 0001173313 us-gaap:RetainedEarningsMember 2017-09-30 0001173313 abvc:BioliteIncMember 2016-08-26 0001173313 2015-10-01 2016-09-30 0001173313 2016-10-01 2017-09-30 0001173313 abvc:AdjustmentsMember 2015-10-01 2016-09-30 0001173313 us-gaap:ScenarioPreviouslyReportedMember 2015-10-01 2016-09-30 0001173313 us-gaap:RestatementAdjustmentMember 2015-10-01 2016-09-30 0001173313 abvc:AdjustmentsOneMember 2015-10-01 2016-09-30 0001173313 abvc:CollaborativeArrangementOneMember 2016-10-01 2017-09-30 0001173313 us-gaap:CommonStockMember 2015-10-01 2016-09-30 0001173313 us-gaap:AdditionalPaidInCapitalMember 2015-10-01 2016-09-30 0001173313 us-gaap:CommonStockMember 2016-10-01 2017-09-30 0001173313 us-gaap:AdditionalPaidInCapitalMember 2016-10-01 2017-09-30 0001173313 abvc:SubscriptionReceivableMember 2016-10-01 2017-09-30 0001173313 us-gaap:RetainedEarningsMember 2016-10-01 2017-09-30 0001173313 2015-07-21 2015-09-30 0001173313 us-gaap:RetainedEarningsMember 2015-07-21 2015-09-30 0001173313 us-gaap:RetainedEarningsMember 2015-10-01 2016-09-30 0001173313 us-gaap:CommonStockMember 2015-07-21 2015-09-30 0001173313 us-gaap:AdditionalPaidInCapitalMember 2015-07-21 2015-09-30 0001173313 abvc:SubscriptionReceivableMember 2015-07-21 2015-09-30 0001173313 us-gaap:CollaborativeArrangementMember 2016-05-05 2016-05-06 0001173313 abvc:BioliteIncMember 2016-08-01 2016-08-26 0001173313 abvc:CollaborativeArrangementOneMember 2017-02-01 2017-02-28 0001173313 us-gaap:CollaborativeArrangementMember 2017-07-01 2017-07-24 0001173313 abvc:CodevelopmentagreementMember 2016-10-01 2017-09-30 0001173313 abvc:CodevelopmentagreementMember 2016-10-01 2017-09-30 0001173313 abvc:SubscriptionReceivableMember 2015-10-01 2016-09-30 0001173313 abvc:ShareExchangeAgreementTwoMember 2016-02-04 2016-02-08 0001173313 abvc:ShareExchangeAgreementFourMember 2016-02-04 2016-02-08 0001173313 abvc:ShareExchangeAgreementMember 2016-02-04 2016-02-08 0001173313 abvc:ShareExchangeAgreementOneMember 2016-02-04 2016-02-08 0001173313 abvc:ShareExchangeAgreementThreeMember 2016-02-04 2016-02-08 0001173313 abvc:EquityIncentivePlanMember 2016-02-01 2016-02-17 0001173313 abvc:ShareExchangeAgreementTwoMember 2016-02-08 0001173313 abvc:ShareExchangeAgreementFourMember 2016-02-08 0001173313 2016-03-20 2016-03-21 0001173313 us-gaap:CollaborativeArrangementMember 2016-05-06 0001173313 us-gaap:CollaborativeArrangementMember 2017-02-28 0001173313 abvc:CollaborativeArrangementOneMember 2017-02-28 0001173313 abvc:CollaborativeArrangementOneMember 2016-03-01 2016-03-31 0001173313 abvc:CodevelopmentagreementMember 2017-05-01 2017-05-26 0001173313 us-gaap:CollaborativeArrangementMember 2016-10-01 2017-09-30 0001173313 abvc:CollaborativeArrangementOneMember 2016-03-31 0001173313 us-gaap:CollaborativeArrangementMember 2017-09-30 0001173313 abvc:BioliteIncMember 2017-10-01 2017-12-31 0001173313 abvc:BioFirstCorporationMember 2017-10-01 2017-12-31 0001173313 abvc:RgeneCorporationMember 2017-10-01 2017-12-31 0001173313 abvc:LiongeneCorporationMember 2017-10-01 2017-12-31 0001173313 abvc:YuangeneCorporationMember 2017-10-01 2017-12-31 0001173313 abvc:AsiangeneCorporationMember 2017-10-01 2017-12-31 0001173313 abvc:EuroAsiaMember 2017-10-01 2017-12-31 0001173313 abvc:KimhoConsultantsMember 2017-10-01 2017-12-31 0001173313 abvc:LoanAgreementMember 2017-01-26 0001173313 abvc:LoanAgreementMember 2017-01-01 2017-01-26 0001173313 abvc:YuangeneCorporationMember 2016-10-01 2017-09-30 0001173313 abvc:BioFirstCollaborativeAgreementMember 2017-09-30 0001173313 abvc:EuroAsiaAgreemenMember 2016-10-01 2017-09-30 0001173313 abvc:KimhoAgreementMember 2016-10-01 2017-09-30 0001173313 abvc:EuroAsiaAgreementMember 2016-10-01 2017-09-30 0001173313 abvc:KimhoAgreementtMember 2016-10-01 2017-09-30 0001173313 2015-10-30 0001173313 us-gaap:CollaborativeArrangementMember 2016-09-15 2016-10-02 0001173313 us-gaap:CommonStockMember 2017-10-01 2017-12-31 0001173313 us-gaap:CommonStockMember 2017-12-31 0001173313 us-gaap:AdditionalPaidInCapitalMember 2017-10-01 2017-12-31 0001173313 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001173313 us-gaap:RetainedEarningsMember 2017-10-01 2017-12-31 0001173313 us-gaap:RetainedEarningsMember 2017-12-31 0001173313 abvc:SubscriptionReceivableMember 2017-10-01 2017-12-31 0001173313 abvc:SubscriptionReceivableMember 2017-12-31 0001173313 abvc:CollaborativeArrangementOneMember 2017-09-01 2017-09-25 0001173313 abvc:EugeneJiangMember 2017-10-01 2017-12-31 0001173313 abvc:EugeneJiangMember 2017-12-31 0001173313 abvc:BioLiteMember 2017-10-01 2017-12-31 0001173313 abvc:BioLiteMember 2016-10-01 2017-09-30 0001173313 2018-03-28 0001173313 abvc:EuroAsiaAgreemenMember 2017-10-01 2017-12-31 0001173313 abvc:KimhoAgreementMember 2017-10-01 2017-12-31 0001173313 2017-12-01 2017-12-22 0001173313 2016-10-01 2016-12-31 0001173313 us-gaap:CollaborativeArrangementMember 2017-10-01 2017-12-31 0001173313 abvc:BioFirstCollaborativeAgreementMember 2017-10-01 2017-12-31 0001173313 abvc:BioFirstCollaborativeAgreementMember 2016-10-01 2017-09-30 0001173313 abvc:AsiangeneCorporationMember 2017-10-01 2017-12-31 0001173313 abvc:AsiangeneCorporationMember 2016-10-01 2017-09-30 0001173313 abvc:YuangeneCorporationMember 2017-10-01 2017-12-31 0001173313 abvc:EugeneJiangMember 2016-10-01 2017-09-30 0001173313 abvc:EugeneJiangMember 2017-10-01 2017-12-31 0001173313 abvc:CodevelopmentagreementMember 2017-12-31 0001173313 abvc:CodevelopmentagreementMember 2017-10-01 2017-12-31 0001173313 abvc:EuroAsiaAgreementMember 2017-10-01 2017-12-31 0001173313 abvc:KimhoAgreementtMember 2017-10-01 2017-12-31 0001173313 abvc:LiongeneCorporationMember 2016-10-01 2017-09-30 0001173313 us-gaap:CollaborativeArrangementMember 2017-12-31 0001173313 2017-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure American BriVision (Holding) Corp 0001173313 false --12-31 10-KT 2017-12-31 2017 FY No No Yes Smaller Reporting Company 213926475 994830 173537 204851 93332 2550000 2550000 2754851 2643332 2754851 2643332 4113000 4229320 100000000 100000000 6500000 6500000 109220 3957000 160000 3000 6500000 3000000 450000 3000000 3950000 160000 3000 0 100 450000 4147914 4400247 6500000 56470 6556470 213747 213747 13788574 13805936 4733401 4733461 60 70000 -15395384 -15776598 -6500000 -4823401 -11323401 633357 -6379118 -1393063 -1756915 -6500000 120882 -6379118 897001 159623 1087378 -350000 166274 1132685 -350000 -315602 210822 4733461 -11323401 213747 13788574 -15395384 213747 13805936 -15776598 2754851 2643332 213746647 213746647 213746647 213746647 289731 599303 707142 -3500060 4497263 997263 60 185188 45701 10000000 3151162 10000000 10000000 3000000 25198 17362 397960 138038 157 397803 138038 17362 -352794 -10997295 -3996342 -6499940 -4497295 -10997295 -60 -210386 -6499940 -4506963 -11006963 -60 -381214 -11007799 -4071983 -6499940 -4507799 -11007799 -60 -4071983 -315602 -315602 -11007799 -381214 -210337 -0.00 -0.06 -0.02 -0.06 0.00 -0.06 0.00 -0.00 159622964 166273921 210821647 213746647 213746647 3250000 5850000 2032 3247968 2925 5847075 51958 6651 45307 900000 1468750 5850000 3000000 3000000 3000000 2550000 2031423 2925000 6650957 562500 2925000 -2636 42359 -44995 42359253 157050 350000 350000 3070000 3070000 -1295324 60 1295324 1295324 -60 17362 138038 -3815 -3815 18370 -18370 136013 -261900 -3186 116320 6477483 2353000 6500000 -22517 6477483 -111519 -3474707 -1598686 -520000 1110000 -46586 350000 2350000 2653414 1630000 -111519 -821293 31314 836 830 5850000 2550000 0.2536 6500000 60 6500000 6500000 3500000 10000000 6500000 0.06 6500000 6500000 2600000 650000 1756915 1393063 <table cellspacing="0" cellpadding="0" style="font: 12pt times new roman, times, serif; width: 100%; border-collapse: collapse"><tr><td style="vertical-align: bottom; width: 48px">&#160;</td><td style="vertical-align: top; width: 24px"><font style="font-size: 10pt">&#9679;</font></td><td style="text-align: justify"><font style="font-size: 10pt">upfront payment shall upon the signing of this BioLite Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week.</font></td></tr><tr><td style="vertical-align: bottom">&#160;</td><td style="vertical-align: top">&#160;</td><td style="text-align: justify">&#160;</td></tr><tr><td style="vertical-align: bottom">&#160;</td><td style="vertical-align: top"><font style="font-size: 10pt">&#9679;</font></td><td style="text-align: justify"><font style="font-size: 10pt">upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week.</font></td></tr><tr><td style="vertical-align: bottom">&#160;</td><td style="vertical-align: top">&#160;</td><td style="text-align: justify">&#160;</td></tr></table><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr><td style="vertical-align: bottom; width: 48px">&#160;</td><td style="vertical-align: top; width: 24px"><font style="font-size: 10pt">&#9679;</font></td><td style="text-align: justify"><font style="font-size: 10pt">at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months.</font></td></tr><tr><td style="vertical-align: bottom">&#160;</td><td style="vertical-align: top">&#160;</td><td style="text-align: justify">&#160;</td></tr><tr><td style="vertical-align: bottom">&#160;</td><td style="vertical-align: top"><font style="font-size: 10pt">&#9679;</font></td><td style="text-align: justify"><font style="font-size: 10pt">upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week.</font></td></tr><tr><td style="vertical-align: bottom">&#160;</td><td style="vertical-align: top">&#160;</td><td style="text-align: justify">&#160;</td></tr><tr><td style="vertical-align: bottom">&#160;</td><td style="vertical-align: top"><font style="font-size: 10pt">&#9679;</font></td><td style="text-align: justify"><font style="font-size: 10pt">at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months.</font></td></tr><tr><td style="vertical-align: bottom">&#160;</td><td style="vertical-align: top">&#160;</td><td style="text-align: justify">&#160;</td></tr><tr><td style="vertical-align: bottom">&#160;</td><td style="vertical-align: top"><font style="font-size: 10pt">&#9679;</font></td><td style="vertical-align: bottom"><font style="font-size: 10pt">upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week.&#160;</font></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> 3500000 10000000 3000000 Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene Entity controlled by controlling beneficiary shareholder of Yuangene Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene Controlling beneficiary shareholder of the Company Shareholder; entity controlled by controlling beneficiary shareholder of Yuangene Shareholder of the Company Shareholder of the Company Former President and Chairman 950000 The loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. 950000 950000 160000 160000 17460 8460 7000 3000 109220 100 0.00 0.00 0.00 0.00 7000 0 3000 109220 0 3000000 3000000 3000 0 100 397960 138038 55000 80000 55000 80000 5000 10000 5000 10000 70000 5000 0 52205 836 830 836 830 836 830 832913 594501 832913 594501 0.31 0.31 0.31 0.0884 0.0884 0.0884 0.36 0.29 -0.2684 -0.0384 -0.1084 213746647 193981153 212648770 213746647 193981153 212648770 -0.00 -0.06 -0.02 -0.00 -0.06 -0.02 4950 4950 2482 29129 61093 2609 29075 8460 17460 23845 110800 34914 170927 32 -32 80 361 149 49 28500 10170 74960 141 -28420 -9668 -74811 49 -381214 -11006963 -4071153 -210337 836 830 213746647 193981153 212648770 210821647 19500 66500 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif"><b>1. ORGANIZATION AND DESCRIPTION OF BUSINESS</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><br /> American BriVision (Holding) Corporation (the &#8220;Company&#8221; or &#8220;Holding entity&#8221;), a Nevada corporation, through the Company&#8217;s operating entity, American BriVision Corporation (the &#8220;BriVision&#8221;), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology and focuses on the development of new drugs and innovative medical devices to fulfill unmet medical needs. &#160;The business model of the Company is to integrate research achievements from world-famous institutions (such as Memorial Sloan Kettering Cancer Center (&#8220;MSKCC&#8221;) and MD Anderson Cancer Center), conduct clinical trials of translational medicine for Proof of Concept (&#8220;POC&#8221;), out-license to international pharmaceutical companies, and exploit global markets. BriVision had to predecessor operations prior to its formation on July 21, 2015.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Reverse Merger</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">On February 8, 2016, a Share Exchange Agreement (the &#8220;Share Exchange Agreement&#8221;) was entered into by and among American BriVision (Holding) Corporation, American BriVision Corporation&#160;(&#8220;BriVision&#8221;), and Euro-Asia Investment &#38; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People's Republic of China (&#8220;Euro-Asia&#8221;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock of the Company, and the owners of record of all of the issued share capital of BriVision (the&#160;&#8220;BriVision Stock&#8221;).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the&#160;&#8220;Acquisition Stock&#8221;) (subject to adjustment for fractionalized shares as set forth below) of the Company&#8217;s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&#8217;s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger (the &#8220;Merger&#8221;).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Pursuant to the Merger, all of the issued and outstanding common shares of BriVision were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583pre-stock split) common shares of the Company and BriVision has become a wholly owned subsidiary of the Company. The holders of Company&#8217;s common stock as of immediately prior to the Merger held an aggregate of 205,519,223(65,431,144 pre-stock split) shares of Company&#8217;s common stock.&#160;Because of the exchange of the BriVision Stock for the Acquisition Stock (the&#160;&#8220;Share Exchange&#8221;), BriVision has become a wholly owned subsidiary (the &#8220;Subsidiary&#8221;) of the Company and there was a change of control of the Company following the closing.&#160;&#160;There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Because&#160;of the consummation of the Share Exchange,&#160;BriVision&#160;is now our wholly owned subsidiary and its shareholders own approximately&#160;79.70% of our issued and outstanding common stock.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Following the Share Exchange, we have abandoned our prior business plan and we are now pursuing&#160;BriVision&#8217;s&#160;historically proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs.&#160;&#160;The business model of the Company is to integrate research achievements from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept (&#8220;POC&#8221;), out-license to international pharmaceutical companies, and exploit global markets.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.2pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif"><u>Accounting Treatment of the Reverse Merger</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">For financial reporting purposes, the Share Exchange represents a &#8220;reverse merger&#8221;&#160;rather than a business combination and&#160;BriVision&#160;is deemed the accounting acquirer in the transaction. The&#160;Share Exchange is being accounted for as a reverse-merger and recapitalization. BriVision&#160;is the acquirer for financial reporting purposes and the&#160;Company&#160;is the acquired company. Consequently, the assets and liabilities and the operations reflected in the historical financial statements prior to the Share Exchange will be those of&#160;BriVision&#160;and recorded at the historical cost basis of&#160;BriVision. In addition, the consolidated financial statements after completion of the Share Exchange will include the assets and liabilities of the Company and BriVision, and the historical operations of&#160;BriVision&#160;and operations of the Combined Company from the closing date of the Share Exchange.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif"><b>2. CORRECTIONS TO PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company discovered that it had erroneously stated that the research and development expenses were understated during the year ended September 30, 2016. Instead, our research and development expenses were $10,000,000 for the year ended September 30, 2016 and were restated in the Adjustments No. 1 column. Moreover, there were typographical errors on Selling, General and Administration expenses which were corrected in the Adjustments No. 2 column.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The following tables present the effect of the corrections discussed above and other adjustments on selected line items of our previously reported consolidated financial statements as of and for the year ended September 30, 2016,</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">ITEMS</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Previously&#160; Reported on Form 10K</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Adjustments No.1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Adjustments No.2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Restated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Consolidated Balance Sheets</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>As of September 30, 2016</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Due to related party</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,500,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,500,000</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Liabilities</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">56,470</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,556,470</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Additional paid-in capital</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4,733,401</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">60</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4,733,461</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accumulated deficit</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(4,823,401</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(6,500,000</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(11,323,401</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total equity (deficit)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">120,882</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(6,500,000</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(6,379,118</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Consolidated Statements of Operations and Comprehensive Loss</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>For the year ended September 30, 2016</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Selling, general and administrative expenses</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4,497,263</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(3,500,060</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">60</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">997,263</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development expenses</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,000,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net loss from operations</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(4,497,295</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(6,499,940</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(60</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(10,997,295</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loss from continuing operations before income taxes</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(4,506,963</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(6,499,940</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(60</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(11,006,963</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net Loss</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(4,507,799</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(6,499,940</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(60</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(11,007,799</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Basic and diluted loss per share</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(0.00</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(0.06</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(0.00</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(0.06</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Consolidated Statements of Cash Flow</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">For the year ended September 30, 2016</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net loss from continuing operations</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(4,507,799</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(6,499,940</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(60</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(11,007,799</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance of common stock for compensation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,295,324</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(60</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">60</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,295,324</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">(Decrease) increase in due to related party</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(22,517</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,477,483</td><td style="text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">As a result of the restatement of the consolidated balance sheet as of September 30, 2016, Due to related party and Total liabilities were increased by $6,500,000; changed from $0 to $6,500,000 and from $56,470 to $6,556,470. Additional paid in capital was increased by $60 and changed from $4,733,401 to $4,733,461. Accumulated deficit was increased by $6,500,000 and changed from $(4,823,401) to $(11,323,401). Total equity (deficit) was decreased by $6,500,000 and changed from $120,882 to $(6,379,118).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">As a result of the restatement of the consolidated statement of operations and comprehensive loss for the year ended September 30, 2016, Selling, general and administrative expenses were decreased by $3,500,000 and changed from $4,497,263 to $997,263. Research and development expenses were increased by $10,000,000 and changed from $0 to $10,000,000. Net loss from operations was increased by $6,500,000 and changed from $(4,497,295) to $(10,997,295). Loss from continuing operations before taxes was increased by $6,500,000 and changed from $(4,506,963) to $(11,006,963). Net loss was increased by $6,500,000 and changed from $(4,507,799) to $(11,007,799). Basic and diluted loss per share were also increased by 0.06 and changed from $0 to $(0.06).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">As a result of the restatement of the consolidated statement of cash flow for the year ended September 30, 2016, Net loss from continuing operations was increased by $6,500,000; changed from $(4,507,799) to $(11,007,799). Issuance of common stock for compensation did not have changes and stated as $1,295,324. (Decrease) increase in due to related party was increased by $6,500,000 and changed from $(22,517) to $6,477,483. There were no changes in Net cash used in operating activities.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">ITEMS</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Previously&#160; Reported on Form 10K</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Adjustments No.1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Adjustments No.2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Restated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Consolidated Balance Sheets</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>As of September 30, 2016</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Due to related party</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,500,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,500,000</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Liabilities</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">56,470</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,556,470</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Additional paid-in capital</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4,733,401</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">60</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4,733,461</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accumulated deficit</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(4,823,401</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(6,500,000</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(11,323,401</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total equity (deficit)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">120,882</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(6,500,000</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(6,379,118</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Consolidated Statements of Operations and Comprehensive Loss</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>For the year ended September 30, 2016</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Selling, general and administrative expenses</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4,497,263</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(3,500,060</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">60</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">997,263</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development expenses</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,000,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net loss from operations</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(4,497,295</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(6,499,940</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(60</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(10,997,295</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loss from continuing operations before income taxes</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(4,506,963</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(6,499,940</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(60</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(11,006,963</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net Loss</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(4,507,799</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(6,499,940</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(60</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(11,007,799</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Basic and diluted loss per share</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(0.00</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(0.06</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(0.00</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(0.06</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Consolidated Statements of Cash Flow</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">For the year ended September 30, 2016</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net loss from continuing operations</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(4,507,799</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(6,499,940</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(60</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(11,007,799</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance of common stock for compensation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,295,324</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(60</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">60</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,295,324</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">(Decrease) increase in due to related party</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(22,517</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,477,483</td><td style="text-align: left">&#160;</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Basis of Presentation</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The accompanying consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the &#8220;U.S. GAAP&#8221;). All significant intercompany transactions and account balances have been eliminated.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company&#8217;s financial statements are expressed in U.S. dollars.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Fiscal Year</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company changed its fiscal year from the period beginning on October 1<sup>st</sup> and ending on September 30<sup>th</sup> to the period beginning on January 1<sup>st</sup> and ending on December 31<sup>st</sup>, beginning January 1, 2018. As a result, the current fiscal period is a three-month transition period ended on December 31, 2017. In these consolidated statements, including the notes thereto, the current period financial results ended December 31, 2017 are for a three-month period. Audited results for the twelve months ended September 30, 2017 and 2016 are both for twelve-month periods. In addition, the Company's consolidated statements of operations and consolidated statements of cash flows include unaudited comparative amounts for the three-month period ended December 31, 2016.&#160;All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30<sup>th</sup> of such year.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Use of Estimates</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Reclassifications</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Forward Stock split</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to Articles of Incorporation.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Fair Value Measurements</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company applies the provisions of ASC Subtopic 820-10,&#160;&#8220;Fair Value Measurements&#8221;,&#160;for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements.&#160;&#160;ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;&#160;When determining the fair value measurements for assets and liabilities, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of&#160;September 30, 2017 and 2016.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Cash and Cash Equivalents</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of December 31, 2017 and September 30, 2017, the Company&#8217;s cash and cash equivalents amounted $93,332 and $204,851, respectively. Some&#160;of the Company&#8217;s cash deposits are held in financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Concentration of Credit Risk</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company&#8217;s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation&#8217;s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes. Concentration of credit risk with respect to trade and notes receivables is limited due to the wide variety of customers and markets in which the Company transacts business, as well as their dispersion across many geographical areas. The Company performs ongoing credit evaluations of its customers and generally does not require collateral, but does require advance deposits on certain transactions.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Receivable from Collaboration Partners</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Receivable from collaboration partners is stated at carrying value less estimates made for doubtful receivables. An allowance for impairment of receivable from collaboration partners is established if the collection of a receivable becomes doubtful. Such receivable becomes doubtful when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of the receivables. Significant financial difficulties of the debtor, probability that the debtor will enter into bankruptcy or financial reorganization, and default or delinquency in payments are considered indicators that the receivable is impaired. The amount of the allowance is the difference between the asset&#8217;s carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. An impairment loss is recognized in the statement of operations, as are subsequent recoveries of previous impairments.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Research and Development Expenses</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><br /> <u>Stock-based Compensation</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company measures expense associated with all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with ASC Topic 718 &#8220;Compensation-Stock Compensation&#8221;. Total employee stock-based compensation expenses were $0 for the three months ended December 31, 2017, and $0 and $397,960 for the years ended September 30, 2017 and 2016, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company accounted for stock-based compensation to non-employees in accordance with ASC Topic 505-50 &#8220;Equity-Based Payments to Non-Employees&#8221; which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee stock-based compensation expenses were $17,362 for the three months ended December 31, 2017, and $138,038 and $0 for the years ended September 30, 2017 and 2016, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Income Taxes</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.2pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Under ASC 740, a tax position is recognized as a benefit only if it is&#160;&#8220;more likely than not&#8221;&#160;that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the three months ended December 31, 2017 and for the years ended September 30, 2017 and September, 30, 2016. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">For the three months ended December 31, 2017, the Company&#8217;s income tax expense amounted $0. For the years ended September 30, 2017 and 2016, the Company&#8217;s income tax expense amounted $830 and $836, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; background-color: white">On December 22, 2017, the SEC issued Staff Accounting Bulletin (&#8220;SAB 118&#8221;), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company&#8217;s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions we may take. The Company is continuing to gather additional information to determine the final impact.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Loss Per Share of Common Stock</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company reports loss per share in accordance with ASC Topic 260-10 &#34;Earnings per Share.&#34; Basic earnings (loss) per share are computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Commitments and Contingencies</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company has adopted ASC Topic 450 &#8220;Contingencies&#8221; subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Recent Accounting Pronouncements</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b><i>Revenue Recognition:&#160;&#160;&#160;&#160;&#160;</i></b>In May 2014, the FASB issued Accounting Standards Update No.&#160;2014-09,&#160;<i>Revenue from Contracts with Customers: Topic&#160;</i>606 (ASU 2014-09), to supersede nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for us in our first quarter of fiscal 2018 using either of two methods: (i)&#160;retrospective to each prior reporting period presented with the option to elect certain practical expedients as defined within ASU 2014-09 (full retrospective method); or (ii)&#160;retrospective with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined per ASU 2014-09 (modified retrospective method). We are currently assessing the materiality of the impact to our consolidated financial statements, and have not yet selected a transition approach.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b><i>Disclosure of Going Concern Uncertainties:&#160;&#160;&#160;&#160;&#160;</i></b>In August 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No.&#160;2014-15,&#160;<i>Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</i>(ASU 2014-15), to provide guidance on management&#8217;s responsibility in evaluating whether there is substantial doubt about a company&#8217;s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective for us in our fourth quarter of fiscal 2017 with early adoption permitted. We do not believe the impact of our pending adoption of ASU 2014-15 on the Company&#8217;s financial statements will be material.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b><i>Leases</i></b>:&#160;&#160;&#160;&#160;&#160;In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (&#8220;ASU 2016-2&#8221;), which provides guidance on lease amendments to the FASB Accounting should Standard Codification. This ASU will be effective for us beginning in May 1, 2019. We are currently in the process of evaluating the impact of the adoption of ASU 2016-2on our consolidated financial statements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b><i>Stock-based Compensation</i></b>:&#160;&#160;&#160;&#160;In March 2016, the FASB issued ASU 2016-09,&#160;Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Stock-Based Payment Accounting&#160;(ASU 2016-09). ASU 2016-09 changes how companies account for certain aspects of stock-based awards to employees, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU 2016-09 is effective for us in the first quarter of&#160;2018, and earlier adoption is permitted. We are still evaluating the effect that this guidance will have on our consolidated financial statements and related disclosures.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b><i>Financial Instruments - Credit Losses:&#160;</i></b>In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): The amendments in this Update require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments broaden the information that an entity must consider in developing its expected credit loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss, which will be more decision useful to users of the financial statements. ASU 2016-13 is effective for the Company for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is allowed as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is still evaluating the effect that this guidance will have on the Company&#8217;s consolidated financial statements and related disclosures.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b><i>Statement of Cash Flows:&#160;</i></b>In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): The amendments in this Update apply to all entities, including both business entities and not-for-profit entities that are required to present a statement of cash flows under Topic 230. The amendments in this Update provide guidance on the following eight specific cash flow issues. The amendments are an improvement to GAAP because they provide guidance for each of the eight issues, thereby reducing the current and potential future diversity in practice described above. ASU 2016-15 is effective for the Company for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is still evaluating the effect that this guidance will have on the Company&#8217;s consolidated financial statements and related disclosures.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">In November 2016, the FASB issued ASU No. 2016-18,&#160;Statement of Cash Flows&#160;(Topic 230): &#8220;Restricted Cash&#8221;(&#8220;ASU 2016-18&#8221;). ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. ASU 2016-18 will become effective for us beginning April 1, 2018, or fiscal 2019. ASU 2016-18 is required to be applied retrospectively. Upon the adoption, amounts described as restricted cash will be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period amounts shown on the statements of cash flows.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b><i>Business Combination</i></b>: &#160;In January 2017, the FASB issued ASU No. 2017-1 &#8220;Topic 805, Business Combinations: Clarifying the Definition of a Business&#8221;. The amendments in this update provide a screen to determine when a set is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. The amendments in this update affect all reporting entities that must determine whether they have acquired or sold a business. Public business entities should apply the amendments in this update to annual periods beginning after December 15, 2017, including interim periods within those periods. All other entities should apply the amendments to annual periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019. We do not expect the adoption of ASU 2017-1 to have a material impact on our consolidated financial statements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">From time to time, new accounting pronouncements are issued by FASB that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company's financial statements upon adoption. Management does not believe that any recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying financial statements.&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>4. GOING CONCERN</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since its inception resulting in an accumulated deficit of $15,776,598 and $15,395,384 as of December 31, 2017 and September 30, 2017, respectively, and incurred net loss of $381,214 for the three months ended December 31, 2017, and $4,071,983 during the year ended September 30, 2017. The Company also had working capital deficiency of $1,756,915 and $1,393,063 at December 31, 2017 and September 30, 2017, respectively. &#160;The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company upon signing of that agreement. On May 6, 2016, the Company and BioLite agreed to amend the BioLite Collaborative Agreement, through enter into the Milestone Payment Agreement, whereby the Company has agreed to pay the Milestone Payment to BioLite $2,600,000 in cash and $900,000 in newly issued shares of its common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares. The cash payment and shares issuance were completed in June 2016. Pursuant to the BioLite Collaborative Agreement, the 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. On February 2017, the Company agreed to pay this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of its common stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. The cash payment and shares issuance were completed in February 2017. This BioLite Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen years as of the first commercial sales of the Product in the Territory and automatically renew for five more years unless either party gives the other party six month written notice of termination prior to the expiration date of the term.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; background-color: white">In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management&#8217;s plans to obtain such resources for the Company include&#160;(1) obtaining capital from the sale of its equity securities (2) short-term and long-term borrowings from banks and third-parties, and (3) short-term borrowings from stockholders or other related party(ies) when needed. However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; background-color: white">The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually to secure other sources of financing and attain profitable operations.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif"><b>5.&#160;COLLABORATIVE AGREEMENTS</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b><u>Collaborative agreement with BioLite Inc., a related party</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">On December 29, 2015, American BriVision Corporation entered into a collaborative agreement (the &#8220;BioLite Collaborative Agreement&#8221;) with BioLite Inc. (the &#8220;BioLite&#8221;), a related party (See Note 7), pursuant to which BioLite granted BriVision sole licensing rights for drug and therapeutic use of five products, including BLI-1005 CNS-Major Depressive Disorder, BLI-1008 CNS-Attention Deficit Hyperactivity Disorder, BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1, BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer, and BLI-1501 Hematology-Chronic Lymphocytic Leukemia, in the U.S.A and Canada. Under the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of BriVision with equivalent value, according to the following schedule:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font-family: Times New Roman, Times, Serif"> <td style="vertical-align: bottom; width: 0.25in; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; width: 0.25in; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;&#160;</font></td> <td style="text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">upfront payment shall upon the signing of this BioLite Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week.</font></td></tr> <tr style="font-family: Times New Roman, Times, Serif"> <td style="vertical-align: bottom; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="font-family: Times New Roman, Times, Serif"> <td style="vertical-align: bottom; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; padding-left: 0; text-indent: 0; padding-right: 0; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week.</font></td></tr> <tr style="font-family: Times New Roman, Times, Serif"> <td style="vertical-align: bottom; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="font-family: Times New Roman, Times, Serif"> <td style="vertical-align: bottom; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months.</font></td></tr> <tr style="font-family: Times New Roman, Times, Serif"> <td style="vertical-align: bottom; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="font-family: Times New Roman, Times, Serif"> <td style="vertical-align: bottom; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week.</font></td></tr> <tr style="font-family: Times New Roman, Times, Serif"> <td style="vertical-align: bottom; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="font-family: Times New Roman, Times, Serif"> <td style="vertical-align: bottom; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months.</font></td></tr> <tr style="font-family: Times New Roman, Times, Serif"> <td style="vertical-align: bottom; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="font-family: Times New Roman, Times, Serif"> <td style="vertical-align: bottom; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="vertical-align: bottom; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week.&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">This BioLite Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen years as of the first commercial sales of the Product in the Territory and automatically renew for five more years unless either party gives the other party six month written notice of termination prior to the expiration date of the term.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Pursuant to the BioLite Collaborative Agreement, an upfront payment of $3,500,000 (the &#8220;Milestone Payment&#8221;), which is 3.5% of total payments due under the BioLite Collaborative Agreement, was to be paid by the Company upon signing of that agreement. On May 6, 2016, the Company and BioLite agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company agreed to pay the Milestone Payment to BioLite with $2,600,000 in cash and $900,000 in the form of newly issued shares of its common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares. The cash payment and shares issuance were completed in June 2016.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Pursuant to the BioLite Collaborative Agreement, the 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. On February 2017, the Company agreed to pay this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of its common stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. The cash payment and shares issuance were completed in February 2017.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Pursuant to the BioLite Collaborative Agreement, the 15% of total payment, $15,000,000 shall be made at the completion of first phase II clinical trial. As of December 31, 2017, the first phase II clinical trial research has not completed yet.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company determined to fully expense the entire amount of $10,000,000 since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence the entire amount is fully expensed as research and development expense.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">On January 12, 2017, the Company entered into an Addendum (the &#8220;Addendum&#8221;) to the BioLite Collaborative Agreement which was previously entered into with BioLite. Pursuant to the Addendum, the Company and BioLite agreed to include one more product, namely, &#8220;Maitake Combination Therapy&#8221; as one of the Products defined in the BioLite Collaborative Agreement (the &#8220;Sixth Product&#8217;) and defined the Territory of the Sixth Product to be worldwide and restate the Territory of the Five Products to be the U.S.A and Canada.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b><u>Co-Development agreement with Rgene Corporation, a related party</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">On May 26, 2017, American BriVision Corporation entered into a co-development agreement (the &#8220;Co-Dev Agreement&#8221;) with Rgene Corporation (the &#8220;Rgene&#8221;), a related party under common control by controlling beneficiary shareholder of Yuangene Corporation and the Company (See Note 7). Pursuant to Co-Dev Agreement, BriVison and Rgene agreed to co-develop and commercialize certain products that are included in the Sixth Product as defined in the Addendum. Under the terms of the Co-Dev Agreement, Rgene should pay the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017. The payment is for the compensation of BriVision&#8217;s past research efforts and contributions made by BriVision before the Co-Dev Agreement was signed and it does not relate to any future commitments made by BriVision and Rgene in this Co-Dev Agreement. Besides of $3,000,000, the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene, if any, and any development cost shall be equally shared by both BriVision and Rgene.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">On June 1, 2017, the Company has delivered all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of Yuangene Corporation and the Company, the Company has recorded the full amount of $3,000,000 in connection with the Co-Dev Agreement as additional paid-in capital during the year ended September 30, 2017. As of the date of this report, the Company has received $450,000 in cash. The Company is still in discussion with Rgene with respect to the schedule of the outstanding balance.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b><u>Collaborative agreement with BioFirst Corporation, a related party</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">On July 24, 2017, American BriVision Corporation entered into a collaborative agreement (the &#8220;BioFirst Collaborative Agreement&#8221;) with BioFirst Corporation (&#8220;BioFirst&#8221;), pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the &#8220;Product&#8221;): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a controlling beneficiary shareholder of Yuangene Corporation and the Company is one of the directors and common stock shareholders of BioFirst (See Note 7).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Pursuant to the BioFirst Collaborative Agreement, the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $3,000,000 in cash or stock of the Company before September 30, 2018. The amount of $3,000,000 is in connection with the compensation for BioFirst&#8217;s past research efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate to any future commitments made by BioFirst and BriVision in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive 50% of the future net licensing income or net sales profit, if any, and any development cost shall be equally shared by both BriVision and BioFirst.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision. No payment has been made by the Company as of the date of this report. The Company determined to fully expense the entire amount of $3,000,000 since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence the entire amount of $3,000,000 is fully expensed as research and development expense during the year ended September 30, 2017.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>6. ACCRUED EXPENSES</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Accrued expenses as of December 31, 2017 and September 30, 2017 consisted of:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">December 31,<br /> 2017</font></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">September&#160;30,<br /> 2017</font></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Accrued consulting fee</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">29,075</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">2,609</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Accrued professional service fees</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">13,592</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Accrued interest expense &#8211; related party(Note 7)</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">17,460</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">8,460</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Accrued payroll</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">110,800</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">23,845</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Total</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">170,927</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">34,914</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"></font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">December 31,<br /> 2017</font></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">September&#160;30,<br /> 2017</font></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Accrued consulting fee</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">29,075</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">2,609</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Accrued professional service fees</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">13,592</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Accrued interest expense &#8211; related party(Note 7)</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">17,460</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">8,460</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Accrued payroll</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">110,800</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">23,845</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Total</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">170,927</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">34,914</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr></table> 13592 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>7. RELATED PARTIES TRANSACTIONS</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The related parties of the company with whom transactions are reported in these financial statements are as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="width: 38%; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Name of entity or Individual</b></font></td> <td style="width: 1%; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 61%; border-bottom: Black 1.5pt solid; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Relationship with the Company and its subsidiaries</b></font></td></tr> <tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">BioLite Inc.&#160;(the &#8220;BioLite&#8221;)</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene</font></td></tr> <tr style="background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">BioFirst Corporation (the &#8220;BioFirst&#8221;)</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Entity controlled by controlling beneficiary shareholder of Yuangene</font></td></tr> <tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Rgene Corporation (the &#8220;Rgene&#8221;)</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene </font></td></tr> <tr style="background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Liongene Corporation (the &#8220;Liongene&#8221;)</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene</font></td></tr> <tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Yuangene Corporation (the &#8220;Yuangene&#8221;)</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Controlling beneficiary shareholder of the Company</font></td></tr> <tr style="background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Asiangene Corporation (the &#8220;Asiangene&#8221;)</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Shareholder; entity controlled by controlling beneficiary shareholder of Yuangene</font></td></tr> <tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Euro-Asia Investment &#38; Finance Corp Ltd. (the &#8220;Euro-Asia&#8221;)</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Shareholder of the Company</font></td></tr> <tr style="background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Kimho Consultants Co., Ltd. (the &#8220;Kimho&#8221;)</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Shareholder of the Company</font></td></tr> <tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Eugene Jiang</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Former President and Chairman </font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Due to related parties</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Amount due to related parties consisted of the following as of the periods indicated:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-family: Times New Roman, Times, Serif">December 31,</font></td><td style="font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-family: Times New Roman, Times, Serif">September&#160;30,</font></td><td style="font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2017</font></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2017</font></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">BioLite Inc.</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">109,220</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">BioFirst Corporation</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">3,957,000</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">3,950,000</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Asiangene Corporation</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">160,000</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">160,000</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Yuangene Corporation</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">3,000</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">3,000</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Eugene Jiang</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">100</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Total</font></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">4,229,320</font></td><td style="padding-bottom: 4pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">4,113,000</font></td><td style="padding-bottom: 4pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Related party transactions</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"> <td style="width: 0.3in; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(1)</font></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">During the three months ended December 31, 2017, BioLite advanced in an aggregate amount of $109,220 to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand. As of December 31, 2017 and September 30, 2017, the outstanding advance balance is $109,220 and $0, respectively.</font></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"> <td style="width: 0.3in; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(2)</font></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">On January 26, 2017, the Company and BioFirst entered into a loan agreement for a total commitment (non-secured indebtedness) of $950,000 to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The loan will be matured on February 1, 2018. As of December 31, 2017 and September 30, 2017, the outstanding loan balance is $950,000 and $950,000, and accrued interest is $17,460 and $8,460, respectively (See Note 6). Interest expenses in connection with this loan is $28,500 for the three months ended December 31, 2017, and $74,960 and $0 for the years ended September 30, 2017 and 2016, respectively.</font></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -24.1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"> <td style="width: 0.3in; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(3)</font></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">On July 24, 2017, BriVision entered into a collaborative agreement (the &#8220;BioFirst Collaborative Agreement&#8221;) with BioFirst (See Note 5). In September 2017, BioFirst has delivered all research, technical, data and development data to BriVision, and the Company has recorded full amount of $3,000,000 due to BioFirst. As of December 31, 2017 and September 30, 2017, the outstanding balance is $3,000,000 and $3,000,000, respectively.</font></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -24.1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"> <td style="width: 0.3in; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(4)</font></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">During the three months ended December 31, 2017, BioFirst also advanced in an aggregate amount of $7,000 to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand. As of December 31, 2017 and September 30, 2017, the outstanding advance balance is $7,000 and $0, respectively.</font></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -24.1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"> <td style="width: 0.3in; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(5)</font></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">In September 2017, Asiangene entered an investment and equity transfer agreement (the &#8220;Investment and Equity Transfer Agreement&#8221;) with Everfront Biotech Inc. (the &#8220;Everfront&#8221;), a third party. Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by Asiangene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. Asiangene also agreed to loan the proceeds to the Company for working capital purpose. The non-secured loan bears 0% interest rate and is due on demand. As of December 31, 2017 and September 30, 2017, the outstanding loan balance is $160,000 and $160,000, respectively.</font></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"> <td style="width: 0.3in; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(6)</font></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">During the year ended September 30, 2017, Yuangene Corporation advanced in an aggregate amount of $3,000 to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand. As of December 31, 2017 and September 30, 2017, the outstanding advance balance is $3,000 and $3,000, respectively.</font></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -24.1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"> <td style="width: 0.3in; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(7)</font></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">During the three months ended December 31, 2017, Eugene Jiang, the former President and Chairman of the Company, has advanced in an aggregate amount of $100 to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand. As of December 31, 2017 and September 30, 2017, the outstanding advance balance is $100 and $0, respectively.</font></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"> <td style="width: 0.3in; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(8)</font></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">On May 26, 2017, BriVision entered into a co-development agreement (the &#8220;Co-Dev Agreement&#8221;) with Rgene (See Note 5). As of December 31, 2017, the Company has received an aggregate amount of $450,000 in cash and has recorded $2,550,000 as receivable from collaboration partners. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of Yuangene Corporation, the Company has recorded the full amount of $3,000,000 in connection with the Co-Dev Agreement as additional paid-in capital during the year ended September 30, 2017.</font></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -24.1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"> <td style="width: 0.3in; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(9)</font></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">On January 1, 2017, Euro-Asia Investment &#38; Finance Corp Ltd. and the Company entered into a service agreement (the &#8220;Euro-Asia Agreement&#8221;) for the maintenance of the listing in the U.S. stock exchange market. During the three months ended December 31, 2017 and during the year ended September 30, 2017, the Company recognized non-employee stock based compensation expenses of $5,000 and $55,000 in connection with the terms in the Euro-Asia Agreement, respectively.</font></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -24.1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"> <td style="width: 0.3in; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(10)</font></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">On January 1, 2017, Kimho Consultants Co., Ltd. and the Company entered into a service agreement (the &#8220;Kimho Agreement&#8221;) for the maintenance of the listing in the U.S. stock exchange market. During the three months ended December 31, 2017 and during the year ended September 30, 2017, the Company recognized non-employee stock based compensation expenses of $10,000 and $80,000 in connection with the terms in the Kimho Agreement, respectively.</font></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -24.1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"> <td style="width: 0.3in; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(11)</font></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">During the year ended September 30, 2017, the Company provided a one-time consulting service to Liongene Corporation for $70,000. Since both Liongene and the Company are related parties and under common control by a controlling beneficiary shareholder of Yuangene Corporation, the Company has recorded the full amount of $70,000 as additional paid-in capital during the year ended September 30, 2017.</font></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -24.1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"> <td style="width: 0.3in; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">(12)</font></td><td style="text-align: justify; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">During the year ended September 30, 2017, the Company entered an operating lease agreement with Asiangene for an office space in Taiwan for the period from October 1, 2016 to July 31, 2017. The monthly base rent is approximately $5,000. Rent expenses under this lease agreement amounted to $52,205 and $0 for the years ended September 30, 2017 and 2016, respectively.</font></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="width: 38%; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Name of entity or Individual</b></font></td> <td style="width: 1%; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 61%; border-bottom: Black 1.5pt solid; text-align: center; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Relationship with the Company and its subsidiaries</b></font></td></tr> <tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">BioLite Inc.&#160;(the &#8220;BioLite&#8221;)</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene</font></td></tr> <tr style="background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">BioFirst Corporation (the &#8220;BioFirst&#8221;)</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Entity controlled by controlling beneficiary shareholder of Yuangene</font></td></tr> <tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Rgene Corporation (the &#8220;Rgene&#8221;)</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene </font></td></tr> <tr style="background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Liongene Corporation (the &#8220;Liongene&#8221;)</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene</font></td></tr> <tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Yuangene Corporation (the &#8220;Yuangene&#8221;)</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Controlling beneficiary shareholder of the Company</font></td></tr> <tr style="background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Asiangene Corporation (the &#8220;Asiangene&#8221;)</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Shareholder; entity controlled by controlling beneficiary shareholder of Yuangene</font></td></tr> <tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Euro-Asia Investment &#38; Finance Corp Ltd. (the &#8220;Euro-Asia&#8221;)</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Shareholder of the Company</font></td></tr> <tr style="background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Kimho Consultants Co., Ltd. (the &#8220;Kimho&#8221;)</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Shareholder of the Company</font></td></tr> <tr style="background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Eugene Jiang</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Former President and Chairman </font></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"></font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-family: Times New Roman, Times, Serif">December 31,</font></td><td style="font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-family: Times New Roman, Times, Serif">September&#160;30,</font></td><td style="font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2017</font></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">2017</font></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">BioLite Inc.</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">109,220</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">BioFirst Corporation</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">3,957,000</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">3,950,000</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Asiangene Corporation</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">160,000</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">160,000</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Yuangene Corporation</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">3,000</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">3,000</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Eugene Jiang</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">100</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Total</font></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">4,229,320</font></td><td style="padding-bottom: 4pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">4,113,000</font></td><td style="padding-bottom: 4pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"></td></tr></table> 2018-02-01 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>9. INCOME TAX</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company files income tax returns in the U.S. federal jurisdiction, and various state and local jurisdictions. The Company is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years before 2013.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">On&#160;December 22, 2017<i>&#160;</i>H.R.&#160;1<i>,</i>&#160;originally known as the Tax Cuts and Jobs Act, (the &#8220;Tax Act&#8221;) was enacted. Among the significant changes to the U.S. Internal Revenue Code, the Tax Act lowers the U.S. federal corporate income tax rate (&#8220;Federal Tax Rate&#8221;) from&#160;35%&#160;to&#160;21%&#160;effective January 1, 2018<i>.&#160;</i>The&#160;21%&#160;Federal Tax Rate will apply to earnings reported for the full&#160;2018&#160;fiscal year. In addition, the Company must re-measure its net deferred tax assets and liabilities using the Federal Tax Rate that will apply when these amounts are expected to reverse. As of&#160;December 31,&#160;2017,&#160;the Company can determine a reasonable estimate for certain effects of tax reform and is recording that estimate as a provisional amount. The provisional remeasurement of the deferred tax assets and allowance valuation of deferred tax assets at December 31, 2017 resulted in a&#160;net effect of $0 discrete tax expenses (benefit) which lowered the effective tax rate by&#160;13%&#160;for the year ended December 31, 2017. The provisional remeasurement amount is anticipated to change as data becomes available allowing more accurate scheduling of the deferred tax assets and liabilities primarily related to net operating loss carryover.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Components of income tax (benefits) for the three months ended December 31, 2017, and for the years ended September 30, 2017 and 2016 are as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="10" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>Three Months ended <br /> December 31, 2017</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="10" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>Year ended <br /> September 30, 2017</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="10" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>Year ended <br /> September 30, 2016</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>Federal</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>State</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>Total</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>Federal</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>State</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>Total</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>Federal</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>State</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>Total</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><font style="font-family: Times New Roman, Times, Serif">Current</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">830</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">830</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">836</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">836</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Deferred</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">830</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">830</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">836</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">836</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Significant components of the Company&#8217;s deferred tax accounts at December 31, 2017 and September 30, 2017:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Deferred Tax Account - noncurrent:</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif"><b>December 31, 2017</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif"><b>September 30, 2017</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Tax losses carryforwards</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">594,501</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">832,913</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"><font style="font-family: Times New Roman, Times, Serif">Less: Valuation allowance</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(594,501</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(832,913</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 30pt"><font style="font-family: Times New Roman, Times, Serif">Total deferred tax account - noncurrent</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The difference between the effective rate reflected in the provision for income taxes on loss before taxes and the amounts determined by applying the applicable statutory U.S. tax rate are analyzed below:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>Three&#160;Months ended December 31,</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>Years ended <br /> September 30,</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>2017</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>2017</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>2016</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Statutory federal tax benefit, net of state tax effects</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">31</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">31</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">31</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">State income taxes</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">8.84</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">8.84</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">8.84</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Provisional remeasurement of deferred taxes</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(13</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)%</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Nondeductible/nontaxable items</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(29</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)%</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(36</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)%</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Change in valuation allowance</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(26.84</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)%</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(10.84</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)%</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(3.84</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)%</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">Effective income tax rate</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>8. EQUITY</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">During October 2015, $350,000 of subscription receivable was fully collected from the shareholders.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">On February 8, 2016, a Share Exchange Agreement (&#8220;Share Exchange Agreement&#8221;) was entered into by and among American BriVision (Holding) Corporation (the&#160;&#8220;Company&#8221;), American BriVision Corporation&#160;(&#8220;BriVision&#8221;), Euro-Asia Investment &#38; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People's Republic of China (&#8220;Euro-Asia&#8221;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock of the Company, and the owners of record of all of the issued share capital of BriVision (the&#160;&#8220;BriVision Stock&#8221;). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the&#160;&#8220;Acquisition Stock&#8221;) (subject to adjustment for fractionalized shares as set forth below) of the Company&#8217;s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&#8217;s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of BriVision&#8217;s common stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583 pre-stock split) shares of Company&#8217;s common stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company&#8217;s common stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company&#8217;s common stock,&#160;Because of the exchange of the BriVision Stock for the Acquisition Stock (the&#160;&#8220;Share Exchange&#8221;), BriVision became a wholly owned subsidiary (the &#8220;Subsidiary&#8221;) of the Company and there was a change of control of the Company following the closing.&#160;&#160;There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">On February17, 2016, pursuant to the 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;), 157,050 (50,000 pre-stock split) shares were granted to the employees.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the &#8220;Forward&#160;Stock&#160;Split&#8221;) and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The majority of the shareholders of the Company approved the amendment to Articles of Incorporation.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">On May 6, 2016, the Company and BioLite agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of our first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">On August 26, 2016, the Company issued 1,468,750 shares (&#8220;Shares&#8221;) of the Company&#8217;s common stock, par value $0.001 (the &#8220;Offering&#8221;) to BioLite, Inc., a non-U.S. accredited investor (the &#8220;Purchaser&#8221;) pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the &#8220;SPA&#8221;). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), pursuant to Regulation&#160;S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. The proceeds may be used for general corporate purposes.&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Pursuant to the BioLite Collaborative Agreement (See Note 5), BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. In February 2017, the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of our common stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">On October 1, 2016, the Company entered into a consulting agreement with Kazunori Kameyama (&#8220;Kameyama&#8221;) for the provision of services related to the clinical trials and other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company&#8217;s common stock at $1.00 per share for any amount exceeding $3,000. The Company&#8217;s stocks shall be calculated and issued in December every year. On October 1, 2017, the Company and Kameyama agreed to extend the service period for one more year expiring on September 30, 2018. As a result, the non-employee stock-based compensation related to this consulting agreement was $2,362 during the three months ended December 31, 2017 and $3,038 for the year ended September 30, 2017.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">On January 1, 2017, Euro-Asia Investment &#38; Finance Corp Ltd. and the Company entered into a service agreement (the &#8220;Euro-Asia Agreement&#8221;) for the maintenance of the listing in the U.S. stock exchange market. During the three months ended December 31, 2017 and during the year ended September 30, 2017, the Company recognized professional fees of $18,000 and $69,000, and non-employee stock based compensation expenses of $5,000 and $55,000 in connection with the terms in the Euro-Asia Agreement, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -24.1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">On January 1, 2017, Kimho Consultants Co., Ltd. and the Company entered into a service agreement (the &#8220;Kimho Agreement&#8221;) for the maintenance of the listing in the U.S. stock exchange market. During the three months ended December 31, 2017 and during the year ended September 30, 2017, the Company recognized professional fees of $21,000 and $113,000, and non-employee stock based compensation expenses of $10,000 and $80,000 in connection with the terms in the Kimho Agreement, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Pursuant to ASC 505-50-30, the transactions with the non-employees were measured based on the fair value of the equity instruments issued as the Company determined that the fair value of the equity instruments issued in a stock-based payment transaction with nonemployees was more reliably measurable than the fair value of the consideration received. The Company measured the fair value of the equity instruments in these transactions using the stock price on the date at which the commitments Kameyama, Euro-Asia, and Kimho for performance were rendered.</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="10" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>Three Months ended <br /> December 31, 2017</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="10" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>Year ended <br /> September 30, 2017</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="10" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>Year ended <br /> September 30, 2016</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>Federal</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>State</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>Total</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>Federal</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>State</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>Total</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>Federal</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>State</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>Total</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><font style="font-family: Times New Roman, Times, Serif">Current</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">830</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">830</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">836</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">836</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Deferred</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">830</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">830</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">836</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">836</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Deferred Tax Account - noncurrent:</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif"><b>December 31, 2017</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif"><b>September 30, 2017</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Tax losses carryforwards</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">594,501</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">832,913</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"><font style="font-family: Times New Roman, Times, Serif">Less: Valuation allowance</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(594,501</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(832,913</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 30pt"><font style="font-family: Times New Roman, Times, Serif">Total deferred tax account - noncurrent</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>Three&#160;Months ended December 31,</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>Years ended <br /> September 30,</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>2017</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>2017</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><b>2016</b></font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Statutory federal tax benefit, net of state tax effects</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">31</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">31</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">31</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">State income taxes</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">8.84</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">8.84</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">8.84</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Provisional remeasurement of deferred taxes</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(13</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)%</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Nondeductible/nontaxable items</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(29</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)%</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(36</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)%</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Change in valuation allowance</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(26.84</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)%</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(10.84</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)%</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(3.84</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)%</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">Effective income tax rate</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">%</font></td></tr> </table> -0.13 Internal Revenue Code, the Tax Act lowers the U.S. federal corporate income tax rate (&#8220;Federal Tax Rate&#8221;) from&#160;35%&#160;to&#160;21%&#160;effective January 1, 2018<i>.&#160;</i>The&#160;21%&#160;Federal Tax Rate will apply to earnings reported for the full&#160;2018&#160;fiscal year. In addition, the Company must re-measure its net deferred tax assets and liabilities using the Federal Tax Rate that will apply when these amounts are expected to reverse. As of&#160;December 31,&#160;2017,&#160;the Company can determine a reasonable estimate for certain effects of tax reform and is recording that estimate as a provisional amount. The provisional remeasurement of the deferred tax assets and allowance valuation of deferred tax assets at December 31, 2017 resulted in a&#160;net effect of $0 discrete tax expenses (benefit) which lowered the effective tax rate by&#160;13%&#160;for the year ended December 31, 2017. <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>10. LOSS PER SHARE</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed by dividing net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the year.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>Three&#160;Months Ended</b><br /> <b>December 31,</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>Years Ended</b><br /> <b>September&#160;30,</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>2017</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>2017</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>2016</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">Numerator:</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">Net loss</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">(381,214</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">(4,071,983</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">(11,007,799</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">Denominator:</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">Weighted-average shares outstanding:</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">Weighted-average shares outstanding - Basic</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">213,746,647</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">212,648,770</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">193,981,153</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">Stock options</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">Weighted-average shares outstanding - Diluted</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">213,746,647</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">212,648,770</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">193,981,153</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">Loss per share</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">-Basic</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">(0.00</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">(0.02</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">(0.06</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">-Diluted</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">(0.00</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">(0.02</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">(0.06</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Diluted loss per share takes into account the potential dilution that could occur if securities or other contracts to issue common stock were exercised and converted into common stock.</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>Three&#160;Months Ended</b><br /> <b>December 31,</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>Years Ended</b><br /> <b>September&#160;30,</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>2017</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>2017</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>2016</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">Numerator:</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">Net loss</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">(381,214</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">(4,071,983</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">(11,007,799</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">Denominator:</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">Weighted-average shares outstanding:</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">Weighted-average shares outstanding - Basic</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">213,746,647</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">212,648,770</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">193,981,153</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">Stock options</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">Weighted-average shares outstanding - Diluted</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">213,746,647</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">212,648,770</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">193,981,153</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">Loss per share</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">-Basic</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">(0.00</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">(0.02</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">(0.06</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">-Diluted</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">(0.00</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">(0.02</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif">(0.06</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>11. COMMITMENTS AND CONTINGENCIES</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Operating Commitment</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The total future minimum lease payments under the non-cancellable operating lease with respect to the office&#160;as of December 31, 2017 are payable as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">As of December 31,</font></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">Amount</font></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="width: 88%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">2018</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">4,950</font></td><td style="width: 1%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">Total minimum payments</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">4,950</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Rental expense was $2,482 for the three months ended December 31, 2017. Rental expense was $61,093 and 29,129 for the year ended September 30, 2017 and 2016, respectively.</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">As of December 31,</font></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">Amount</font></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="width: 88%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">2018</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="width: 9%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">4,950</font></td><td style="width: 1%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">Total minimum payments</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">4,950</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>12. TRANSITION PERIOD COMPARATIVE DATA</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The following table presents certain financial information for the three months ended December 31, 2017 and 2016, respectively:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">Three Months Ended</font></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">December 31, <br /> 2017</font></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">December 31, <br /> 2016</font></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-family: Times New Roman, Times, Serif">(Unaudited)</font></td><td style="font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-family: Times New Roman, Times, Serif">(Restated)</font></td><td style="font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Revenues</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Cost of revenues</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Gross profit</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Operating expenses</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Selling, general and administrative expenses</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">289,731</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">185,188</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Research and development expenses</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">45,701</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">25,198</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Stock based compensation</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">17,362</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Loss from operations</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(352,794</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(210,386</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Other income (expense)</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Interest income</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">80</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">49</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Interest expense</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(28,500</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"><font style="font-family: Times New Roman, Times, Serif">Total other income (expenses)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(28,420</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">49</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Loss from continuing operations before provision income tax</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(381,214</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(210,337</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Provision for income tax</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Net loss</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(381,214</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(210,337</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Net loss per share attributable to common stockholders</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Basic and diluted</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(0.00</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(0.00</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Weighted average number of common shares outstanding</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Basic and diluted</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">213,746,647</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">210,821,647</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr></table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">Three Months Ended</font></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">December 31, <br /> 2017</font></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">December 31, <br /> 2016</font></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-family: Times New Roman, Times, Serif">(Unaudited)</font></td><td style="font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-family: Times New Roman, Times, Serif">(Restated)</font></td><td style="font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: bold 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Revenues</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Cost of revenues</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Gross profit</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Operating expenses</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Selling, general and administrative expenses</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">289,731</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">185,188</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Research and development expenses</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">45,701</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">25,198</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Stock based compensation</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">17,362</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Loss from operations</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(352,794</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(210,386</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Other income (expense)</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Interest income</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">80</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">49</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Interest expense</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(28,500</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"><font style="font-family: Times New Roman, Times, Serif">Total other income (expenses)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(28,420</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">49</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Loss from continuing operations before provision income tax</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(381,214</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(210,337</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">Provision for income tax</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">-</font></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Net loss</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(381,214</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(210,337</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">Net loss per share attributable to common stockholders</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Basic and diluted</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(0.00</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(0.00</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">Weighted average number of common shares outstanding</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Basic and diluted</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">213,746,647</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif">210,821,647</font></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>13. SUBSEQUENT EVENT</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company has evaluated subsequent events through the date which the financial statements were available to be issued. All subsequent events requiring recognition as of December 31, 2017 have been incorporated into these financial statements and there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, &#8220;Subsequent Events.&#8221;</font></p> 3000000 <p style="margin: 0pt"></p> <p style="margin: 0pt">Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by Asiangene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. Asiangene also agreed to loan the proceeds to the Company for working capital purpose. The non-secured loan bears 0% interest rate and is due on demand.</p> ABVC 0.00 0.00 0.00 360000000 360000000 0.001 0.001 0.001 1 to 3:141 350000 350000 51945225 65431144 52336000 52936583 52936583 50000 163159952 205519223 164387376 166273921 166273921 157050 0.7970 0.7970 1.00 1.60 2350000 0.2536-for-1 1.60 2.0 2.0 3000000 6500000 15000000 0.0050 0.00065 0.0050 0.00035 0.15 650000 The Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company&#8217;s common stock at $1.00 per share for any amount exceeding $3,000. 69000 113000 18000 21000 2362 3038 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Basis of Presentation</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The accompanying consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the &#8220;U.S. GAAP&#8221;). All significant intercompany transactions and account balances have been eliminated.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company&#8217;s financial statements are expressed in U.S. dollars.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Fiscal Year</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company changed its fiscal year from the period beginning on October 1<sup>st</sup> and ending on September 30<sup>th</sup> to the period beginning on January 1<sup>st</sup> and ending on December 31<sup>st</sup>, beginning January 1, 2018. As a result, the current fiscal period is a three-month transition period ended on December 31, 2017. In these consolidated statements, including the notes thereto, the current period financial results ended December 31, 2017 are for a three-month period. Audited results for the twelve months ended September 30, 2017 and 2016 are both for twelve-month periods. In addition, the Company's consolidated statements of operations and consolidated statements of cash flows include unaudited comparative amounts for the three-month period ended December 31, 2016.&#160;All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30<sup>th</sup> of such year.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Use of Estimates</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Reclassifications</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Forward Stock split</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to Articles of Incorporation.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Fair Value Measurements</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company applies the provisions of ASC Subtopic 820-10,&#160;&#8220;Fair Value Measurements&#8221;,&#160;for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements.&#160;&#160;ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;&#160;When determining the fair value measurements for assets and liabilities, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of&#160;September 30, 2017 and 2016.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Cash and Cash Equivalents</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of December 31, 2017 and September 30, 2017, the Company&#8217;s cash and cash equivalents amounted $93,332 and $204,851, respectively. Some&#160;of the Company&#8217;s cash deposits are held in financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Concentration of Credit Risk</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company&#8217;s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation&#8217;s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes. Concentration of credit risk with respect to trade and notes receivables is limited due to the wide variety of customers and markets in which the Company transacts business, as well as their dispersion across many geographical areas. The Company performs ongoing credit evaluations of its customers and generally does not require collateral, but does require advance deposits on certain transactions.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Receivable from Collaboration Partners</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Receivable from collaboration partners is stated at carrying value less estimates made for doubtful receivables. An allowance for impairment of receivable from collaboration partners is established if the collection of a receivable becomes doubtful. Such receivable becomes doubtful when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of the receivables. Significant financial difficulties of the debtor, probability that the debtor will enter into bankruptcy or financial reorganization, and default or delinquency in payments are considered indicators that the receivable is impaired. The amount of the allowance is the difference between the asset&#8217;s carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. An impairment loss is recognized in the statement of operations, as are subsequent recoveries of previous impairments.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Research and Development Expenses</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Stock-based Compensation</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company measures expense associated with all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with ASC Topic 718 &#8220;Compensation-Stock Compensation&#8221;. Total employee stock-based compensation expenses were $0 for the three months ended December 31, 2017, and $0 and $397,960 for the years ended September 30, 2017 and 2016, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company accounted for stock-based compensation to non-employees in accordance with ASC Topic 505-50 &#8220;Equity-Based Payments to Non-Employees&#8221; which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee stock-based compensation expenses were $17,362 for the three months ended December 31, 2017, and $138,038 and $0 for the years ended September 30, 2017 and 2016, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Income Taxes</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.2pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Under ASC 740, a tax position is recognized as a benefit only if it is&#160;&#8220;more likely than not&#8221;&#160;that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the three months ended December 31, 2017 and for the years ended September 30, 2017 and September, 30, 2016. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">For the three months ended December 31, 2017, the Company&#8217;s income tax expense amounted $0. For the years ended September 30, 2017 and 2016, the Company&#8217;s income tax expense amounted $830 and $836, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; background-color: white">On December 22, 2017, the SEC issued Staff Accounting Bulletin (&#8220;SAB 118&#8221;), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company&#8217;s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions we may take. The Company is continuing to gather additional information to determine the final impact.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Loss Per Share of Common Stock</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company reports loss per share in accordance with ASC Topic 260-10 &#34;Earnings per Share.&#34; Basic earnings (loss) per share are computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Commitments and Contingencies</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">The Company has adopted ASC Topic 450 &#8220;Contingencies&#8221; subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Recent Accounting Pronouncements</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b><i>Revenue Recognition:&#160;&#160;&#160;&#160;&#160;</i></b>In May 2014, the FASB issued Accounting Standards Update No.&#160;2014-09,&#160;<i>Revenue from Contracts with Customers: Topic&#160;</i>606 (ASU 2014-09), to supersede nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for us in our first quarter of fiscal 2018 using either of two methods: (i)&#160;retrospective to each prior reporting period presented with the option to elect certain practical expedients as defined within ASU 2014-09 (full retrospective method); or (ii)&#160;retrospective with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined per ASU 2014-09 (modified retrospective method). We are currently assessing the materiality of the impact to our consolidated financial statements, and have not yet selected a transition approach.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b><i>Disclosure of Going Concern Uncertainties:&#160;&#160;&#160;&#160;&#160;</i></b>In August 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No.&#160;2014-15,&#160;<i>Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</i>(ASU 2014-15), to provide guidance on management&#8217;s responsibility in evaluating whether there is substantial doubt about a company&#8217;s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective for us in our fourth quarter of fiscal 2017 with early adoption permitted. We do not believe the impact of our pending adoption of ASU 2014-15 on the Company&#8217;s financial statements will be material.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b><i>Leases</i></b>:&#160;&#160;&#160;&#160;&#160;In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (&#8220;ASU 2016-2&#8221;), which provides guidance on lease amendments to the FASB Accounting should Standard Codification. This ASU will be effective for us beginning in May 1, 2019. We are currently in the process of evaluating the impact of the adoption of ASU 2016-2on our consolidated financial statements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b><i>Stock-based Compensation</i></b>:&#160;&#160;&#160;&#160;In March 2016, the FASB issued ASU 2016-09,&#160;Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Stock-Based Payment Accounting&#160;(ASU 2016-09). ASU 2016-09 changes how companies account for certain aspects of stock-based awards to employees, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU 2016-09 is effective for us in the first quarter of&#160;2018, and earlier adoption is permitted. We are still evaluating the effect that this guidance will have on our consolidated financial statements and related disclosures.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b><i>Financial Instruments - Credit Losses:&#160;</i></b>In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): The amendments in this Update require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments broaden the information that an entity must consider in developing its expected credit loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss, which will be more decision useful to users of the financial statements. ASU 2016-13 is effective for the Company for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is allowed as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is still evaluating the effect that this guidance will have on the Company&#8217;s consolidated financial statements and related disclosures.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b><i>Statement of Cash Flows:&#160;</i></b>In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): The amendments in this Update apply to all entities, including both business entities and not-for-profit entities that are required to present a statement of cash flows under Topic 230. The amendments in this Update provide guidance on the following eight specific cash flow issues. The amendments are an improvement to GAAP because they provide guidance for each of the eight issues, thereby reducing the current and potential future diversity in practice described above. ASU 2016-15 is effective for the Company for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is still evaluating the effect that this guidance will have on the Company&#8217;s consolidated financial statements and related disclosures.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">In November 2016, the FASB issued ASU No. 2016-18,&#160;Statement of Cash Flows&#160;(Topic 230): &#8220;Restricted Cash&#8221;(&#8220;ASU 2016-18&#8221;). ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. ASU 2016-18 will become effective for us beginning April 1, 2018, or fiscal 2019. ASU 2016-18 is required to be applied retrospectively. Upon the adoption, amounts described as restricted cash will be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period amounts shown on the statements of cash flows.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b><i>Business Combination</i></b>: &#160;In January 2017, the FASB issued ASU No. 2017-1 &#8220;Topic 805, Business Combinations: Clarifying the Definition of a Business&#8221;. The amendments in this update provide a screen to determine when a set is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. The amendments in this update affect all reporting entities that must determine whether they have acquired or sold a business. Public business entities should apply the amendments in this update to annual periods beginning after December 15, 2017, including interim periods within those periods. All other entities should apply the amendments to annual periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019. We do not expect the adoption of ASU 2017-1 to have a material impact on our consolidated financial statements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">From time to time, new accounting pronouncements are issued by FASB that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company's financial statements upon adoption. Management does not believe that any recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying financial statements</font></p> 69924306 EX-101.SCH 9 abvc-20171231.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements Of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Corrections to Previously Issued Consolidated Financial Statements link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Collaborative Agreements link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Related Parties Transactions link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Income Tax link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Loss Per Share link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Transition Period Comparative Data link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Corrections to Previously Issued Consolidated Financial Statements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Related Parties Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Income Tax (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Transition Period Comparative Data (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Organization and Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Corrections to Previously Issued Consolidated Financial Statements (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Corrections to Previously Issued Consolidated Financial Statements (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Going Concern (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Collaborative Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Related Parties Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Related Parties Transactions (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Related Parties Transactions (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Equity (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Income Tax (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Income Tax (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Income Tax (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Income Tax (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Transition Period Comparative Data (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 abvc-20171231_cal.xml XBRL CALCULATION FILE EX-101.DEF 11 abvc-20171231_def.xml XBRL DEFINITION FILE EX-101.LAB 12 abvc-20171231_lab.xml XBRL LABEL FILE Type of Arrangement and Non-arrangement Transactions [Axis] Collaborative Arrangement [Member] Collaborative Arrangement One [Member] Adjustments for Error Corrections [Axis] Adjustments [Member] Scenario [Axis] Scenario, Previously Reported [Member] Restatement Adjustment [Member] Adjustments One [Member] Related Party Transaction [Axis] BioLite Inc [Member] BioFirst Corporation [Member] Asiangene Corporation [Member] Yuangene Corporation [Member] BioLite Collaborative Agreement [Member] Co-Dev Agreement [Member] Equity Components [Axis] Common Stock [Member] Additional paid-in capital Subscription receivable Retained Earnings [Member] Legal Entity [Axis] Share Exchange Agreement Two [Member] Share Exchange Agreement Four [Member] Share Exchange Agreement [Member] Share Exchange Agreement One [Member] Share Exchange Agreement Three [Member] Plan Name [Axis] Equity Incentive Plan [Member] Related Party [Axis] Rgene Corporation [Member] Liongene Corporation [Member] Euro-Asia [Member] Kimho Consultants [Member] Loan Agreement [Member] BioFirst Collaborative Agreement Agreement [Member] Euro-Asia Agreement [Member] Kimho Agreement [Member] EuroAsiaAgreementMember KimhoAgreementtMember Common Stock Additional Paid-In Capital Retained Earnings / Accumulated Deficit Eugene Jiang [Member] BioLite [Member] Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Trading Symbol Amendment Flag Current Fiscal Year End Date Document Type Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Statement of Financial Position [Abstract] Assets Current assets Cash Receivable from collaboration partners - related parties Total Current Assets Total Assets Liabilities and Equity Accrued expense Due to related parties Total Liabilities Commitments and Contingencies Stockholders' deficit Common Stock 360,000,000 authorized at $0.001 par value; shares issued and outstanding 213,746,647 at December 31, 2017 and September 30, 2017 Additional paid-in capital Accumulated deficit Total stockholders' deficit Total Liabilities and Equity Common stock, par value Common stock, authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues Cost of revenues Gross profit Operating expenses Selling, general and administrative expenses Research and development expenses Stock based compensation Loss from operations Other income (expense) Interest income Interest expense Gain on exchange differences Total other expenses Loss before provision income tax Provision for income tax Net loss Net loss per share: Basic and diluted Weighted average number of common shares outstanding: Basic and diluted Statement [Table] Statement [Line Items] Common stock Accumulated deficit Balance Balance, shares Issuance of common shares Issuance of common shares, shares Reverse merger recapitalization Reverse merger recapitalization, shares Stock based compensation, shares Receipt of subscription receivable Capital contribution from related parties under common control Net loss for the period Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities Net loss from continuing operations Adjustments to reconcile net loss to net cash used in operating activities: Issuance of common stock for compensation and recapitalization Stock based compensation for nonemployees Changes in operating assets and liabilities: Decrease in prepaid expenses and deposits Increase (decrease) in accounts payable Increase (decrease) in accrued expenses and other current liabilities Increase in due to related parties Net cash used in operating activities Cash flows from financing activities Capital contribution from related parties under common control Borrowings from related parties Decrease in due to shareholder Proceeds from subscription receivable Proceeds from issuance of common shares Net cash provided by financing activities Effect of exchange rate changes on cash and cash equivalents Net increase (decrease) in cash and cash equivalents Cash and cash equivalents Beginning Ending Supplemental disclosure of cash flows Cash paid during the year for: Interest expense paid Income taxes paid Non-cash financing and investing activities Common shares issued for due to related parties Capital contribution from related parties under common control Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND DESCRIPTION OF BUSINESS Accounting Changes and Error Corrections [Abstract] CORRECTIONS TO PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Going Concern [Abstract] GOING CONCERN Collaborative Agreements COLLABORATIVE AGREEMENTS Payables and Accruals [Abstract] ACCRUED EXPENSES Related Party Transactions [Abstract] RELATED PARTIES TRANSACTIONS Equity [Abstract] EQUITY Income Tax Disclosure [Abstract] INCOME TAX Earnings Per Share [Abstract] LOSS PER SHARE Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Quarterly Financial Information Disclosure [Abstract] TRANSITION PERIOD COMPARATIVE DATA Subsequent Events [Abstract] SUBSEQUENT EVENT Basis of Presentation Fiscal Year Use of Estimates Reclassifications Forward Stock split Fair Value Measurements Cash and Cash Equivalents Concentration of Credit Risk Receivable from Collaboration Partners Research and Development Expenses Stock-based Compensation Income Taxes Loss Per Share of Common Stock Commitments and Contingencies Recent Accounting Pronouncements Schedule of corrections and consolidated financial statements Schedule of accrued expenses Schedule of related party transactions Schedule of amount due to related party Summary of income tax (benefits) Schedule of deferred tax Schedule of statutory rate and effective rate reconciliation Schedule of loss per share Schedule of future minimum lease payments Schedule of financial information Organization and Description of Business (Textual) Common stock issued post-stock split Common stock issued pre-stock split Percentage of common shares issued and outstanding Percentage of issued share capital Common stock converted to exchange ratio Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Error Corrections and Prior Period Adjustments Restatement [Line Items] Consolidated Balance Sheets Due to related party Total Liabilities Total equity (deficit) Consolidated Statements of Operations and Comprehensive Loss Net loss from operations Loss from continuing operations before income taxes Net Loss Basic and diluted loss per share Consolidated Statements of Cash Flow Issuance of common stock for compensation (Decrease) increase in due to related party Corrections to Previously Issued Consolidated Financial Statements (Textual) Total liabilities Total liabilities increased Additional paid in capital Additional paid in capital increased Accumulated deficit increased Total equity (deficit) decreased Selling, general and administrative expenses decreased Research and development expenses increased Loss from continuing operations before taxes Loss from continuing operations before taxes increased Basic and diluted loss per share increased Net loss from continuing operations increased (Decrease) increase in due to related party increased Net cash used in operating activities increased Summary of Significant Accounting Policies (Textual) Forward split ratio Cash and cash equivalents amounted Income tax expense Stock-based compensation expenses Non-employee stock-based compensation expenses Schedule of Going Concern [Table] Going Concern [Line Items] Going Concern (Textual) Working capital deficiency Milestone payments to BioLite in cash Common stock newly issued, value Share price Percentage of payments under collaborative agreement Accounts payable Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Agreements (Textual) Description of payment settlement schedule Amount received from BriVision Upfront payments Common stock newly issued, shares Licensing rights Company cash payments Research and development expense Accrued consulting fee Accrued professional service fees Accrued interest expense - related party(Note 7) Accrued payroll Total Relationship with the Company and its subsidiaries, description Loan agreement [Member] BioFirst Collaborative Agreement [Member] Euro-Asia Agreement [Member] Kimho Agreement [Member] BioLite one [Member] Asiangene [Member] BioFirst [Member] BioLite Inc. [Member] Related Parties Transactions (Textual) Total commitment Loan maturity date Loan agreement, description Outstanding loan Accrued interest Interest expenses Research and development cost of amount Aggregate working capital Interest rate percentage Outstanding advance Common stock new issues Due to BioFirst Stock based compensation expenses Consulting service Monthly base rent Rent expenses Related party transactions, description Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Equity (Textual) Description of forward split Subscription receivable Purchase price per share Net proceeds from offering Exchange ratio Total payment upon first IND submission Remitted amount Consulting agreement, description Professional fees Non-employee stock-based compensation Federal Current Deferred Federal Total State Current Deferred State total Current total Deferred total Total Income Tax Details 1 Deferred Tax Account - noncurrent: Tax losses carryforwards Less: Valuation allowance Total deferred tax account - noncurrent Statutory federal tax benefit, net of state tax effects State income taxes Provisional remeasurement of deferred taxes Nondeductible/nontaxable items Change in valuation allowance Effective income tax rate Income Taxes (Textual) Corporate tax rate, description Numerator: Denominator: Weighted-average shares outstanding: Weighted-average shares outstanding - Basic Stock options Weighted-average shares outstanding - Diluted Loss per share -Basic -Diluted Operating Leases, Future Minimum Payments [Abstract] 2018 Total minimum payments Commitments and Contingencies (Textual) Rent expense Revenues Total other income (expenses) Loss from continuing operations before provision income tax Net loss Net loss per share attributable to common stockholders Weighted average number of common shares outstanding Accrued consulting fee Current And Noncurrent. Represents the types error corrections made to the financial statements. The set of legal entities associated with a report. Capital contribution from related parties under common control. Amount of capital contributions from related parties under common control for the reporting period. Contractual arrangement one that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Amount of common shares issued for due to related parties for the reporting period. Common stock issued after stock split. Common stock issued before stock split. the amount of consultinf services. The exchange ratio per stock split. Equity incentive plan member. The amount of federal total. Disclosure of accounting policy for forward stock splits. Going concern disclosure. Line items represent going concern concept included in a table. Going concern textual. increase Decrease in accumulated deficit. Increase Decrease in additional paid in capital. Increase decrease in basic and diluted loss per share. Increase decrease in loss from continuing operations before taxes. Increase decrease in net loss from continuing operations. Increase decrease in research and development expenses. Increase decrease selling general and administrative expenses decreased. Total equity (deficit) was decreased. Increase decrease in total liabilities. increased decrease in operating activities. The payments which are paid during the term of agreement. Organization and description of business textual. Percentage of issued share capital. Percentage of payments under collaborative agreement. Proceeds From Subscription Receivable. It represents related party descriptions. Schedule of going concern. Tabular disclosure of related party transactions. Amount due to related party. Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements. The amount of state total. Stock based compensation for nonemployees. Capital contribution from related parties under common control. Stock issued during period receipt of subscription receivable. Stock issued during period reverse merger recapitalization. Stock issued during period reverse merger recapitalization shares. Summary of significant accounting policies textual. Supplemental disclosure of cash flow information abstract. The amount of upfront payments which are paid during the term of agreement. The amount of working capital deficiency. Percentage of the provisional remeasurement of deferred taxes. Assets, Current Assets [Default Label] Liabilities and Equity [Default Label] Gross Profit Nonoperating Income (Expense) Weighted Average Number of Shares Outstanding, Basic and Diluted Shares, Outstanding Stock Issued During Period, Value, Share-based Compensation, Gross Increase (Decrease) in Prepaid Expenses, Other Net Cash Provided by (Used in) Operating Activities CapitalContributionFromRelatedPartiesUnderCommonControl Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) CapitalContributionFromRelatedParty Fiscal Period, Policy [Policy Text Block] Commitments and Contingencies, Policy [Policy Text Block] Accrued Professional Fees, Current Debt Instrument, Maturity Date Common Stock, Share Subscribed but Unissued, Subscriptions Receivable Federal Total Current State and Local Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) State Total Deferred Tax Assets, Valuation Allowance, Noncurrent Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent Operating Leases, Future Minimum Payments Due Revenue, Net EX-101.PRE 13 abvc-20171231_pre.xml XBRL PRESENTATION FILE XML 14 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document and Entity Information - USD ($)
3 Months Ended
Dec. 31, 2017
Mar. 28, 2018
Jun. 30, 2017
Document and Entity Information [Abstract]      
Entity Registrant Name American BriVision (Holding) Corp    
Entity Central Index Key 0001173313    
Trading Symbol ABVC    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Document Type 10-KT    
Document Period End Date Dec. 31, 2017    
Document Fiscal Year Focus 2017    
Document Fiscal Period Focus FY    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Filer Category Smaller Reporting Company    
Entity Public Float     $ 69,924,306
Entity Common Stock, Shares Outstanding   213,926,475  
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2017
Sep. 30, 2017
Current assets    
Cash $ 93,332 $ 204,851
Receivable from collaboration partners - related parties 2,550,000 2,550,000
Total Current Assets 2,643,332 2,754,851
Total Assets 2,643,332 2,754,851
Liabilities and Equity    
Accrued expense 170,927 34,914
Due to related parties 4,229,320 4,113,000
Total Liabilities 4,400,247 4,147,914
Commitments and Contingencies
Stockholders' deficit    
Common Stock 360,000,000 authorized at $0.001 par value; shares issued and outstanding 213,746,647 at December 31, 2017 and September 30, 2017 213,747 213,747
Additional paid-in capital 13,805,936 13,788,574
Accumulated deficit (15,776,598) (15,395,384)
Total stockholders' deficit (1,756,915) (1,393,063)
Total Liabilities and Equity $ 2,643,332 $ 2,754,851
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2017
Sep. 30, 2017
Statement of Financial Position [Abstract]    
Common stock, par value $ 0.001 $ 0.001
Common stock, authorized 360,000,000 360,000,000
Common stock, shares issued 213,746,647 213,746,647
Common stock, shares outstanding 213,746,647 213,746,647
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Operations - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Sep. 30, 2016
Income Statement [Abstract]      
Revenues
Cost of revenues 32
Gross profit (32)
Operating expenses      
Selling, general and administrative expenses 289,731 707,142 599,303
Research and development expenses 45,701 3,151,162 10,000,000
Stock based compensation 17,362 138,038 397,960
Loss from operations (352,794) (3,996,342) (10,997,295)
Other income (expense)      
Interest income 80 149 361
Interest expense (28,500) (74,960) (10,170)
Gain on exchange differences 141
Total other expenses (28,420) (74,811) (9,668)
Loss before provision income tax (381,214) (4,071,153) (11,006,963)
Provision for income tax 830 836
Net loss $ (381,214) $ (4,071,983) $ (11,007,799)
Net loss per share:      
Basic and diluted $ (0.00) $ (0.02) $ (0.06)
Weighted average number of common shares outstanding:      
Basic and diluted 213,746,647 212,648,770 193,981,153
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)
Common stock
Additional paid-in capital
Subscription receivable
Accumulated deficit
Total
Balance at Jul. 20, 2015 $ 159,623 $ 1,087,378 $ (350,000) $ 897,001
Balance, shares at Jul. 20, 2015 159,622,964        
Issuance of common shares $ 6,651 45,307 51,958
Issuance of common shares, shares 6,650,957        
Net loss for the period (315,602) (315,602)
Balance at Sep. 30, 2015 $ 166,274 1,132,685 (350,000) (315,602) 633,357
Balance, shares at Sep. 30, 2015 166,273,921        
Issuance of common shares $ 2,032 3,247,968 3,250,000
Issuance of common shares, shares 2,031,423        
Reverse merger recapitalization $ 42,359 (44,995) (2,636)
Reverse merger recapitalization, shares 42,359,253        
Stock based compensation $ 157 397,803 397,960
Stock based compensation, shares 157,050        
Receipt of subscription receivable 350,000 350,000
Net loss for the period (11,007,799) (11,007,799)
Balance at Sep. 30, 2016 $ 210,822 4,733,461 (11,323,401) (6,379,118)
Balance, shares at Sep. 30, 2016 210,821,647        
Issuance of common shares $ 2,925 5,847,075 5,850,000
Issuance of common shares, shares 2,925,000        
Stock based compensation 138,038 138,038
Capital contribution from related parties under common control 3,070,000 3,070,000
Net loss for the period (4,071,983) (4,071,983)
Balance at Sep. 30, 2017 $ 213,747 13,788,574 (15,395,384) (1,393,063)
Balance, shares at Sep. 30, 2017 213,746,647        
Stock based compensation 17,362 17,362
Net loss for the period (381,214) (381,214)
Balance at Dec. 31, 2017 $ 213,747 $ 13,805,936 $ (15,776,598) $ (1,756,915)
Balance, shares at Dec. 31, 2017 213,746,647        
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements Of Cash Flows - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Sep. 30, 2016
Cash flows from operating activities      
Net loss from continuing operations $ (381,214) $ (4,071,983) $ (11,007,799)
Adjustments to reconcile net loss to net cash used in operating activities:      
Issuance of common stock for compensation and recapitalization 1,295,324
Stock based compensation for nonemployees 17,362 138,038
Changes in operating assets and liabilities:      
Decrease in prepaid expenses and deposits 3,815 3,815
Increase (decrease) in accounts payable (18,370) 18,370
Increase (decrease) in accrued expenses and other current liabilities 136,013 (3,186) (261,900)
Increase in due to related parties 116,320 2,353,000 6,477,483
Net cash used in operating activities (111,519) (1,598,686) (3,474,707)
Cash flows from financing activities      
Capital contribution from related parties under common control 520,000
Borrowings from related parties 1,110,000
Decrease in due to shareholder (46,586)
Proceeds from subscription receivable 350,000
Proceeds from issuance of common shares 2,350,000
Net cash provided by financing activities 1,630,000 2,653,414
Effect of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents (111,519) 31,314 (821,293)
Cash and cash equivalents      
Beginning 204,851 173,537 994,830
Ending 93,332 204,851 173,537
Cash paid during the year for:      
Interest expense paid 19,500 66,500
Income taxes paid 830 836
Non-cash financing and investing activities      
Common shares issued for due to related parties 5,850,000
Capital contribution from related parties under common control $ 2,550,000
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Organization and Description of Business
3 Months Ended
Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION AND DESCRIPTION OF BUSINESS

1. ORGANIZATION AND DESCRIPTION OF BUSINESS


American BriVision (Holding) Corporation (the “Company” or “Holding entity”), a Nevada corporation, through the Company’s operating entity, American BriVision Corporation (the “BriVision”), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology and focuses on the development of new drugs and innovative medical devices to fulfill unmet medical needs.  The business model of the Company is to integrate research achievements from world-famous institutions (such as Memorial Sloan Kettering Cancer Center (“MSKCC”) and MD Anderson Cancer Center), conduct clinical trials of translational medicine for Proof of Concept (“POC”), out-license to international pharmaceutical companies, and exploit global markets. BriVision had to predecessor operations prior to its formation on July 21, 2015.

 

Reverse Merger

 

On February 8, 2016, a Share Exchange Agreement (the “Share Exchange Agreement”) was entered into by and among American BriVision (Holding) Corporation, American BriVision Corporation (“BriVision”), and Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People's Republic of China (“Euro-Asia”), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock of the Company, and the owners of record of all of the issued share capital of BriVision (the “BriVision Stock”).

 

Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the “Acquisition Stock”) (subject to adjustment for fractionalized shares as set forth below) of the Company’s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company’s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger (the “Merger”).

 

Pursuant to the Merger, all of the issued and outstanding common shares of BriVision were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583pre-stock split) common shares of the Company and BriVision has become a wholly owned subsidiary of the Company. The holders of Company’s common stock as of immediately prior to the Merger held an aggregate of 205,519,223(65,431,144 pre-stock split) shares of Company’s common stock. Because of the exchange of the BriVision Stock for the Acquisition Stock (the “Share Exchange”), BriVision has become a wholly owned subsidiary (the “Subsidiary”) of the Company and there was a change of control of the Company following the closing.  There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.

 

Because of the consummation of the Share Exchange, BriVision is now our wholly owned subsidiary and its shareholders own approximately 79.70% of our issued and outstanding common stock.

 

Following the Share Exchange, we have abandoned our prior business plan and we are now pursuing BriVision’s historically proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs.  The business model of the Company is to integrate research achievements from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept (“POC”), out-license to international pharmaceutical companies, and exploit global markets.

 

Accounting Treatment of the Reverse Merger

 

For financial reporting purposes, the Share Exchange represents a “reverse merger” rather than a business combination and BriVision is deemed the accounting acquirer in the transaction. The Share Exchange is being accounted for as a reverse-merger and recapitalization. BriVision is the acquirer for financial reporting purposes and the Company is the acquired company. Consequently, the assets and liabilities and the operations reflected in the historical financial statements prior to the Share Exchange will be those of BriVision and recorded at the historical cost basis of BriVision. In addition, the consolidated financial statements after completion of the Share Exchange will include the assets and liabilities of the Company and BriVision, and the historical operations of BriVision and operations of the Combined Company from the closing date of the Share Exchange.

XML 21 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Corrections to Previously Issued Consolidated Financial Statements
3 Months Ended
Dec. 31, 2017
Accounting Changes and Error Corrections [Abstract]  
CORRECTIONS TO PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS

2. CORRECTIONS TO PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS

 

The Company discovered that it had erroneously stated that the research and development expenses were understated during the year ended September 30, 2016. Instead, our research and development expenses were $10,000,000 for the year ended September 30, 2016 and were restated in the Adjustments No. 1 column. Moreover, there were typographical errors on Selling, General and Administration expenses which were corrected in the Adjustments No. 2 column.

 

The following tables present the effect of the corrections discussed above and other adjustments on selected line items of our previously reported consolidated financial statements as of and for the year ended September 30, 2016,

 

ITEMS  Previously  Reported on Form 10K   Adjustments No.1   Adjustments No.2   Restated 
                 
Consolidated Balance Sheets                
As of September 30, 2016                
Due to related party   -    6,500,000    -    6,500,000 
Total Liabilities   56,470    6,500,000    -    6,556,470 
Additional paid-in capital   4,733,401    -    60    4,733,461 
Accumulated deficit   (4,823,401)   (6,500,000)   -    (11,323,401)
Total equity (deficit)   120,882    (6,500,000)   -    (6,379,118)
                     
Consolidated Statements of Operations and Comprehensive Loss                    
For the year ended September 30, 2016                    
Selling, general and administrative expenses   4,497,263    (3,500,060)   60    997,263 
Research and development expenses   -    10,000,000    -    10,000,000 
Net loss from operations   (4,497,295)   (6,499,940)   (60)   (10,997,295)
Loss from continuing operations before income taxes   (4,506,963)   (6,499,940)   (60)   (11,006,963)
Net Loss   (4,507,799)   (6,499,940)   (60)   (11,007,799)
Basic and diluted loss per share   (0.00)   (0.06)   (0.00)   (0.06)
                     
Consolidated Statements of Cash Flow                    
For the year ended September 30, 2016                    
Net loss from continuing operations   (4,507,799)   (6,499,940)   (60)   (11,007,799)
Issuance of common stock for compensation   1,295,324    (60)   60    1,295,324 
(Decrease) increase in due to related party   (22,517)   6,500,000         6,477,483 

 

As a result of the restatement of the consolidated balance sheet as of September 30, 2016, Due to related party and Total liabilities were increased by $6,500,000; changed from $0 to $6,500,000 and from $56,470 to $6,556,470. Additional paid in capital was increased by $60 and changed from $4,733,401 to $4,733,461. Accumulated deficit was increased by $6,500,000 and changed from $(4,823,401) to $(11,323,401). Total equity (deficit) was decreased by $6,500,000 and changed from $120,882 to $(6,379,118).

 

As a result of the restatement of the consolidated statement of operations and comprehensive loss for the year ended September 30, 2016, Selling, general and administrative expenses were decreased by $3,500,000 and changed from $4,497,263 to $997,263. Research and development expenses were increased by $10,000,000 and changed from $0 to $10,000,000. Net loss from operations was increased by $6,500,000 and changed from $(4,497,295) to $(10,997,295). Loss from continuing operations before taxes was increased by $6,500,000 and changed from $(4,506,963) to $(11,006,963). Net loss was increased by $6,500,000 and changed from $(4,507,799) to $(11,007,799). Basic and diluted loss per share were also increased by 0.06 and changed from $0 to $(0.06).

 

As a result of the restatement of the consolidated statement of cash flow for the year ended September 30, 2016, Net loss from continuing operations was increased by $6,500,000; changed from $(4,507,799) to $(11,007,799). Issuance of common stock for compensation did not have changes and stated as $1,295,324. (Decrease) increase in due to related party was increased by $6,500,000 and changed from $(22,517) to $6,477,483. There were no changes in Net cash used in operating activities.

XML 22 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies
3 Months Ended
Dec. 31, 2017
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the “U.S. GAAP”). All significant intercompany transactions and account balances have been eliminated.

 

This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company’s financial statements are expressed in U.S. dollars.

 

Fiscal Year

 

The Company changed its fiscal year from the period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January 1, 2018. As a result, the current fiscal period is a three-month transition period ended on December 31, 2017. In these consolidated statements, including the notes thereto, the current period financial results ended December 31, 2017 are for a three-month period. Audited results for the twelve months ended September 30, 2017 and 2016 are both for twelve-month periods. In addition, the Company's consolidated statements of operations and consolidated statements of cash flows include unaudited comparative amounts for the three-month period ended December 31, 2016. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.

 

Reclassifications

 

Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.

 

Forward Stock split

 

On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to Articles of Incorporation.

 

Fair Value Measurements

 

The Company applies the provisions of ASC Subtopic 820-10, “Fair Value Measurements”, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements.  ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  When determining the fair value measurements for assets and liabilities, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.

 

ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

 

-         Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

-         Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.

 

-         Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

 

There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of September 30, 2017 and 2016.

 

Cash and Cash Equivalents

 

The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of December 31, 2017 and September 30, 2017, the Company’s cash and cash equivalents amounted $93,332 and $204,851, respectively. Some of the Company’s cash deposits are held in financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.

 

Concentration of Credit Risk

 

The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation’s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes. Concentration of credit risk with respect to trade and notes receivables is limited due to the wide variety of customers and markets in which the Company transacts business, as well as their dispersion across many geographical areas. The Company performs ongoing credit evaluations of its customers and generally does not require collateral, but does require advance deposits on certain transactions.

 

Receivable from Collaboration Partners

 

Receivable from collaboration partners is stated at carrying value less estimates made for doubtful receivables. An allowance for impairment of receivable from collaboration partners is established if the collection of a receivable becomes doubtful. Such receivable becomes doubtful when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of the receivables. Significant financial difficulties of the debtor, probability that the debtor will enter into bankruptcy or financial reorganization, and default or delinquency in payments are considered indicators that the receivable is impaired. The amount of the allowance is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. An impairment loss is recognized in the statement of operations, as are subsequent recoveries of previous impairments.

 

Research and Development Expenses

 

The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred.


Stock-based Compensation

 

The Company measures expense associated with all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with ASC Topic 718 “Compensation-Stock Compensation”. Total employee stock-based compensation expenses were $0 for the three months ended December 31, 2017, and $0 and $397,960 for the years ended September 30, 2017 and 2016, respectively.

 

The Company accounted for stock-based compensation to non-employees in accordance with ASC Topic 505-50 “Equity-Based Payments to Non-Employees” which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee stock-based compensation expenses were $17,362 for the three months ended December 31, 2017, and $138,038 and $0 for the years ended September 30, 2017 and 2016, respectively.

 

Income Taxes

 

The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.

 

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the three months ended December 31, 2017 and for the years ended September 30, 2017 and September, 30, 2016. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.

 

For the three months ended December 31, 2017, the Company’s income tax expense amounted $0. For the years ended September 30, 2017 and 2016, the Company’s income tax expense amounted $830 and $836, respectively.

 

On December 22, 2017, the SEC issued Staff Accounting Bulletin (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions we may take. The Company is continuing to gather additional information to determine the final impact.

 

Loss Per Share of Common Stock

 

The Company reports loss per share in accordance with ASC Topic 260-10 "Earnings per Share." Basic earnings (loss) per share are computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available.

 

Commitments and Contingencies

 

The Company has adopted ASC Topic 450 “Contingencies” subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.

 

Recent Accounting Pronouncements

 

Revenue Recognition:     In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (ASU 2014-09), to supersede nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for us in our first quarter of fiscal 2018 using either of two methods: (i) retrospective to each prior reporting period presented with the option to elect certain practical expedients as defined within ASU 2014-09 (full retrospective method); or (ii) retrospective with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined per ASU 2014-09 (modified retrospective method). We are currently assessing the materiality of the impact to our consolidated financial statements, and have not yet selected a transition approach.

 

Disclosure of Going Concern Uncertainties:     In August 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern(ASU 2014-15), to provide guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective for us in our fourth quarter of fiscal 2017 with early adoption permitted. We do not believe the impact of our pending adoption of ASU 2014-15 on the Company’s financial statements will be material.

 

Leases:     In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-2”), which provides guidance on lease amendments to the FASB Accounting should Standard Codification. This ASU will be effective for us beginning in May 1, 2019. We are currently in the process of evaluating the impact of the adoption of ASU 2016-2on our consolidated financial statements.

 

Stock-based Compensation:    In March 2016, the FASB issued ASU 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Stock-Based Payment Accounting (ASU 2016-09). ASU 2016-09 changes how companies account for certain aspects of stock-based awards to employees, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU 2016-09 is effective for us in the first quarter of 2018, and earlier adoption is permitted. We are still evaluating the effect that this guidance will have on our consolidated financial statements and related disclosures.

 

Financial Instruments - Credit Losses: In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): The amendments in this Update require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments broaden the information that an entity must consider in developing its expected credit loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss, which will be more decision useful to users of the financial statements. ASU 2016-13 is effective for the Company for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is allowed as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is still evaluating the effect that this guidance will have on the Company’s consolidated financial statements and related disclosures.

 

Statement of Cash Flows: In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): The amendments in this Update apply to all entities, including both business entities and not-for-profit entities that are required to present a statement of cash flows under Topic 230. The amendments in this Update provide guidance on the following eight specific cash flow issues. The amendments are an improvement to GAAP because they provide guidance for each of the eight issues, thereby reducing the current and potential future diversity in practice described above. ASU 2016-15 is effective for the Company for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is still evaluating the effect that this guidance will have on the Company’s consolidated financial statements and related disclosures.

 

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): “Restricted Cash”(“ASU 2016-18”). ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. ASU 2016-18 will become effective for us beginning April 1, 2018, or fiscal 2019. ASU 2016-18 is required to be applied retrospectively. Upon the adoption, amounts described as restricted cash will be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period amounts shown on the statements of cash flows.

 

Business Combination:  In January 2017, the FASB issued ASU No. 2017-1 “Topic 805, Business Combinations: Clarifying the Definition of a Business”. The amendments in this update provide a screen to determine when a set is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. The amendments in this update affect all reporting entities that must determine whether they have acquired or sold a business. Public business entities should apply the amendments in this update to annual periods beginning after December 15, 2017, including interim periods within those periods. All other entities should apply the amendments to annual periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019. We do not expect the adoption of ASU 2017-1 to have a material impact on our consolidated financial statements.

 

From time to time, new accounting pronouncements are issued by FASB that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company's financial statements upon adoption. Management does not believe that any recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying financial statements. 

XML 23 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
Going Concern
3 Months Ended
Dec. 31, 2017
Going Concern [Abstract]  
GOING CONCERN

4. GOING CONCERN

 

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since its inception resulting in an accumulated deficit of $15,776,598 and $15,395,384 as of December 31, 2017 and September 30, 2017, respectively, and incurred net loss of $381,214 for the three months ended December 31, 2017, and $4,071,983 during the year ended September 30, 2017. The Company also had working capital deficiency of $1,756,915 and $1,393,063 at December 31, 2017 and September 30, 2017, respectively.  The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company upon signing of that agreement. On May 6, 2016, the Company and BioLite agreed to amend the BioLite Collaborative Agreement, through enter into the Milestone Payment Agreement, whereby the Company has agreed to pay the Milestone Payment to BioLite $2,600,000 in cash and $900,000 in newly issued shares of its common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares. The cash payment and shares issuance were completed in June 2016. Pursuant to the BioLite Collaborative Agreement, the 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. On February 2017, the Company agreed to pay this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of its common stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. The cash payment and shares issuance were completed in February 2017. This BioLite Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen years as of the first commercial sales of the Product in the Territory and automatically renew for five more years unless either party gives the other party six month written notice of termination prior to the expiration date of the term.

 

In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management’s plans to obtain such resources for the Company include (1) obtaining capital from the sale of its equity securities (2) short-term and long-term borrowings from banks and third-parties, and (3) short-term borrowings from stockholders or other related party(ies) when needed. However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans.

 

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually to secure other sources of financing and attain profitable operations.

XML 24 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Agreements
3 Months Ended
Dec. 31, 2017
Collaborative Agreements  
COLLABORATIVE AGREEMENTS

5. COLLABORATIVE AGREEMENTS

 

Collaborative agreement with BioLite Inc., a related party

 

On December 29, 2015, American BriVision Corporation entered into a collaborative agreement (the “BioLite Collaborative Agreement”) with BioLite Inc. (the “BioLite”), a related party (See Note 7), pursuant to which BioLite granted BriVision sole licensing rights for drug and therapeutic use of five products, including BLI-1005 CNS-Major Depressive Disorder, BLI-1008 CNS-Attention Deficit Hyperactivity Disorder, BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1, BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer, and BLI-1501 Hematology-Chronic Lymphocytic Leukemia, in the U.S.A and Canada. Under the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of BriVision with equivalent value, according to the following schedule:

 

  ●  upfront payment shall upon the signing of this BioLite Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week.
     
  upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week.
     
  at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months.
     
  upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week.
     
  at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months.
     
  upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week. 

 

This BioLite Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen years as of the first commercial sales of the Product in the Territory and automatically renew for five more years unless either party gives the other party six month written notice of termination prior to the expiration date of the term.

 

Pursuant to the BioLite Collaborative Agreement, an upfront payment of $3,500,000 (the “Milestone Payment”), which is 3.5% of total payments due under the BioLite Collaborative Agreement, was to be paid by the Company upon signing of that agreement. On May 6, 2016, the Company and BioLite agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company agreed to pay the Milestone Payment to BioLite with $2,600,000 in cash and $900,000 in the form of newly issued shares of its common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares. The cash payment and shares issuance were completed in June 2016.

 

Pursuant to the BioLite Collaborative Agreement, the 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. On February 2017, the Company agreed to pay this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of its common stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. The cash payment and shares issuance were completed in February 2017.

 

Pursuant to the BioLite Collaborative Agreement, the 15% of total payment, $15,000,000 shall be made at the completion of first phase II clinical trial. As of December 31, 2017, the first phase II clinical trial research has not completed yet.

  

The Company determined to fully expense the entire amount of $10,000,000 since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence the entire amount is fully expensed as research and development expense.

 

On January 12, 2017, the Company entered into an Addendum (the “Addendum”) to the BioLite Collaborative Agreement which was previously entered into with BioLite. Pursuant to the Addendum, the Company and BioLite agreed to include one more product, namely, “Maitake Combination Therapy” as one of the Products defined in the BioLite Collaborative Agreement (the “Sixth Product’) and defined the Territory of the Sixth Product to be worldwide and restate the Territory of the Five Products to be the U.S.A and Canada.

 

Co-Development agreement with Rgene Corporation, a related party

 

On May 26, 2017, American BriVision Corporation entered into a co-development agreement (the “Co-Dev Agreement”) with Rgene Corporation (the “Rgene”), a related party under common control by controlling beneficiary shareholder of Yuangene Corporation and the Company (See Note 7). Pursuant to Co-Dev Agreement, BriVison and Rgene agreed to co-develop and commercialize certain products that are included in the Sixth Product as defined in the Addendum. Under the terms of the Co-Dev Agreement, Rgene should pay the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017. The payment is for the compensation of BriVision’s past research efforts and contributions made by BriVision before the Co-Dev Agreement was signed and it does not relate to any future commitments made by BriVision and Rgene in this Co-Dev Agreement. Besides of $3,000,000, the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene, if any, and any development cost shall be equally shared by both BriVision and Rgene.

 

On June 1, 2017, the Company has delivered all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of Yuangene Corporation and the Company, the Company has recorded the full amount of $3,000,000 in connection with the Co-Dev Agreement as additional paid-in capital during the year ended September 30, 2017. As of the date of this report, the Company has received $450,000 in cash. The Company is still in discussion with Rgene with respect to the schedule of the outstanding balance.

 

Collaborative agreement with BioFirst Corporation, a related party

 

On July 24, 2017, American BriVision Corporation entered into a collaborative agreement (the “BioFirst Collaborative Agreement”) with BioFirst Corporation (“BioFirst”), pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the “Product”): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a controlling beneficiary shareholder of Yuangene Corporation and the Company is one of the directors and common stock shareholders of BioFirst (See Note 7).

 

Pursuant to the BioFirst Collaborative Agreement, the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $3,000,000 in cash or stock of the Company before September 30, 2018. The amount of $3,000,000 is in connection with the compensation for BioFirst’s past research efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate to any future commitments made by BioFirst and BriVision in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive 50% of the future net licensing income or net sales profit, if any, and any development cost shall be equally shared by both BriVision and BioFirst.

 

On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision. No payment has been made by the Company as of the date of this report. The Company determined to fully expense the entire amount of $3,000,000 since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence the entire amount of $3,000,000 is fully expensed as research and development expense during the year ended September 30, 2017.

XML 25 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accrued Expenses
3 Months Ended
Dec. 31, 2017
Payables and Accruals [Abstract]  
ACCRUED EXPENSES

6. ACCRUED EXPENSES

 

Accrued expenses as of December 31, 2017 and September 30, 2017 consisted of:

 

   December 31,
2017
   September 30,
2017
 
Accrued consulting fee  $29,075   $2,609 
Accrued professional service fees   13,592    - 
Accrued interest expense – related party(Note 7)   17,460    8,460 
Accrued payroll   110,800    23,845 
Total  $170,927   $34,914 
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
Related Parties Transactions
3 Months Ended
Dec. 31, 2017
Related Party Transactions [Abstract]  
RELATED PARTIES TRANSACTIONS

7. RELATED PARTIES TRANSACTIONS

 

The related parties of the company with whom transactions are reported in these financial statements are as follows:

 

Name of entity or Individual   Relationship with the Company and its subsidiaries
BioLite Inc. (the “BioLite”)   Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene
BioFirst Corporation (the “BioFirst”)   Entity controlled by controlling beneficiary shareholder of Yuangene
Rgene Corporation (the “Rgene”)   Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene
Liongene Corporation (the “Liongene”)   Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene
Yuangene Corporation (the “Yuangene”)   Controlling beneficiary shareholder of the Company
Asiangene Corporation (the “Asiangene”)   Shareholder; entity controlled by controlling beneficiary shareholder of Yuangene
Euro-Asia Investment & Finance Corp Ltd. (the “Euro-Asia”)   Shareholder of the Company
Kimho Consultants Co., Ltd. (the “Kimho”)   Shareholder of the Company
Eugene Jiang   Former President and Chairman

 

Due to related parties

 

Amount due to related parties consisted of the following as of the periods indicated:

 

   December 31,   September 30, 
   2017   2017 
BioLite Inc.  $109,220   $- 
BioFirst Corporation   3,957,000    3,950,000 
Asiangene Corporation   160,000    160,000 
Yuangene Corporation   3,000    3,000 
Eugene Jiang   100    - 
Total  $4,229,320   $4,113,000 

 

Related party transactions

 

(1)During the three months ended December 31, 2017, BioLite advanced in an aggregate amount of $109,220 to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand. As of December 31, 2017 and September 30, 2017, the outstanding advance balance is $109,220 and $0, respectively.

 

(2)On January 26, 2017, the Company and BioFirst entered into a loan agreement for a total commitment (non-secured indebtedness) of $950,000 to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The loan will be matured on February 1, 2018. As of December 31, 2017 and September 30, 2017, the outstanding loan balance is $950,000 and $950,000, and accrued interest is $17,460 and $8,460, respectively (See Note 6). Interest expenses in connection with this loan is $28,500 for the three months ended December 31, 2017, and $74,960 and $0 for the years ended September 30, 2017 and 2016, respectively.

 

(3)On July 24, 2017, BriVision entered into a collaborative agreement (the “BioFirst Collaborative Agreement”) with BioFirst (See Note 5). In September 2017, BioFirst has delivered all research, technical, data and development data to BriVision, and the Company has recorded full amount of $3,000,000 due to BioFirst. As of December 31, 2017 and September 30, 2017, the outstanding balance is $3,000,000 and $3,000,000, respectively.

 

(4)During the three months ended December 31, 2017, BioFirst also advanced in an aggregate amount of $7,000 to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand. As of December 31, 2017 and September 30, 2017, the outstanding advance balance is $7,000 and $0, respectively.

 

(5)In September 2017, Asiangene entered an investment and equity transfer agreement (the “Investment and Equity Transfer Agreement”) with Everfront Biotech Inc. (the “Everfront”), a third party. Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by Asiangene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. Asiangene also agreed to loan the proceeds to the Company for working capital purpose. The non-secured loan bears 0% interest rate and is due on demand. As of December 31, 2017 and September 30, 2017, the outstanding loan balance is $160,000 and $160,000, respectively.

 

(6)During the year ended September 30, 2017, Yuangene Corporation advanced in an aggregate amount of $3,000 to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand. As of December 31, 2017 and September 30, 2017, the outstanding advance balance is $3,000 and $3,000, respectively.

 

(7)During the three months ended December 31, 2017, Eugene Jiang, the former President and Chairman of the Company, has advanced in an aggregate amount of $100 to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand. As of December 31, 2017 and September 30, 2017, the outstanding advance balance is $100 and $0, respectively.

 

(8)On May 26, 2017, BriVision entered into a co-development agreement (the “Co-Dev Agreement”) with Rgene (See Note 5). As of December 31, 2017, the Company has received an aggregate amount of $450,000 in cash and has recorded $2,550,000 as receivable from collaboration partners. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of Yuangene Corporation, the Company has recorded the full amount of $3,000,000 in connection with the Co-Dev Agreement as additional paid-in capital during the year ended September 30, 2017.

 

(9)On January 1, 2017, Euro-Asia Investment & Finance Corp Ltd. and the Company entered into a service agreement (the “Euro-Asia Agreement”) for the maintenance of the listing in the U.S. stock exchange market. During the three months ended December 31, 2017 and during the year ended September 30, 2017, the Company recognized non-employee stock based compensation expenses of $5,000 and $55,000 in connection with the terms in the Euro-Asia Agreement, respectively.

 

(10)On January 1, 2017, Kimho Consultants Co., Ltd. and the Company entered into a service agreement (the “Kimho Agreement”) for the maintenance of the listing in the U.S. stock exchange market. During the three months ended December 31, 2017 and during the year ended September 30, 2017, the Company recognized non-employee stock based compensation expenses of $10,000 and $80,000 in connection with the terms in the Kimho Agreement, respectively.

 

(11)During the year ended September 30, 2017, the Company provided a one-time consulting service to Liongene Corporation for $70,000. Since both Liongene and the Company are related parties and under common control by a controlling beneficiary shareholder of Yuangene Corporation, the Company has recorded the full amount of $70,000 as additional paid-in capital during the year ended September 30, 2017.

 

(12)During the year ended September 30, 2017, the Company entered an operating lease agreement with Asiangene for an office space in Taiwan for the period from October 1, 2016 to July 31, 2017. The monthly base rent is approximately $5,000. Rent expenses under this lease agreement amounted to $52,205 and $0 for the years ended September 30, 2017 and 2016, respectively.
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
Equity
3 Months Ended
Dec. 31, 2017
Equity [Abstract]  
EQUITY

8. EQUITY

 

During October 2015, $350,000 of subscription receivable was fully collected from the shareholders.

 

On February 8, 2016, a Share Exchange Agreement (“Share Exchange Agreement”) was entered into by and among American BriVision (Holding) Corporation (the “Company”), American BriVision Corporation (“BriVision”), Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People's Republic of China (“Euro-Asia”), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock of the Company, and the owners of record of all of the issued share capital of BriVision (the “BriVision Stock”). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the “Acquisition Stock”) (subject to adjustment for fractionalized shares as set forth below) of the Company’s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company’s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of BriVision’s common stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583 pre-stock split) shares of Company’s common stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company’s common stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company’s common stock, Because of the exchange of the BriVision Stock for the Acquisition Stock (the “Share Exchange”), BriVision became a wholly owned subsidiary (the “Subsidiary”) of the Company and there was a change of control of the Company following the closing.  There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.

 

On February17, 2016, pursuant to the 2016 Equity Incentive Plan (the “2016 Plan”), 157,050 (50,000 pre-stock split) shares were granted to the employees.

 

On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the “Forward Stock Split”) and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.

 

The majority of the shareholders of the Company approved the amendment to Articles of Incorporation.

 

On May 6, 2016, the Company and BioLite agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of our first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016.

 

On August 26, 2016, the Company issued 1,468,750 shares (“Shares”) of the Company’s common stock, par value $0.001 (the “Offering”) to BioLite, Inc., a non-U.S. accredited investor (the “Purchaser”) pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the “SPA”). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. The proceeds may be used for general corporate purposes. 

 

Pursuant to the BioLite Collaborative Agreement (See Note 5), BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. In February 2017, the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of our common stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares.

 

On October 1, 2016, the Company entered into a consulting agreement with Kazunori Kameyama (“Kameyama”) for the provision of services related to the clinical trials and other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company’s common stock at $1.00 per share for any amount exceeding $3,000. The Company’s stocks shall be calculated and issued in December every year. On October 1, 2017, the Company and Kameyama agreed to extend the service period for one more year expiring on September 30, 2018. As a result, the non-employee stock-based compensation related to this consulting agreement was $2,362 during the three months ended December 31, 2017 and $3,038 for the year ended September 30, 2017.

 

On January 1, 2017, Euro-Asia Investment & Finance Corp Ltd. and the Company entered into a service agreement (the “Euro-Asia Agreement”) for the maintenance of the listing in the U.S. stock exchange market. During the three months ended December 31, 2017 and during the year ended September 30, 2017, the Company recognized professional fees of $18,000 and $69,000, and non-employee stock based compensation expenses of $5,000 and $55,000 in connection with the terms in the Euro-Asia Agreement, respectively.

 

On January 1, 2017, Kimho Consultants Co., Ltd. and the Company entered into a service agreement (the “Kimho Agreement”) for the maintenance of the listing in the U.S. stock exchange market. During the three months ended December 31, 2017 and during the year ended September 30, 2017, the Company recognized professional fees of $21,000 and $113,000, and non-employee stock based compensation expenses of $10,000 and $80,000 in connection with the terms in the Kimho Agreement, respectively.

 

Pursuant to ASC 505-50-30, the transactions with the non-employees were measured based on the fair value of the equity instruments issued as the Company determined that the fair value of the equity instruments issued in a stock-based payment transaction with nonemployees was more reliably measurable than the fair value of the consideration received. The Company measured the fair value of the equity instruments in these transactions using the stock price on the date at which the commitments Kameyama, Euro-Asia, and Kimho for performance were rendered.

XML 28 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Tax
3 Months Ended
Dec. 31, 2017
Income Tax Disclosure [Abstract]  
INCOME TAX

9. INCOME TAX

 

The Company files income tax returns in the U.S. federal jurisdiction, and various state and local jurisdictions. The Company is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years before 2013.

 

On December 22, 2017 H.R. 1, originally known as the Tax Cuts and Jobs Act, (the “Tax Act”) was enacted. Among the significant changes to the U.S. Internal Revenue Code, the Tax Act lowers the U.S. federal corporate income tax rate (“Federal Tax Rate”) from 35% to 21% effective January 1, 2018The 21% Federal Tax Rate will apply to earnings reported for the full 2018 fiscal year. In addition, the Company must re-measure its net deferred tax assets and liabilities using the Federal Tax Rate that will apply when these amounts are expected to reverse. As of December 31, 2017, the Company can determine a reasonable estimate for certain effects of tax reform and is recording that estimate as a provisional amount. The provisional remeasurement of the deferred tax assets and allowance valuation of deferred tax assets at December 31, 2017 resulted in a net effect of $0 discrete tax expenses (benefit) which lowered the effective tax rate by 13% for the year ended December 31, 2017. The provisional remeasurement amount is anticipated to change as data becomes available allowing more accurate scheduling of the deferred tax assets and liabilities primarily related to net operating loss carryover.

 

Components of income tax (benefits) for the three months ended December 31, 2017, and for the years ended September 30, 2017 and 2016 are as follows:

 

   Three Months ended
December 31, 2017
   Year ended
September 30, 2017
   Year ended
September 30, 2016
 
   Federal   State   Total   Federal   State   Total   Federal   State   Total 
Current  $        -   $       -   $       -   $            -   $830   $830   $         -   $836   $836 
Deferred   -    -    -    -    -    -    -    -    - 
   $-   $-   $-   $-   $830   $830   $-   $836   $836 

 

Significant components of the Company’s deferred tax accounts at December 31, 2017 and September 30, 2017:

 

Deferred Tax Account - noncurrent:  December 31, 2017   September 30, 2017 
Tax losses carryforwards  $594,501   $832,913 
Less: Valuation allowance   (594,501)   (832,913)
Total deferred tax account - noncurrent  $-   $- 

 

The difference between the effective rate reflected in the provision for income taxes on loss before taxes and the amounts determined by applying the applicable statutory U.S. tax rate are analyzed below:

 

   Three Months ended December 31,   Years ended
September 30,
 
   2017   2017   2016 
Statutory federal tax benefit, net of state tax effects   31%   31%   31%
State income taxes   8.84%   8.84%   8.84%
Provisional remeasurement of deferred taxes   (13)%   -%   -%
Nondeductible/nontaxable items   -%   (29)%   (36)%
Change in valuation allowance   (26.84)%   (10.84)%   (3.84)%
Effective income tax rate   -%   -%   -%
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Loss Per Share
3 Months Ended
Dec. 31, 2017
Earnings Per Share [Abstract]  
LOSS PER SHARE

10. LOSS PER SHARE

 

Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed by dividing net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the year.

 

   Three Months Ended
December 31,
   Years Ended
September 30,
 
   2017   2017   2016 
             
Numerator:            
Net loss  $(381,214)  $(4,071,983)  $(11,007,799)
                
Denominator:               
Weighted-average shares outstanding:               
Weighted-average shares outstanding - Basic   213,746,647    212,648,770    193,981,153 
Stock options   -    -    - 
Weighted-average shares outstanding - Diluted   213,746,647    212,648,770    193,981,153 
                
Loss per share               
-Basic  $(0.00)  $(0.02)  $(0.06)
-Diluted  $(0.00)  $(0.02)  $(0.06)

 

Diluted loss per share takes into account the potential dilution that could occur if securities or other contracts to issue common stock were exercised and converted into common stock.

XML 30 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies
3 Months Ended
Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

11. COMMITMENTS AND CONTINGENCIES

 

Operating Commitment

 

The total future minimum lease payments under the non-cancellable operating lease with respect to the office as of December 31, 2017 are payable as follows:

 

As of December 31,  Amount 
2018  $4,950 
Total minimum payments  $4,950 

 

Rental expense was $2,482 for the three months ended December 31, 2017. Rental expense was $61,093 and 29,129 for the year ended September 30, 2017 and 2016, respectively.

XML 31 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Transition Period Comparative Data
3 Months Ended
Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]  
TRANSITION PERIOD COMPARATIVE DATA

12. TRANSITION PERIOD COMPARATIVE DATA

 

The following table presents certain financial information for the three months ended December 31, 2017 and 2016, respectively:

 

   Three Months Ended 
   December 31,
2017
   December 31,
2016
 
       (Unaudited) 
       (Restated) 
         
Revenues  $-   $- 
           
Cost of revenues   -    - 
           
Gross profit   -    - 
           
Operating expenses          
Selling, general and administrative expenses   289,731    185,188 
Research and development expenses   45,701    25,198 
Stock based compensation   17,362    - 
           
Loss from operations   (352,794)   (210,386)
           
Other income (expense)          
Interest income   80    49 
Interest expense   (28,500)   - 
Total other income (expenses)   (28,420)   49 
           
Loss from continuing operations before provision income tax   (381,214)   (210,337)
           
Provision for income tax   -    - 
           
Net loss   (381,214)   (210,337)
           
Net loss per share attributable to common stockholders          
Basic and diluted  $(0.00)  $(0.00)
           
Weighted average number of common shares outstanding          
Basic and diluted   213,746,647    210,821,647 
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Subsequent Event
3 Months Ended
Dec. 31, 2017
Subsequent Events [Abstract]  
SUBSEQUENT EVENT

13. SUBSEQUENT EVENT

 

The Company has evaluated subsequent events through the date which the financial statements were available to be issued. All subsequent events requiring recognition as of December 31, 2017 have been incorporated into these financial statements and there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events.”

XML 33 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Dec. 31, 2017
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the “U.S. GAAP”). All significant intercompany transactions and account balances have been eliminated.

 

This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company’s financial statements are expressed in U.S. dollars.

Fiscal Year

Fiscal Year

 

The Company changed its fiscal year from the period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January 1, 2018. As a result, the current fiscal period is a three-month transition period ended on December 31, 2017. In these consolidated statements, including the notes thereto, the current period financial results ended December 31, 2017 are for a three-month period. Audited results for the twelve months ended September 30, 2017 and 2016 are both for twelve-month periods. In addition, the Company's consolidated statements of operations and consolidated statements of cash flows include unaudited comparative amounts for the three-month period ended December 31, 2016. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year.

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.

Reclassifications

Reclassifications

 

Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.

Forward Stock split

Forward Stock split

 

On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to Articles of Incorporation.

Fair Value Measurements

Fair Value Measurements

 

The Company applies the provisions of ASC Subtopic 820-10, “Fair Value Measurements”, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements.  ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  When determining the fair value measurements for assets and liabilities, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.

 

ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

 

-         Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

-         Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.

 

-         Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

 

There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of September 30, 2017 and 2016.

Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of December 31, 2017 and September 30, 2017, the Company’s cash and cash equivalents amounted $93,332 and $204,851, respectively. Some of the Company’s cash deposits are held in financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.

Concentration of Credit Risk

Concentration of Credit Risk

 

The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation’s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes. Concentration of credit risk with respect to trade and notes receivables is limited due to the wide variety of customers and markets in which the Company transacts business, as well as their dispersion across many geographical areas. The Company performs ongoing credit evaluations of its customers and generally does not require collateral, but does require advance deposits on certain transactions.

Receivable from Collaboration Partners

Receivable from Collaboration Partners

 

Receivable from collaboration partners is stated at carrying value less estimates made for doubtful receivables. An allowance for impairment of receivable from collaboration partners is established if the collection of a receivable becomes doubtful. Such receivable becomes doubtful when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of the receivables. Significant financial difficulties of the debtor, probability that the debtor will enter into bankruptcy or financial reorganization, and default or delinquency in payments are considered indicators that the receivable is impaired. The amount of the allowance is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. An impairment loss is recognized in the statement of operations, as are subsequent recoveries of previous impairments.

Research and Development Expenses

Research and Development Expenses

 

The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred.

Stock-based Compensation

Stock-based Compensation

 

The Company measures expense associated with all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with ASC Topic 718 “Compensation-Stock Compensation”. Total employee stock-based compensation expenses were $0 for the three months ended December 31, 2017, and $0 and $397,960 for the years ended September 30, 2017 and 2016, respectively.

 

The Company accounted for stock-based compensation to non-employees in accordance with ASC Topic 505-50 “Equity-Based Payments to Non-Employees” which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee stock-based compensation expenses were $17,362 for the three months ended December 31, 2017, and $138,038 and $0 for the years ended September 30, 2017 and 2016, respectively.

Income Taxes

Income Taxes

 

The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.

 

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the three months ended December 31, 2017 and for the years ended September 30, 2017 and September, 30, 2016. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.

 

For the three months ended December 31, 2017, the Company’s income tax expense amounted $0. For the years ended September 30, 2017 and 2016, the Company’s income tax expense amounted $830 and $836, respectively.

 

On December 22, 2017, the SEC issued Staff Accounting Bulletin (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions we may take. The Company is continuing to gather additional information to determine the final impact.

Loss Per Share of Common Stock

Loss Per Share of Common Stock

 

The Company reports loss per share in accordance with ASC Topic 260-10 "Earnings per Share." Basic earnings (loss) per share are computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available.

Commitments and Contingencies

Commitments and Contingencies

 

The Company has adopted ASC Topic 450 “Contingencies” subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

Revenue Recognition:     In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (ASU 2014-09), to supersede nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for us in our first quarter of fiscal 2018 using either of two methods: (i) retrospective to each prior reporting period presented with the option to elect certain practical expedients as defined within ASU 2014-09 (full retrospective method); or (ii) retrospective with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined per ASU 2014-09 (modified retrospective method). We are currently assessing the materiality of the impact to our consolidated financial statements, and have not yet selected a transition approach.

 

Disclosure of Going Concern Uncertainties:     In August 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern(ASU 2014-15), to provide guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective for us in our fourth quarter of fiscal 2017 with early adoption permitted. We do not believe the impact of our pending adoption of ASU 2014-15 on the Company’s financial statements will be material.

 

Leases:     In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-2”), which provides guidance on lease amendments to the FASB Accounting should Standard Codification. This ASU will be effective for us beginning in May 1, 2019. We are currently in the process of evaluating the impact of the adoption of ASU 2016-2on our consolidated financial statements.

 

Stock-based Compensation:    In March 2016, the FASB issued ASU 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Stock-Based Payment Accounting (ASU 2016-09). ASU 2016-09 changes how companies account for certain aspects of stock-based awards to employees, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU 2016-09 is effective for us in the first quarter of 2018, and earlier adoption is permitted. We are still evaluating the effect that this guidance will have on our consolidated financial statements and related disclosures.

 

Financial Instruments - Credit Losses: In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): The amendments in this Update require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments broaden the information that an entity must consider in developing its expected credit loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss, which will be more decision useful to users of the financial statements. ASU 2016-13 is effective for the Company for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is allowed as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is still evaluating the effect that this guidance will have on the Company’s consolidated financial statements and related disclosures.

 

Statement of Cash Flows: In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): The amendments in this Update apply to all entities, including both business entities and not-for-profit entities that are required to present a statement of cash flows under Topic 230. The amendments in this Update provide guidance on the following eight specific cash flow issues. The amendments are an improvement to GAAP because they provide guidance for each of the eight issues, thereby reducing the current and potential future diversity in practice described above. ASU 2016-15 is effective for the Company for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is still evaluating the effect that this guidance will have on the Company’s consolidated financial statements and related disclosures.

 

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): “Restricted Cash”(“ASU 2016-18”). ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. ASU 2016-18 will become effective for us beginning April 1, 2018, or fiscal 2019. ASU 2016-18 is required to be applied retrospectively. Upon the adoption, amounts described as restricted cash will be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period amounts shown on the statements of cash flows.

 

Business Combination:  In January 2017, the FASB issued ASU No. 2017-1 “Topic 805, Business Combinations: Clarifying the Definition of a Business”. The amendments in this update provide a screen to determine when a set is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. The amendments in this update affect all reporting entities that must determine whether they have acquired or sold a business. Public business entities should apply the amendments in this update to annual periods beginning after December 15, 2017, including interim periods within those periods. All other entities should apply the amendments to annual periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019. We do not expect the adoption of ASU 2017-1 to have a material impact on our consolidated financial statements.

 

From time to time, new accounting pronouncements are issued by FASB that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company's financial statements upon adoption. Management does not believe that any recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying financial statements

XML 34 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Corrections to Previously Issued Consolidated Financial Statements (Tables)
3 Months Ended
Dec. 31, 2017
Accounting Changes and Error Corrections [Abstract]  
Schedule of corrections and consolidated financial statements

ITEMS  Previously  Reported on Form 10K   Adjustments No.1   Adjustments No.2   Restated 
                 
Consolidated Balance Sheets                
As of September 30, 2016                
Due to related party   -    6,500,000    -    6,500,000 
Total Liabilities   56,470    6,500,000    -    6,556,470 
Additional paid-in capital   4,733,401    -    60    4,733,461 
Accumulated deficit   (4,823,401)   (6,500,000)   -    (11,323,401)
Total equity (deficit)   120,882    (6,500,000)   -    (6,379,118)
                     
Consolidated Statements of Operations and Comprehensive Loss                    
For the year ended September 30, 2016                    
Selling, general and administrative expenses   4,497,263    (3,500,060)   60    997,263 
Research and development expenses   -    10,000,000    -    10,000,000 
Net loss from operations   (4,497,295)   (6,499,940)   (60)   (10,997,295)
Loss from continuing operations before income taxes   (4,506,963)   (6,499,940)   (60)   (11,006,963)
Net Loss   (4,507,799)   (6,499,940)   (60)   (11,007,799)
Basic and diluted loss per share   (0.00)   (0.06)   (0.00)   (0.06)
                     
Consolidated Statements of Cash Flow                    
For the year ended September 30, 2016                    
Net loss from continuing operations   (4,507,799)   (6,499,940)   (60)   (11,007,799)
Issuance of common stock for compensation   1,295,324    (60)   60    1,295,324 
(Decrease) increase in due to related party   (22,517)   6,500,000         6,477,483 
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accrued Expenses (Tables)
3 Months Ended
Dec. 31, 2017
Payables and Accruals [Abstract]  
Schedule of accrued expenses

   December 31,
2017
   September 30,
2017
 
Accrued consulting fee  $29,075   $2,609 
Accrued professional service fees   13,592    - 
Accrued interest expense – related party(Note 7)   17,460    8,460 
Accrued payroll   110,800    23,845 
Total  $170,927   $34,914 
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Related Parties Transactions (Tables)
3 Months Ended
Dec. 31, 2017
Related Party Transactions [Abstract]  
Schedule of related party transactions

Name of entity or Individual   Relationship with the Company and its subsidiaries
BioLite Inc. (the “BioLite”)   Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene
BioFirst Corporation (the “BioFirst”)   Entity controlled by controlling beneficiary shareholder of Yuangene
Rgene Corporation (the “Rgene”)   Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene
Liongene Corporation (the “Liongene”)   Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene
Yuangene Corporation (the “Yuangene”)   Controlling beneficiary shareholder of the Company
Asiangene Corporation (the “Asiangene”)   Shareholder; entity controlled by controlling beneficiary shareholder of Yuangene
Euro-Asia Investment & Finance Corp Ltd. (the “Euro-Asia”)   Shareholder of the Company
Kimho Consultants Co., Ltd. (the “Kimho”)   Shareholder of the Company
Eugene Jiang   Former President and Chairman
Schedule of amount due to related party

   December 31,   September 30, 
   2017   2017 
BioLite Inc.  $109,220   $- 
BioFirst Corporation   3,957,000    3,950,000 
Asiangene Corporation   160,000    160,000 
Yuangene Corporation   3,000    3,000 
Eugene Jiang   100    - 
Total  $4,229,320   $4,113,000
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Tax (Tables)
3 Months Ended
Dec. 31, 2017
Income Tax Disclosure [Abstract]  
Summary of income tax (benefits)
   Three Months ended
December 31, 2017
   Year ended
September 30, 2017
   Year ended
September 30, 2016
 
   Federal   State   Total   Federal   State   Total   Federal   State   Total 
Current  $        -   $       -   $       -   $            -   $830   $830   $         -   $836   $836 
Deferred   -    -    -    -    -    -    -    -    - 
   $-   $-   $-   $-   $830   $830   $-   $836   $836 
Schedule of deferred tax
Deferred Tax Account - noncurrent:  December 31, 2017   September 30, 2017 
Tax losses carryforwards  $594,501   $832,913 
Less: Valuation allowance   (594,501)   (832,913)
Total deferred tax account - noncurrent  $-   $- 
Schedule of statutory rate and effective rate reconciliation
   Three Months ended December 31,   Years ended
September 30,
 
   2017   2017   2016 
Statutory federal tax benefit, net of state tax effects   31%   31%   31%
State income taxes   8.84%   8.84%   8.84%
Provisional remeasurement of deferred taxes   (13)%   -%   -%
Nondeductible/nontaxable items   -%   (29)%   (36)%
Change in valuation allowance   (26.84)%   (10.84)%   (3.84)%
Effective income tax rate   -%   -%   -%
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Loss Per Share (Tables)
3 Months Ended
Dec. 31, 2017
Earnings Per Share [Abstract]  
Schedule of loss per share
   Three Months Ended
December 31,
   Years Ended
September 30,
 
   2017   2017   2016 
             
Numerator:            
Net loss  $(381,214)  $(4,071,983)  $(11,007,799)
                
Denominator:               
Weighted-average shares outstanding:               
Weighted-average shares outstanding - Basic   213,746,647    212,648,770    193,981,153 
Stock options   -    -    - 
Weighted-average shares outstanding - Diluted   213,746,647    212,648,770    193,981,153 
                
Loss per share               
-Basic  $(0.00)  $(0.02)  $(0.06)
-Diluted  $(0.00)  $(0.02)  $(0.06)
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies (Tables)
3 Months Ended
Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]  
Schedule of future minimum lease payments
As of December 31,  Amount 
2018  $4,950 
Total minimum payments  $4,950 
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Transition Period Comparative Data (Tables)
3 Months Ended
Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]  
Schedule of financial information
   Three Months Ended 
   December 31,
2017
   December 31,
2016
 
       (Unaudited) 
       (Restated) 
         
Revenues  $-   $- 
           
Cost of revenues   -    - 
           
Gross profit   -    - 
           
Operating expenses          
Selling, general and administrative expenses   289,731    185,188 
Research and development expenses   45,701    25,198 
Stock based compensation   17,362    - 
           
Loss from operations   (352,794)   (210,386)
           
Other income (expense)          
Interest income   80    49 
Interest expense   (28,500)   - 
Total other income (expenses)   (28,420)   49 
           
Loss from continuing operations before provision income tax   (381,214)   (210,337)
           
Provision for income tax   -    - 
           
Net loss   (381,214)   (210,337)
           
Net loss per share attributable to common stockholders          
Basic and diluted  $(0.00)  $(0.00)
           
Weighted average number of common shares outstanding          
Basic and diluted   213,746,647    210,821,647 
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Organization and Description of Business (Details)
Feb. 08, 2016
shares
Share Exchange Agreement Four [Member]  
Organization and Description of Business (Textual)  
Common stock issued post-stock split 205,519,223
Common stock issued pre-stock split 65,431,144
Percentage of common shares issued and outstanding 79.70%
Share Exchange Agreement [Member]  
Organization and Description of Business (Textual)  
Common stock issued post-stock split 164,387,376
Common stock issued pre-stock split 52,336,000
Share Exchange Agreement One [Member]  
Organization and Description of Business (Textual)  
Common stock issued post-stock split 166,273,921
Common stock issued pre-stock split 52,936,583
Share Exchange Agreement Three [Member]  
Organization and Description of Business (Textual)  
Common stock issued post-stock split 166,273,921
Common stock issued pre-stock split 52,936,583
Common stock converted to exchange ratio 0.2536
Share Exchange Agreement Two [Member]  
Organization and Description of Business (Textual)  
Common stock issued post-stock split 163,159,952
Common stock issued pre-stock split 51,945,225
Percentage of common shares issued and outstanding 79.70%
Percentage of issued share capital 100.00%
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Corrections to Previously Issued Consolidated Financial Statements (Details) - USD ($)
2 Months Ended 3 Months Ended 12 Months Ended
Sep. 30, 2015
Dec. 31, 2017
Dec. 31, 2016
Sep. 30, 2017
Sep. 30, 2016
Jul. 20, 2015
Consolidated Balance Sheets            
Due to related party   $ 4,229,320   $ 4,113,000    
Total Liabilities   4,400,247   4,147,914    
Additional paid-in capital   13,805,936   13,788,574    
Accumulated deficit   (15,776,598)   (15,395,384)    
Total equity (deficit) $ 633,357 (1,756,915)   (1,393,063) $ (6,379,118) $ 897,001
Consolidated Statements of Operations and Comprehensive Loss            
Selling, general and administrative expenses   289,731 $ 185,188 707,142 599,303  
Research and development expenses   45,701 25,198 3,151,162 10,000,000  
Net loss from operations   (352,794) (210,386) (3,996,342) (10,997,295)  
Net Loss (315,602) $ (381,214) $ (210,337) $ (4,071,983) $ (11,007,799)  
Basic and diluted loss per share   $ (0.00) $ (0.00) $ (0.02) $ (0.06)  
Consolidated Statements of Cash Flow            
Net loss from continuing operations $ (315,602) $ (381,214) $ (210,337) $ (4,071,983) $ (11,007,799)  
Issuance of common stock for compensation     1,295,324  
(Decrease) increase in due to related party   $ 116,320   $ 2,353,000 6,477,483  
Restatement Adjustment [Member]            
Consolidated Balance Sheets            
Due to related party         6,500,000  
Total Liabilities         6,556,470  
Additional paid-in capital         4,733,461  
Accumulated deficit         (11,323,401)  
Total equity (deficit)         (6,379,118)  
Consolidated Statements of Operations and Comprehensive Loss            
Selling, general and administrative expenses         997,263  
Research and development expenses         10,000,000  
Net loss from operations         (10,997,295)  
Loss from continuing operations before income taxes         (11,006,963)  
Net Loss         $ (11,007,799)  
Basic and diluted loss per share         $ (0.06)  
Consolidated Statements of Cash Flow            
Net loss from continuing operations         $ (11,007,799)  
Issuance of common stock for compensation         (1,295,324)  
(Decrease) increase in due to related party         6,477,483  
Scenario, Previously Reported [Member]            
Consolidated Balance Sheets            
Due to related party          
Total Liabilities         56,470  
Additional paid-in capital         4,733,401  
Accumulated deficit         (4,823,401)  
Total equity (deficit)         120,882  
Consolidated Statements of Operations and Comprehensive Loss            
Selling, general and administrative expenses         4,497,263  
Research and development expenses          
Net loss from operations         (4,497,295)  
Loss from continuing operations before income taxes         (4,506,963)  
Net Loss         $ (4,507,799)  
Basic and diluted loss per share         $ 0.00  
Consolidated Statements of Cash Flow            
Net loss from continuing operations         $ (4,507,799)  
Issuance of common stock for compensation         (1,295,324)  
(Decrease) increase in due to related party         (22,517)  
Adjustments One [Member]            
Consolidated Balance Sheets            
Due to related party          
Total Liabilities          
Additional paid-in capital         60  
Accumulated deficit          
Total equity (deficit)          
Consolidated Statements of Operations and Comprehensive Loss            
Selling, general and administrative expenses         60  
Research and development expenses          
Net loss from operations         (60)  
Loss from continuing operations before income taxes         (60)  
Net Loss         $ (60)  
Basic and diluted loss per share         $ 0.00  
Consolidated Statements of Cash Flow            
Net loss from continuing operations         $ (60)  
Issuance of common stock for compensation         60  
(Decrease) increase in due to related party          
Adjustments [Member]            
Consolidated Balance Sheets            
Due to related party         6,500,000  
Total Liabilities         6,500,000  
Additional paid-in capital          
Accumulated deficit         (6,500,000)  
Total equity (deficit)         (6,500,000)  
Consolidated Statements of Operations and Comprehensive Loss            
Selling, general and administrative expenses         (3,500,060)  
Research and development expenses         10,000,000  
Net loss from operations         (6,499,940)  
Loss from continuing operations before income taxes         (6,499,940)  
Net Loss         $ (6,499,940)  
Basic and diluted loss per share         $ (0.06)  
Consolidated Statements of Cash Flow            
Net loss from continuing operations         $ (6,499,940)  
Issuance of common stock for compensation         (60)  
(Decrease) increase in due to related party         $ 6,500,000  
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Corrections to Previously Issued Consolidated Financial Statements (Details Textual) - USD ($)
2 Months Ended 3 Months Ended 12 Months Ended
Sep. 30, 2015
Dec. 31, 2017
Dec. 31, 2016
Sep. 30, 2017
Sep. 30, 2016
Jul. 20, 2015
Corrections to Previously Issued Consolidated Financial Statements (Textual)            
Due to related party   $ 4,229,320   $ 4,113,000    
Total liabilities   4,400,247   4,147,914    
Total liabilities increased       6,500,000    
Additional paid in capital   13,805,936   13,788,574    
Additional paid in capital increased       60    
Accumulated deficit   (15,776,598)   (15,395,384)    
Accumulated deficit increased       6,500,000    
Total equity (deficit) $ 633,357 (1,756,915)   (1,393,063) $ (6,379,118) $ 897,001
Total equity (deficit) decreased       6,500,000    
Selling, general and administrative expenses   289,731 $ 185,188 707,142 599,303  
Selling, general and administrative expenses decreased       3,500,000    
Research and development expenses   45,701 25,198 3,151,162 10,000,000  
Research and development expenses increased       10,000,000    
Net loss from operations   (352,794) (210,386) (3,996,342) (10,997,295)  
Loss from continuing operations before taxes increased       6,500,000    
Net loss for the period (315,602) $ (381,214) $ (210,337) $ (4,071,983) $ (11,007,799)  
Basic and diluted loss per share   $ (0.00) $ (0.00) $ (0.02) $ (0.06)  
Basic and diluted loss per share increased       $ 0.06    
Net loss from continuing operations $ (315,602) $ (381,214) $ (210,337) $ (4,071,983) $ (11,007,799)  
Net loss from continuing operations increased       6,500,000    
Issuance of common stock for compensation and recapitalization     1,295,324  
(Decrease) increase in due to related party   $ 116,320   2,353,000 6,477,483  
(Decrease) increase in due to related party increased       $ 6,500,000    
Restatement Adjustment [Member]            
Corrections to Previously Issued Consolidated Financial Statements (Textual)            
Due to related party         6,500,000  
Total liabilities         6,556,470  
Additional paid in capital         4,733,461  
Accumulated deficit         (11,323,401)  
Total equity (deficit)         (6,379,118)  
Selling, general and administrative expenses         997,263  
Research and development expenses         10,000,000  
Net loss from operations         (10,997,295)  
Loss from continuing operations before taxes         (11,006,963)  
Net loss for the period         $ (11,007,799)  
Basic and diluted loss per share         $ (0.06)  
Net loss from continuing operations         $ (11,007,799)  
Issuance of common stock for compensation and recapitalization         (1,295,324)  
(Decrease) increase in due to related party         6,477,483  
Scenario, Previously Reported [Member]            
Corrections to Previously Issued Consolidated Financial Statements (Textual)            
Due to related party          
Total liabilities         56,470  
Additional paid in capital         4,733,401  
Accumulated deficit         (4,823,401)  
Total equity (deficit)         120,882  
Selling, general and administrative expenses         4,497,263  
Research and development expenses          
Net loss from operations         (4,497,295)  
Loss from continuing operations before taxes         (4,506,963)  
Net loss for the period         $ (4,507,799)  
Basic and diluted loss per share         $ 0.00  
Net loss from continuing operations         $ (4,507,799)  
Issuance of common stock for compensation and recapitalization         (1,295,324)  
(Decrease) increase in due to related party         (22,517)  
Adjustments One [Member]            
Corrections to Previously Issued Consolidated Financial Statements (Textual)            
Due to related party          
Total liabilities          
Additional paid in capital         60  
Accumulated deficit          
Total equity (deficit)          
Selling, general and administrative expenses         60  
Research and development expenses          
Net loss from operations         (60)  
Loss from continuing operations before taxes         (60)  
Net loss for the period         $ (60)  
Basic and diluted loss per share         $ 0.00  
Net loss from continuing operations         $ (60)  
Issuance of common stock for compensation and recapitalization         60  
(Decrease) increase in due to related party          
Adjustments [Member]            
Corrections to Previously Issued Consolidated Financial Statements (Textual)            
Due to related party         6,500,000  
Total liabilities         6,500,000  
Additional paid in capital          
Accumulated deficit         (6,500,000)  
Total equity (deficit)         (6,500,000)  
Selling, general and administrative expenses         (3,500,060)  
Research and development expenses         10,000,000  
Net loss from operations         (6,499,940)  
Loss from continuing operations before taxes         (6,499,940)  
Net loss for the period         $ (6,499,940)  
Basic and diluted loss per share         $ (0.06)  
Net loss from continuing operations         $ (6,499,940)  
Issuance of common stock for compensation and recapitalization         (60)  
(Decrease) increase in due to related party         $ 6,500,000  
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 21, 2016
Dec. 31, 2017
Dec. 31, 2016
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2015
Summary of Significant Accounting Policies (Textual)            
Forward split ratio 1 to 3:141          
Common stock, par value   $ 0.001   $ 0.001    
Common stock, authorized   360,000,000   360,000,000    
Cash and cash equivalents amounted   $ 93,332   $ 204,851 $ 173,537 $ 994,830
Income tax expense     830 836  
Stock-based compensation expenses   17,362 138,038 397,960  
Non-employee stock-based compensation expenses   $ 17,362   $ 138,038  
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
Going Concern (Details) - USD ($)
1 Months Ended 2 Months Ended 3 Months Ended 12 Months Ended
May 06, 2016
Jul. 24, 2017
Feb. 28, 2017
Mar. 31, 2016
Sep. 30, 2015
Dec. 31, 2017
Dec. 31, 2016
Sep. 30, 2017
Sep. 30, 2016
Going Concern (Textual)                  
Accumulated deficit           $ (15,776,598)   $ (15,395,384)  
Net loss for the period         $ (315,602) (381,214) $ (210,337) (4,071,983) $ (11,007,799)
Working capital deficiency           $ 1,756,915   1,393,063  
Common stock newly issued, value         $ 51,958     $ 5,850,000 $ 3,250,000
Collaborative Arrangement [Member]                  
Going Concern (Textual)                  
Milestone payments to BioLite in cash $ 2,600,000                
Common stock newly issued, value $ 900,000 $ 3,000,000              
Issuance of common shares, shares 562,500                
Share price $ 1.60   $ 2.0            
Percentage of payments under collaborative agreement   0.50%       15.00%   0.035%  
Accounts payable           $ 15,000,000      
Collaborative Arrangement One [Member]                  
Going Concern (Textual)                  
Milestone payments to BioLite in cash     $ 650,000            
Common stock newly issued, value     $ 5,850,000            
Issuance of common shares, shares     2,925,000            
Share price     $ 2.0            
Percentage of payments under collaborative agreement       0.065%          
Accounts payable       $ 6,500,000          
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Agreements (Details) - USD ($)
1 Months Ended 2 Months Ended 3 Months Ended 12 Months Ended
May 06, 2016
Sep. 25, 2017
Jul. 24, 2017
May 26, 2017
Feb. 28, 2017
Mar. 31, 2016
Sep. 30, 2015
Dec. 31, 2017
Dec. 31, 2016
Sep. 30, 2017
Sep. 30, 2016
Jun. 01, 2017
Aug. 26, 2016
Dec. 29, 2015
Collaborative Agreements (Textual)                            
Amount received from BriVision               $ 4,229,320   $ 4,113,000        
Common stock newly issued, value             $ 51,958     5,850,000 $ 3,250,000      
Research and development expense               $ 45,701 $ 25,198 $ 3,151,162 $ 10,000,000      
Collaborative Arrangement [Member]                            
Collaborative Agreements (Textual)                            
Description of payment settlement schedule                  
 upfront payment shall upon the signing of this BioLite Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week.
   
 upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week.
   

 at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months.
   
 upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week.
   
 at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months.
   
 upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week. 

       
Amount received from BriVision     $ 3,000,000                     $ 100,000,000
Upfront payments                   $ 3,500,000        
Percentage of payments under collaborative agreement     0.50%         15.00%   0.035%        
Milestone payments to BioLite in cash $ 2,600,000                          
Common stock newly issued, value $ 900,000   $ 3,000,000                      
Common stock newly issued, shares 562,500                          
Share price $ 1.60       $ 2.0                  
Licensing rights                   $ 10,000,000        
Accounts payable               $ 15,000,000            
Co-Dev Agreement [Member]                            
Collaborative Agreements (Textual)                            
Amount received from BriVision       $ 3,000,000               $ 450,000    
Percentage of payments under collaborative agreement       0.50%                    
Common stock newly issued, value                   3,000,000        
Company cash payments       $ 3,000,000                    
Collaborative Arrangement One [Member]                            
Collaborative Agreements (Textual)                            
Amount received from BriVision                         $ 100,000,000  
Percentage of payments under collaborative agreement           0.065%                
Milestone payments to BioLite in cash         $ 650,000                  
Common stock newly issued, value         $ 5,850,000                  
Common stock newly issued, shares         2,925,000                  
Share price         $ 2.0                  
Licensing rights   $ 3,000,000                        
Accounts payable           $ 6,500,000                
Research and development expense                   $ 3,000,000        
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accrued Expenses (Details) - USD ($)
Dec. 31, 2017
Sep. 30, 2017
Payables and Accruals [Abstract]    
Accrued consulting fee $ 29,075 $ 2,609
Accrued professional service fees 13,592
Accrued interest expense - related party(Note 7) 17,460 8,460
Accrued payroll 110,800 23,845
Total $ 170,927 $ 34,914
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
Related Parties Transactions (Details)
3 Months Ended
Dec. 31, 2017
BioFirst Corporation [Member]  
Relationship with the Company and its subsidiaries, description Entity controlled by controlling beneficiary shareholder of Yuangene
Rgene Corporation [Member]  
Relationship with the Company and its subsidiaries, description Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene
Liongene Corporation [Member]  
Relationship with the Company and its subsidiaries, description Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene
Yuangene Corporation [Member]  
Relationship with the Company and its subsidiaries, description Controlling beneficiary shareholder of the Company
Asiangene Corporation [Member]  
Relationship with the Company and its subsidiaries, description Shareholder; entity controlled by controlling beneficiary shareholder of Yuangene
Euro-Asia [Member]  
Relationship with the Company and its subsidiaries, description Shareholder of the Company
Kimho Consultants [Member]  
Relationship with the Company and its subsidiaries, description Shareholder of the Company
BioLite Inc [Member]  
Relationship with the Company and its subsidiaries, description Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene
Eugene Jiang [Member]  
Relationship with the Company and its subsidiaries, description Former President and Chairman
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
Related Parties Transactions (Details 1) - USD ($)
Dec. 31, 2017
Sep. 30, 2017
Due to related parties $ 4,229,320 $ 4,113,000
Yuangene Corporation [Member]    
Due to related parties 3,000 3,000
Eugene Jiang [Member]    
Due to related parties 100  
Asiangene Corporation [Member]    
Due to related parties 160,000 160,000
BioFirst Corporation [Member]    
Due to related parties 3,957,000 3,950,000
BioLite Inc [Member]    
Due to related parties $ 109,220
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
Related Parties Transactions (Details Textual) - USD ($)
1 Months Ended 2 Months Ended 3 Months Ended 12 Months Ended
Jan. 26, 2017
Sep. 30, 2015
Dec. 31, 2017
Dec. 31, 2016
Sep. 30, 2017
Sep. 30, 2016
Related Parties Transactions (Textual)            
Amount received from BriVision     $ 4,229,320   $ 4,113,000  
Outstanding loan     950,000   950,000  
Accrued interest     17,460   8,460  
Interest expenses     28,500 74,960 $ 10,170
Aggregate working capital     $ 7,000      
Interest rate percentage     0.00%      
Outstanding advance     $ 7,000   0  
Common stock new issues   $ 51,958     5,850,000 3,250,000
Stock based compensation expenses         138,038 397,960
Additional paid-in capital     13,805,936   13,788,574  
Monthly base rent         5,000  
Rent expenses         $ 52,205 $ 0
Related party transactions, description        

Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by Asiangene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. Asiangene also agreed to loan the proceeds to the Company for working capital purpose. The non-secured loan bears 0% interest rate and is due on demand.

 
Liongene Corporation [Member]            
Related Parties Transactions (Textual)            
Consulting service         $ 70,000  
BioLite [Member]            
Related Parties Transactions (Textual)            
Aggregate working capital     $ 109,220      
Interest rate percentage     0.00%      
Outstanding advance     $ 109,220   0  
Loan agreement [Member]            
Related Parties Transactions (Textual)            
Total commitment $ 950,000          
Loan maturity date Feb. 01, 2018          
Loan agreement, description The loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender.          
BioFirst Collaborative Agreement [Member]            
Related Parties Transactions (Textual)            
Outstanding advance     3,000,000   3,000,000  
Due to BioFirst         3,000,000  
Yuangene Corporation [Member]            
Related Parties Transactions (Textual)            
Amount received from BriVision     3,000   3,000  
Aggregate working capital         $ 3,000  
Interest rate percentage         0.00%  
Outstanding advance     3,000   $ 3,000  
Additional paid-in capital         70,000  
Euro-Asia Agreement [Member]            
Related Parties Transactions (Textual)            
Stock based compensation expenses     5,000   55,000  
Kimho Agreement [Member]            
Related Parties Transactions (Textual)            
Stock based compensation expenses     10,000   80,000  
BioLite one [Member]            
Related Parties Transactions (Textual)            
Amount received from BriVision     6,500,000   0  
Asiangene [Member]            
Related Parties Transactions (Textual)            
Amount received from BriVision     160,000   160,000  
Outstanding loan     160,000   160,000  
BioFirst [Member]            
Related Parties Transactions (Textual)            
Amount received from BriVision     3,957,000   3,950,000  
BioLite Inc. [Member]            
Related Parties Transactions (Textual)            
Amount received from BriVision     109,220    
Eugene Jiang [Member]            
Related Parties Transactions (Textual)            
Amount received from BriVision     100      
Aggregate working capital     $ 100      
Interest rate percentage     0.00%      
Outstanding advance     $ 100   0  
Co-Dev Agreement [Member]            
Related Parties Transactions (Textual)            
Amount received from BriVision     450,000      
Common stock new issues     $ 2,550,000   $ 3,000,000  
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
Equity (Details) - USD ($)
1 Months Ended 2 Months Ended 3 Months Ended 12 Months Ended
May 06, 2016
Mar. 21, 2016
Feb. 08, 2016
Jul. 24, 2017
May 26, 2017
Feb. 28, 2017
Oct. 02, 2016
Aug. 26, 2016
Mar. 31, 2016
Feb. 17, 2016
Sep. 30, 2015
Dec. 31, 2017
Sep. 30, 2017
Sep. 30, 2016
Jun. 01, 2017
Dec. 29, 2015
Oct. 30, 2015
Equity (Textual)                                  
Common stock, authorized                       360,000,000 360,000,000        
Common stock, par value                       $ 0.001 $ 0.001        
Description of forward split   1 to 3:141                              
Subscription receivable                           $ 350,000     $ 350,000
Issuance of common shares                     $ 51,958   $ 5,850,000 3,250,000      
Due to related parties                       $ 4,229,320 4,113,000        
Stock based compensation expenses                         138,038 $ 397,960      
Non-employee stock-based compensation                       2,362 $ 3,038        
BioLite Inc [Member]                                  
Equity (Textual)                                  
Common stock, par value               $ 0.001                  
Issuance of common shares               $ 1,468,750                  
Purchase price per share               $ 1.60                  
Net proceeds from offering               $ 2,350,000                  
Equity Incentive Plan [Member]                                  
Equity (Textual)                                  
Common stock issued pre-stock split                   50,000              
Common stock issued post-stock split                   157,050              
Collaborative Arrangement [Member]                                  
Equity (Textual)                                  
Issuance of common shares $ 900,000     $ 3,000,000                          
Issuance of common shares, shares 562,500                                
Share price $ 1.60         $ 2.0                      
Due to related parties       $ 3,000,000                       $ 100,000,000  
Total payment upon first IND submission                       $ 15,000,000          
Percentage of payments under collaborative agreement       0.50%               15.00% 0.035%        
Consulting agreement, description             The Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company’s common stock at $1.00 per share for any amount exceeding $3,000.                    
Share Exchange Agreement [Member]                                  
Equity (Textual)                                  
Common stock issued pre-stock split     52,336,000                            
Common stock issued post-stock split     164,387,376                            
Share Exchange Agreement Two [Member]                                  
Equity (Textual)                                  
Common stock issued pre-stock split     51,945,225                            
Common stock issued post-stock split     163,159,952                            
Percentage of common shares issued and outstanding     79.70%                            
Percentage of issued share capital     100.00%                            
Share Exchange Agreement Three [Member]                                  
Equity (Textual)                                  
Common stock issued pre-stock split     52,936,583                            
Common stock issued post-stock split     166,273,921                            
Exchange ratio     0.2536-for-1                            
Share Exchange Agreement One [Member]                                  
Equity (Textual)                                  
Common stock issued pre-stock split     52,936,583                            
Common stock issued post-stock split     166,273,921                            
Share Exchange Agreement Four [Member]                                  
Equity (Textual)                                  
Common stock issued pre-stock split     65,431,144                            
Common stock issued post-stock split     205,519,223                            
Percentage of common shares issued and outstanding     79.70%                            
Co-Dev Agreement [Member]                                  
Equity (Textual)                                  
Issuance of common shares                         $ 3,000,000        
Company cash payments         $ 3,000,000                        
Due to related parties         $ 3,000,000                   $ 450,000    
Percentage of payments under collaborative agreement         0.50%                        
Collaborative Arrangement One [Member]                                  
Equity (Textual)                                  
Issuance of common shares           $ 5,850,000                      
Issuance of common shares, shares           2,925,000                      
Share price           $ 2.0                      
Due to related parties               $ 100,000,000                  
Total payment upon first IND submission                 $ 6,500,000                
Percentage of payments under collaborative agreement                 0.065%                
Remitted amount           $ 650,000                      
Euro-Asia Agreement [Member]                                  
Equity (Textual)                                  
Professional fees                       $ 18,000 69,000        
Stock based compensation expenses                       5,000 55,000        
Kimho Agreement [Member]                                  
Equity (Textual)                                  
Professional fees                       21,000 113,000        
Stock based compensation expenses                       $ 10,000 $ 80,000        
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Tax (Details) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Sep. 30, 2016
Federal      
Current
Deferred
Federal Total  
State      
Current 830 836
Deferred  
State total 830 836
Current total   830 836
Deferred total  
Total $ 830 $ 836
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Tax (Details 1) - USD ($)
Dec. 31, 2017
Sep. 30, 2017
Deferred Tax Account - noncurrent:    
Tax losses carryforwards $ 594,501 $ 832,913
Less: Valuation allowance (594,501) (832,913)
Total deferred tax account - noncurrent
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Tax (Details 2)
3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Sep. 30, 2016
Income Tax Disclosure [Abstract]      
Statutory federal tax benefit, net of state tax effects 31.00% 31.00% 31.00%
State income taxes 8.84% 8.84% 8.84%
Provisional remeasurement of deferred taxes (13.00%)    
Nondeductible/nontaxable items (29.00%) (36.00%)
Change in valuation allowance (26.84%) (10.84%) (3.84%)
Effective income tax rate 0.00% 0.00% 0.00%
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Tax (Details Textual)
1 Months Ended
Dec. 22, 2017
Income Taxes (Textual)  
Corporate tax rate, description Internal Revenue Code, the Tax Act lowers the U.S. federal corporate income tax rate (“Federal Tax Rate”) from 35% to 21% effective January 1, 2018The 21% Federal Tax Rate will apply to earnings reported for the full 2018 fiscal year. In addition, the Company must re-measure its net deferred tax assets and liabilities using the Federal Tax Rate that will apply when these amounts are expected to reverse. As of December 31, 2017, the Company can determine a reasonable estimate for certain effects of tax reform and is recording that estimate as a provisional amount. The provisional remeasurement of the deferred tax assets and allowance valuation of deferred tax assets at December 31, 2017 resulted in a net effect of $0 discrete tax expenses (benefit) which lowered the effective tax rate by 13% for the year ended December 31, 2017.
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.8.0.1
Loss Per Share (Details) - USD ($)
2 Months Ended 3 Months Ended 12 Months Ended
Sep. 30, 2015
Dec. 31, 2017
Dec. 31, 2016
Sep. 30, 2017
Sep. 30, 2016
Numerator:          
Net loss for the period $ (315,602) $ (381,214) $ (210,337) $ (4,071,983) $ (11,007,799)
Weighted-average shares outstanding:          
Weighted-average shares outstanding - Basic   213,746,647   212,648,770 193,981,153
Stock options    
Weighted-average shares outstanding - Diluted   213,746,647   212,648,770 193,981,153
Loss per share          
-Basic   $ (0.00)   $ (0.02) $ (0.06)
-Diluted   $ (0.00)   $ (0.02) $ (0.06)
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies (Details)
Dec. 31, 2017
USD ($)
Operating Leases, Future Minimum Payments [Abstract]  
2018 $ 4,950
Total minimum payments $ 4,950
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies (Details Textual) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Sep. 30, 2016
Commitments and Contingencies (Textual)      
Rent expense $ 2,482 $ 61,093 $ 29,129
XML 59 R46.htm IDEA: XBRL DOCUMENT v3.8.0.1
Transition Period Comparative Data (Details) - USD ($)
2 Months Ended 3 Months Ended 12 Months Ended
Sep. 30, 2015
Dec. 31, 2017
Dec. 31, 2016
Sep. 30, 2017
Sep. 30, 2016
Quarterly Financial Information Disclosure [Abstract]          
Revenues      
Cost of revenues   $ 32
Gross profit   (32)
Operating expenses          
Selling, general and administrative expenses   289,731 185,188 707,142 599,303
Research and development expenses   45,701 25,198 3,151,162 10,000,000
Stock based compensation   17,362 138,038 397,960
Loss from operations   (352,794) (210,386) (3,996,342) (10,997,295)
Other income (expense)          
Interest income   80 49 149 361
Interest expense   (28,500) (74,960) (10,170)
Total other income (expenses)   (28,420) 49 (74,811) (9,668)
Loss from continuing operations before provision income tax   (381,214) (210,337) (4,071,153) (11,006,963)
Provision for income tax     830 836
Net loss $ (315,602) $ (381,214) $ (210,337) $ (4,071,983) $ (11,007,799)
Net loss per share attributable to common stockholders          
Basic and diluted   $ (0.00) $ (0.00) $ (0.02) $ (0.06)
Weighted average number of common shares outstanding          
Basic and diluted   213,746,647 210,821,647 212,648,770 193,981,153
EXCEL 60 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 61 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 62 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 136 193 1 false 41 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://metuboutique.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://metuboutique.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://metuboutique.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations Sheet http://metuboutique.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) Sheet http://metuboutique.com/role/StatementsOfStockholdersEquityDeficit Consolidated Statements of Stockholders' Equity (Deficit) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements Of Cash Flows Sheet http://metuboutique.com/role/ConsolidatedStatementsOfCashFlow Condensed Consolidated Statements Of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Description of Business Sheet http://metuboutique.com/role/OrganizationAndDescriptionOfBusiness Organization and Description of Business Notes 7 false false R8.htm 00000008 - Disclosure - Corrections to Previously Issued Consolidated Financial Statements Sheet http://metuboutique.com/role/CorrectionsToPreviouslyIssuedConsolidatedFinancialStatements Corrections to Previously Issued Consolidated Financial Statements Notes 8 false false R9.htm 00000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://metuboutique.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Going Concern Sheet http://metuboutique.com/role/GoingConcern Going Concern Notes 10 false false R11.htm 00000011 - Disclosure - Collaborative Agreements Sheet http://metuboutique.com/role/CollaborativeAgreement Collaborative Agreements Notes 11 false false R12.htm 00000012 - Disclosure - Accrued Expenses Sheet http://metuboutique.com/role/AccruedExpenses Accrued Expenses Notes 12 false false R13.htm 00000013 - Disclosure - Related Parties Transactions Sheet http://metuboutique.com/role/RelatedPartiesTransactions Related Parties Transactions Notes 13 false false R14.htm 00000014 - Disclosure - Equity Sheet http://metuboutique.com/role/Equity Equity Notes 14 false false R15.htm 00000015 - Disclosure - Income Tax Sheet http://metuboutique.com/role/IncomeTax Income Tax Notes 15 false false R16.htm 00000016 - Disclosure - Loss Per Share Sheet http://metuboutique.com/role/EarningsPerShare Loss Per Share Notes 16 false false R17.htm 00000017 - Disclosure - Commitments and Contingencies Sheet http://metuboutique.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 00000018 - Disclosure - Transition Period Comparative Data Sheet http://metuboutique.com/role/TransitionPeriodComparativeData Transition Period Comparative Data Notes 18 false false R19.htm 00000019 - Disclosure - Subsequent Event Sheet http://metuboutique.com/role/SubsequentEvent Subsequent Event Notes 19 false false R20.htm 00000020 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://metuboutique.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://metuboutique.com/role/SummaryOfSignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - Corrections to Previously Issued Consolidated Financial Statements (Tables) Sheet http://metuboutique.com/role/CorrectionstoPreviouslyissuedconsolidatedfinancialstatementsTables Corrections to Previously Issued Consolidated Financial Statements (Tables) Tables http://metuboutique.com/role/CorrectionsToPreviouslyIssuedConsolidatedFinancialStatements 21 false false R22.htm 00000022 - Disclosure - Accrued Expenses (Tables) Sheet http://metuboutique.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://metuboutique.com/role/AccruedExpenses 22 false false R23.htm 00000023 - Disclosure - Related Parties Transactions (Tables) Sheet http://metuboutique.com/role/RelatedPartiesTransactionsTables Related Parties Transactions (Tables) Tables http://metuboutique.com/role/RelatedPartiesTransactions 23 false false R24.htm 00000024 - Disclosure - Income Tax (Tables) Sheet http://metuboutique.com/role/IncomeTaxTables Income Tax (Tables) Tables http://metuboutique.com/role/IncomeTax 24 false false R25.htm 00000025 - Disclosure - Loss Per Share (Tables) Sheet http://metuboutique.com/role/EarningsPerShareTables Loss Per Share (Tables) Tables http://metuboutique.com/role/EarningsPerShare 25 false false R26.htm 00000026 - Disclosure - Commitments and Contingencies (Tables) Sheet http://metuboutique.com/role/CommitmentsandContingenciesTables Commitments and Contingencies (Tables) Tables http://metuboutique.com/role/CommitmentsAndContingencies 26 false false R27.htm 00000027 - Disclosure - Transition Period Comparative Data (Tables) Sheet http://metuboutique.com/role/TransitionPeriodComparativeDataTables Transition Period Comparative Data (Tables) Tables http://metuboutique.com/role/TransitionPeriodComparativeData 27 false false R28.htm 00000028 - Disclosure - Organization and Description of Business (Details) Sheet http://metuboutique.com/role/OrganizationAndDescriptionOfBusinessDetails Organization and Description of Business (Details) Details http://metuboutique.com/role/OrganizationAndDescriptionOfBusiness 28 false false R29.htm 00000029 - Disclosure - Corrections to Previously Issued Consolidated Financial Statements (Details) Sheet http://metuboutique.com/role/CorrectionsToPreviouslyIssuedConsolidatedFinancialStatementsDetails Corrections to Previously Issued Consolidated Financial Statements (Details) Details http://metuboutique.com/role/CorrectionstoPreviouslyissuedconsolidatedfinancialstatementsTables 29 false false R30.htm 00000030 - Disclosure - Corrections to Previously Issued Consolidated Financial Statements (Details Textual) Sheet http://metuboutique.com/role/CorrectionsToPreviouslyIssuedConsolidatedFinancialStatementsDetailsTextual Corrections to Previously Issued Consolidated Financial Statements (Details Textual) Details http://metuboutique.com/role/CorrectionstoPreviouslyissuedconsolidatedfinancialstatementsTables 30 false false R31.htm 00000031 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://metuboutique.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://metuboutique.com/role/SummaryOfSignificantAccountingPoliciesPolicies 31 false false R32.htm 00000032 - Disclosure - Going Concern (Details) Sheet http://metuboutique.com/role/GoingConcernDetails Going Concern (Details) Details http://metuboutique.com/role/GoingConcern 32 false false R33.htm 00000033 - Disclosure - Collaborative Agreements (Details) Sheet http://metuboutique.com/role/CollaborativeAgreementDetails Collaborative Agreements (Details) Details http://metuboutique.com/role/CollaborativeAgreement 33 false false R34.htm 00000034 - Disclosure - Accrued Expenses (Details) Sheet http://metuboutique.com/role/AccruedExpensesDetails Accrued Expenses (Details) Details http://metuboutique.com/role/AccruedExpensesTables 34 false false R35.htm 00000035 - Disclosure - Related Parties Transactions (Details) Sheet http://metuboutique.com/role/RelatedPartiesTransactionsDetails Related Parties Transactions (Details) Details http://metuboutique.com/role/RelatedPartiesTransactionsTables 35 false false R36.htm 00000036 - Disclosure - Related Parties Transactions (Details 1) Sheet http://metuboutique.com/role/RelatedPartiesTransactionsDetails1 Related Parties Transactions (Details 1) Details http://metuboutique.com/role/RelatedPartiesTransactionsTables 36 false false R37.htm 00000037 - Disclosure - Related Parties Transactions (Details Textual) Sheet http://metuboutique.com/role/RelatedPartiesTransactionsDetailsTextual Related Parties Transactions (Details Textual) Details http://metuboutique.com/role/RelatedPartiesTransactionsTables 37 false false R38.htm 00000038 - Disclosure - Equity (Details) Sheet http://metuboutique.com/role/EquityDetails Equity (Details) Details http://metuboutique.com/role/Equity 38 false false R39.htm 00000039 - Disclosure - Income Tax (Details) Sheet http://metuboutique.com/role/IncomeTaxDetails Income Tax (Details) Details http://metuboutique.com/role/IncomeTaxTables 39 false false R40.htm 00000040 - Disclosure - Income Tax (Details 1) Sheet http://metuboutique.com/role/IncomeTaxDetails1 Income Tax (Details 1) Details http://metuboutique.com/role/IncomeTaxTables 40 false false R41.htm 00000041 - Disclosure - Income Tax (Details 2) Sheet http://metuboutique.com/role/IncomeTaxDetails2 Income Tax (Details 2) Details http://metuboutique.com/role/IncomeTaxTables 41 false false R42.htm 00000042 - Disclosure - Income Tax (Details Textual) Sheet http://metuboutique.com/role/IncomeTaxtextual Income Tax (Details Textual) Details http://metuboutique.com/role/IncomeTaxTables 42 false false R43.htm 00000043 - Disclosure - Loss Per Share (Details) Sheet http://metuboutique.com/role/EarningsPerShareDetails Loss Per Share (Details) Details http://metuboutique.com/role/EarningsPerShareTables 43 false false R44.htm 00000044 - Disclosure - Commitments and Contingencies (Details) Sheet http://metuboutique.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://metuboutique.com/role/CommitmentsandContingenciesTables 44 false false R45.htm 00000045 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://metuboutique.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) Details http://metuboutique.com/role/CommitmentsandContingenciesTables 45 false false R46.htm 00000046 - Disclosure - Transition Period Comparative Data (Details) Sheet http://metuboutique.com/role/TransitionPeriodComparativeDataDetails Transition Period Comparative Data (Details) Details http://metuboutique.com/role/TransitionPeriodComparativeDataTables 46 false false All Reports Book All Reports abvc-20171231.xml abvc-20171231.xsd abvc-20171231_cal.xml abvc-20171231_def.xml abvc-20171231_lab.xml abvc-20171231_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 66 0001213900-18-004408-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-18-004408-xbrl.zip M4$L#!!0 ( (]MC4PW?[1W/=, )5+# 1 86)V8RTR,#$W,3(S,2YX M;6SLO6MSVTBR(/I](_8_X'K=Y]@1I,SWPY[N#5J6>M1M2PY)[CF],1$.D"R* MF 8!#AZ2-;_^9F95 040($$2)$$*LV=G9)) 969EY;LR__9_?\Q,[9$YKF%; M/[^JG]5>:OCYU;>[ZN#N_.KJE?9_?_G?_TN#__SM_ZM6M4N#F>/W MVB=[5+VR)O8'[5J?L??:K\QBCN[9S@?M#]WT\1/[?S[>?H9_\O>_UUIGC8:N M5:L9WO8'L\:V\^WV*GC;U//F[]^]>WIZ.K/L1_W)=OYRST9VMM?=V;XS8L&[ M;M[_\^OMS:=OY_=7-]??$F?:;/73_.9@QQQCIEO;1,?XP$'+MS=]M M$VGR5CNWG?D_&[5ZM]YHUK_7:[_?_W,P=PQ3JS4K&GS>^^?_7-[^4Q\^CK[+ M7YW]F !-/ND>+(R_^*GQJ=;"_VK>USKOF]WWM?;_RXB%IWN^&V!1^U$3_^&/ M_^W'T#&-]_C?&NRKY;[_X1H_OU((]]0\LYV'=XU:K?[N?[Y\OAM-V4RO&I;K MZ=:(O9)/F8;U5])S]7Z__XZ^E3]=^"4N+M=HOL.OA[H;OAD!7/+[!4C@V[$7 M/*#^N/V.?QGYJ9'XTP[_J2%_.F:QW[EL=/9@/[Z#+^#W]5:U5J\VZ_+G#IND M@MQY!]_*'QJNW6K4N\OPX[^0#_AN]4'7Y\$#$]T=TH_%%PA,-PH,?./8)G,3 MGZ%O$AZR;,OR9\EPC3WGG?<\9^_@1U7X%?)^\-SJAZ(/ SX<3)T]$T"="/; MMSSG.7E+Q)=)C_F. [(J[3GQ;<*#[,=HFOP0?I/P@&$],M=+?H1_AP\U8S37 MC9&;_ Q]E;".:XR2'X O\.?UV,^]N9/R>_@FX0&42L$#,^;Y0]OWC'_[#,3H M[)T45Z^D(,+#^]XE$7'+)AJ=^_=3.@WXIFHHW]SQ*_$U[O'/KUQC-C?A$+^3 MK^*":61;'OOA:<;XYU?G_._OS2\7WVOU[S"FS/,-[#CX-/C?&^,W$8(Y&.+ ()TM*G5_]_NH7$*#U>K?9K#?_]B[^ M<+C!$*$&>.AZ+_%]KN>@UV1+XI_&[A,5!^RD,-V,-P^7'D M$?EY! #YH2#XZET8N-]O)M^;M>]W;([T;D?W(>'S(]L'KE@\)&B[6NM7F[5@ M"?'-;@G:22%HYP0(VCD$0;LI!#U:2:$0M+M'@B:(V!,1O1&"1F3H+@G:Z$O" M165H\N>@+6\F \?1K0<@D^4-?ACN]W/;-/6A#;X4N"3*EU_8;,B<@^U"J-/8 M X*C?"&^&@,P/^:F,3($K-K8@%]RWU*8M.\3<7[UB_QZ.?)_>Y>XC@KCNV0@ MS#979V8 M1MGS.,8'W.^=!A12]_O2<%P/$Y#DVMC6"]KX9-1?%@<,7 ,]68N]0!9(Q_UE M\<"?_HME@5347Q8'@##\#%KP9(S$3.(_@O&I[O="$/B+_KR8F4G^/"4(/&:/ MS+3G^(G^X+#33R.(^&\ZW@=EGEI[3Z'?6OW[;[ZUR#S)GY?,5K )&:"Y$G\O$QA'DT*$WBH6VVTBE:H\7V)"5"&.0[,,$6L[%G%,&6 MTO&Q4!EH*9R;?7Q,5$9J2A;:7I65H9X7P#"-FG2L8C6C"9\?;Q%NF[R/PA$T M+ :Y^++*SF6W=>?;HK],XA$O159W8&-X'/(K'R3F#\=A M\::;7W5C?&6=ZW/#T\T7Q45+:5!RU)H<=>^"ZO/0MF,L$#M ME0XCKH]2OF3@[+*#X1%T,'Q9S%>V/4S O&2YX]#D)W,WZL1[)1XE?Z_V%\KN MZT?0??U4O:0RPU;(#-M1BKJMV:U,RQ4L+7>4;)A!XY92K_A2[UB4[-;L5DJ] M(DN]%\.&905#<2H87B8'EF4/!R][.!+&.^=MK!OUY)OL)S!K-F9YX\7N-3>B M7="-*(7 40F!XO)>SL&'DO&*QGA%#3?D+_3*B$,1(@[%%77Y3ECHM@S)F*AAQIP4GMMXP\>ZNR']^KE M38T"W]2(,U-O$T]"O>"Q:V:Z9,.$83F]I,_+:J'CJA;J5FN-3<*HC6JCMR_V M*VI6E-&_">.N*I(+FCDE?9ZH=.^FNL,N?HRF^.E 'O_[)_LT^&^9WEV! M^J']7' T6FNS'CRT)T=C5ZQW:?O.2^6]$/>2^0["?"^5\4JF.R#3O8BXW@K4 M2]8[C)TWA3]>*O,IR)?LERVG$66_>C?A\Z^F;EWK,T9]VL-G=L3:GL]YP@QCI)GY=U6<=0&=,E2VK]RICVSHN@=]PO M\:1YKIC&UY&49(FY+:6N/2U=&W4?5:59F/$_I00KN 3;U_B?2\>>T1HD(SV; M_]T GOT^XK;8J=P56U%<[&(?ZO";HEXEZVZFS&A'=Z/,,G'0I>&XWKGMS.E\ MV2>23]V$E9(I4?+4FCQU^\ L5C)4,AE*;EJ3FSX#Z4J&0H9*I43)4VORU)^^ M7O(4\50J)4J>6I.G!JY1,I68!Y-*BI*KUN2J"]^QD9POE).BZ)?>'Z)NFY>O'RPLMX[:6Y@X7W_PJ?%EXGG[>, M\\*@LYK@>FEB+PL53C7)EW.ABW28)/5.@X66E1@D8UR*KUUR&3E4)R:FEO%8 M$KXEA^W>,(N?[1-AM=4:,07QDN=VSW/1L_YB."X1[9+?ECL!:0W[%CX_LON= MBO%++>MV;?R*X%&]G=#J$&]J-I+.=EDF6>PRR?BUEGZUOG;/?I0 C;UG3P0] MR\E+A9B\5+Q4R<"]F93L4AQVB<1J(ON^MX)LR0/EZ*PBC\XZ&E%2LE'!V*A M(J:<15JL6:1'(U1*QCDXXQ1 C(C2L')&0$%G!!1>G)0,5#@&VKM8J?5#L0)_ M-]J2*\K;[D6Z[1XOYNIO%D]OM' TV&>#"O@8!4KEE$$Y MO12^*1*C%,>V_6C8GPWO1!1.IO*Y$-U2/"0Q2R?"+)0B+IGEX"G!HN7WA2[I M46_BWO'F[ 4"AQ*_90UJ 4Y7847QJNN*)U;K=U1EI45FFD:$:1J-(Q//<3IO M,O6=\-Z;G=3A^WK,=-[(Q.@<2 B&921E"5L12]B*+!Q7MWFVZ\W3YZ9B=HLX1IE4)BA+";2V!%J@8+/7:=8:W6[)/"]=XB2709SRH*75 M/%.D<4O%*8XH>:(H/%%PD;)^HO?%<%$1VW,<(P.5O398,7IM%)9YEKA0Y6"( M8@^&*)Z'E7IOOTRX%B3ANB\S.>"$6@>X[?0^_D2^37T67P+>EO-^=Z@YS4Y<03$4_VG@-@.\[H/[] M#E^SL-38>(0M620O/G[MSQ@<"=M9/'1KD"$.9M);E44_,&=:J95>3)KYN MTHOE]Q$J9*#IW$\@910T_$GV/1LSX_T%\?\M>S!<#R20=ZW/F";X\Y9-PD91 MS2]JI[=N?";K)S:*?O[JEP&0W!CIEO;1,?XP4#1J;_YN@TBS'MYJJ##_]BX- M@D4(S^&@.KIY98W9C]_9K MZY[[CH,?&^Y(-_]DNG/!U7-.(%2EQ%^VE@K/)WOD(YRHXG*" 4R6W^\Y!.K; MDU;]2D(U7Q*H>B]UK21@0CI=PB=NCN!$ 8FMDPX*ASA/8"[_3 )%66?QO/Z# MF>;OEOUDW8$8LBTVOG)='Y1W/@!=V^IY35EK$:@_;-.WP!A^OC1,YN1%G2@P ML342)!D_7K<,' 8/9"'>>,YMI_Y$Q;1JK468"-9S8/ 'V\E+MM[-=!/>J@6+ M:WB96[>>50 C"R?0*NQO19:$>^-[:&>A#HF &;L_HJ&:HR^$L:.-V<@ @-R? M7UU=7\+QJC?[C4ZKVXY0:\EJ$K; >-?=Z< :X__@3?5'W61X2=T[UQWG&7[_ MAV[ZR:(IWL=^H87EPN<*.F@;*K@ F?O]5@_-T+4 VQTV:2U@.]FP 67<;G8+ M@\WJ&0-+L6G46KUV_=#8))S.U%.[E-.:S69C2V0^^0S#2THTQ6"ND%)[V9%V M&VP^Y;@L R@OX//:@*V '[@N\_9*ZFX[ROT1"#8&+S=B=EI1?LX W@')MCY M.R94PN&XMQ,Y$83$M6V-]L=YK7J]&3\G66#; 4IY;4*KT>@W&T5 J=&7H$<- ME^3/-^D4O=0^J(G_%($2G>\#_V'1Z$G^?"U*A#U[CH48ZUB WR\\MZ6]*R12 MRG:'6WNZ.[OK,Y$J4G;!#,DU<1\-VS0\=F6-,@FW?N- "B\5>G'?*)[T7H9& ML]_N'HH;D_%8WI\.G='A#@RI;V[Z M',3-[T9MXHQHQL>+#48C?^83;)_8!&].[4-K5.OM9K_=["EJ8S5@^:*2ES(! M5+K=3KO?.QPJ13J?&1BWNN#/%9E@.]!/U5:O$550QT> 3=56M5YO'A'RA74O MR1F8VN:8.2X?_K:/\OE.L]EL*X[)(A0YP;EE87RUT^SVZ_7>'B#=6A,V^\U: MI[D[2/-3=-UVIU]O%V+WBZG'#DF0'>BI>J/6ZS6*C-[&6FA_\J$ O+P?)=.H MR1*&6*ESPN=+-Z?7!]>FOK.M60?.D.V2!JQ^5^)R68Y3N]]I[$[0YXC7THGV M*Y*8O6ZSN[MSE2.22^<"+Q4>S?9.Q7Z..*9,4B^*K9GO\>IT&FH<>F<2?6N\ MMCA>X#QU>OLPP;9&LK#'*T<.F GG_.!RR:%"XN7EOHMX5L&.F29\_"NSF*.;&(<=SPR+.C3B):V+'W-FN3FUWEMZ MB'O];E,U?3/!E2,VEW^JV*3YUQF3>.U^OUEK%@:;-'.'6WXAKJZ MT:Y'"][7 (Z\Z8^ZR\88C(9?T(6'W:OF>K>IZH=D,+8 -E=EW.QW^Q'C;;?0 M;JE\,;#=[!6(MCG7;76/![7-LQ/ &S>NGNMZ&,;* M8&VO6NQFC@/:@'I7ULB>L<^VF]-,G!71^$:WKQ1^)$"Q*:"Y6L] 7XP8]]M[ M '5+T[G:[/<[334Q=$"B%B%(5>VT^OU^JU8,@NSD]F]K7[RY]T#5/@]> =@Y M6RRGVLF7F3>,V50;=7 =.FN!$GZ#B^(^&)8/3XA'<=8SF]@.X[^[UW\P]^*' MY^BV,S: FYZO@(PN-OF#)QV;\CE7@(@#%#Z.'=Y(8.V0:D>W03L1H.U:IZ^F M@TN"[TZ@UVLEL8])P>QQ>ZZ9MU_WHU=OJ#U:(^NO#US.+@<-NZ M&:U:M][O-0]&O&)JZGT384?:<(=\=QB-4-_ M^%37WB$^;GKG&1;>._";W/W*VSHXY^'U1CVYD\7:?<<6;LWO'[X]M (HEI#? M[/9USKH[_XW:@RS-'^@]B]/\$3BD1"U4^CD=^'UDG;=:?4],F%L&>2?!@_WF ME%?"L5$2H-G-2 9)7_!G9';;&&&1IV'Z7LH-V>U"/M_GS/E.:RWN7AIV MV$2RV6_4=X[=3MOSI;:YJ/4:]4B;BQUAM]/>:-F;>&R)W09]J?*$#1?@C5\^ M^0[\@$M7F@!VS9[HFSUD-IN-I'Z+3(V:VN#IN#'? MXIY3H]7M=^)MSHK+S_FR0+\1[QY\M)AOS@+M7JM;ZYX,(7+O1%D$I')L7;X1 M.GFGL-KU?OMP0N=0":]]L5M1KL@5:(/64PR=3CO>,_F8N7.+'M_M9BW>1?:8 M*5$,Y2#PJK6_?]&?%_5#K9/T^5I]-;)T$4L:U[3WO06A-? ?%FG0Z"1\_ID] MZ.:%Y<&^$O8?#=LT/"S>S7+'L]7I==M%0/B2#1>C HU>TN<[:*9R:*; Z(/'T=IC]R"Y'9<@,1Y8 XH%^Y! M&O_94P>X:J.#DT(VAK 8*.8:HP!MT.Z?.DDVCUQ@8PGLO'#:]-DN4%=HU/*P M9C=&D$O(0Q_Z%#%/)[_1;F[!W!R_M?1@,1M4IM;E=&L98CW+,,O&0\"7<^]F MDLRL>RA'$([1%D 6!<]=W50I.%ZYW",H.(Z[U%('1V[CT;Y[.KN"H1![QQCZ M^ (,U2@!-8.YWZPQ<_@1HQ_:YAZ&%-2ZJPFP(?1%)\PAA%V!\=VB?JEDHD,9 MT 5&???U"\DVXZ_.KGK_[!/6G%L!-?KM9B,^('=]4/>'\?IZK0YV, MN9M";/]A.A<=WS'9_^"?4R11 =LK;4G6T&98^-VE[5R#FI[-3?N9I<37=C'F M)CM(.2&QK0I=;8_E %9.K_IP:]-D_OV2!*M^1 ME;UFM[:,NC&(=H'"M@R2/P[$0^<^Z%?+^VSH0\,TT"_=@^II=FKUYC)<4D#+ M%Z>\T_#U?FWI!AT J:VE4EUM!)\C2I]\=F]'XR%[X+MZI]E8ND4)8.6'2Z[\ MUFEUNZW>TD.T1V2VY+-&L]VL+3\\A=J90@0.VK$*W:+3;!<]C1N-=KU[["38 MU.DOE@@HP*G9>/CO-?/.=7?ZU;$?C3$;?WS^!MX::+>Y&'PR '@?]V0<5>OU M>KL>[8R9$;B?,5?!PE24;HW8S42IBSJXM,\.5:Y[ MW6BVTR5L(DR[0"+_#4\Q*"\-"^#;O7>R8_#R98%.N]F*=>_."-Q.T=K6=N@T MHYR].5H7DPEXWS>3BQ^C*=ZCNP6[X\;"EX$.P__!JK%'W41_^B#LM#6 NS8C MXUZH]\L)&K;5J#7FZH8W08Q98 D MEC ?RCE9"4.NK-%K1ET/=?7M@=MRCS?9;.!:@T5;E\+K8139X,0)T;P-U5]5CK-_P/%O6-R-, M*U!(N5VT%TS2D4B!:A4NHY$_\XFW/[&),3*2@[I[WI!%J+)P%>?. J&Q"-4* M-.X8C03_E5G,T4U,V8YGAF6X'N_B(NL8Y0-[L'J:*U!<%^(5!+AE+M.=$9K- MG\+>7O(M>X@9U&K+\5T.X KL5L^-)XMR]VBN8MR,@*Y -S:5!5\J![;L;8P6 MGW/32<5T"8PKL+MFWC(R'7X35P"8-5F#Q8K[-L*SEFDE !?9M2^&R<"LLMA7 M_7F6&EHJ1/O<1D?=S07 MT#KT UB.^W,B/W#=OX")A6F"]>9S!KMQEV*7>QI M=_IUV=\I#8[-@LT,P(KSU!*R]-[YLPP%?M%MT"'WTSNF.>9M+V[ M[32[]*3\\E^F]\'CV4*P,-RYC@%Z1)[^/=?'8_EOUWLVV<^O)@#?>ZW>F'N: M9\Q 2%GL20/1IUL5_D%%TW^ M]>J_'KP/!(43_#66BX'#XQDCW:SJIO%@O8>W>'#4@E>W>O,?_'E]-O_P?^J= M&CW_SANO?I5GSX/W-%KR/? ((J@B6W6-_S!$8^XI:_4[W3Y?#'\CGTU<&;=3 MKHK5@,;D.?-B_GSBX$_F_!1K[E0W3P#\-5_MHV)\- MCVF17=<"W_2]UCQK_T2_1HM9OO5,&TP\YF@.I8[Q??%EX5\S[:-C_&&@_UD) MUIGJ+KP*#HT)ZS@:PC;6/1T_"WZM&98&Z=P0&9>V&+[LSZ: MNG]ICQX&D>*QKF#2B>&XGG9U_4ES_>',< 4+!?S!>1I8K:(-?4^S; WEIP// MZI8&VH4DE59O5S04A.^U3C8>=AF(U?&Z+(Q@@A#\2W]@)1>'?Z*&D/^:)ZB" M>U(%UZ *;KDJN.>JX(ZK@IGN/!BP<"W@GG?S ,0-M<^*)4OML_T1UCTZP"-[ M-C<9=0V$8\>/\WR*F;ZK*VUD&A9BIGF.H9N9SS78+U[D8'=AW4SG&A2=L_:Q M7@37]?SQ,[P6KW,LG'0/@[C:#$@R=5_<:2]U%@OXY2HOO=6#/'^MR.D*\6V=%M6\W?RRWUVAJ6^@=MF0#BYGL8-UX[YA6)\'WC MX8:E4=8-9G/G/WTJD@F(01T/ WXV1IBK.K?=G"HM\\T1(.X,_&VC#\%\J-(;,HB*P[SYH;?=&?/I+(8H+5UL5K MST2Y1)?PW';F-L]Y2>IB7S/'],SQ34B>-.A+4!.J<9T-6H=H1 MX#MPC52$%79X,?M_X3LVTF3UD3@"9'XW9E,;V-;U34\/N\0<-U(7/K+2;\BV M$I]+VYD!*E\=YAIC-/AU:ZR=3W7# 7-Z2Y2D@<,[5]FSF>&E)HBY0=SH?/]- MMQ*J#I(^7S:,\[.M6X,U9COV8]<98R#',<)[XU>6ZSD^?GL%* #]/+R=1#[" MBL**W:'XRSWPHPE?@$C1'1>\+PZ9IGM:_2=M#CM-$0;MC>UH++A=@BY;O<&_ M!]_&G[TE-E"86S-<D%_P:W,/PY?1*\_F__D^]^0&^P\?@K7!"SD*" MKJ#80G'TU'8\^,T,GQN APF.Y8WON7 6,8G">]+LOKXCSA:9P,H/EUS+/PZ$ MRS9ZM-GIU>OM6G_%AF<":K\4,GW(M?FF) 2'3R K'X >2<*KT9+RO]SW8-N&.-)@6%C.'.= MGYWN/JR*IN2,7:8@ 09!,\6D^HW&_@%<,/2:O4ZSUNAV5P70LD&Z(DZ*6CUO MOHY?.:+Y>K4S55 N@69;P/?.Z(=!=W/.+RJ\60Y"OK"O:B>^+X&?%9Y MH]-MUYL%.]E+]F8Q_G</&LJN3[9MJM?O]E7',QM< M.\,FIV$]1X--2I6"3'5(N9;A-%&[B./'G/(BZXCS7NW(\%YFW<7W/0L!CF[C MEQ$@NOU%WO_L^=EJ8T3W* MC=&Z5F)ZE&D[MWE=&5Z#06+++Y0&4BS?&N-WNKDW M4T\M"4R"("\PMR4EN/SM-4$58ZLNV1C[O=SK/\3O/E+ARV%ZYF\"TZ[[G6X/ M4_XM3C^Q"0.HQ@*HH(=A ;9P"]!VO9.Y@99S\WK)6G:VG%[.G?O67'T'_7KY M :/A4""T/H-N+98XV@"RW353S033KA#)L_'J1HC((QQYJH@R)B< *F!1@<@=]!T(E(^A9#BG"O$%' MN/PERPZ!W9V!"A .7)=Y[J^.[;K7MC7B&[2/GIZ]9J.OCEE>!5.>."0(RXWJ M!MK]5KM6SQ&'/W33)[[ (,83#G@IV*8L W!GV.UMN[;"[IIY.]^LM0]V9J"V MH'&VD23&(PO$(E8!W6)[II%A&IS@TH-'.>I[MO,<^?&>:N.:"G/D /6^"+&% M;CME0JRE-XM+B&3+(O^Q%FE%?;U>:ST:I &\<^3S/P='BWP>O']8Y$%MC=G8 MAY\-3;8L5+\UR^>AOS)#NP-9W5EODY) W2/*>7!FHW\8E,]IU,>5E<%PW(MT MK@(I.NL>TC60. 2-\CX@0*-:\Z1IM/V) AK5:WNDT3^8\3#UV%CC0T(.^31.T"W 4:-.K-;JO3:75#*JP%9OXX;G$24G"L]YM]O!_: M+"B.:W%RZCXV.JU>MUO+"4:$[.#,@&+^S$R6;.BAV$3 M WHAV*5W$'?'[ND@"XRFM8#53>ZE[X'CL87PS)F_DP6C]ZR MF6Y@EYN;R:7ACG3S3Z8[^TC\M/IMM5/1IJ!N@O,G/]F%.SB& -@*?&[#@7O7 M; ^M3QJM7B,5AR@PVT.>:WU&HU]70U)[!7W;"7#UFCHC/A/HO.$%[]QR'A2N M7[*EG)Y7BKK1J?5ESXT$$+:",:_3V.C7NNTU@90M< 2Y5XYFSCOSWPI&WJX& M*$?X\R*YZ)NT)@+!G1'^!,A&;#!).8OS_55=-)J]EG(_(!V8?,#.C>3U6B]R M\69=N)5)T.*'X-;OM^"EV>K76PLHK L?W3R.P6U?J.[+3ZW[)%9?OX9YDS5 M(DL7WW45WQJ+[Z#2WG:]FXD X3 5]2LAR/>FOF+N19;>%JY][DW"[< .O]&X M[AI4+/C5L0]UGV+5^KGN?57=?&7E[8#*?^/3UL]OVZ^L1S!29D%=]/YZ3?8B MW3Z2H=@*VGRE1:>^5W"W;=S1ZN\(W.RL%PL1; )/Q(3>0PR@UX[VH(FLOPEX MN?)@'1#9)7A;\ERW%>E\LP5X^8FW2]MAQH/%[BVU U\J*-O!G*^Q MU.]T>GL&>4M15.VV>O7ZSF#.00=FAHA_B8<&5T5JQ2]Q\<.D%+Q^,2S;,;QG M*6+!W8Z^Y>+?/GS]A7E3>QPJX]UXW#&[NU=OJ"&//6)7-,+F>T;K]5JMT^\T M2]+F+DM:M6ZTU.,%4G9#B5=MU&O-9K= I"M&\XABW.7.>!.Z&+>W,P*[K-HR M7FP)G+2CRI)\JGS3X=TAU@>O^RT U@>H!-XKUIFD>2I>M5ZCO@,>EO+]JVZ, M]U+Q4>\G1GO$^IN M^L$T?HP;%N?T5F'1#?.@VX9_^'W,T"5VZ8QYE[(M%W?8?> QD?3'OV5#PO\LNTLZO2YX!-] M9IC/[Y>_*7A\B'_4SVCLVLWMKX/KJ_\WN+^ZN=8&UY^T3Q=WY[=77^G?-Y?: MQV]W5]<7=W6]$2,%@&=_"K*$1/4V,T MU9YTG/LG@0));5@$S6^^^:RA&,&9[/A".BLXQ/(3,_4GD*T5@.V2F/:>)CO 2"W9L[/@/+OW6L"S[D5K_ M:S,V!M1,@@&>,4:,)L=/?'-BF"9(BQE('O$C> L;NV=:."D>!QH.?=>PF.MJ M,WO,S-C839Q,"*_#880/B*^&@D%W@!#Z:&H C-SYH#GV3[9CCI'3;-\E> P+ MN-+S>>^:-ZZ/3[G:%S8##P&@N:-1BK\S'+^&VW6.U[\<[9RAW-+>*#ORY>[W M\W-U-X@*7SYI RR[='$_U6=ALT 6X1U.;60:5D ?#Y=U"4,,8\RA2V[U5-/F% #W!AW 0;5B..AO_C_%BO$$^>'486 .X>$?3HN4VY:.PPV7]I=LZ/@X3[I'!ZR#^HH,:.WBQXCN MNFI!6^H%_9+VPXB 0SU#PHQ4#)SP(5<3(%U!5$J-1L"LT,NK]%^X+6]6*T$$ M 5N(5[&'N!;&;P1^S1[?/VXQ,EKF3/MLS Q0E4BDD50KJ@KU48KSP;;Z$\GG MOR.2O^-_WYZ?.*-=LL>2-!Q9?65V7.3_;<+'\_](>FX;WEX\7IX1'=3-3H6PF-HE$Y $.#OE=T-AZ:[ 5N-\/R9W,3!1\*?"\8"6/B,;EX$UF P19_2Y0%@3R/(W"?N; T0P!%:GI?R, MSX*?49-\L%)U$(?P_P&("%H 'T$$9(\.D%] 1% (3Q8)J8P$T3'2C3L"KX+% M$U!86"I&IU>DR!*DS>I(F P M^KEM#+>(-Z;*0;G[*:R+4]/A:\,!Y\>%(\>8*S1.O=.LU-O]2K_= /E;K_1; M[4JCT0[E+P&S((,SP83REU@I5&MB.X;!*8(?(!@.\^2$=@_'7/G.\YF&+I1" M9H*$[_[(AB>I,X89;+'#YCRTHG7[9]W:3S$QCZO8D7O#*J0QSVR&?@MP*[Q= MGWA"@YZ;-KAS#Q7A@(&'(03*A%,WSJ.5$"1E%;F(C?8&EW:@KN7G*60Y#B(4Q*B8D^"H/,(KV?.9A'++\KO M%>6X1?UH_,AP@6>>0*HZJ3Q/05Y@$U>UC^!7FCZ?._8/8T92)7PE-R;D&< W M9S H2F[:%S==2KD2\%",7T"2@#!\A*,^A(TB_P(WD6N-($ _-U%;P(["KW62 M/$_&*9@D)$B%M@T _Q'MBD[E, . 3B1I0SH]MH.^;P@0E$ MNI6D.%S@':,!J9SOJ->K'/606B"4IN25H]0.I3@<[J'!3[[, ZXR%\9H_O&H ME1YP&OP)=J4#*X@PDQ?>W""7)7Q%#"?#%?%N\3(V)GFF<[,U\.BKPJ/GH0\1 M ! %(TJ*,@(I!U' 18&D)027!GKXAH@?PU\9J$SQVK',(9RAW'7!MH;-,45 M3:>FHO1>,[S''L;:P\RIPR88G E#F:%>5&!V@X(7H2H5+RY&U"=4<$/8A:E- MWM72/14DM9TQVFA>'("1[7K:4'<--_E%O"KE"MAJ/#9D900W3'D5#^YH A(B M3H0$-%FZ^])E50W. MP.GS_3KL#H9_JX0GY5QM5>UVN8YJ54KXR!X5):VC)!70\] MCK67NJ)A!D&*!.$:C\Z2@$F'J2%A.H[S= *6J3P\2NP1 M.QAC;1=/%%&4EGJL!YG*4$W06?-==-_UH8T!!-299'?JRM9BR(<)>\=$_]4 MSB6-RL,,X*K3N21(N*'&B]!7V1/T#EZ^F.%\5$JN2@$WZ<7$!QKF'^=HYUD/ M6.1-_W;G^DC^6RP^1%O2J6+.49^[[+TF__H UMS8F[ZGU-X'+2N0KT)X$!1' MKH/)'11(\B0,;<^S9^&OT="A)\81ZC_1I0/\N3F.'B633;P/F@"?O^V]]M'4 MP?*IG[4!3&)!6N *M#Y7^=Y8$F[I.H)NP6OIA4E[+-X70P!(")2V?G[5>)41 MF1&5;&5$YVMX[ )HL(*)'SXAQ1$<<%YGL&6_IZ*>B"??ZPBP2U _;E+&U%B] MI%1&2C5*2J51ZE:8;SNFT#O/V5K4KMB"32BZ\2O+%7>T8AZ,DGI.Z,?GJKWW M43>I.NYNRICG'AS[[G M(:_^,34\MDQ()8)T;V/1M-)3>W/9O6R9#/1/)GJ[4VEUTRF^[F*'168U!QT7 M/NG"X+CP@'W)E<_V;7XD0C<0J7>LWM*-<15+>7F)1,&HWZITF\U*JY8>%#LN M;CJ94W$J8DHP6"$5C-9O6I5>8X/3_+9H>&RH MJXN&QZD(HS?U>J69!V,50C=SJUMJ%5ZO?0$S)$Q4'F@"X4' M[$>SVZ_4Z[W#G^?-E'%A2;OF@R5")4*%0VC?:CI#$=!B"C(LJL;L4MATF@K. ML-C485-FN7CI#+M+G_J>E0B5"!VAF$C5_OC19::RZA.GZ^KQN4+IK[?C)!]7ZN['4X M+_YVU56K@M']5.(_X=6U$T&HW)@BJW*<;V&"#\[;K827M@M&_#=";_?;QZWF MWG0 CWZEWSIR=?WFV.V--W"<^WEPU.$T].?@V&*G 3[@36V[,*01;]2Q>\8T M#X>\%6T36F"\=BK]=:H+@D"]#@HZ!XXJC&XN8'R<3FVWTNWWCYQ9 MRE-;$ 3HU.; 48?3Q31TC[O*8A @&=6@C'DKT*)1O'9V[/4>B,)B@N'H4"AW M85^J=@6>AZ5CF?@H$3IVA/:B?7.H1SG7W:EV:=I/I[XA)4(E0D(Q,Z,)VI=@& MG5DN[YA;K%VH8T*QTFRT3D1''/VQ.)FZLKPYZW#*^LTG-L(IG.PMYJ;I+^QJ M/<[2"NK IZ'1J+3KW2,_$2?6;.7D['+LN-*MM'J[JB%]1_VIPX^2_LM\4=V\ M=]8C?A!.YG%],^@#+P8,J(.F(BW;AZ*%IXLM/$6O]H2F[%I2]SQ*0O)[]/&) M+S1)0(I<&IW\.A &'\20S3%WH5[7\,7AU[Q5/'W#.P+)K_F_SK185QTM[*I# M,SR#50D06IF_,[IJT/*&7A_T)X'7+S;XB+XWBDW"J\,&''SD*"Z@-$]X>Z8E M-Q^@9<8LZS*B.0#!'U[E+D=&S1\ M DB4!9M+6#"XXD),*.XCG&FRH)]38NG\E.BI4H:I+"[&!4'XDS,MK:(X30XL M/[.BZO.+HN)^-3]H31]*82.7PB-,'VGC'-;M+3(*(&2=CB7 MFP9+>5C+'KE!",9@*EBVQV?H\F6X>!43F "JUX'G>Z:MX3IF/9@$AD",NW=O MA6TCK' :R:C,#)=0PKI(7-H1W^63F01!:4(CR' RO5:/K5MKK%Q\)MW=:,K& MOLEN)O%':.B=83M?@0/ML3(_(GC7B8VH*R?^9(CC;%E<44[\D="4$W\V(F4Y M\:><^),WI3OPI M=[^<^+/7LH!RXD^!\3F5)D?EQ)]#4K^<^%-,/$ZFB+2<^+,_6I<3?XJ%QZD( MHW+BS]Y)7D[\*0_T3O>CG/A3W@TH$2H1*H(+74[\*9FP1.CH$"HG_I1L4R)T M@@@5PDTO)_X4!I]RXD_!$"DG_I3QGVWP*"?^%!2/6I/38$BM2LM)SX!$JA-]?A+R?^')D#6 ;1"H) D8)H MY<2?$]$11W\L3J:NK)SX<_@]*"?^%/!@G)Q=OJN)/_2G'/83]AO?IF5XO/WX M1]\U+.:ZGY@[$G8T_VJ;QLA@A>LYOKM)!?#X,*!^^-=1CBP(D&GR MX11WW[Y\&=S^J=U<:G=7OUY?75Z=#Z[OM<'Y^?K\ZO+NX. MC;WXT+#&#%]8.VL;5BX4B9ZYH]U5'__ '#8?2@%&]U>'N4"KT,;VR]TKXN[= M3QD!J(_0*]*M9XQZ1":&3 P+/"E#-S4W3(/0A(TA8Y8V=QB86GQ@!;[$&9/? M]61X4PJBBBL^YC-^BU'4,?V,RW-X&DPX8VZ*F6+P#GSFFV4$:1=*N0QF /!( MU][@MYSLO4:C]N';V=V9]NM@\#7XK/[A[9DV, %8H)0Q@8> - 9V_Q;X:9ZC M@^\W"B\4"W#DG#0.28@@,XT9D *B?>')A5A7@9HJ!!ME 8R; >;?,1WH < MHL_G8">0[!$_%%R;;W[ MP4T^9_@J6 *$J9@)0QP_QA$?3NHLF"/8RU/@QT#Q71HNN+L$[)_ 'X=6=^7^ M1%6;.&S!W"G#P\.&6\8S?!3S1[$Q)S\%I#X 9E'TW]+ B; Q[4?=L5R?<'=Y M^FS26#+019:?IC.58, ;%LCXMVAWEV15-A$RN&TI,CX0H8%@ @D8I1 MX"@._#5 !U@8X1%O(0CD<#3OB8&*T>@!-RTQW*6=P0PQK32TX>7T GHXLII+ MQ-!%/U&.EF#6_W8CY"$PW$@5RL( R41B1J:\N8*R3/,M7>!)5I&X'&3Z&G\*H7N MW'_,=-2 JX_FM*2!]*8I0.208M^N0,8&-N) M9BSV2+8MD"LS;,Q(OF&B$YCD+:[P"0D&!UL^@L@&M"W]@<^W!.$QT_\"\UDR M$W?V7->?S;G<]*:ZI^F3"1MY8G:F&,$F!2'Z#F!X>\*Z#YNYBTI]=P06O^\$ M?,L+!QYP];3G^$HHIA/'6$2VR^1/2\%9N/,7",Y;-C*!W2C8$9:JE [( MP7$X9XZG&WR<8VR+E #:3!\S:>EPBXA[)4F2 'XFY*A\0IK!PJ *@ZX\T.#$ M>$/$MG!,KF: Y0>2SZ88GAA(&7AE,A]^Z&G\(OU!VG49>SM?$T?[1A+U'!?S(PB6H[KK029!!#G\\= M^Q%M%/ <02B,I:TSP*(+DYM&5];(=N <JM.ID507T%.N$^^%OJ>/L@$'PP$AP*<=$/1C9=:5; $0WO439]I MK_&F6CV\SEBA93I!1Q0>2Z%7W/V+ M!V,I12/2-7@^#9?,(O3K[LZU.W_HV7-CI/4:M6H=Q$-(@3#YAYR@)7!!F I4 MGL.8U@0?X )IICX@O+?0XE*;(?7P')P MT3E45A/>)/R/<"8##Q=>,+1]+PWA4F 6[L %]C MOR08?&OQ]\1!28+^3)-Z0@6;TCV:B:TZ28.)MR!X_%A%WH!F>( ;@?!@R/J+ MJ?$ +_1X.$.@Z%LZ%8"",?4TDVJ1ORHB@H1K M"JDHW!]%P,I2@T6>?:YHS,"*#_"/,!8&5B5RN27_5>% ^4/08,#XE+N# MV8H&HHP#!;Z3J#!U/<<_I--2'H #'8!F9E$;L0&0BU4#03RMV$(%V8,34>,Y M19M$5OX)_L!D5[)2%/;<6(M&78 EL!@.5B)1L5CHV"H#.V? I\"^K_= %;#LQ2AIV+O8,+-GC33/?":24B0'8%.GBA 1!G"7%B&1VA\\.QTEXTI MIS5DO-R2A>R!M;4RQ)Q0C6HEU9!&:D$CMP3H[53P&5M&5 >!+'O=;U::S0;] MZC5V4>BUZWB_P9WSG)KY+*[?V3,6[G$T:[:XYIC-;=<05Q*FS*3"+"7"#7:5 MX?D\PF7:(UV4;MWKQI..@3*4PU3 BZ%(4;5 ]08/6%@@ X6PB[P0"HO)AL . MNF<[:)6"H)7]'(:Z]9!3"<).AT_C5$=Q^;02BW_# UM7+ M:-KA<0B$K0T;;7E.R!78=(]OU:WA_G5H>5MN6*)L3;G,I#A<80*,_9ACPDO4 M,X6[S8L(^%8[L-5<7O,@'B!DF,]!07N2#.1R314(7@!,2[IQC:@9=D>!I$9^L5 RD2B!S<8IFS\0$/7 Y^ M;03<9U ))'[!;0=%AIL"ZT0.8'Q'2#L*92*R06/N)/%+&CR%A)Z3BZ*68!>I M3=&A ]7,$RAA,+8=@_$BCA&P):@C1P2Y12 XR+"HJ1J99'%A(WBW@ K&5)\H M747Q9X-RJG-X&\*OCQPL8YLABU*8FMD/CCZ?\E@9EK=$*0O/88$=;)[U8--M M6(X]"_Q%'AU'EHI '=8N!YLC/ -@8Q.KY^!;GGI"%J(?R1]0?@FV.M"R /B( MEP]&+JR6.JH8.NHVX')^OK!@^APW>2BKKK[JC@?\<'#OH-PZCD/2CHTB.S87 M.X9BB\HL*"PPTAV'+L7ST !:_LJ5 BK>1>DZMOVA-_%-5?Z!Y0_B!U,]=+8I M2@\RQG!0,$O#)OR]M@*F,%<'EK6\.V":O-D*W5507S9D.+;'#0 [T^[P%M3B M+[AHEN"33Q/8Z3:%/&@TFI$UR(?'"9 J4_ M;Q! "6VN!VS'@'T7L5F,V@;E>Q$ZWBGQMU#+X<4% _17Z*6A !V"QU#!FJ*A MK$T(0.9?//O1%7$+83N4UH.P^Z9?Q'YW?T^#3#B0ZK4NT..!P6 MWB$?40G$7'\.[VU+7Y,4T"KAYK$]^3MUK"RX,5"GD)'U/@ M(+=/*=BD7@N8=W6PB -/0,CSO*#<<-4"*%'A%-0U1>\VBHOVG* 8[.<7]ND% MCW"V^<;+^G5EJ;(DJ7@B6-&>?#9H$%+[I,P'O5#G@Y:*\^ X+%1NBLA+D+L; M88$4G$*TQA_ X ??@?ZBCF1DQ#MILV#IT8A2P-CY/95^=IM8^EEMM*MU--!% M[X\'W^ -9JAH=,RD4SDD6::;('PL[L]P(88U,J(IR A,;7%-G62&/?9'GH22 MQ^Y\T64C#6#.L"CH1/X R$PQOREL _=G4W$-.H5$^X$<+V/@XT-'>Q>"*\\W M742I#C$J2F9"I-EJ>:0/CD/\2(LTF"MY%*T(&\P?U/3\LBX:3+.Y:3\SQF]W MB-U56^EJ.EXM<84/AK8() MQD22#HT"85WQTP[@,N<1*UUE]PJU315/$2*&BMRI]]064RK_5OD-JPA+A]7F M(*5L3\]"J% 4H)W]NH:B-"@\:V9X0;VX)IB?_I9G'E--0"Z3D<^B2I]Q*"J$8" O)'Q. MV!?2(:.3K2*0^73#:6UV&M&F*MF.=[W9J]2:/?P' ?&Z/.+'?,0#\^B*)BIS MO@JF*A>G@*!5.VO,O7+7,K@_ZFQL8?>$-S74"DEQ#57'^ZTD/"F>X\I $,HD M;D)A]D.Y"0-R;XRMD!R10H&59"D3]UBX_/'G-C>=3.,O9AI3VQ[S-B% C_\$ M:1Q\>,@L-C&X6R8\))(E9]HWV'YG)?@\("-A$IAC<$;*RT!$80,!7)&'AGB M+LB\A=$K-Q*^B@6KEK1@"?)::JPN:'@BFT$Q1[M"@Z*C*&=!&0!R!_S#'S(Z:LJQ%5;+ F JE\!YG( M:LG-JZ"R4X)T !FXLH:\B@5H6B)Y5(K\@^) 9XI 1".LVP+]K'.>LT4D(AH, MQ4"GW&5P?\0"(/1KY#D^IABE3GIZ(8\Z;-WE/=M7UV!Q/&6;- M^;,3PW&1[/"Y0<).7ONCFW%4&!Z>MBHG0A6)4.6GC?H:1!:D4Q?!%,6F2-]Y)L$$%%0 $MZ(TM$&' N3#\V MEK<0;!IF)L(P0UBZ$+Z*R 4@?U4[[@3O5"FKW)FP;,VTK0?LT;44@Q%P&+;P M4@ >LVH&F!-5:-CP,1V7$#+T?=R)@0V.OS)+-X-K\D$^2$8\@_-#EP)!/HJD M&;]R&&AERJ")WD7R:KRK_B 6-*(&2&&7Y6L[4K0_)YC$%1*9H$(X1-@Y8LA- M=9>W9@I 7C<^$S0(R.BK!1]7@OF2O*\YO\@O8]W1"+AM*=O+15>TV5,EQ!47 MF[]6V.EP6MI3QSV4O_:<<*TFMZ$@Q06$-?.M,M5 MS$MPQ((-&RW6:XHP9J]9QBL*@D/2L*ZG8%B7:& 5<%NCH7+;W<4YJ ;7Y\TZ M)Q,M'-^C??1-D\%?VAO%BKT;?-3J]9YBN+ZM"(43)/E4H:<(KT NQ_Q, .- M@L$(5*UX??@N/>)A!]$_4+1";U)9Y0\/F![4P#,:9;;%8KW"Q>OA9.@C+T@- M4O!1CAC4+6IP8P@ZV1+@5P02, M2/LD^0'2U]2?A"G\)*_"P>*B#YPQ U\-TWOFLQI_"'AYX0S]8VJ8J3$*ZK*; ML!D!@+S1I#3KN5-% 0OT'[ S,"^ 9E0R%(1LQHS-R%J^.KL]NSNKB$DT_+5/ MC'[O 6&CMHCB#JP<[MB1LA4/ MZ8^Z88;EN;Q-I]HU4XBC)X8E%1C,>62._J!V_52?-RC.QYTI8(RYFG9%#M/@8[W2%2W.I MI(L22276)LH@ VN%,VT@IH1=FCH53;B8V.,/EU+%6V!GR;I[6:/"?0E^-< 4 MAIGL<(AA/V&84>A/U./3 DH>%'NG1V.#"2,=,DYQX$W*D'2ZQ:/+PH;F(?" MUF?:9_:@F\JLN5AYGBB:$^1_EE44PK#HN3(Q+;KF4=RO9 P@',B+/"= M&AR,XA!]'UV,6>+NB.WGSIVGF;"P)B M3:GN'\EXB!+Z^>K8EHUYZ;)5\Q%LY%#^8? =I7$S!/9MF&]XOT$[)B2$$9!D MR,NAM"_@[39J]1;WZ"\'=Q^E!%8WW/=>]2>!V:AWMS>#NFR;6>4OM/EP?;QFS,5:[Z-CX ME@JE?QBNQU.7M&ZDP$=&!0@8'FX+AMAR7W]D.T$'6I/Q?D+!LB(S'.3TPDE MHEVL/3-0Z#_8]I@RTT$I)NH$V;F7*G?X!,+P"C/OX"NTD^A52E%&-RC*QMML M>IB#-GC!^$@D\]3^P3SWA>''!4C.5'QD-1'>XZ;I<(],4VL!* (VFF)3#][3 M(T8=X AN]=!-;=>N2!TOU0>52/S+'S]07(L:7"N7-Y]EA$[4LG)]*M16TO8% M8&'F6@][/XU%Z#38^V!3U7H"WJ-Q\BSRJ[*4E4?&>+<3BO^$=?#$IH'9%=27 M!28$7J$GE1W;'CMHY"?>I5PB%YV?*>!D4JL6==3BX@]Q?@06KKE\SE>T"C<$ M^RS.I^&=0.0&/PBB\?3SOWW=\;AC.0GGI^(P2E%()[K_H8WQ9(L;!'!"WQAO MP_/I,,^Q9<(H )1/T8FGLN6%1]5HLN?!A R*IX^4B3US)#V5;B"3CPUNQ(5M MM 6GJ$B_H>:#4: XX&\_X!%X8Z0#'QIR?-0.?*;$\WERW!!]#BDFC)BIBZME M1%&35#P8&8M,"6'*B%"+ Q&@5^*(BJL@D^\2\SGE"!2T9_:8LO3)J)]I_V \ MG1]T_4&+VPW*):5=IPST$.%<+"?RG<51F,D!=,2)YBJA,?O,/&QASJ63KD:. M92EC:2\6S,SXM#!0[U<2Z]2/Q+&T;[*J$8L8\C,^!OX#9HP4^R/@KD3K@X;T M$(1OT%)YNYFI4F\GF2J?(LY5!&$Q@0'TS@7U#8\DW0;YN:,2)%&LJVS8*)B9$$,'*#*"=O_RV(_6$H4Z$F=PGL)**U:>5," MB5!R%E'>W;?#;!@A(WJR")8@ISH$7)8636S;PW8TJA0[$W68 )9,%QD+N8W!^]0;3V 3R3[ M,@^+EP6.4IZ6 JY@ NXSSM)RD\30!M(,)-I]K(7(N!<1N1AY"3M8+^N@2*(A1%.9CB]W. >(R]RZN.!"U,A@8TA#%]IL6.#BU!"*3:&;+"Q M> B!$+:U8("D#.,Y7C8]R:.F7$$/@NV1:^B;'D"*5M#DOM0SQ\^;&HI(NC%< M;WQ(N$Y,9D5P$?GM>^UJ1N/K@I,E+V3RU'#TYJ9RVL*UWR@@O3U3 0RJ&Z;V MDU*Q) IX%JIWE$(B]>ZCN/6-/I2\VQFOH8]6;$6*;:F-^P1\/531W(3'4^5C MV\^@M OU+>8I>5 E;+8<:?P6K7U-["L3-K.)TB'%$)"74.,.:\22ZW&@Y475 M0(P8;LPDH XV'MW\B MCRI0\'0VC,"Y"9H8QD?H:6\H>X9UI//H;'B>\Q^Z3HUM5;#& M33HT0Z:$;T1X R\8BDA8+ PIVH_AP8M!/@3/?RSN&D8JI40J4(QDHA)"&5*3 MQ7.BF8M,K 9KBOZ0E)0*BO^4X6,!CB*B)9NV88FSG&D!EI6/H1T.L)@ A0E0 M$%E><"TGA-<(QI4R<=\0UF5D]:@_XO)%PH0F4 +0TL +W =\W9B->$TAP()] MX42X&/X53EA-N2 4\MNB8%5+"/GE3?*J>)5Y:.#I$Y2T08$Q^,IDZ564:DIN M!T8N+H3!6PP\JZ\^TRZBWAIF'?&")\^/!OAD (9 $ #U(L'=[,#$2OHVT H$ M!<6ZECB)QZ8IRJ3<>A:NV$894J"Y!)=\L%CVF-=2C0%L?J<:4.$2THEL-&M) M^D&$?D(=PR_R.8S*\1G:WC3HZ!O\0C86KH*PJ((AC+<(@^^4>:HB M"4.A(-[6D-\M33'_1+8F0&%!3\0T7%)@C"0+CV8J'J4?]E-$$#9?B$@OI MZBXL0H4K5&HB+7Q$@*Y]#4'P^WSN]O/BZB@Y*=,A!!=?G*]"V^FPX3,OLE93 M.\(WYK%_&^OX41R(+@"@@[!A,H_EB=P'J@%WY!A#%)-#@%&5[@GQLV727936 M+)?PW0T%ZJ)T#VQOY8T\2!#\B/*=T47R$,W:"K',TZY')II+,NBI6E=C<+5AQCD&F&PVC"0-TL0B>3*/BPFH83SVZ MO5CO)CW-349[T=1E.IJB!=J83Q/UIFI+-(-^L4U!]&,0VF8 M'HH92BU(5.EYRN5&/XJ.5U'P$C8LQ1<"V11$,B)!Q,'<,4P10^SQCAI!B+\? M?:OA1E3,D(GQY;&$)YKOWV0G%BEG*A)=4>JP!%%I@ ?7A2C/D#[QA4H^,.T+ MPL.4>Q(@6+4G5;%!%*"PQN$G(F++M\&=VD^6%%AJD[U(P*0T"8LFBQ9-PH_" M?)(1SZ'H:9$8\-0B,0D,D4]82!!T8M6#)Z/-%),M,C]JD8'H E>6Q>XZT3OI78B1R_N?A#;O*E(,OS*@&F8!&*=KC\7D=P*4^9 M,<'I8+% V$TP%XK%3=P,2@BKQ#9'YP:2;JH-):)F.T58@@TC,&1;%[)YR8@* MR(GE8]AR0D7LJS\T@?4670:19Q(>QU) T1^Q@/%-:63F;*6*#T&;( MQ(F8 M4T:]HK"MC(_TY,C51(C6?%F?GY,PE\U#1VFY,A0+ #'?MK!26^;8RC3:,>!P M&=R1-69\5 _\;P5$P9.:PIE'*KG5RQC@=)+6"!QS>:U%7"X+>N@%(3?A,&-P M-/ DD3TX\UU-B//0_?%=&K$75J.HL]Y$0#A,Z#I4@H[A4 Z8*^MQ9*Q3=\(J ML6#E2CC+(DBZ)/*R@LM_I]1B4+4[.M"\AW,%PH+ XA&+/SW&H:=(4 ;$ M:?IVB*F$@O 5Q2-5,)$UA5:0G2-<*#^7>"I7\?;?WOEN]4'7Y^^E*O]$ABYA M/[#&85[R*YQ_O"!T#QS\T;1'?_WRO_^7!O_YFSY\'+VG2B51J!260@6_I5(@ M^,)[K?[]9N1]1SET7ZM]Y_]W?_.]6?\. M#+L)2%\N,F)G21E<)&PE4@/AK2]Y50\.)G:S)"MHQ+@"Q[Y]INP#I=/%95Y^ MS&C,#1Q5DJ>OP2CH=CN5=K\G6A.W*\T^_/]>2PASM?60#$&D3S=5N_Q(HT4 MBUD]2J7ALLU>O=*HM]9OGDP@O&Y5:MUZI=]KJD$+ZN.2UHTK&@"DYEMXX^_) M=OXB>NMS X,?Z5MU!C=XAU0)+EJ$.S.@;V#4*T#) MR53/,KXS]GEW##?+Q("Q'6A2>3."=GB,4B!2MB9&"P6-;S'R$BTMX0:&[8SY M>0W2T&[*C^-=:[D#1#'[H4I)X1&H6T5F!#6RP]8DHG>D_N PT?KPAE?"=2J+ M';@(F(^&_1F'(- CY,^1EQ&PA/Q>F5T'(FD@%\ 7@@/Z,%7'9>%S7PR3N1ZV M10I*C\)GGD0"0@6&+CD'0 ?!" LO@I^(.%ZW:AT:K5*K5:C3C$R%/:Z'WX( MUJEBZ/'F!'(^H^A8@-5*%5DVP"^UT+$]Z]3X50_94:'"\_8@!Q\ U@=T$$9 2;Z,_ >](92JH$NK(,_"ZY?9]P1 MIG7.VC\1.U#(5:Q?T5YW$$ B#, ABX&!U8/^T+R4Z>KZ$X8X9@ E-49%DYB[ MX+K+O_ $L&&I&_&:6G#:C7&;NKG'[- MF2&>F^]QXZRF9=O>1J7?:$O:!?7B&VYRA% B"+-B9_F65304XW3DPSY!E!O% M@9*4,W78C#?3DG8\3[6!%P\"DA_96$DRPB"8$.#H"O+E'D6A"%_0M_A@1%[A@E,+0M<>GRG#!L5L%"BR9:@I MG15F2V71X,4(9')7+N6:FK3(L$VS[]#UTB^)-U:XH#=UBQ0]-V8TEX_$%(\N MY+"%I:!DY^IO%3M(KATT!<2S)>42H\DJFLO KN6&SIO&6U3QCE=%GN6V(?:T M!_SH$SCFCD/5!**M!LZEE'TC#&=+R(VAW;_;3^P1.]$JL1;1\BX(NE,,1XZG3IX(2HVV1VC:8/F8 MZ(D$$M)PIQ1TM)X%I<*-*8]Q,8]QX-T*DUA(WF @]YK^"&]+$SHS(9N8SPJ7 M<$5.!S;(FJJVP1S#912"QVO)--*;)SH?82$JIJ27X_F3&DB>\[ 4E3@1*TI) M'"1Z0VE<^;=W64)6,KPEXV,1Y3]P'$RIXQ$K;K0KU\!66XDEGM]\_CSX>',[ MN+_ZXX)?SOOU]N+BR\7U_=VA@UWYYF>CPN%DT#*#SF,*3W-)$1BU9/%+R_?* M&F&GRZ@:(N3#5C G0YV3VO2%EL]]BCBT*]H !UM@ ZN/CO$'+QD_%Z7I- R- M.M"/>>1 5Z>;/[(PD*&]08FNE!6L\)74PB9NP<39+.V-T9N-,5;4WMPQO*L- M[^C"MW/AGJ,>X6DCN0)H&[J)$.+LVF*P_,+\6QH9Y/@/L@$8*"KF@\<35/DC M9F(:;:0B]N/GJVJ]5FMKY]=WU2_ZOVQ,TF)YJXM/@,(@N[HB?]>CWPT\JNNT MY7[Q$.[?GU&=\;FUS_%'6[5ZM:X-X*GJO0\^G5J_@4$. /BY>H?A-8U_SUM: MXN^_?JK6E;D4ZL-AU94"O@-?I8UV9:D4P MK RN*!O*@W$8S-##TK;7=1Y?B<0OY(!&_$'X GY)/"C7XE4CE2!-$$P\CM81 MNZ,I&_LF>W^\LF)-6YC;6R-FFNY<1XOLYU>U5_3O.?IYXM]KX_EDC+TI_K3V MTP?TCH -JB1]YBY[K\F_7H7P("C.IBCC&]#.H[>,Y5O C:+PB23RT/8\>Q; M5CMKM WK@R;PK)+ H)V1GYALXH5;%:3>/F@;:*4=[:@W7H, GCTO"/99F$C! MO=_I]C!X^_.)8XO0-&(DXY\\L!P$E".YB=5!SO=:,RET?:8-J B) M]P^C201\>?F# P*;@1"MA*LA_D%*@$T\1X#E9Z-=4^GX',@DK&Y!U8',O97 M@ECU(N)#^M>1"N*$AA1]L9UY!R4$-.NKK21 M:?!)R#C-R\RL+,,J27G[!J!+4I8!)'%7DI+GZ^K*1;!=SQ_+F3\+ZI,*4P,( M>(%JJ4I?JK0H56FI2HO%+04Z'*4JS>9B2@UTE9>;V7L/_[V.ESFQL0=RZ626 MA_^HT"W0Z2\U8X'(5_C#46K&]9W,0$MN[E#VWS?6"K[B58NUU6*HS==P*$M' M\H5+A%)=ENJR6-Q2H,.Q!W59K/W=W)>\_C3(P8/$"<,)3[[7FNEN90!&&(]U MC1_KZT_$8+5;N9%0>$<5B)&/3J&NLI XX$78+)6X"9=AM7POPA(4&UZ&U7*Z M"$LP;'$95BLOPA8*AXWN\X.A1X3PG]*@@"#+V MJ8BW,5C1GX(W-%C9I")H=K%]0P-L6I&QHT&L8<4V_0S"IA7'>SI?K(0I.X8< M7<>0X^70%WW*D@I3*M0MK99XR@3S+:N;(1BBM3/@6BWT7%/.U]*Z&^QVP>B( MHH.%31U"+GQFWFDPW@FPH.RY((5ET"J9!";OE8 =>2T^)(3:"COJ9/C7]?"B M(N_\%X[&Y&W.^,77A?NJHMUOV '5A)4MSNZB(YSO8I^5@7J+<7!WKG6;M6J] M5FVT\5*H/N1C6)*?%HU'_^T;;M '7-R!E7"0P4D0^"X7D0'KHD05T[BXA.4W M6[')"O65'M*P N>!$ROU,4$_$,O@%(X-( !1+SL\47B$9G M!!CT>!##X=[JD^V8XR?>L6A,XS:HZ7O2XY<(G$1%ZOTA2[Y5?KR'X10.-#X> M;T!2_13*W:0.)+?8\U1M3''J;4A.8)^%X,:X4:,CA?:Z[4:J$3LA5?AP#DIN M,$(<1* L<-'">^@7T7AWS8(H1O_ MX5#( =&RB4G8_S^89"1T0E1(ZPLZ0VHWI6\'Q;6#&/TBZ+7 M-NS@V"8VZ\!=$8,2Y=T#WO55>O9&V#)P%!_BK?8"4309Z'WL=A+8C&R"59:B M;]C4IDEU?5VYKB7(=!6"1?2#7N3\( $) ME"A 5/C9EL5HR!,7>(F2!%LXAOU5,>%3%0F,H/M]YF;Z@T!PAYE*&J:'-6^) MF*!@&&NO6]& +XG=R#X$LSEQ,#>?#Q.@I8ATT4]?>D^RNY*$RO8]&@U#>Z.; M&)HM#WSAC/O5W04O*>19FO?'A$,@VD$/-UJ;VO>9VPE*%EFOG^ "8VEO$EX; M-?@3VP;R%\F^@9'VN?#W@VF#^(G'8@D2-# Q.HD1?-$QD.>KN T=QS06.T&( MWFL?+\^I09_VA^$YS/9=[0X''!J>[_'!S?3YR+-GSV(0.'^BQ"E M$GPYJ3H71:>.7E9"3&.#H!-#I*43(G-XZ@*D;P(,(B[0\9Z44SCM*2FUI:OZDN@6Q&PZ\7=Q*.,ZT*RLP22MQ M,9&O8QDXDH&DB3F3V@:.I$2R%$%%,#C"\]H(QKD&;)B'.QEL_AGHGB!6A&_& M46^\YE.A>V%N_KI=W$6I<4R?>\UH-N=[L1 M7E**PS8$]S83.\F+:)Q @-19>^X=YLH@L )PC/7SJ\:K#9%1#\2(8C]!+W>) MWT=3!SU$6&HT S0/7*6$"##"J;8H)QWM'7Y/XB';]B7NASP/&0E1LMW+8+M M!85(@RY2&2_ ]509,/W&=IH&6)Q6D)H="ZG37T M6929\'9PWL8-PHF&BICC/6$L&U](];RV=X5U^5[/QBV+G2J?5/DIOS4'[_P+&=^_:+=JKE*#3/J+Y# M7-OG+?"=1[RR!_K.7<>B+;A8. 8VW1;:W"1!O5EI]QN[!+7HA"UY]5AXM7HZ M;%ID'ZT8&LN@,B4W2/2$P,I$?OU#;!B[*%,IQ_%>P?B:/,AZ MCY7LNY8WK2)*&P!*&]O^T&2'9NV,N90=89&C,UJK]!L;UA>TCD7"E.>A/ _9 MT&BV*OUZZ\2/@U2X]*?LB!X6EV]8(1XO-+\3-[!O)EE>>(_?O*AJ\[(ZMZS. M+0CDAA*NV.KYRQK,XMV?F$V+FLSBU^GKBL MSBW+1'8?12ZK/1)>+:MS"Y8X+:MS2_%0'/%05N>6O'HLO%I6YQ;5ZRJK M<\ORPU5[4?CRP[(ZMSP>Y?$HJW-/P&(1[L#]?C/YWJQ]OV/SA#+Y0=40@UP:FUP#*@Q&QDSW72QI/:7>K/= M;T3JH9< % ?_ED>3OV(P^=[1+5>G\0\ONJ=VE_?4OKWX/+B_^*1]'=S>7UW< M:?>W@^N[P?G]U"% O ,0O"*Q-CLC]@-1[!(>Y$"!@:_9^6EWYN_Z:"1NZ5H:$ MMNY:GX5Y13@2-*;F&4?.7%ECX]$8^\(=3-GHK-5I2V((6^*\QS*[3CW31B85 M?A]D;YW0PCN-/ M017<+HP&C7,^_:)D^]-6 MJ+UP*?@?=7G@7YH_(XG/9Q*#5$^'#B_.CXP0@( M5QZ,@QR,\V3^#N\'+1P<>6!>O. ?N$8&!@]^57+XP46_E/'JA>]2UN?B9?F. M7456UZZL1^;2;'%Q"IJ]#]HEI0OX0=$^>^.S .3X<0E>5!Z7@Q^7%$OIQ0O^ MWXW9U 9J4+,('3-?Y_99A?AZ@9_IMR4OGSHOGX8,)V/F-[17"K+3+X)++VUG M!@SZU6&N,98C[A%.S$N=3W7#@>?6BK.$A4?%KDPXA>H*?-S'/S[Y7+IXMA:K MM"!\_ "SXT3S!+9J,,.".X)Q[#-M<:,B<^3)U^6U+.@0Z$'!S!Q>:(]=S;#& M(#?@Q^7$^;*G96*[N\,581>K(=T>.@OF@4E:N\KC)'KA 3P2KDCO)GF<9%_J MV92RM&S>FK8#^VG>>JH=64NN*KFJ")+\)?;YE06I$DXJ7\W$#64[U TQ.+IV MJ/5:O])H9&R741@RKZM[2GY^*?RY+9BT 24MF+3VH#8B6=$FE/.LO\ZPW3^NDEZQ: )*6K/IR/:<=YFYYK78 M\?*:[0W1*5#B.5I16#;)WE]2K.P?7QZ-\FALGE\[XH-QQ)YBD?O%;USX=21- MLC>J!2MFI^R-4,E-PH IV^A7FEEK4I9TS#[HENRY/+(\)2_ME-3K:WC#QWU* M5EWT/*6[9L7$P12W/46?>(*6)H]&NF833B_KQN=:5P,WNO\GD:YZ]IP0%_^4 M1[D68)UNJ6YTN3M ,5XU5SMK&M:^+[J_J6><;IO8''V_L'[R'=CY0%-F^@]> ML?6F#F/:#!:;NAJSQFRLR"E/PW+^BB:[$>OC1^PN0^WI=?B_AP>'/>CX M!5WXU>S)>A"\%K7 >$-8[1,]L1WMR7;^PNO (WUN@.&OS7UG;KOL3+N?!H"X MVI#ICE;[*1Q@[.A*^7FF_^#E?VRHCS>5;4L;,Z#P^$P;T#7D!6+0SX.;:EJS M)FF$\-N^YWKP@[6W0N #?IU)_VNX(6UPP=>P#* W9R#U'IGYO+2H/G$P2GYR MD/^_LT8;3V2&N0 'F0]1"LE]"Z;#;&,!8"X*1/9L9O,?7&\NVJBX;^7R9,1N" M560QUWV+L8[0U0@OW;-QYU4VW DND_@%J]P5^F6Y8_>TM;H&X) MB$T'WXXD@E_/]><0$EK??):JQD1EYZQ)C'N)Y9-AFH JG'F/]@/TQB4;.L0M M7%'TUM @ZP&1J&X$\17U(1F"U(?X1X4K.SZG*22-X:ZKMFGX.W\U#=>.:B?M MS1T8%=M"01@CIHU>I0V(XB'+ M;M(0[-U6I2_QH!>L;T ]$[_S91;- GHU_-$IG/H.M;=4U-7_O[UW;6X;.1:& MOZ2]5LBSG.%E;CJ5-WGQ2#<&AB"P(\. B6?GU3W?/ M## @08F421$@^YS-KDCBTCW3]^[I[APUVYN/Z;"RWJ*R[NZPLDY!\'2.,I>?F:>GCVW_=,;)>\RRR&7E3V2 ME984R9RO9P R%C&X,CY @;@+4%<@@$!6N6/0'=(=!TC:#6[>$OU;0G3E,I!JRCRS%68I70(H?U4>*;SPNI82H\./PJ>C4:D"@:#HV'A7' MIF9B4\>Y<&2AR$*Q"D*Q5Q^A^&E%TW;6(LP/^1G;%CWAO!T\\B6&04RN;(01 MDX6&;MY'?G79=*'>\HC!>P%$-XIPT4!JHP5*S6'FV]*;R^PGK!@A$1A- MB%2ST8>F\S6-XE3 B[4D_U1KN&),6/MZ//=B/ M5_H(%DIX5#@#";I.6M37[N5Z9G65'H'R\@+J\%JP_H_*7IKI-O/.IKTDI.V? MMR,4-:+FLE'H8CQT9?UNQV'Q::N!H.*CLU:!FHP:/UO/;R2":,B!U+S^4#EE MSVDH5O^H_OOU4?_/]8DPU+PPTMQP2J> K=TGZK)/Y)3[1-W9@%'51"7[1?LH M&(]W7S N%RRRIZXT],R!XCR0PAR0E46C)1 ;%/)^NEH*BWP>$Z8K%@NL+GF7 M$Z:K@;&JY%U0_%39\!);G"Q84;">U$>PKII+_2SLHJ='4JF'=MIP<8CI/#S\ M(._*HT.K04:A)#41O9@X76#^%4NV=")2@B@9%D3RBM9?+K^/=)4-5K2(>$PR MJY#N?-5I]$PECGDYL>@H"B=V,CI<<8\PN!7(*&XZ5QY)SS!;F=FR*!3PLP-X M\)J4:KMT0$K/Y%PQFO% 9+#:('/+/RG='EJXU:V Q8GETG(C?&V1*AW2V4,/ MKT(U*KPA"//GZ> AF3)/NVT5T&?L%NRC]CK=7>UERG8MRW^UF;ES E3KO54# M[Z0D8QG=>>YCE48Y>.7I$U/8B.'S1!*LSW).? ^V#X22IP+@OS>OFK CH?N' M([^[8Q3.R Q_R*3I?,C%UR/.U0_X!2IJCUX>S>GU'M,B5!:]&S*]0!$LE.VK@5(ZPGIY)?"D7%\-FF.?AA<() WF8 M @TPA@T!HH[K0=6+D;Y#63(7,H6)?VK8Y(VA=A.=O$CX9W50TB/Q8*>%=Y9 M]8C $K&@TO#.<194XY@-"^7]$,HU.FO] D+9*GX-IQ*%"%:Q22RWS(,M:*&M M!D5>9TC'MN'AHQ$:^4C-$DV\:^'=BR"SR-64>A7/OW23D*H6"=X^RG@ZEX;S MK5M:)V9<\!/OSVS0^O!5B^DXW!?J*!;[75CN@#U[L^F&< M1O(:6."]#Q[!KW_^$V+QL[GURAW+8>K+R]&BAUSC^[+[2?_!AV]R],O!N?K[ MIOOYXJ;5OH'MOD$,KUNM&_7/]>5-MWT#OE'Q^X-??U3P+Y5Q1KUPL)RLMF7S MK.Q>&_*7IP?@KD5(KM3_?8!_?!&3 MW&P"VP8V$RO2@;D^!4,/#,]4-[X<9'M;QC:/XH]S!Q]ID?IRBN'9_?XT(OWV M4AM9-O]X*YM+4@;%RMB;9IA9.P-P;X&NWR)+;<8QS#,W@O^TG'/7<44OG71;V1\!BK+^G5Y62M6^68@+ZS'97;9 M.KLLL)3V7O _5K186E;(M+SKM+P;,CP_HUV1G=X+*OTX!?6FEGKN+!J66M5VT2L/ M8$VH(BM"RU'"+GFU7?9'34&6I6N<:KK% >.;8*:G2Z76@2MUY5]J=QZ=TETY MGF.J8JJJ@B1_.6=?&_G'_96.9VQB3J^IX#-P4KW?4M1@5;RNYJ9LR?M_!KQ; MG5:MX3U]-KQK&TFM1V1NC"RJ,:>=Z7E?Z/EP)REY'?IN[8F:K2JVN9+=58S0 MBG-_'2CR1Z%=&\-W&Z<]FJ6S26BKOK9,KG4BU]9ND6N5G;'MKE]I;1ES_GYR MOA[_LCM\S\1:@25E8F4/ZAF+5E;5S[R^G[S>W2U.9U*MP)(RJ>ZOY[3!W*TJ M;LT@?KS(]9GH5"CQ7*PH?*+G3M6)??/XK#$IMJ20>31K7I?M8-:HSEY4GC66 MS*_5F#%J["G.KOK1U%+&N(KJ,>M8RVL3I,VP_ M=@9MMO_L!SE(/@5Q$J5X0/VS2-+(2QX^X##6LM-JYVD,...!M;^)8/[ 6J=? M\OT"",^^>_'-;Z$(LLD4G^F,Q,&OHG\.G+^>7G"^?Z[/\G*AID]%0@\I)3>M7&;D:RUARM:WT( M.YNX[/D2A[<@&3N)^.Y$$J@]B L3=482Y*KP 8[(BX>>JT86X/G8.Q%Y81H# M,&:B,E#^S)6Q:N9MWNC%3A 2##XVY8JP[^M_I)M@CVW[;8VYAUI0RN^ <4#9 MCQA[A^!W(DW&(3 JCG7 [MRJ,_= PM\2>W!W2VJHZ[)MCZGWNN!P&>18%(XN M=CJJ63H^WRO!EK[[W^8WJ^=M.[NVD5^2_PQD ,@(WW]P_@C"^P!'92 U@Z!V MSM-$C?WX6SB(G3,W:! 1^+Z-XGN-63!18U M4WM?6S!_U'?@$[^)8OM?:M!O'0?L_27_D(3YWYVV]8,'( MK7GFH/.\-L['UD<;-: \0 'G<'DX(P<>+N(PH+/O$M@71R700KHR2@0(=K6U M-.=+B7SX<8(($S2>F3ZC\ 74LH?@Q!DU$"A60V<4>DK V]]'4B\S=2+2GA1=; 70Y$(4' H&.#*.^'YM.>TGKAY$]1\PG53@CA6 M9CS^\,2&V&0_C6#K(Q#QA3E+ 8NK35[)(QCH,,H>@B!L%G3;A4'E MA (04 M&SZRM(>A]3@?K+C,B$-E[ZTX]03%'H$@T"1#LHS?U7=95R0-;CZRV<*-U1RT MJB;0GH7%HG/.[>=,L-G6&><,]6L4/QE.GVTQ1-=$SEN\;%XFK;K?/YC<8JIE MJLU1_[<]X[>$6N?5(I,KDVM]R+6_3^1:]0Y#S,N;X>79QC"U8&432-LC_F02 MK!8)7F%JA@F0"7!K/F-6QL8$R 3(2IA)\&,4:'-8,:HSEXP8U1H M,Y@QJK,7S!@5V@QFC.KL!3-&A3:#&:,Z>\&,4:'-8,:HSEXP8VQ],W;C?.3V MYJ35#N ?&NQ6\3J*#6&Q;7%R5!=APIS G,"J#DOS"8IW]*T MW/RKM4T#5O_?[/2\8-/8U66.\14\T!MYK@#8$5 W&Q=M!H/KP?(*V9-.^_BG M>&98N.OJN?9EP]AQ_//\^$N>_,R3GU_B\+-S#01ZI@@T@_;0"<+ 55V22PAQ M9\J*?JB7^=/%._/=SM>"IJ];@1M1DF&UI4G/&T/T92O;MHC&3I%EILMRNJSQ M2.?:%Y&9WBK]'^I4DO,,?E+/6,?Z@O;)X/;#.(;+71%%#Z,PNA?1,%Z.4+@_ MSV8]0 WOZ?;[\_1.CQJ]5GMC9%&-B ?3\[[0\TFWTSAM=W>2GFO<AW"3ZX,Y#)O90!U0!(^-9- MO#OI1"*!?\F1#Y_!"O#4[],HO/-B].%'801?NN%$HH4 ;X7O,/(-CX.?S)=8 M%(#WB8FJ'!C*1$83+Y!#@F+PX(CIU'\ @E:7P0>PU3"1'BG!^;UXU MR0HAD 0\6P3"?_@O0#60?GC/)09<8K!1)]?GH>D:G;4/3=\\NM?C2,HEU5!S,K5UC4ORLIUK1-B^F/Z8_IC^EL#_?7WB?ZJG'_2[G[_Z-D% M-^L\AV+B.AFP(PED*7P*\0QD($=>TG "F>"Y%(P"42Q)1Z:XD+(*H=PJ5J!U MZU9,^1]1FOIJZF>$KX3R8D4<8K_L3I6A*-" MX36;4_LJ#%XO>U1CNZOZAK75GA+HDN7*%5953)U,G=6E3HXUS<+U)<2"N-1- MO($OWP9PL_A.1P@,O(#LA TFYOB:0&-V%\ZWEW-=B1KUI7,%[!LWF1P\UXJA=B M9$Y@3F!.8$Y@3MA53C#F)_UI6K+]_#:-#V^%F+[[1';6M?C^P8M=/\2*M6L M\;T?NG_\^N<_(57^;*Z]2N#+<>C#-L87_Y=ZR<.7,)$E-SHNP (?OLG1+P?G MZN^;[N>+FU;[YM)-;O#T^G6K=:/^N;Z\Z;9O/DBW^/W!KPAS-?MZ^?H8\4F3 M>/?B'[]_NOXW+?$@6^S"?KQ$QS+]I1<,<1Z6TVJN:SR>O]*AZ;HT9_N01L#' M!"/09(@==X#^>@WG5;?7:K1:+3J@G YB-_*F%"^/I"N].VK2=B]B9Y3Z_@.U M75,]]$91.*$V=_%81%+S27/':&$'>B1>!@3?1SF(4A$]."R$&0^R4 M&-PZ9Q. QA6!\S[R_DDEPP32Z_\%H@&B?..Q)PBX3\&=C!-:#759]^0GYZ,78 *)7M%T M?O,F'G "KJ2K8",_7KT=%B(%.^\[K7:72[?9("TT@>QJCYG'CJ>\D;Q=YX MLQFT"5OJJ"N*HS8;67_,LO<)WS?7>W&; M9\X@0B"85<(-)CY98D$$]E?%'8%'P*A-K];J/=.VV<]CH@!MJ-TZ->H]/I/2(&EH,)10"14B:<]%:H M3KD9)\%%"$8D$X].B0 J$9TD>6@ZU_"BN:4V%@A(2S_;WD@"O#&N\/%I\[CU MEQE)@V\(TR1.X ]C!#TBR!QO,I%##Z@5WB!&B1;BYV#VP]T-I#]I! KN: F- M-G*0D-"Q-VT1)H+A$0D([Q#PC#O800E,&MTBS^MW?::/\[+NL[YL7M3.+(#> M3(+!?NOB[;R7"&@88 R?-%X"S\Q7@?@5WXE3JKO]0UB5PW9#60)PG;@%L7N+ M9ZM)\90Q(<'R"-$]27"(8KY\ ^FB=!#./; ![*(B1S1O/=C8"'15<OR]#L)-)M:II&'FV3OAS.6_G!N%3JM7J/7/@5>ZSJO^[W&4;?=:!\=S?%= M3B=++4,CEU?O80G2.).0V5XM$*J&D.<9;J$8)#&C/$+]\*(!LOQVT#L<^]'9 M3P71.L.G6M]$RD$!*RRO_H$KT2N/0G_VIE&(=4!&_;B*J9NS".)?U^K1^*\@ MA%=$$3 ;V-8A^4 W$%SI1.:0FYQ.; R@!)(DOK.O0<"/G.; M\FT1QC+9D@O%[E*IN]0^-N[2=$;:XK>.B@LYGP)L2X<&_%=?!'/43)?B+T7^ M:/>.&ZU>"_1NZS'3F^ A*KQ% M1:$EEZ,O7#!]#E3#)5()G/(@)SO=,V!$-2 M-A3*_?D YHV;A-&L!85# J+P3BH- ?P_)$,1=O@,L^6^$ON?,K<210C\J/K' M@\(T]4TD@V-.E>,(,Y=C(OX#! $"4A.]'2I>^%O7J+-&])T4!? 01?8EXV\J(X M(8M1F' 2_#)5^,S9&G,8*W]%PV_"+@O/ M=#JE7*1=^';CJ'_2..ZULNC4K"<6/^(J+788Y]2Q"LW/V J7.%\)0R?V*X X M-0LW4"XW,1 >A,$AC3@2+M@)0T\1(8;2@5UFG_HU!8L);(FH\%B;^ 7%#H5G MQ7L=5KQA2O'UF&>>=RJ]GQ6#QM0D0QX[RQ<"B3O+$5B$6&:&3IR*568" M LS234'%>?",,Y?8NWW:[1*_DZ0#N.;@*-Q2] ELY+_)V]2?R6-<.7/O520$ M[P;].4G]6UH+-B>*P+8C,VPBAS MI,TZ9<1!YF\1A3KU%!.,A4JW+$GP=!4U)C% M70R'8\(#E'^_V5,A6P),*^:&\ZJ/6IV _[Q?1/.GHBA5"DE?)G2[I^^?, 8 MUP0D.$5^,E^&ODRT?M9N(RIHD*).EJ?%ZI"B)@#IH^Y*QEZLA]"9)(/9!%J- M5_U>9!RWBRR?,1.X[33 M,TL7<=BB&L:'J09IEQD?A9P^IKF#./4II9'S#9'(# 22)/^"HIJP*PHIA%OP\C M-&Q4RIP>0OQ'WYIL2R0\E<&/@Y6_.E4G/ Q:#A6Y8SHYGVP4 DOZ."-AI=O5Q)R[*'TU-C M)0X=RNSY;JHV+H.2)%TVF [36@_.@Q1@G%P&3I$"C^><2((BPS%?7F +XTKJ MG4"4O%!9$RCJ)SB[$]\#UTX]LF\PK6'/',-7GC2=LYCR;;A!ZOUHR)H JT+Q M< #VT] $M*8RB(UE:%&I%R]@$A#[: CU.\Z0*K'H)0F.\U-;&I=,[Z/E4,(; M]J![8EB&8%!HT3US"!VS:*V":/V;"$B59X2=)\.?+"]R?DO 0C$5%0ODL2'[ MG,YF?8UB45-Y\981Q%0#(@.[@;(8R+-34B1+7,%J_B&3IO-A*;(F M, JD;;'#HR0]:PNYX6U L680RB,9ZT:4(ZF,EU?M$Q*9Q#S]4Q5-Q@\V7RN[ MA= AWG8*? TB _[6C^OE3^OU,MNJ)*V'$X%CLU[Y?EO1*9 R4U/ L'D^5?^/ M09>90,QAYZC9WGS-?]U9]N_>9!P"V1G='G%G[E^9+UI\KA!G.KLZ= M7JMWV&L=(M'17D8"J,%5E1C9#MLD%*O2#=V8>*A%O/'0A6?"GJ9 YM$B#ET' M:8@\G_RNH@4K/E*5=UE691;YM]!26 %&&4)9@)_L6K [/3$ SUUA2(7Z ,PB M_(K>C"KN-T$0@U:V5H_AHXM:+)SHE?',GJ2Q$3J*E7740(&' 5MT1%1,1($W MF7B)>J"Q]2V#24D(Q;,C7=$(QCZ&,$@JTE:K4EY :@'EY^> EC[;,WK+RQ&N&>P-P'LYRHX572C!]%X-?KO&/=G$,2$ZV>1@_:0^G_7+0>N /L=3 MX9K/Q9-H6#09V$Q ML_K9W,YVJXZ#.Z_1WLEP^FS;/72-'D4^;P2MNM]UGO;)5%LQJOTW6-L92B74 M.F^",[DRN=:'7'F6,AM,.\_+M1QT_E%-K]XG_F02K!8)TA!.)D FP*WYC%CQ MPP3(!,A*F$EP3TF0E3 3("MA)L#])4!6PDR"K(29 />9 /=.">_&R*VLJN,O MZUC,;5*Y>3_."&/[?I]#/@W4Q3XU_QL^&U^D>7=#SZH;]^ M; &6[$==F0U;@N28,_::,Y@?F!^8'Y@?F!^8'YB#F(.8@]8UN^:DVV):9EIF M6F9:9EJNB67#M@OSR&[PR(_*^S[3,M,RTW*%:;G&,\PWE@[_($C%&K1W *T@6 ,H9ANG E]NFY27K*#:$Q;;% MR5%=A ES G,"4V->8%Y@7J@Y+\PF*=_2M%S\RIK_^_PQOHLG ILCDO" MLSB627P6#'_SQ,#SO<23,4\#?OGA=B]P(-:![7;.7#=,@R2#]A#G=KNJ<^Z[ M30ON+9::_%!_ZZ<+.N8[8*\%35^WAS93?S.LMC3]=V.(OFRUTQ;1V"FRS.:E MYG19XS&_M2\L,OTV^C_4O2+G&?RDGK&.]07MD\'MAV!VQ(XKHNAA%$;W(AK& MRQ$*]VS9K%>@X3W=?L^6WNE1H]=J;XPLJN$%,SWO"SV?=#N-TW9W)^FYQGV( M%JN_&5NDJ!4[:]**O\DX?IB\"5.^R36ZRDH>O'%E5V7=>IKX_FM75W73XLS9DS* Q-8#41WQVA M JN%@.JFA10GPO8A$<;E$J8QPEL"9(6ZEG4P_3'],?TQ_:V!_OK[1']53A=H=[]_].SZB/^D<>*- M'M:QPE>)2-(DC!XR8$<2R%+XE!<8J-+\AA/(Q E'\ Z12/I%4N"%Z]ZJ$'FK M8L%0MVZU;W]A4F929E)F4F92KM!2/TK*.U*XN69K3CH>Y<+03)-+&FBUX/]Z M,?V6.?VD>7*T24!?6%P)=O [A9?*>*;P,O(#MA@XDYOJ80"/VEXYW5[-[Q)IU M)7,%<\5/K]LMY@KF"N:*&>-TEYEB1R)]"]L+K6,%L[8+EJ%J:LZ<2"0;MU"Y M9B)$Y@3F!.8$Y@3EA5SEAM39:J_>_,KVTQ.#.?6=5P'VS"^ * M_;D F[7TS'+2P%./F,)K#IRA=+V)\.-?#CY]^7CPZV&KV>[^_'85N&;[@EF3 MI6 S L+^@XS=R)M2 -5&XV,43A"^PW;GL-5.0O-WIW/PZR<\H8U5@=_DG0Q2 MZ9R'0]EPDK'48X@2QP_O91335[\WKYK9J5DWC*9A5#R%H2QBW-#7B@E/.IW6 M3Q_U'?A$W+3LI_9/;YP10)G#4G)T3 M)",/*:@Y(P/HR^NQ7/! #2%!;J!T[CW?=\1TZC\X2>A($07 7;$324 [D4-@ MK8A6993ZOO5"5L73$!#NA MPM/@C?+[%%84WQ("(.#^Q;))()S%3CC*\2DTK+)Q/K8^VJBY(@ 4@,B 2N&5 M\' 1 [%C.SD9)\ 5 ",NI L>I_ "<]H:ZU&)GB3\.$&$"1H/EQ\(;ZCP!=2R MAPA Q)E:=:X*O:8#NU[XOE#_2N^!"Q:MKCV@)Z(E\EW%R%+0+QJN4,@58B:4Z=JXEQL?-:GTQ_ UOGN6/%CE(M!T*> M\X+A/V?PD+^EW;7(W% LDF-)!S("MYD+WR>$S*Q,NM <\E5&5V,@JDTT(IRN M;CQ-1'3K@4YK;:P^"&\?X!_MEF*:WRZOKIRO%]^F.:1:%? M7Z:K:T77[R789A=0WW;_V)==FF*#V96X*9]>FD<)-ME_=A>(ZUG)W6WF<&N\ MT/N*^K:[1K[LTCRGK>E^T<,>H\ZLP/3 J.\G*ZS<;'AWHP.UL#JKO'H[A<\Z M)4%ED=RU3=LU?)@(&9^MX\-$6$]\V)B!V[^D$QF))(S>U7'K5ZYPK3QS;GQ6 M+P//M+0;VU%KX)F6J@9\E9M\_/BDI>(IRDT:%#+O.HM%;]Y,GN^NS4&^:EBN_0#O+24:-UW&Z\7<5/4=VD%N:K<;K=9QX_ATR;:-]=FL1]FIQJU(JL'*M09^<]U@:KDI MVQ$]+X//#FQ/-8!GGF&>J0\ZU0">>89YAF/'E39U/\@@I%X#^Y)PWB4J9R&T M<]M3#>"99YAGZH-.-8!GGF&>J:^QN[O!W'_--._)8)YOQ<,6<-U(GR73SFU/ M-8!GGF&>J0\ZU0">>89YIKX6\/;#O2LO\,8ZU:]@,SN'CFKT^;(BK7I-^C>Z MST^TS*^/X%A.$+X(PIUVMW%\U&_TCXZW+BJW2<[,H,R@%670#C#G2>/XN,4, MR@S*#%HU!FV?=ANG)^U&N[?D883=9= :Q^"KL]172>C^D>$3TM2+)<\KLEAD ML5@5L;CD_+ Z> M89ZI#SK5 )YYAGF&#PA4VM3]#3N$&SBG,E)!:9^IJ]U0SK;BQ>?LBG67MYJM'4XO+SD3A!F1 M&;$"C-AA1F1&9$;D..LE^4_:9QXHX>U\"C[TP@*]%XL 5_M )73>-'&_DQ!+^\!(/'A%&3@AW1G!)D$3"36('GNG% M<2KAJ\D$GA!G+7;N);Q:?I>1Z\5RZ(A@B+>AGPB?"!C[EN:"E?_Y;1H?W@HQ M?77E:/862KV"I<\UGOLY9:X!W[8AK+=X[YZR?'# -N MM588!WQ08-*G/?1M>=]&=+6;O>D+Y317X_SUF"!U07-F6X$(@5:#7PXZ!S^F MT%Q 3$:56(_K<21EOBB?X3'CV+F =PV+"S2(G+=SBT*_ L/+R0 D8+?=V!SM M5'3]7H)M=@'U1:S47Q,KE=JYM"A.'/K>\&67YM]21'E)[TK<="6G";%3OKS= M%O/54ZBO'H5_:1V_(PN]KZAOVA:HE@!# Y[I@5%G5F!68-29%3)6Z'-TH%96 M9Y57;Z?P6:5: \^TQ, S+>WD=CS+''BYH[M(/89CQY4V=3_(()QXP?XD MG'>)RED([=SV5 -XYAGFF?J@4PW@F6>89^IK[.YN,/=?$JE/#@\%K(:XE1G, MU(-]%DR[=SV5 -XYAGFF?J@4PW@F6>89^IK 6\_W+OR M F^LY>@*-K-SZ/#PK(WO\PMTT:V2('P1A#OM;N/XJ-_H'QUO751NDYR909E! M*\J@'6#.D\;Q\0[/NV &90:M*X.V3[N-TY-VH]U;\C#"[C)HC6/PU5GJJZQ/ M/>(33K']_9+G%5DLLEBLBE@\W'=AR&S);,EL62TB9K9DMF2VK!P1<_)BR\D+ M'O_+ZH!//,,\TQ]T*D&\,PSS#-\0*#2INYOV"')0/7D_$'+W;],$ZC_&['A0O@PSB/_D\:)-WI8BU2!VP?X M1[O=I-4_O_S\^=/UYXLOUU?.V97\T\45;($W22<@D$4L0=X^D#1R4B#KR$G&T@G"X- 5@2M]'V69$YJ]U;?< M>\G8B60\E6[B)"'=$XY&GBOS-1,Q?.6 +)*3 3RVVVX0("B8')"9^%IZ-EPW M"GT_O(]+1DC499E7)!72+@XNKU9VOQRT#NAS/!6N^:Q!T:K?A442TUB^<\Q? M/SEFHG:KM<),[8."IGLZS+7.$-8@](=+;5FIO=-N]N#../2]X3HV[2ROUIRE MU!6LH*51FK5K")OM6.9 04!HP2\'G8-G(F/SD0O20T8OM&>3,"W3*67[4[K@ MAD^6Q+1>]2:;BC]K.7-RLH*8>X\&D^QW8]L MV0OZSQJCTPUB1,[V.E Z:ISVE@P>6QOUJ#S:UN[L?#'Q(X.A'!9<* <=_::CGN44 MGM-O-UJG74<$0Z=SVFAW3K-G/D@1Z6==R6E"#R,XNBWU0'53J]UOF/"#=R?] MA^:"QK3]>?+K\X7R^^?;K$ MFI[/7\^^G5U_^N>%\^'L^HQV:8ME/6M%>X9(:XZ6J1]1)1I8 :)B#]-(QE0T MXH+^%E[@C S-.UY.]"L%BQ;$=K@J9.>C.E5WH78M:M.O6]3F&L5'ALYG)48N M4(SLW)X]RUEZ669DKMN/6*G1T!E&J*G)SHF'N"K&;<]C-%[@'Q##%:. 'Y"WZ\#D]>^!2(=>(H;"CZW6>#S/$W[A$H[G ;FV"HW#34+YLH483)U,G=6ESMJ6)#(#5Y*! M-[6D&^+DEP&WZHO+],KT6F\55 E_9X,)[_,P3NQC=M%&W*)*9>P?JR6OT+F< M53FR\J=REC1N:WP,AQFCBGO!C+'US6!GD(WK>HAC-JZ97NNSI$RO^^@,;F(1 M_QJ%<=YO91J%(V_)-A[,_A7A)\Y",)E6JW MDC*]LG^TGD4LCM]!$'7/52X@9"&P,T* Z;4"2\KT6E^_2?<&.NZOJ1.KFN*( MSUC'HEY)WX>G-C+@;V4 :LVGUE!BB#T1XP35W)U<4;T]HVWK5B7'L]K,5D&( M6&U8MRQ/.B>GC>-N>V/T4:GU9L+>'\)NG_0:[9--]JNNM\+23^<8@M3]@&W+36V+"J.>HWCUI(J<#<7EFFU+K3: :UVNJ16 MJ\/"5L[W6X?^FJGMW) ;F(3N'QD2 Q%+/%P_054FL*WPNFF$2YSWOL2Y?=SH M]CO+(5/C.F?FCBKN1>6Y@P\ U,'OK+(883.\+F;X+J9AF%XKL*1,KW5W'9]= MX+)!(_(W^UC * HG3J@J8<* SXBS);QN:?.ZV^LTCD^/:FP0K]3_E-F"V6(9 MMNBT6XWNR3J&,%22+=@]9'.[(K* S>T*0,OTRO3*[F&ESC\D8VM2E!>XX40Z MKW7]RYI-7N9^YOXZ+2[3*]-KO;75MGVGEROI_(3S;J35\U*I,A8(^RD03EJ[ M(PB83BNPI)LJ-#[='3JMJ'M5@\+-.>6E_:]UTP9G'#CCT#EI]%I+:L?Z)1R8 M*Y@KN%!S#[W)1_5T9TUZ^CI,A)]/5<#0Z6S(-&;QQ.)I$TK[J,-*F[F"N6)U MW[F2#+'C+G650SD<':M+=&P7TSI,KQ584J;7'7($$*%H=U MI,(9R%$821S <.?%\(WQ&Q/QG:7%?DJ+U]V3=J/37O),Q$[Y;TRDM2%2.J'0 M/:X]D;(KQ:;I'O/Q+IJF3*\56%*FUQURI2IV2/VK\99R#RN,-N8Y<5*!DPI[ M4 G C%'%O6#&V/IFL(?(%G<]Q#%;W$RO]5E2IM<=\A"WFFS[(O,C$CXFWICU M]Y+U.7/&1%I](N7,&?M%VX:-^;@FX%9]<9E>F5[9+ZH><8)+1*Z0,Y6P)F,1 MR7RH79)$WB!-Q,"73A+B**!)&,![0O>/,;AQ,F('BF7$SL@(IM<*+"G3ZXOJ MM,JV2SG:7+.4]R+VW.+D5L]/$SE<-VF4X%2]E#< Y0S#%%3\MI.LKY9;_PUA ML;ZP3:OYW/8H1]O/=&_\G#4S 3-!K9E@%US)*IM4;%2S45VGQ65Z97IE)W K M;/,OB:0AAXX 9,6M=()T,I"1$XZR6"4&-//SU6&:Q EX?&!OL!!@(; K0H#I MM0)+RO3ZHDIKVRX4!S$Y?K,&=JUZ(*?3[C:.C_J-_M&2=6@5#.=L3H0R<^PY M<[0:)YWV'C"'T=CT)]:#X*>?WZ;QX:T0TW?_2$64R,A_^.@%(G ]X7\*1F$T M$=B[ZAJ@?N^'[A^__OE/2+(_F[NNW+$PBUQX(/W^3HEX-S M]?=-]_/%3:M]<^DF-YU6^_BZU;I1_UQ?WG3;-Q^D6_S^X%?:%RIL<:7OZWWY MY:!U0)_CJ7#-YR(M@O7ABVDLWSGFKY^<>V^8C'$'6W]9?C=S&V0Y"^BEK9MM MGM@M 7GI8R,5.FD,% *$%/QRT#]X)C(VP[L2AWR *?S$0=]UX'H]CF1>!_89 M;A['SD4P7,V\K,6>/19'X3C]DBO"],?T-T=__5VD/]8$=0LI+^2VYS$:+_ /B.&*4< /R-NUE$#] M'HATZ"5RN%)-7;76FF5B'5AV?3*1%[/Z/%D7^?=-QHE@\HAC-JZ97NNSI$RO^^@,;F(1_QKA?!0#WC0* M1U["[+^?[+]#60@FTPHL*9,I^T?,R=6CNLIP\B[:FTRO%5A2IE?VC]:SB)=3 M&8D$&PD:$.7WJ0QB+B!D(; [0H#IM0)+RO1:7[])]P8Z[J_0&NBQUH+K[2)X M)7T?GMK(@+^5 :@UGQH*BN'$"[PX035W)U=4;Z8GTLH=D;8D.9X!;S6$B ;\ M]-F KZ\;VLEIX[C;WAA]5&J]F;#WA[#;)[U&^^1D)PF[^EY>E?3E-QE+$;GC M8N-=>2?]<#J1\%CV ??;IC[J-8Y;2ZK W5Q8IM6ZT&H'M-KIDEJM#@M;.=]O M'?IKIK9S0VX@3G3.D!B(6.+A^@FJ,H$=>-=-(USBO/5Q0B;X74QPW/3HQH;Q"OU/V6V8+98ABUP]%CW9!U# M&"K)%NP>LKE=$5G YG8%H&5Z97IE][!2YQ^2L34IR@O<<"*=U[K^9FUWMIJV[[3RY5T?L)Y-]+J>:E4&0N$_10()ZW=$01,IQ58TDT5 M&I_N#IU6U+VJ0>'FG/+2_M>Z:8,S#IQQZ)PT>JTEM6/]$@[,%>2-F58M-T MC_EX%TU3IM<*+"G3ZPZY4A4[I/[5>$NYAQ5&&_.<.*G 284]J 1@QJCB7C!C M;'TSV$-DB[L>XI@M;J;7^BPIT^L.>8A;3;9]D?D1"1\3;\SZ>\GZG#EC(JT^ MD7+FC/VB;Q%[;G%RJ^>GB1RNFS1*<*I>RAN *@Y@"O$]-V5.Y;#U)>7HW^D(DIDY#]\] (1N)[P/P6C,)H( M;&5UC7=> R;O_=#]X]<__PG)^.?L(<*7\3=Y)X-48FD*-L.":[_)T2\'Y^KO MF^[GBYM6^^;236XZK?;Q=:MUH_ZYOKSIMF\^2+?X_8&3!IYZQ.]7'PZ<[['W M+O#\7PZ2*)4'SMM58/@8A1-X>/^PW3ILM9-0_=TY[+97?DLZB.7_I3)(+N!- M29PMR7IP_A6W:;JZ2)N(Z-8#^FH5R>T_:9QXHX>U4!SU(ZB^]8"CQ@:UFSPLVS6HO@=J_JP\W R%<&#,Q:Q(^^$GPJ,P\0933N2B-I)QF"UWX[AO](9PC7._=AS MU<>1$0X "OPRH>OO920=<2<\WU2=#:3CQ7$JATWGS/>M5Q <^C41?.5%V#(O MDFYX"XR(+?( MG#D &]("@MUVPT'F02 OI/P7*F:Z$73,"+HO0!>!Y#%"V!# M*QM;M@. \+\@7 !+,A:)!@AP]F+7#^,4_O0 (!=>-X0GPSIXR=CY>';UWCF[ M.G>NPZGG.B>]7L-15'+2Z;1^RD6$HV1$,_NQO8B&+'F\2,#,2J)OTD?\OX+0 M?KB.1! +%Y?O0RI1VEV']N^EPNDLOKDRKY?\,ZS[UY\\]X+ M/WI1G)R'/E !;HYW)\]N(TG[\)DVE"_3QW[;T[C^Y/#/2.V-KR[Q\5&+,WO UC>)4 !DI G<^ M!7M9O]5EYY2BP";TB [\0$ MO/T$'_.JV^BHUS3PHQ(@KT",TIN]V!FFTK3'A)5,B#X(E'9/,[SF7.#*B? " M%!.%Q[>.RIZ5R0WSF*8-O!^'UI+XH0CH#=,H=.$[D (A@6"O ?:>N0^C/_#] MKIAZB":LY32,9=,!P0HB)3B,I0O"8JB>.) BBIW67U TT8 G!R45H:-A!8(; M E+!L%DF E:D74/Z0^F]@Z_15+UZF Q"?TTFR=G[?Y[__';NZ;,<=S$:21=Y M_A,UZKD6W[\!%OA:U1;U,N^*NF;S$'9#VK+DTY>/![]B*4.^I,L#MV:TBC*D MMT"&].N-UA*B\870.B>)=H6U[EC RU,E,R@#EQ U1Q0X\O):]V M*3*+(%PS4L_;GFHCU>G?G*6W\_Q?^OUO\E;X%\# R8.Q%GTO008OLPPWBO65 M=1)&V5 8-8ABJ:A["G"58GT._E@X ;QN/HNH!.WV_/<'O[;1SNB^:Q]9,"\! MP%-2 ;T$, 8&J37/CWJ=3J]G]\NAT\-L/\8IM&R MZ/=[1]UV^^AHA]!?>N<[73(B=@CURT NC_UIM]\[Z>X0]M=C^*,&^+?+\6\? MEWS_U1?!%S&1A+92Q&"/ ++@>>!O2Z/;6ANEGXT2L%IJ(^#;_6Z[=WK:ZRS" M?@:?ZB._BGSOM'J@X3J=A71>.^R7W_>C[LEQ][B_,YBO(-W;_7[GN'O::>\, M\BL)]^VAOPW9WNX=MWH+A?L"5+,X%KWWLTS&X3 /WE_>!^#LC;TI.*@($99 M+W93RC=W0V)^06SN^/38CLXMBU6MEJ-4\&]F/8B6\J\O1XJ8"*YSG6&H,D&T MFYFY\S@6924:ER,5K(D\M[I!)DQP6?&:!6#/HO=59Y$P.XF+@1GC3YC4%O[7 M=.![[N5H)"G=_;B4VQ3",W&+SFS@8FGX9T1Z@,$KRDH9FOJ&T?FMJS+@U$ZO MVS\$ _PPUU8+H)VC57P\;?=CO-B_^2P>2M H_;X4C6*Z//_QQR@V _Y9:'6R M72B&J\N_WR1:G68ML"JS'M>"V%?Q0%4L'\,(T\&>ZTTI\?6;)P8>L+HGR_-S MN3#1='@\*TQ*OE^ \E#>23^<3DC._T YQQ*XS*)_YKJ8\(_A5HR.6HEQN/@\ MC2*$,AA^"0-7?7@\!U,:MR__?AW;/[,@_=[,@JR,W7J7YRR^'"$%J$+(&_W0 ME3AW!L-V;W;/GXWBG'5AJ.?W8"BC\AJC)SCA;ZE?P@E'9=__F$A;F.'NE9E- M2R"VP45Y2998N"ZM?J^""_,B> MXVYURFCZ.;3[Z[55+IA7%V(E^B3P1@]48N@J!+"<$^LE [N6$?0FE5..PQ3G MW#FNB,=..L6'8)UC2_TZ ;S&#:I/5*6$X&[C)7\7$_D@)L*NW#05Q^WCG^)" M!U!=O]FRZS>QPI% 5Q#)[^@%HINJ7M[,7:='MJ#$&1[)&!TMX7^4"\S4-0W^CO9'0(9]#7W/?5#_WJM#7*DYB*X:K(#^^1K) M&$T-%.-4CY[R*:XJ[IXYQ87GD4C+ZU R38JDLU"E!Z#RFY@XU MH?& 9R0BX?L/^"N>R1C298IAX&X/GCWU=6<>3QV=^!W8%ZZCNDLZ/W(V 8!= MX;S&7ZUC4;\WKYK.7\_.OEJGH=[HTV&P4MX(;B+C* '+5QM327[*01WDTN X M ^$CZ J2'$'I>Q-8 @"H6=]MW@U2U>)E@((&R<(B)"^X"_T[&1/]B.D41##) M'GU9E.)!HOQRW'>D=;LNZ)QD7[K$.]I6]]6\B2$7TL/Q;K>/)"V]I6._(7D"'$D_P4*(C0/*@ M1]W(0#-A>KU:&E(/+TTPL7E(,0"E%M5A:7T) 8+783+''_\%.CCT053(1=< M#11X?DKM]0P@09@H^1S))&PX-FSZC;D(5$C$&H;Y<]M9B*& @WH,K .\&.'1 M3R$(\&I\97(O04^HP(=YOKW=UCE1=#;H38,0'DX/H)L+;XMI,;";!ZY=PPZ8 M_$]<6!YU)C:7[:"9POQ$G-%()8M)70PQ?#/RP_M8KZP$)T=H/,FT49$D'7") MG0S?N?51)]1+%[;?S&4&&E&1',%NH5'DX+:A>1;"FMN,!Q8R7/:WWE'N5F;*E1J)'L6ILJX-G]\GS*G6QRGRQ)SPN@D%WL(@![4"HH")R M]43\ <9IQDGD2L5Q.E'GCU3S"T&G;O6)^VD8D?NG)11:YF#6ZG8:OE5]H)K8 MF789AFZ153T\.R^X L; )RB&*95:Y>C0 AL] M<.8FJ:6[8 =\Q ,+G!QF2AA+<^G3$JTHM>9CFR"#E;C[)ET?5H<\ M7VJC,42B1$P_/)':V$6I-[L:6Q=Y+-X4#N+RO 6>]$LJ, MI$1DC.NQ;1YGLV8Q#I>*S3Z+"(SYCG8ZE-/T/H2]I"Y=8&N PQ[-=0X2TVD4 MWJ$%@9EN<"&,)7*&E7^^,EP^97V\4-'!CU*9( (](B073204P,.OZ4J\4QVK M;[:/VJJM3N!&$GL;D>^:M9/'=+K(VV?D/8[LC'C# :/-P69HTGE%W07RU'B# M7J-Z%M'_"!35R^@>>ZB91B4H?LY [/G.B7;.2&Y-Q'_@W6#HZ=6AA^J3_PM7 M3!DXRRS98NFUG/29"R8*+Z+6"9]A,<&:0P#V.T^&*T)[3LOB6.NR=?.$1=?R MD4A*,NB$ W*9%Y/U@K[3U;ESE0X2U4&T:6@Y1_.>MB/?)$1", (CVU71$ M!RZQGJH=S#*;K3F[*!1V@L6#-5-MU<"[% /?B\<(,3A.(,*P;1I!KL!%!\QZ MF_;8X#_:8SB":O"=? M>T"$*;T[52P72]\G6P&9 >ET*CSZ(3'M#47&$P^Z@H[Z3/N%++'*.$,7#M\$Y0Z2Q#)2+9.\8)IJ*D:ZG[F28$B#^>N)@LH$ M?=,Q>L(&FW(=CH\U\J3!]%,0/,56A2>@,9WA1B#<>J:"8.S=CK'))D4=-(II M(,@Y!^'R?VF(_R$!%*O*%[+8%4\HQO50I.,$$\/"%MVC!G[]&\()7H?-\F^R MP@*$P@_O9X$HR =5]( K8U>[E"VD?EFW^#*U!C.KEDF64A) Y2\001]S4>]8 M:VX4K\Z:$#LL4T4_]!>N@2'@G,V0;%0+<'2^)W1\/?3#6T4W1:YYG?/3FZ48 M9H[-6'GL%Z5UEJ(TDQXO4AL26 QZQQ>+3*IY^FKH.!"^4TM%[?Y8 M;DV>=I M]J'A2 _+'< _PH@66)5(Y8'YU%! I0,<1)BHW!#)W13,5C00330G\YUTC62< M1.DVG19F@"TQ0'=I45NP 9"*;0-!WVW90A79@QU1XVN*-NG,-\W!",(%2E'; MFRZE X%@HSA-2K7 Z=HTXRX/8[+LAQ+P'#53P6&K.: M0B\C%.<[7U/+.I7L^^;%?YS36_&O_9&?]AH89E#KX.!";%N$LK@L%9<+CLM8 M#E&>H)+?<9C.4)<%Y;NM4O5JJR--\V ;49 -$/+\AZS:NDRL*5%E\_C4%Q0# M3"QA".(3T^D@*>@K6YJ##")>UTQN0+'E5<,9I(DNK[=OG8@'&H&F*!9/U,>$ MC99IYX2C#T*=)*/S*1-2YWEVO["$N1C#(VZSPFL8 EI!F&"05T9J)%KIHF?E M]6,Y!(*X;6 609UI /<6I#Q)5'"K]80C>$^! 6=WA!2>U@\Z6S-43HPZ01!E MG>UCE)X$NTX]#M.L7NP>]"H8PY$G5:F$.L=-F0P,0NM ;98!L5,I)@D2PT;$ M7D#*5>! .DPG47S8HYSG5#5] ^$?8378!$F4PL@RO(W$=*QB65A$4EQ9N _K MU&#S@MN0SELJ[&7FSZGH-9)4 >J\?C?;'#-=SL4C80G^JE)#2$)TD;F \C^P MU9GBQ#)05857.!*YA-I9K$%F.H:8?<+C]5:_BS# 9DW8RG)O-$Z^%HI;L 2X ML"*.61+6/=7 H6S'W,*.30T1HVM-(V+0"7=%%-$A:N6(HVEN%G(S.D0PHPH*R7=QC.-^EY6[K>>R!&472! M+C.3/35(^C H'U\+H5@3>?X4Z M#D9'&>1(P%NI4@8\@@#/'+M4<##539@DSW(YII8A"UO/N%>:@/4#33)25U"; -,HH^JA M,TH3H],' ML]6"6C-H\0%WP-MJXTU1M_6J1_3>LLIL?EQH+#%I"B[:A[QMVX4Z3Z*\M#W2 M?VHMLJB5M2+.A3EBPZJO$CC,53KJX$:6ZW*QH CX"*WC6S# P1RDOX"[Q\JH MCO1^:_F7[S7=6A#K^=#CXRZ62AYV>H=M-)AUMX?;U%,M1:C("S5?146 :P(%D65CK?#,E-8 M;0S;H/S+A;AFO2&*'2">-+"7$!PE\\SP5V62JX:HY[#2>QLAI_KTPP$&0AU[ M;5C$5 .'61&CTUBQX1FT2T(PJ-!V4 =:T02;3/WP04IUQD+OKFOMKB/P;$*L MY9(HUE5B@I18-#,FE'RA<^7FM=JZ>/K4*"788G""49@<@E$G=9(-S0QMKRGI M ^"J/F)9ZP6[49)*\2&&EAQLG]A-CFSZ/53GG HDG5>+@]2DB=E/+U0NFM!R M?]5"T9X5?A72"PLZ,"C+%FZD_W1/CQNG_5:F(!YH6O63S15FTP"U)>==9$FM M]:4Z)["0DD !XK!R0W)Q61^PG+1[K=YAKV53MYITGFR:TBI2#)TO\.0+ M\V2+T'70+BM%S9PD8YEHEHOS>G!REF<@79@^5T]3<581^9XZ^J4;O6#LCG## M$U]>DM5[.YKXZ6_#\QZU2IWZDKP@6_H,J]KP:/6@!%*>+[ M]GVIF2J HU:S,TU8U"[A8'FTDTZ"NZ@MF?SLA%VSJ(]W"CPW2N*08CZQ"1:A ME%%&$>8[K+,I(,F&V)DGTDD3>),I+E(^D9(HZ314QI#O_2%];QR&0]4< ];C MOUGB!F\>R$"./.7X:1^,I$/3H>;B3X*O@C8&)HTY!G",!,R$#IZ\QS>J\)$* MXF6YMCS"%1="7#,!K4<:CV29+#N>E[7YT-FKF88AL7(ABSMGI;K.K"J]0E"N M@-RB#?$P#42**HST3E!\,J (JLX1TM$\%:3\/L5[E1]BV2<3E2()73=-%))U#Q)JE(8LYBKED7)?7@8)W**7(9Y MU0+<(A+L*AXC;J%U!X(7%= 5,4FSI! M;V&:=N\DRPWHBRP4HB:WF<2'<<4&X9>S1I M*8BP&:@(6>7; AE@\6^.L3D(-8.'.M$G20?@4<9R_ %N;#107+EB[Z1,%^04 MJ*O6%Q\#!ADYNXNV74XZ"*-M&#F> @+U;('T7+!2!_M5O59,^T5]8ZQ1"$CA\&M]B9ZE$,7* P M;%QE 3R4ATO 7*I"\_Z#BW')(4,O(!YYV#3WJPR$GQU\K^[IAON^K7MGJ:+V)IA=C[&%@;:\27<7^1(T< M5WS)U.Q+H]B,65WE34QSM(93.(D?#*U^HVQ/;/>8_(E^"8"1\\ZV4G71V8/.ERD+$B./P$5HS[QVT$>S0\=$,_C-ZA"DBDW1@J MH[9.QZ:VJXMS-9N(6E2.1D[>T=QYG_J^A+^W7VWFFW3RS#]4U#*YPL MC6@+/4MX97)YQL\$,- H.'-!U>K'Y\\2!0\[B^>!HM5ZDPHIOR= ]* &'M H M"P,YT[I:/QXX0[A)EGRD<"+*?37 @%K.A%E042"L1IV M]!K,2 1*:D9RY)M>G3ES*5/67H:0LC-3>UT0:(0PU^B+(++CH9BMH(MI73+[ MVBUA]OQQF8MN:A=M.5"Z6U0M$V3KA861RL@W_G!NRF)!E(C#@'XQY2T-O%RO M$*ZD,AOREC^8;]&7ZOB)/H%JV49E1N^GD;4#8% @A=B@+'Z!-J">?@F!K@E0 M=4]5];'8NN@AVQ+M5F13%0H-CF\+TYG 8OU_W5O GX:IBP\Q_L M^$-&RW,\]*^QYR^,45!OV9+-R !4'1J-6:^<*@I8H/^ #4Y5R;.DLJ(L9#/$ M\4UH+4Y% D:M 9"-;3#_K EDD)RS#UDU=D7.-[HPM(!N.*D1NH$K" M.FAR+9,QT"_\IEK84[1,S6:#/0??(A'62)*\V4HCZRT.$&4B2W=@407A)!A5 MU:\Z0?RI^:UYU6SHZ2;JL?>2KD]@88O5R%YL:$/;K>!T(KC6:SWJJYGE>XJ^ MG[U63\?W%P7J9P/Z%R+"]CBQF8N^KW']W\)8F>BP$(X:;(]G552O04H&;SO2 MSZ9->5!?N;VQJF',!R,^FA[M]+$"2J='NT<_&2Z@^VGWF]EO#@YW<6D@#5WR M&E_T)G^3TE-45SJ9IF@6#U!P@;VB7#12F_HF<2<\/R_&58TL[;Z26K#<2RQW MP+#,G8S$K=T7T[XKSA_XM$1X@M-+*IUTTC7&LV^A[@GN@EVTKS+"6I+\5+"] M,"PBJH'#K(C H) 8AM2(/Q<"1\4"B>).6C40L6DQV6EA5*;058Y.QJJQ5[/M M]./" 2M3:4%2RK5?U20GB\HTL5=)7NVMIUR1VS)_F^H0A:]6$D?H4DDK(J;+ M(3.;0A%M)H*T];AP'I9V!+$W'K[*%EV9-60JZ$UMB++X59&_K\TGTQD0@W/: M?*( G:ZLIQ=8V4IL#5Z,X)6,&UARPH!J[H5+)P(5 ]:6K@I49VO=='Z3M\*W MIHS-E,7I8C6]_ _FZ"->3)F?/'A)[L;,=CVH>&N2+PS@7 H+_&:'\(HX%)]' M1UP><4KT]BL7+'%\>%UBO12#U;%G-DD[6V9Z@GFACD0O7U*[O-:8U3? S];X MM"@,0DR$3O*3UONJ=?!$A Y16-&8X@IM6_%P+XK'-W)@_O#4CM+<$P+[6YX" M>/>,GD6X$%ZV) -5H>1\!@<4Z/Q(.=D?SZ[>&W%M4=!5@DT7L(SW]RF)UB^A MU4D5;S]LG3:*[YH#7Q^PQ%.JKNFA<6[.TKY3BK8,W'ZK[[P^N_K=T>]Y0VTT MXA2/^LHA%J ([ Y+U"CA;\-P2,GBK-X1%8!I;TO%-&I&77Z.N# H7C?T MI,!?G%4^XR$TD:>%/565[>K\FMUD5Z6C,"(X!TG3QL<4^.!A:IH?=B<=.SU/ M02EWC,TR5*^,F=4!BE F#AV7CL.&4>A&5U#5PG_2X2V%FJ@+M'7F\L$$S73! MJ%*>6D>5;5\&%B:31=X@::BCF=G>9YMJI_A5(\/1@TYYFGI1%:Q2740H)),7 MFQ.99C965O*5V0MXCIWT\\SVA%FW._TLZR2W;H],,2"?6J#8P_CF+\11"5A+ M%JN!4\52UQSLYBR=YD?YD!K2+*ZE,L+_EXHH41[B*)^PB>,*=6V;;I&'!L5] MJ,OT@4-?>V]R_HQD$H4FAY,!JB;"S&:7S3E%VT(*I]DP" IQN];TF2DN/553 M()$//66QY;VF-:782+^F#GU%H!3@;WY"%GCM+08^M]K4V!CXS@JQJWRUIYL! M4I@6,;-?;E?V%.U/?6-A^BWE:"E)07T&=,S<"NU9?H')AQO,IQ2VM]">A$-* MG)>CWG3^)56&/>NF@^9UG%4P&B/.FEVA(ZQ8X9-&\\,2RV/:B!/-"$++]4$F MV.=;22=A!W--=2%G_"IF9GR8F^SV5Q+KU%[$SYHL9I M/S\+84JRI2R,S MG!_54?"O9#ROI%05#$W M>X9MZP%\.O^V]$QP4W-HY"D+N(H)N-]P;%1<)H:>(\(J;@ M.P$M@>"A7P];G8:CWN^\5N'$DZ/.FT)MA*:]_F%GZ?((#-+HA((9(I4UH250 M+*&H\\U&-@)=#[/J,76LFR V5#S'FOE\:T]YC*KNZ!09+L]I9#:&-GR-Q8Y] M*7()9=D8IB_&/!/"0H3!G &R8&)-?=1=8+9[V?RX 4K: A=0MY M3O&;'8HH.Y;;[OQ4M.T ^X"A/EJ-/I0Y0#E;UEXLHBK4OU*O\Q'X M>JBBE0F/7)5B.\VLV@KU+28<55 E[TA3]Z IKL,"0\"<])QU M6 N6W(D"VIP&S<2(%\^8!-1X)J'#.$4Y),TH9'+;/$O DBA$CT99#4O*(GV: M5(\>M0V@^O+W3LJHCX7V_9^L;I6'INGH;Y12>_>D#_.W-)!/2:1VMV&Y-H^\ M3AL(!%6WTP>,/+G)NLD^#LG#GG-:7*L+1S6AQ2KO)K;PK'.<0$ MXS7_I3/+V$L%R\Z,0S.05OA&AS?PS)^.A,V$(777,&2\&<@'X/D/]?&_0O&2 MSOOIN454U6=":J:>37=P,5G4[)VZ22-EH+)Z/&M"5X:CCFB97FM8=6P&/X!E ME6)H1P&LQR1AMA-$5I*=E,GA];+)G%(? 83W2K)Z[(N4?#$PH0E4 K0Q\#+W M 1\WE*XJ\P-8L)V;#A?#IWR8Z((S.SF]S0M6NZI/G:F)DJNV=H!8*"8EV/.(EUTQ2U3%3#"BWV&83).&NKFUUANOL>@K X M!$,8#_9EOUE#1W42AD)!JANA.NZYP/S3V9H,A3D],:/AR@)C)#%HVIG*5MR. M$VIJC"9H_BHEL7!=X[F74)4*U948"Q\1H)-8 Q#\J1HQ_3#_=I2XK]AUA:C^) '\P''81=BU4L3^<^4 W@K/D!BLD! MP&A+]Y+XV6/27=?1/"[ACY\I4.>E>V9[6T]408+L(LIW%E^R#M'L/"&65=JU M9J*9Q;#"X9.2;%^07^DTTM.!-[ 2Z/X;5M3P7,Y1:,*C2_93++7Y5'%MBX:5M6(HO9+(IBV04@HAG MT\CS=0SQ1#6YR$+\I\6G>G%!Q0RDGO$]D_!$\_UWTQS%R)F&05>7.CR"J#' MLQ,\E&=8/$F%2CXP[0O"PS=[DB%X&(X.]091@"(8YM_HB*W:AG@';5LNZ51" M"_2W>;MCO3E^YYS[(E(U+YDA\@$+";+VJR*[L]BQL-PB2XL6&8@N<&7ES/$C MX@R!?1M,(:O(;,N\,;:^LR@+Z=;B[$4T68V+:$U24]_I38UF4$ACX MP$$0-&HD'+W1AZGT>(2\]07 B&74TI0&J6(>8<9A6[$3,Z-R_D)E\BU 5N55 M,DS!(M0]<-4!C>R27LA,U+P?^VP!1<&^G<*:%2F[[Y 4XG:0U,L?< MG&'1I\2RMG99R$T[S!@X4'ZN!)DG#U&L M>A3"'*482N^=*F92PAQ\(9$4SDF"D8#;0#[]??3B@(/5$ M^/$O!ZV#7_NGIYVC;JO_\]O2Q\([?W[[?1#YWCO\-WS\?U!+ P04 " "/ M;8U,6^0+]V,/ "XJ $0 &%B=F,M,C Q-S$R,S$N>'-D[5UM<]NX$?[< MSO0_H)[I-#>M+,O.JR^Y&]FR<\XYD6LKN:23F1N(A"0T)," I"SUUQ< WPD2 MA&2[HD^Z#SD:V%WL/HN771"$7O^\[M/ MZ!S>4O;-W[>HF;@;&C(+I;*&QU^OKH>#CZ>CB^&'WX667R_Q'(%W=.Q_[;N( M80L2<,+P)RPT!T]^H8[ Y =P2IGW]?"@]Z)W>-3[O7?PZ^AKWV/8 0='_P2\ M_.77S^?77^%X;OV>4.TO)AR3 0QXPX+B;X>#@Z?BGZ/1P?/CHQ?'!\_^;6A% M (/03ZTX6!S$_YFQO\>^E3*_>G[AT1>+:_QYBLC+\!=X-/6'\.W@U+H*EN^N ME^&7;PO_M]FK\;^<[_/ERV^?WGWN.J?_>/O9>_[;%ZO_(6KRM6_-D L![T;$ M?[.7\]'MT3YET^[AP4&O^_G]Y8VDVXL(CQ<.)M^JR'NO7KWJRMJ$5*%D-BK1^X 36#HR" ;(H"T>-]#UK(0&(R M=" AE(\P/N#C$E'F>9@/(5[PI]>BKQT+;$?< B >^/Q4+U\0=/D8#(6V?6*? MD0 '2S$@F2M;V0/8?K.GI1#MO&P[X$.2-CSCY#8()(% M=\MB)K^^"4 M$I\ZV.8SL'T"'3'\;V8(!7[D@/IJ/?J'''(Q(Z,8_KP<$ L"D:0=]&5LKR#C M=LY0P%=:I\$/15J]4X[,G0*>% 3_L',2QRC%SA].AIX(Z'CK%0.EAD[OG*\AG=K[T80L'D6?,2/7.>6;NG'P3 M?P=1(^!)W,QN')7'QRGT9^<.O=6/HI1*[Z;GJIML1+@MM0X;3H"0#83P[1U- M0S:%!/]7ZL9#K0'R+88]\==PB&B,9YM.=0/&>)_Y&7* M\"PG58RH1.[6NH?GU0Q9?8X)7\,Q=+(>GHRK M.TC0N_-EV9VYMD! 0=8:B)HKCL6TP=RHW%I'WX2N"]F2KU-X2GC*9D&>^E@6 M#7F^0J97'#0+H]BEAK1ZY[TJ.R^6*A>R3"[(!(-$\M8ZZ2WE,/ ^;"$69ZF% M$BW@O8,RX)(7Q,Q;B^DI=1PXIB*JG:/^E"$Y$21S5V6='N>>.BOEI(!4S/9V M8SZD&9^-SQ:>B)#B2:5UM?!'65<$=?RLA_5I&=:(:VL!O"#\$8W@(L(P^U,/ MX[,RC!$CX)Q;"^499(0O\?X58CF"?EX&]I+X/.#.0W%L+[BEU M71S(A9QGHSR*$B$J(EF4K"/00ZZDJ3E1,DLM"-M:#\CU1C;#>R.F'&+7@U&4 M-8 !C+S01*3WA))A9N) ) _D!(J7R7!KW7$3CGW$2TAP-D\CZ'*A'NZ*G#!A M!Y)_B\$U2;G72=/-TO5#)7LT3]?!D^1IF_>@TYVI(+<+AN6VE)7;E9HDFU)^ MNB[WKGAIX$K6\O=XOY;9YAU97Z7W4F/SN$*_/G]H*3@VGQPYY:&G"_O&C-2O7N4=+TY2=SYR.1M_@ %$#LKO/Y/ M&/3^4I)ZTU, XBR-;&![W7:7M_D%=]Z'(+V;EMCL<*1L8]]@=0*S"]G8+L[VFP@RP&HO>N6=A,:Z?2N4++:AK>/.\\T(E[: 3 1=&DR&MWE-*#FSRPOB/-ZS$/^*.J< ?)NJ6-Q!=&; M/1^[GB-N@I)E,X8F;_;$)42=]'XO;MK^PG42$B%:<[>4='(9C;CA1 1DEB)% MN?N*"Z$>DOEO-U$^$1#@0+!?Y9H!HAW>;[KW8;(#QZN:S%F0\X"V7@KY]VHD M[WVK&EGJL ]DZFG6RKT:S(?.J@871]L#V3M(&\F;&]^]UZF*+_EC#?<498:,\3!Z#67RC.E?=U4'+:S9RJJD3/+IKBI@,D=^(.0=K:)$ MCBU^[F0BUE*$0&R9#V65*WJ\*QP^MH2TWBHZ)#SBH9,QK]=^X+'5%4B8Y%.] M"O%%GS(?DC?JRGO'HD-3@Y")PSLRB;E&X@9C]!ZQ*6+7R((>#J 3G[/Q9 M[F>+0K2H MTJ6$9U=L>1$@5[!SO,*QSV.A4(AXRVCH):28D]PW%G)+R[\+(JF$%7#) ^!+ M_H'9%EZ@T<@R(U[?61N,' M-/:.O>(/Z/XK1BV$;%_8H9\ZC"A;ZWCICV@2CX8U[[2#$(UHT7FII\WI6^O: MYMZZ-._8RS9;>D%X WQ6&J#H_Q=D1+DYEQB.L8/S?C6B;+0SVAD)-F]FW[;E M'A)TKB"V+TCLQWIKZQD>D=&6%;JA[)EB%TW>!5QK;Q7MXS%5=L[2MC G?S3O.$ADW,>HL6;(#ATTG-2L(7[?%2^0RSMMJ2OO(J - M %PQ.I>_K F=:UX%A9,$Q7#"0Q[$>%1A.^8B)=)2Y66F?L)'*?')\F,Y% MXE_J'4[.%M8,DBFZ%JCE8IY:@DU'GGELDY0@?D54_;,8JDO,V#8\ _#Y"0=\ MMH5R_LU2A5)I6P.C+.J!":9VEL^HP74-U:9[VSEEMY#9V1P4W3Z\5.(%$\(V M+)C9V\5HZR;M_)2(=9WP89_U-1/2-AAU@NDEIQD2]!ZY8\02"RK*UU77IB[$ MY%X&1GZ^84S,K3($*2MO0KAQ:_KV?T(_^F*GJ'U%!1R+5P96D&C;*NT5^*OK MVF<#[^-\MD$7Q%+Z?KF\#;J>8^8'IY1Y\4RB*%U+L''M^SX68Y"@6O6U%!O7 M_TO8H+Z.8./:GU([>\V61@OE*5-+LW$;JH_Y%&UHH-F\#2*329*"-%X>W=*2 M&4UD[9M)JU4^IR$S,2U/]UAL,['KL=FD+.2-9(_%LM&,/QB-LCQA^ZR+SM3P MP(27\M#VBN>C1:LT!.VSYEJ[I-;6;ESO2\Z@55U'L''MST)&1;15ZCCETHWK M^2MV9S3>Y8!*DE1;NW&]+RDD-K> MK]1N7&_9SVNPKZG;N,YE- ,]V"W2O(BH%NX6:7T6BL7FG4B@RTBK%1O7-MY9 MK-QN;(^6 VJ%HJ1/[#,>2HF8:D*9*]OLQS-VHKP9[=WG^7O>H+\)/2\J@\XI M]&?G#KW-:>Z7S32G;YVI0EWQE4'T =T7!+-]CXJ:UJF?/U%1]DIU7>M,J(X/ ME#[62-8ZPTQ^JB:^=:ML[%JLK0,@_\L9V<]E< NBMZ4W,X0"UR#?[ =O:KK"FLRM757U)*TSJ#J\+%VPC4B M;IV1C;_Z4#9T!8;'9VQO96M[C]GKL:PFLK6&:'\ M6$39$ U!>XVICCRP7YX_\ 4$L#!!0 ( (]MC4Q,N3&%N X ">^ 5 M86)V8RTR,#$W,3(S,5]C86PN>&UL[5WK;]LX$O]^P/T/O"P.UP7.=>RD[3;; MWB*/II>[- Z2=+%W"% P,AT3E44O)3G)_?5'2K(MBA))V9+(8),/>3B MG.%+G ^_/,Y\L$ TQ"3XN#-XO;L#4."1,0[N/^Y\O>X=7A^?G>V ,(+!&/HD M0!]W K+SRS_^_"? OC[\I=<#IQCYXP-P0KS>63 A/X,+.$,'X#,*$(41H3^# M7Z$?\T_(;T=7Y^S/]'$'8/_U< A!KV? [5<4C G]>G6VXC:-HOE!O__P\/ Z M( OX0.CW\+5'S-A=DYAZ:,5K='![>34Z^7I\$, M4>S! !Q1_"OFR,&K?Q*?J^A'<$SH_':X.W@W&.X-O@UV_WUS>SBGV >[>W\' M[/.?;G\[O;J%=POOV[+5Z\<)T\D)C-B#>8N_#D]V]_FWO9O=MP=[[PYVW_S7 M4(H(1G&XDF+W<3?[2LD_^#CX?L"_W<$0 6;I(#QX#/''G9SN'O9>$WK?'^[N M#OJ_?3F_]J9H!GLXX!;WT,Z2BG,IHQN\?_^^G_QWV51J^7A'_>4S]OI+."O. M[+]8T3Z'),0'80+OG'@P2AQ6^QA0V8+_U5LVZ_&/>H-ACYLG'.\LE9]HD!(? M7:$)X#^9!ZZ>.D-1?$?B"/\>(^9YLSYOT&=&BFDR D/AXS3QP?09]K M^7J*4!3J8&H).\!X"2E3U!1%K&OZ&P,NY=(.>MY9$3=N.)J,YCPT,J/64K6: M0W.H\\^YCHCW?H GV<*0#7HM)^QH_AN'TU"LRV'HKS6JM\/VO!OL$?%L!ND3\V1\'^ )'PU$AYY'8A:D M@_M+AL7#2"M3/2[-H?],&'NF,P]1;08J:]NDQ_@^O",\$EXA>3]F 0JN+BO9-]K/9#$=),&3I M@'5G'F#8O,X@2!F0-H9-YX"Y$[),@ M^K0P"%P5S;O.2\WFI_;R5"[G1[F; UZ8 &U8>RKRZ?IM0Q#ORAM MW,)(UA!.5?OV$&F=L)*@/4S#NIB&+6**S/R]JGU[LQ!3#U>3=;)>99SR3#ET MB=IXL%>346>S*4/MU^.B0N]!WXO]9%9SSOX6*)@.4#!&XR4?+D #F_'L8\XG M.SHQ #VPI,K_RJ:W(&4!!!ZMPM=OM O8APSP:AK ?L^3@XP>9 PRV$O@/O$$ ML#X_8D&H:/@,:W*.8@+#N^0P11SV[B&<][E#])$?A$+Z?1@EZBW8\B=$IDUH<7FK]4$UE9K6A5:N9R.V< ML5+!=.'!E6Y3H?ERZ[BFZG,,[["/H]RFCJQOH9%-OTB7#7)P,O6RN'1! D^; M5@SI;?M5B5&*SE5+$\YY'8M*-Z0T)AE:TIB![1BM-V5-73AG2_F 7[79RMK: M'-RQN1<)$E"Z<9S4TG:,J%9[<=Q6(:1SCG0X'B?32.A?0CP^"X[A'$?K>6]) M.*\BL-WIC6VC$=DY$UWQR7R QLO%(9:&XEF]^E;[CY+YH?C&0YP&*7;GMFQ)L4RB"&][0YD;K5Z&G&OAUVA$#$\T^0T M[0+Y9,Z3L]:0&C+;(TYS^QG)[Y[9DI,I1S!$R:D#AE78W"_I>!7MS0RU[X"A MU!*[9Z$+$A!1.&VG4I!8%.0L6* PF7:FF,Z""%'V2;4J7DH02FD-$T7G@Q9CR;KMK([MJ]2[ M3DO8A'ACO@F1Y_PWD/(&KS+NMC99I*NW!.G>RM*-N?>/*^4<30!G"3A/FYLM MS/,YCDM*%IAIZNCI*T-]%JQ2Z2$;BB\TIS+K\'CVF<-"T*UIH&**+XUMKJ7U MI-.G+Y:?Q)2_=)V\PY,<%"M?:DK6YQ4K;)LR=" 7;6?P+57IY%R.(H;Y!*4_ MSX)+BN80KU[;'D531)4#*B-ZZY/Q;2U?3U'/P=#9)0SA)7SBMZ'4L;%$:GMM MO07S5JC'N>@N(T\\,3M>;O3J1PT69H9^\YP,K5'7,S!XR=L%=8Q=2FYFZ+?/ MR= *-35H9/GEZ>1R^&3D((T.3@F]( &:S7WRA$JMQHD-:X-&)D>/(3&84&*IQ-TIUA@55,Y.O\S,+&1>([&IHI,.)I, ML(=H\9QZ[9%#)1]'YWSFUMY,<>V/)?)>R*\@7EX,>84\A!<5DSE.:4+HZ%3. M, R;J\:Y;IJ'SI>8^-L0HTGNS4ZSJ%M!ZNC$;;/0JU2/).S]ON,7M.'0\TD84\3^R+-*;FS+,>/[ MVVMV+>]D-U"\2)#TIZ*DN4> B(#U0T#Z%''W>_4Q(D/9]4=J, M67)$8DL245R,@<2,'*5#R4 MTIEY*@:OEK^U?W*PL;).@O E*7+;41=XE3ZP;96H"T0)4FIS:U>8C:M%"?!K MI=JN1*FJ*R4@EY+O.L]UA5-3:$J *Z5E,>UU!?G8N.24@%Y*VLHLV)4P]>I0 M"0)):5V?%+N2:I/:5()L4L(WG=CSP^H)WPY3SM;EJ031I4%#$SGG^2BE6.@@ MKYL]:3#2H&Y ]N2V=;19O2M!#=*PI,Z8K"-74!7)$H211A_">DF'KFM2,DM M+@T\JA90.A-"4U)+0"\-/N11WPKU'^^V[VVVW[-G\M 3^[SWG:*J#??RIK8W MYVI>+$YT\G1U[B%[>N%%^?PY'+49E(2V]\VV-HJ!6IS;(,V@7\(GIBH_>;%3 M7S=&06-[OV\S(QH(YKC]*)FPP3GFEURSB&!NPRHZVX>0&K&C6BFN[=*:5\$4 MAAG2HH%Z=::C@5*-ZIB"--(B@I$T8&!='N6T2EI),).JHPE3>9E-00!IN6#] MYGHG[E19>E- *45%'@;L8G-0W!I]%OB,;^R M0TMH;30MZ[5B5 M#AJ4A=5A9ZMKD6(1-MXT+F?[QR>"U5$&QOR&)?95M6$*Q<=&UL[5WK<^,XJOP/C*]2V:V*QY;L>?EV3FBH534$R,Q2A!2D_[J\/P(=$4FP I$ "U.@^[-D>=+.[?W@VNAN_ M_.UEYEE/B 0N]C_M]=X<[EG(=_#8]:>?]K[>[0_NSJZN]JP@M/VQ[6$??=KS M\=[?_NM?_\6B__OEW_;WK4L7>>,3ZQP[^U?^!/_5^F+/T(GU*_(1L4-,_FK] M9GL+]A?\Q^GM-?TU_MR)=?RFW[>M_7T);K\A?XS)U]NK);?',)R?'!P\/S^_ M\?&3_8S)]^"-@^78W>$%<="2U_#DV\WM\/SKV?W5\,N(2?GMVGU"UM_Q0_!M M,$/$=6S?.B7N;RZ3W/KIO[''3/2S=8;)_%O_L/>^US_JC7J'_[C_-I@3U[,. MC_[3HG__\.V/R]MO]L.3,TI;O7F94)N@- M)M.#_N%A[^"/S]=WSB.:V?NNSQ!WT%Y*Q;B4T?4^?OQX$/UKVG2MY2W&*C$VPAV[1Q&+_3SOK\JLS%"X>\")T_UP@VDEG!ZS! M <5S,4-^./#'%W[HAJ\,7#*+!*9*1!P?"9I\VF,=:'_5@8+Q7V1HP]^Z8=MKQJ>TQ*]\](A0&(C&%A"W(>&,3:JA'%-)1[-46 MN)1+,]*S<8T8N,%P,IRS692"6LG4? [JI,Y^YR[$SO='.C'2Z?WBSP7MDN=H MXCIN*!*\$I/F+7YF!X^7'GZN:^\BO3J)AV1J^^X_(S#IN#]'@4/<.?MM.#E= M!*Z/ F$OJ<)#I:T)04[4">_Q#4%/+EX$WNM5$"S0.&O(2]>G0\ZUO95%Q3AL MSEOAB%C,9C9YI3W9G?KNA&TV']B.U*HAIE0G93RABR3*MU+W]2MZKIFA>_M%),!:0X46 ML(E/1TUP@\C=(]U0"&T!M%D;6 _D M! 2:-[_12[B0\5BI_E+;NPY)G&LQ:^9L+"DQAZ3ID[+TV)$@;FP'(RDD MGZJ-/8RDH-(,6I2YM['0/0U22\Y]5?FH]F5(]HO2Q@WL9"7%@=HW)Y&P$X($ MS$";'B1M#DH9-"_W\F/[8SRSW8I"KU.W(''TI?T9FCT@4E'5TW" MB*!YN7P<#JJ*EM*TVB?1Q%YX8>U.F9+G9:9_=OUH)KFFO^;DIE,@\L=HG$K. M&"J(Q:%_9GR2(*N>M6^E5-D?;7]LQ2RL'(\FI1>'V>1$[U-YETX ^G.6W$KH MK92!%KG+HVUR2AS)*V']E./W MRFN3Y?P?5LS;^BGA_G,:89=JZ&$GIY;'0OPP*9VEHMEE8@2!8E*NM *>[T;#.,_6AS_^+* M]+5R,J48ENYH19CEH0#PXNE< I]6H JRGB?[9 @@H+E28-9W[2)4N ;',@I MX/0/.X_.J%>B@RJ TAWLIG/AI@A&2D(@'ND%D;DVL!_M!3XG1SL(P+6F(^78 MY<^8 "[\48+%,ILYV0W&X\ANMG=CN^,K_\R>NZ'MB5#ADC4PO)1#)%8 Q*LN M8.L.LBA7B(6#I9?TM\A![A-;4$$ & V/9%0V/YMB?"GAP85'[TBY9>Y*'XU3 M][=HB)2W'Y7-O*; (Y8<7$_T8K-^7N5MJ(MM1^_T8%+AV%,JLIDK2G0G% P7 M891(2OL/!XIB4_.1*)48G+'T#XHX-.A\05C83'0+$V60?D'/T;]P#YX2Y.8# M)JT%.+69"&+<#^NC6*#O*HQE:D X'BO>MI5+=(M8ACW=SI I(G1[$V\KDXA, M:#M7@Y6YB&VD$03>6_W@Q7U-(80QP^T#,J,7!.<[_3N44SM 440"\@-H<&87 M_;7VY@(G%AO"Y;VY:UUET*HS,Q_1FCI!<']H:5:EA_QY.)R4G_RKSJA<9N9" MN*%.$(0?6X$P\8ZQB/BR8?)?4!/F0W*\^E2AV?48-L5<-VIH?Z23DF^C* MN_34.'M_06$M^%DKADTJ55H:)2MZ[[ H>D1B+6F:[77<(BDY.7OK_2E#;"VI&S8H M5$ E)VN_*&M"9:W(FI11HI)*3MRCHK@) ROA8.59-"EZH>1*3LSCHIAIXR8% M6B_!DI/I;5&FN+T5$31J**@>2TZ\=T7QV$;!HC160M3LZ!979<[B4+XZ8;+>NG^(,-6X1?$":GI'!%;4EDZ>(P M.>DK+; M:0)5DQ+]BW5W_);CV$<=55&>E),^&#@S=3 M"8)8<^*)+HQ-3E9IL!\TD[X"77NRW>O%B_/(Y%DZ.B_Q@O#C\ 5DFE)5ZHXX M7$TSU5-Q)6QJX*(W.:4Q4'2DK)0*,O0%62M\*EV)*XT!D]<,7-5:P>:>TM1! M)T.G*W.E,7R*NH&+33L(/>,Z^*14H^-M0R>G&83-L6)L9#P72=6MP4,0$JH< M@%<-3J,/ID;#;*(0!)WB+5PFYS9VP@\F(2+1[W=SSX5@$I&UCHD"4^.*ZK6T MD5N3Y11-,$'5(2K2;1M&I?J!^P<#JC%\1N$C'E_Y3RB(W.G#9Q^1X-&=WR#B MT-_M*<>5*,VBPS#74A7/"BKDYQ&E)F_&Y<9=:QX>EKYI>DH3\>S%C@&?\FM)FO MZ;M(5==9< MV,O3N=J7-)28%S47EY:2(]=S1-HIAL9B6M G-N]9M&'Z3KV_- MZB*MWOAFY!'=6Y4UU7894F&D80D5VKKSR @@:^M$RK==-71&?O"8J+MJ6C*, M[QSDVW0D2U8BSC??OMT/URZF>6!3&;_ZP1PY[L1%8]&JQ2'17+6XU.#% Y) M7^-V&"H1,GDWH01%DZL69Z:/U9PB+@,*$NF*>!$/H6(]4+X*X+C3O+PE:JX< MD[=HCDF(QB+,1)2Z@BVJ B>E1UNA%5"1BNQ;,(*8BBHL1KWWFBKMJO0*UM-: M==[8@[*V>.'#(B7^!AZ4D@_:1WP@E7%]',QUJUZ[]X'IN MZ/+JDF8:=1JO-3W,/"4 Y>YYGJU2@DYCQ=5)=;1%,T7G!XZSF"VBV:'P(I>X M /TZ;:?1E%6O*Z$:58(Q.@TWXB$KS&,67/2$/SYEMA&ASR;8,9 E=(6SK%B!6@VVBN3^5 MJ5M:TGC+< 0UA-"K6WM8#7HK*5GEW+AVRX)*O[)#'$>_+,.#@HL7:@,JO.O; MY#5:P]B).BZMZT6*AXC0E0[N!0U^=,MZ4^.6 IT?'2R#O%W0E^@&@J7YJ==" M[:M3.W =MHZYWB)KXJGM_28MY2]?_$JX$W!-AF:-;"Z$\@^A"?4%.T5=WXRR+2!!5.QS%/__ ME5]R?<+=S(G).PMX!>U >#,NEP[F,26Y7TO]LNE,1VL%;16F,UG)EW=I3;NT MIEU:TRZM:9?69$9@[RZM:9?6M$MKVJ4U[=*:=FE-JLV]2VO:I369O?O9I36U MO%79I37MTIIV:4W&9L?LTIIV:4TJKB/K^ZGE*LDJ_,(V76HJ-@K47W8Y4TW> MWQH&*68<"OAJJ(ZN#/>)R6]@K2J6LFYDE/YYEH 0Z\H^!9#7E(2#U MYEIU,R>VC0%:-66V;EY5M:UO+$G5 ;E.NI7(55,> E)OBM5VY[RV,G 5),#6 M3FB2'LUR4@8I05E>3'EWK\IX*[N"2M. ?42O?VJ;LJ3;V7#73IE6G4ZUWC.Y MPLD[N?ALMA+=^H8 T=;K >MJAGP;8[ARNGQ/;\6A7;Y\=_J6ON1YQ<66UF=# ML5*1.M++C"2_K>PM"BP"=@2]U9:Z5$6AC0FA2DD%O4Z\;2NIT :ZF]57:-S9 M5Q"'=<%44NEIFL-C*Y&M:040Y+J.0&F0Z0S#6SBD@1;P^8' EK($&+RB.X?B MQRZWT=JECNJ*''V]:1O;7)&CI8/?ID4[^GI=1H &P_ 1D0V[00F/'[ O@%8 M.T1#X5;CE6!+7]B 6N5))AB23[R5L%95'\13X^OB=XO9S":OP\F=._7=B>O8 M?CAP')8ES18P:B#'1=QWQ(]ZQ<(["4\+3ZP,5VO%UDKY9MX+7UF@ 2U_Q?2K M%' '$9^K2[^H2T1I):0;/F\.#+^L<-><@CVL,=!6Y6RP2E?-?@RJE\-(N!3Z MJ^!P[+8^GB6T[T;!FGOZ@>%D0(CM3^.4.&[2--"\_:1I61"PC/@@8'K#T%=B M!G'&BKWZRSW]*;#C14N4_U>9D9ZT:3XX>#.5P$55<[D631B;G'C=8#\P.1W[ M#'L45AR' 67T$B'/IQN]TU1PI.8 Q55U@]!\ISS?MUP44;D=(=WH8R<1DM<- M0NBC8H1RFP"I#&L.Q:C7=E)\I?VG4'+(Z+I+3C2;JJ,;,QX4U5-O>#CJW9K6 MNZ;O#CHE@H,;2+63V.^8?&<2QVEW<5= OE.6$ M"D+LHQO[-5H/ 6NOM>N,F0')(?L:\$8B<$'V!3U'_U+SRG%)W@GDJBL$ :HW M0Q=0(+KL#.HC6J#? DA+-0)/.'HQ9:+>$-?AY8$MVW0*FX+4D/WKQML!BQ#M M 0Z=F>TI&D[26?JK3[^4/V5-"4)9]TEAB:K(I1.XU-8+0D[O\X/)!5= U6"N MZDVJ/%5FU0F\-U,.=#?H?-.DK(]R;QB/UI\IR?"PEDR"#2\;F_5=)HXE!_CG MK)=IS=TA[^FL]Q4CGB11H)+T$R7JOJ7_LK:1'E&^&V@,J]T%<:M5M97#M[M: MWETM[ZZ6=U?+/^S5F:GC:O^-M_?*3]0RY95EZ =]3453&_R1%-1>U-#")9NH->,UO>( MS)B-/MN^C\AP!JO="J8^8'-6@I@$'/W5'W,*JEH>H@">5!*-W# ="A4]$+:L-1 MNH5A==4,#6)H)S!EF\ MU4UUB(26$)5NHE20W\R0AVLJGQ^@,QR4+FM)LVRK M;J*QKH%$-,*/%H+2261KJLF[Z=6(?[KMNL0D4L%QYW8<["+QWI@$<3$R!V7 P02XBME+JMHAGYJ3#K MB.;*_[8H?\+'2AA964Y&!+G=@0^4L&VAQZ[[V"H M%>"H#TY?L__"C[^JPD-?4%8Y2%+7%AQKF'97D94S_[ U'[>TK9Y8J1IVAX$K MO.=M6HS49@B9'.G4 (K-1#@!WO!3%U^Z) C/,)GCN'(J-_8";*\I2HDS"+"D MU*HG-<#2MU/D(UDSES=N8" H-#)'9N4'.<#&U_2S55JQL0>!6\W:,,&H[=2T2N86R U>$BNV]\6" M8"8*U\;Y1J.W)MNU1%;P&EBQ+?_ASAXQJ^]*-UJV'\*!\*QU>6-=Y;7D;,N1 M&;R/56QCNL/QW) ]6"3:ON6:C32%7TIOV]:E!>] E<\ ;!;Z.YN-!)- H=WH M@\DV+1<7O,Y4O0DN/RZ=H\ A[IS].)QDCU'0]K@B&[H)U8.)V)]67QT(LT-] MCG6AC[I7[J1^5\M);?5V;NJ=F_I'08X3Z4L+E"A+4>JN@LO ]RH4H;G:]"60[6N@\H IZJLE=<%5^YA[5AR M9T_3Y"1]/JRD2!<=+DDL9[G;Y7T]MTO"<^=\V3E?=LZ7G?/%,(AVSI>=\V7G M?%&S8[^F.UK1=GW5IC.'_W6IVSKX7V/;'T@5'RMIV9D3)R1[BV?-Y,1;EMXD M>=R'24T(1JEX\AB6RCN+GJ:W.%5>6O1X;V[V5#^ZJ>[:HJ\I%$[AO46?%_Y&;6?&S46_ M*W?.Y9+#1R)C+IN/NG+@!$0'3_+J*RVK+7Y]U)63J%@+$(/:A])=DKJ92>IU MZZV:D )MF%]ZEZ2^2U)OT1.M+JW7@+->G;1>32DZA9 "N;K_TO2C(TUH5$[* MD=$#@D?OG-9:I$_K6-:'J%X$$!=DO5O%8?C(*FO/9F[(?XBAT+"[H)4J8N:^ M[QP]A%<^U6@1G3SL<$%V/77\ZF+'*LS"D M4N3=!;:">A"\>M\/*/9,AR [0$FYSK2CRH_84O+NPEM!/0A>O6\(I#(*Z^P6 M&G87LE)%('#T/@$056*G&^:T*&[VP LCQ:/J+FQBK<"CO.(;V^F4H"G]]N^8 M?*=3N&//W7"5"U"\KBUOW4$G,_ BYBA^8NN4SDGC,SQCDU%TY2*E\%X'!G3]F[H MPG[EGX$'C;2+E1-T$"P9A4#4]#I4,L\PW7*OC0H-NXM2J2(@.GH]*M>1>\X? M,T%M3[@HE3;O+E(<=4"\]#Z]6+&&9_7=),"HNQC74A1$/^.[:;L(Q\6?"W:5 MR7N%ZT.QTD9,8\9[6XN'P!V[-GF]LSTTG$3'NFN)NAH".IWG]J5H0Q);^C,* M'S%=F)]0$"*4$?CT=;UQVDQ4H4/I5\RI[R'5'XJ^@ 8LWHU*(??T \/)@!"6 M*,0,RX_)!IKK"[]N C@LHS((LMZSS$K,((X LU=_R2YT8 1J>B2HRDA/A#%71!#2Z:H[U!P^!=T@A%37)2J71E2Q0D"EJT)N8^CD-8.P45T^ MI%R62[P@-FJ%=48.@75('A45XY2G<&NZT$H!;B(]8+=)\I1*=\JBJ8T M(=VHU]W-FJ1R($BJ]VS%:EB5:G]IKD2E Z>1O!]>J.UP"J4 DNEU53O3H'] M87W@FU>]+L ;S_:_V#/$=^3F6VVS_[;,'J:E6:8RB@HW%-OI<;J66K35P55H%]C69$A0RM9,P+DO)GB MIX,QA8U[/AE4)P!/)#]M9]\3J;83]2+'(T!H,%79*(^\]5Z%W9 MK2M(U#Y6:;;4M XM?8433#AC]'XUD% M9SA.%72 D*B;!">+Q& 2TFF^,A %LB[B4*H"!(/>K+9U_T9T]_;LTSG^T9W3 MA=J)KDTYLZ$T"\.AK*<.Z&!3.[I6GQU.XDX6SL A >O/; M6BF%83: U56!H-1;: A0(#Z0UL>R0-]I,$MU <_F>CTI&1?1#7$=B1,Y1-$1 MR+C2P]Y%O?>D!#L(C0-6*X7U*=MWT!6SJNW=+!X\UQE.)HCU/\X5JBR+;L!8 M41T0U[I.%;C2"','1-G':?#C+2M\ F[W@?:&HR A.VARO2Z0:+!'(Y\SPRW; M& X#("]H>KT5E#,%-*+4?\>=VW$6O?W@TH.AR]LV2!!W RQI14 4-1=*;NM1 MB$Z@64D9$%&]3H^!X[#JW 'MF7K_Z8/7)1 M]G2WA'M$@HOAR-76" 1-<7WE6S1S0]J+;.CA@+A23K91!TQ>)C!HT;J.#&&9 MOV5>RWA5#@C>@7.(.F!Q&07 *V7-X;\$3U 01)7O+A%W]U=H:3@N7*E!,#27 M+FFGL&DG@*NB"PBGWGB-U"F2^+KH[N3W*/DF.G@D94&#(3GS;)=7IJL2FVZ M6T,E$..,+Z/MNG%7/OT1W=LOW-)Q'XNEXV(RB])ERL>ME&A!T%ZII,>'$I): MO99E[9?+VI.1M=^6K&'<]A@6^L(E/MRE!ZG+G==SCHZ+;>UY?>EM/ MJ9:Z5Y10&G&+;^'8BFW'1[QS.[2Y<+TK:K9B9L7W/D-I+G_Q=QWP'GO8MK1[3L)EE1;Y'[]Z]\W;KQ#.XR))\X<_?O7I]FAQ>W)Q\16JZBA/HJS(\1^_ MRHNO_OW?_N?_0.3__O"_CH[0>8JSY#TZ+>*CBWQ5_"NZBM;X/?J ZWKS_LV; MSY\_?Y,73]'GHORU^B8N[,3=%DT9XU[6\OW?KF^6IY].[BZ65[]0+?]VF3YA M])_%??6WQ1J7:1SEZ+A,?TRIYNC5?Q09[:*OT4E1;O[V[=MWOW_W[7?O?GGW M]D]W?UMLRC1#;[][C2'*<7_^?;T M[??T?[Z[>_N[]]_]_OW;?_XORU;44=U4?2O>?GG;_A]G_T.6YK^^I_]S'U48 MD9'.J_=?JO2/7PWZ[O-WWQ3EPYMOW[Y]]^:O'R]OXT>\CH[2G(YXC+_JN*@4 M&=^['W[XX0W[MB,5*+_CHW;='='BJY*NN\UD/ED6&;_ *L6:^KY\W9!)4Z7J34:78 M9X\E7LF5R5_D^,',N()_:$?Z ^]^QW]H7]J/[Z,[G'V%:*4!./*=OTP MDM4RO?&M[#69#T5REL_3>LH=2'TR=\IZAP8,^;TWX:ZHHVR6\D-.[VI?X7D] MON7SW]-DK<+S>GK >1"U:U%EY^Z5]VM&/[PD?XU4Q%]JL@CCI%.2BM!88/8+ M;&%H9??2BW@D-Z/6O"BE;6T)7T#<[JJOODB'YR]/9= M:[[_J?WXESOR \O5HBRC_ &O<5XOOJ15]T.LE7_\RD#[9JH]Y5J471.B,C;T M0TOQ)B[(*K:ICS+>XYQ]519KHPIM9Q4&PE^R^UXN[UGRTXH&C,A*7#%WR&E@ MAZVPZ!PQC5#Y,^?;&79T+W"TW0L0*+'=@4K;98ZE4+)E\@$EMP90*-EQ!(>2 MDYKV4"*<>X/3?JS865D6)=G+EIB;V$6>7!,OM^2^[B+Y>U/55/7J!I/M6,V: M+==%HU]G#_)1/BWG(SAK:V4/\3O IY:%QTXDX$(9618G83Z/! M;^_)H5!8]L'/JRVYA,B;Y58JV%MJ@2(XC+1JZ0 R^[>=FB^C7$>$4!K#*>" MUJ?ETZH[-%U2PN"@L=%NBIV.!-2FHU/JNL1/:=%4&3&,FZ*L<:+==IC9O(+) MLA$C7!EXX$#,3E$5VEZC+2/J.('9KL%:O#6P6OQI.7Q"ST+U(>HTY& 9]9Q MBK4!!]JR''J?.UB+M5M;.5T(GTB]@941!0>$23.=XAYVSW6<%EE:XXL\5EL8D<:; M=5&IUUN6*4%P!.BTFHXY(;LD9(C0'7HU(3]UGI953<,PV$E;D6L'7$7L<^3U M"@\A(*<$@P6M>A)0,'HT8#BXKU&E],PUQU;PT%'[\SN,*F^]#R4I#(08]1,\ MD8[!)T9^:AP@HB'VAA"CPCU E)0P\&%2;PJ/CMXG.MJE3+M3$6E\KB92]8:+ MR(@ QL@KM%+Y$9.+M(<2>[J13? 3SHH-_;&H^U7=9:R.WN,]K%GMP16LFA@& M5BPT%"]>CT[QTP& LN:BY11HG!1M:4%=$A"UUD5^6Q?QKX9@)('.;_R10LUQR-&$" QN5)J)1HG2 M(48(S" MDB2ESE2474=I=B,B=CO4;].X?$IOXPR.(RLU!// M]CDQZJ@/LJY5./[FH7AZD^"4(NA[^@<%SO<#X)"/?KG$#U%VEM?$(Y,XTE(* M'Q#1J$9Q(?DZ.!C4.DT1P*@0)SOLA<[M8U3BLR_Q(ST#ZG=V=Y\+S5IC8O&W MW-@IOUUQ]/3! >*@I+#N4"[4L0WVZ(3QT X@FC($QA%HOH&&&T9 M(.-(T-(:2)0S#))<400$04[H@8^<>:@) ACMM8*1)3!LU)<.!GK(X#%=22CQ ML\_(*3<7B/ XHVC$%-H-$AM@L]%?5)D5#[,V4&!7N M38B2,C@,K-137#GU#(@A!):E4$2)5O3YWO8;]Q!>J0 $;V:AED$^$JX@T-S MMLKZ\-^#VK ;ZR@N%:4WZZ57M3==I_H.&O*@L:::ER<"84_OT:JVM:9&7T-8\2E.@EN"R$Z MHE2''ML_I>O'XH0L44U61]H7]RI*;V.M5[4?4_HY;MX]3AJE[S%"PXPOP6,C<#,F[ M(343#/0X:*IY322/#?<&M6[YZW[0[%1,*;T[%W)5!2=C3 8#,EK=U$Z'-S2P M-<["T,CI_+H>)D,B(X*! HUFJ("@H(.!!;UR,I,@H?9B M#:S-06A[8&<00*% IYK4)$QI=0@XX(GRS,4WCF"8=H";S]39'IV3W0$=&$QP[!L6$Q82C8TO+PLK"P>*$P+:,LHL\ MP5_^A)^5C1/H_ )#H>88&1,B0-"0:Z; 1DN,BY"'0<5=&M++>[?/ZOI"U M:_*]+S1(U>I0,/H2Q.C+-!)*[W :Q(E"C/6"K%T)>^V310^25DR^]S764K6Z ML1Y]"6*L91H)F_N.!E&B$&-]TI0EU3&MXBC["4?E69[0&IB2!JE)?2' I&P' M!A4="%P8E!,.YC@YXO2(,A"7,F&%2D, IO-M[XA82>O&7_L"ADRI#@S#[T M0**0<@-!:4*.N'59&M&'0(E%7CI?,YO<505.4XNJJH13L$MZ/T>31C4'A]1*(A!H,A& M0\61!64Z^I5RH8X-<;YPC\PD>AYA@V$R) <)%K MIH!)3XPX=C[=ZX M9T*<*QR.&(Y/B%O^4)3JP_,)E5_42%4<@V5$ @@C,KT4T&"DJ*,-!XCKYCY+ MX_.LB*97N@H:OV"0J#>&PH $!!$K10PX(2(409<7;9A>"RW2+5LZJJ.(,Z,!-XR<#WWZ].7J/,VC/$[) M?K"H4DVHB1MKD!3W%HV19KK7\ 7'Y QEA;Q%?=W(8H5Z9M1Q'RCL9(<$YU6% MZ\H PRF1UQ3F4@5'(<@C"C @DJHEUG6B1)"@T/KS5H@0:/T#0Z&NB(\)(3"8 MR+53W4-&@%!S$E6/BSRA_Z$)F)ZB#-/*(/5)5);/9 W^,5/:IH6 @AH#$ =?.^J01OLRC>[3+*5VB2RK M[$#BL<@28KAX5DJ#.VW/[A,QKHT:8LJ6%\S*Y:BPF*RM9^V@#1FMNSXZ\2Y,F/KT-*Q@\NNDKA#@U&-4%3#]^,,7,"T2P9=BPTL)R MX43%Y'[<@ X&%NBU4EJOV8E(GIP4.0UKP'FLQH:6PW?%6(/JT_0I"G(P-L>L MHRR/2LO!?+$1#PR(.>\0H.P)W'8!+\#O=_;TAPS_%R7[232R/\/5WJ1KC]T% MLD!%K=6'Z1,:,&A1**:M:/W=[]Z^?ON6_3^*FOJQ*--_$/O???][RGZ*8Y8C WWW M[C6BD& ,MZ3_VX_?\H]A@%.1>DFU\U%1 RB?+=U8RDFAI5G2J^FO9O:^JJF, MDT8-,D"U": 4W6##&+)(LKHANMQ>(A<8NVFMJN00HT_J!6JM%?T&:PIK?%( ]QMP,"%O8[*9@K82I*8K=A8H-S,)IKZMB#U+QX.A^CP$.A#QL>]%O MC,P=(7($ IU*=078IN000:;040^N[:X6*+K8NU=K9'7405$U5EF+*$X*%TTC M_?1(&IU_ 63^N&0'4M06"D>#=G0PP68^<&0%&4%M)="%WEKEJ=E(9S1.-W(9*H-UYY!@1@("#32EQ;*O;:KP2% MAP]E45779;%2'H*/*'QB0:+:$ F#KV$="8F*3:' *-"&D<" P7*#Z4N*_.&, M1P&:GGIJZ'U"Q*CV$#!*8C!FQ*3A%$<]?1>\"<2HW.*,R'SX@'.B7[;(DT6R M3G.6-9T6F6Q;ISK"MV3V>CGBU*#1A8D5)Q@$.JDKA+QPYM?H@;.S,^UH) 8 M4&]PA4E/TS>.IV19SHH-]='U^#3P^'63+=0?^\X:!C @M-%2]+(Y#\-+9]6X9&EDU*" 956/6GP'KJGU"@>D,, M4;_L\\.%2^),FAR*(640!TU45>J:;]K&,B[R)]P MQ2+M>8LN\AJ3?E.?6*O(_1Y9ZY4>GUG+:<&@RJ"@>&K-OV[Q! 5%7"F]>RY0 M^<6,5,4Q5$8D?A#R T=(CA]H6(ANH9.KI\0'J$>CYT6)TX>I*8_@+)C7!>N,8;M%H3F6^*O& MAK1JV>]'^,3A=&3ZX.ICFA&3J1UP_%LG6EU!M.[UJX#^, MP6O7BJ$17GX>S#+@O\W2'?T]^Q%Z9_>45C3C6+O3JJ,OD&8]:7]KMHYQCM67 MNDIJ_[-)J;*(?($4&$I5^DT1==VCB( *')*N<&T\6)S0>'4^9.J-'(XA 3 G M0Z+:%!R$!F7D:QA@Z%[B=:\(CJ,JC>G%3)HU9"MI.#JTYO8)(,"N@48&-4_/:6T[T(J+%3]].TBLD\ M:4ICV-1L:8"@:6JR V15HEX*E WZ3R'^%YP^/-(7ZM$3V;L\8)0W+ %'L:*7 MS.SA@?#B (C%[51?<,VOF.++%>N4P;,*.T,\5YC/2;!;@X=S8)XD:!E!=FK% M"['U_2.-.YIF7!5',B$*4E5GI*"T?@ZC &-'I6JI:^+\S,B /)#IU;I,H@=#_AD#B7NP?6\>^)&YU:Z% MTZ8DRE^S1K-<,5?X,_M&[>)8\7K/6V;;',$JF1@!^4;VV@K16N1+BD/AH $T M(/DDFXE(@1D )!4-LL#DA!,Z*.7J6J-R7^8RNG^*&>;>?=LBCGZB4IH^WB9N MVD=OKJCDP8:LN,F[P1<+NKEPG>DOR.(7X2+RAOH]H1RCB0POH+#XTMW,<&! MOKONML\V0WD4,4XW]7)UV]Q7<4G^)*ILRY@Z37N#I/ FVJJI9O.L%1,-U07L5#OISS!)3\&9H2%2S_-_H70 M&-^Q:TS8GRD>])S8K4UB07$FC5CVK3C^TGI2*@XU5&2WJ8RYT$ GY([1JG[/ MQ76KLEPO98@@#62N'S'B)Z@O[3K"[WT0[Z.S7/L04Z/EC,L(>,?Z(6Z 3%VN M5/*%'.RWM^++U4E4/9YGQ6=3/**>)4CP@D9Y:1B#A!Z,#;504AW:0%Q"RH08 M%[BTL<3P4^W82Y8$)\?/G\BFZR+O\Z0LXCI]XF4Q#-E%9@CR_-QD9D,GJ[RC M%# @GJVZZ+\1-*\8FH?Y,D3M@X\1JB?U/ M\3+G[8^AO)N>Y%/Z=TSM94//,FD:"XFQ!/(V0!>:(#^^9?F/9P0Z:*4!.+6W M;;)M&(I&%+2\0;LUPR8V@)WMTV.&XT3@\T96:,9Y45X5.5YOLN(9:RY? MS8Q^#SAM&S(^MS1Q!3?HSJK:WB$QZ.4#?AC&EZQ/)2;*GF+^W\&*U)Z7FLO# M6 OPG!S"L6&3?!&6W,$1.UME87_%DEQ5$V^AJG#-JTMFVVJ30#P'LG1,FP%94KJFD3A<'XZNDY?R:XC)JF=&& M@MBDP?PD;!3% 0.9 M]K]97VB#OR!1?X:;S.,8 MXZ2:=,/S*;Y7F6@]BT]C;*/\T.SJZ,$86 LEA1#!HBR+SS2;AQ1^,)"F\."7 MJU4:X[):Y,DP#-5M&Z 4 F G9FB@Q99,(0$,8F>IK3NA;3=I+."5?;>]^HLX?E+KK3Q^VK0B MT/WS07;I>\J>O5KAN%ZNSMH*7#?$!5[FM N( T+_0U\V/469II:0FPBO>;)G M-&Z4'-N!'XS5G:'T%,- M\3AUO!7]Z";")ZSG-&Z4ZM2!'Y9UGJ&YS#ZG\GM9X)AVF=BF*@>S1$$UW=KZ M!C/DO$A3;G-OX(IM[S9L09ROLGPFCA(+2[DMC.MJ MK@!!HUL3K\@0D3]YX6=ZZ)HGD@/8;5DWPVYW=[&^3W?VT0E3 M%WP7F6#@O:>&"(="17[$7:CM07U.@T=;\1Z"Z_BM&+O8XH^TSXO2'&+OR.O/ M%W-LSM9#LV0,CL@YVJH*-?&:DBD3P%XQ'R;>?G9W&'.Y+!^BO,T?0;J@*K(T8?\@MO^:=#?=%M-_+E?M2A!E?:HVTWGX MGF3[=!/VVAU#7V$O@H.;YT.T9CJKAK)?HY%TYCX,Y=-#FOX7T/8GP*4-W*G# MM@[7'?Y2'V?J2*S]_\R+F7R:3MK;/)3\QF]C2JH;)LS.FP^+JXO_6MQ=+*_0 MXNH4G9[=GMQ<7+-_+\_1\:?;BZNSVUL8TZY] T]3B? @"](99V59E"=%6>)8 M=Z@_3X37!'@S&C=*;.? #P;F,Y26E!%M1: N=0Q=5Y@4-! #;A&Q:;MIA7"4 M 0W/6MON).!%(=IDE4^6-S=G)]0&WZ*[);J^.?OQ8OGI]O(G='%[^^GL%)V0 M;Y:7%Z>+._*/\XNKQ=7)Q>(2W=Z1#SZ>7=V!L]?79/V*+=*8:AC"8%>EN!RH M4VJ J%2HJ+&J'0HL! QT MYVHN! 9\^OAQKNXNH#NB8F]>3B;&?C MJ3A"_%#018&.=YGK0D_D=-X."75J]J>",J+@B#%I-D4$(T4M[1ZMF\7XF\\ M[%B"H,*P-[>AAX<5^SWSAR4U%L0%.SF[N3K835=&1!8T)I+.E^A:IG?T+I),%K@(![TT:Q M /;LP>$Y7V=QWWEYN3A>WBSN+GX\0XL/-V>0=I-MYLN*>W]E$V6F[:26P^L; M9K/JH]?+:G(P:#/K*+Q8;CG8\5S' VY3.GUW=[KZQW _"AZ$0=V25J"*KFQ,SFT_, MVC9B"$X3#Q@46BHJ5F'F82J,#PT9P5E950OM+:N3! C(M+2@#NS@\6IO*6_. M+ME=QO7BYN[B[!;=W2RN;A?\"@0&8GGQ6M.3X0F1U\? 4@5'SWQ'%�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end